"ID","URL","PDF","Country","Region","Date","Completion","Trial status","Design","Blinding","Arms","COVID-19 status","Patient setting","Outcome","Treatment","Size"
"NCT04784897","https://ClinicalTrials.gov/show/NCT04784897",NA,"United States","Illinois","2021-Mar","2021-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Treatment-emergent Adverse Events","Antibiotics + Standard of care, Standard of care",120
"NCT04784897","https://ClinicalTrials.gov/show/NCT04784897",NA,"United States","Louisiana","2021-Mar","2021-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Treatment-emergent Adverse Events","Antibiotics + Standard of care, Standard of care",120
"NCT04784897","https://ClinicalTrials.gov/show/NCT04784897",NA,"United States","Ohio","2021-Mar","2021-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Treatment-emergent Adverse Events","Antibiotics + Standard of care, Standard of care",120
"NCT04784897","https://ClinicalTrials.gov/show/NCT04784897",NA,"Russia","Moscow","2021-Mar","2021-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Treatment-emergent Adverse Events","Antibiotics + Standard of care, Standard of care",120
"NCT04784897","https://ClinicalTrials.gov/show/NCT04784897",NA,"Russia","Novgorod","2021-Mar","2021-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Treatment-emergent Adverse Events","Antibiotics + Standard of care, Standard of care",120
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"United States","California","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"United States","Illinois","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"United States","Massachusetts","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"United States","Oklahoma","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"United States","Oregon","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"United States","Texas","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"United States","Virginia","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"Brazil","Brasilia","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"Brazil","Minas Gerais","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"Brazil","Parana","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"Brazil","Rio Grande Do Sul","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"Brazil","Santa Catarina","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04629703","https://ClinicalTrials.gov/show/NCT04629703",NA,"Brazil","Sao Paulo","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Other, Standard of care",308
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"United States","California","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"United States","Florida","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"United States","Michigan","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"United States","Tennessee","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"United States","Texas","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"Australia","Canberra","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"Brazil","Brasilia","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"Mexico","Aguascalientes","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"Mexico","Mexico","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04551898","https://ClinicalTrials.gov/show/NCT04551898",NA,"South Africa","Pretoria","2020-Sep","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Serious Adverse Events, Weight, Height or BMI","Other, Standard of care",181
"NCT04779879","https://ClinicalTrials.gov/show/NCT04779879",NA,"United States","Alabama","2021-Mar","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Serious Adverse Events, ECG","Monoclonal antibody",40
"NCT04779879","https://ClinicalTrials.gov/show/NCT04779879",NA,"United States","California","2021-Mar","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Serious Adverse Events, ECG","Monoclonal antibody",40
"NCT04779879","https://ClinicalTrials.gov/show/NCT04779879",NA,"United States","Florida","2021-Mar","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Serious Adverse Events, ECG","Monoclonal antibody",40
"NCT04779879","https://ClinicalTrials.gov/show/NCT04779879",NA,"United States","Illinois","2021-Mar","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Serious Adverse Events, ECG","Monoclonal antibody",40
"NCT04779879","https://ClinicalTrials.gov/show/NCT04779879",NA,"United States","Maryland","2021-Mar","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Serious Adverse Events, ECG","Monoclonal antibody",40
"NCT04780685","https://ClinicalTrials.gov/show/NCT04780685",NA,"United States","California","2021-Mar","2021-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Adverse Events, Radiographic Findings","Stem cells",40
"NCT04780685","https://ClinicalTrials.gov/show/NCT04780685",NA,"United States","Texas","2021-Mar","2021-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Adverse Events, Radiographic Findings","Stem cells",40
"NCT04780581","https://ClinicalTrials.gov/show/NCT04780581",NA,"Spain","Burgos","2021-Mar","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Adverse Events","Corticosteroids, Dexamethasone",290
"NCT04780581","https://ClinicalTrials.gov/show/NCT04780581",NA,"Spain","Madrid","2021-Mar","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Adverse Events","Corticosteroids, Dexamethasone",290
"NCT04780581","https://ClinicalTrials.gov/show/NCT04780581",NA,"Spain","Salamanca","2021-Mar","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Adverse Events","Corticosteroids, Dexamethasone",290
"NCT04780581","https://ClinicalTrials.gov/show/NCT04780581",NA,"Spain","Valladolid","2021-Mar","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Adverse Events","Corticosteroids, Dexamethasone",290
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Alabama","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","California","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Colorado","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","District Of Columbia","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Florida","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Georgia","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Hawaii","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Illinois","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Iowa","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Louisiana","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Maryland","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Massachusetts","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Michigan","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Minnesota","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Missouri","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Nebraska","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","New Jersey","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","New Mexico","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","New York","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","North Carolina","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Oklahoma","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Oregon","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Pennsylvania","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Texas","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Utah","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Virginia","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"United States","Washington","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"Japan","Tokyo","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"South Korea","Gyeonggi","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"South Korea","Seoul","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"Mexico","Mexico","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04640168","https://ClinicalTrials.gov/show/NCT04640168",NA,"Singapore","Singapore","2020-Nov","2021-Apr","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",1500
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","Arizona","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","California","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","Florida","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","Georgia","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","Illinois","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","Nebraska","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","Nevada","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","New York","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","North Carolina","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","North Dakota","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","Ohio","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","South Carolina","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","Tennessee","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United States","Texas","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"Germany","Berlin","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"Germany","Hamburg","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"Hungary","Budapest","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"Mexico","Chihuahua","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"Mexico","Mexico","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United Kingdom","Blackpool","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United Kingdom","Bristol","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United Kingdom","Down","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United Kingdom","Leicester","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"NCT04723394","https://ClinicalTrials.gov/show/NCT04723394",NA,"United Kingdom","Rochdale","2021-Jan","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","mAb, Standard of care",1700
"2020-002733-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002733-15/FR/",NA,"Brazil","Brasilia","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, ICU Admission, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Distress","Other, Standard of care",40
"2020-002733-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002733-15/FR/",NA,"France","Paris","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, ICU Admission, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia, Distress","Other, Standard of care",40
"2020-003654-71","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003654-71/GR/",NA,"Brazil","Brasilia","2020-Nov",NA,"Completed","Randomised","Double",2,"Suspected","Outpatient","ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Labor Absenteeism, Treatment-emergent Adverse Events, Weight, Height or BMI, Antibodies","Monocloncal antibody + monoclonal antibody, Standard of care",2000
"2020-003654-71","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003654-71/GR/",NA,"Chile","Santiago","2020-Nov",NA,"Completed","Randomised","Double",2,"Suspected","Outpatient","ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Labor Absenteeism, Treatment-emergent Adverse Events, Weight, Height or BMI, Antibodies","Monocloncal antibody + monoclonal antibody, Standard of care",2000
"2020-003654-71","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003654-71/GR/",NA,"Greece","Athens","2020-Nov",NA,"Completed","Randomised","Double",2,"Suspected","Outpatient","ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Labor Absenteeism, Treatment-emergent Adverse Events, Weight, Height or BMI, Antibodies","Monocloncal antibody + monoclonal antibody, Standard of care",2000
"2020-003654-71","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003654-71/GR/",NA,"Israel","Jerusalem","2020-Nov",NA,"Completed","Randomised","Double",2,"Suspected","Outpatient","ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Labor Absenteeism, Treatment-emergent Adverse Events, Weight, Height or BMI, Antibodies","Monocloncal antibody + monoclonal antibody, Standard of care",2000
"2020-003654-71","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003654-71/GR/",NA,"Mexico","Mexico","2020-Nov",NA,"Completed","Randomised","Double",2,"Suspected","Outpatient","ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Labor Absenteeism, Treatment-emergent Adverse Events, Weight, Height or BMI, Antibodies","Monocloncal antibody + monoclonal antibody, Standard of care",2000
"2020-003654-71","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003654-71/GR/",NA,"Moldova","Chisinau","2020-Nov",NA,"Completed","Randomised","Double",2,"Suspected","Outpatient","ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Labor Absenteeism, Treatment-emergent Adverse Events, Weight, Height or BMI, Antibodies","Monocloncal antibody + monoclonal antibody, Standard of care",2000
"2020-003654-71","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003654-71/GR/",NA,"United States","Washington, Dc","2020-Nov",NA,"Completed","Randomised","Double",2,"Suspected","Outpatient","ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Labor Absenteeism, Treatment-emergent Adverse Events, Weight, Height or BMI, Antibodies","Monocloncal antibody + monoclonal antibody, Standard of care",2000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"Argentina","Buenos Aires","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"Chile","Santiago","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"Colombia","Bogota","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"India","New Delhi","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"Peru","Lima","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"United States","Washington, Dc","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"Czechia","Prague","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"France","Paris","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"Germany","Berlin","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"Italy","Rome","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"Netherlands","Amsterdam","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005226-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005226-28/DE/",NA,"Spain","Madrid","2020-Nov",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed","Visits or Returns to Emergency Department, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Antibodies, SpO2, Radiographic Findings","Standard of care, Vaccine",40000
"2020-005395-35","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005395-35/GB/",NA,"United Kingdom","London","2020-Nov",NA,"Status Unclear","Randomised","Unspecified",2,"Confirmed","Outpatient","Hospitalization, Viral Load or Clearance","Anticoagulants, Standard of care",600
"2020-005395-35","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005395-35/GB/",NA,"United States","Washington, Dc","2020-Nov",NA,"Status Unclear","Randomised","Unspecified",2,"Confirmed","Outpatient","Hospitalization, Viral Load or Clearance","Anticoagulants, Standard of care",600
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Argentina","Buenos Aires","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Belgium","Brussels","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Colombia","Bogota","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Dominican Republic","Santo Domingo","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"France","Paris","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Germany","Berlin","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Mexico","Mexico","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Netherlands","Amsterdam","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Panama","Panama","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Peru","Lima","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003998-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003998-22/NL/",NA,"Spain","Madrid","2020-Nov",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",36500
"2020-003643-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003643-29/DE/",NA,"Colombia","Bogota","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Antibodies","Standard of care, Vaccine",30000
"2020-003643-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003643-29/DE/",NA,"Philippines","Manila","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Antibodies","Standard of care, Vaccine",30000
"2020-003643-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003643-29/DE/",NA,"South Africa","Pretoria","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Antibodies","Standard of care, Vaccine",30000
"2020-003643-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003643-29/DE/",NA,"United States","Washington, Dc","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Antibodies","Standard of care, Vaccine",30000
"2020-003643-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003643-29/DE/",NA,"Belgium","Brussels","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Antibodies","Standard of care, Vaccine",30000
"2020-003643-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003643-29/DE/",NA,"France","Paris","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Antibodies","Standard of care, Vaccine",30000
"2020-003643-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003643-29/DE/",NA,"Germany","Berlin","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Antibodies","Standard of care, Vaccine",30000
"2020-003643-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003643-29/DE/",NA,"Spain","Madrid","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Antibodies","Standard of care, Vaccine",30000
"2020-003643-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003643-29/DE/",NA,"United Kingdom","London","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Antibodies","Standard of care, Vaccine",30000
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Argentina","Buenos Aires","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Israel","Jerusalem","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Japan","Tokyo","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Mexico","Mexico","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Nigeria","Niger","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Peru","Lima","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Thailand","Nan","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"United States","Washington, Dc","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Denmark","Copenhagen","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"France","Paris","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Germany","Berlin","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Greece","Athens","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"Spain","Madrid","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-002542-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002542-16/DE/",NA,"United Kingdom","London","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Antibodies","Igs, Standard of care",500
"2020-004571-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004571-41/HU/",NA,"Ukraine","Kyiv (Kiev)","2020-Dec",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Antirheumatic, Standard of care",300
"2020-004571-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004571-41/HU/",NA,"Bulgaria","Sofia","2020-Dec",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Antirheumatic, Standard of care",300
"2020-004571-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004571-41/HU/",NA,"Hungary","Budapest","2020-Dec",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Antirheumatic, Standard of care",300
"2020-004571-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004571-41/HU/",NA,"Poland","Warsaw","2020-Dec",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Antirheumatic, Standard of care",300
"2020-004571-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004571-41/HU/",NA,"Romania","Bucharest","2020-Dec",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Antirheumatic, Standard of care",300
"2020-004571-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004571-41/HU/",NA,"Slovakia","Bratislava","2020-Dec",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Antirheumatic, Standard of care",300
"2020-003403-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003403-33/BE/",NA,"Georgia","Tbilisi","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance","Hormone therapy, Standard of care",300
"2020-003403-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003403-33/BE/",NA,"Russia","Moscow","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance","Hormone therapy, Standard of care",300
"2020-003403-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003403-33/BE/",NA,"Ukraine","Kyiv (Kiev)","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance","Hormone therapy, Standard of care",300
"2020-003403-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003403-33/BE/",NA,"Belgium","Brussels","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance","Hormone therapy, Standard of care",300
"2020-003403-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003403-33/BE/",NA,"Hungary","Budapest","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance","Hormone therapy, Standard of care",300
"2020-003403-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003403-33/BE/",NA,"Poland","Warsaw","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance","Hormone therapy, Standard of care",300
"2020-005366-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005366-34/IE/",NA,"Bulgaria","Sofia","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Fever, Adverse Events, SpO2, Radiographic Findings","Antivirals, Standard of care",220
"2020-005366-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005366-34/IE/",NA,"Ireland","Dublin","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Fever, Adverse Events, SpO2, Radiographic Findings","Antivirals, Standard of care",220
"2020-005366-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005366-34/IE/",NA,"United Kingdom","London","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Fever, Adverse Events, SpO2, Radiographic Findings","Antivirals, Standard of care",220
"2020-005979-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005979-12/GR/",NA,"Turkey","Ankara","2021-Feb",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, SpO2, Respiratory Rate, Radiographic Findings","Other, Standard of care",722
"2020-005979-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005979-12/GR/",NA,"Bulgaria","Sofia","2021-Feb",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, SpO2, Respiratory Rate, Radiographic Findings","Other, Standard of care",722
"2020-005979-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005979-12/GR/",NA,"Greece","Athens","2021-Feb",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, SpO2, Respiratory Rate, Radiographic Findings","Other, Standard of care",722
"2020-005979-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005979-12/GR/",NA,"Romania","Bucharest","2021-Feb",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, SpO2, Respiratory Rate, Radiographic Findings","Other, Standard of care",722
"2020-005979-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005979-12/GR/",NA,"Spain","Madrid","2021-Feb",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, SpO2, Respiratory Rate, Radiographic Findings","Other, Standard of care",722
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Brazil","Brasilia","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Chile","Santiago","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Indonesia","Jakarta","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Malaysia","Kuala Lumpur","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"South Africa","Pretoria","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Belgium","Brussels","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"France","Paris","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Germany","Berlin","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Italy","Rome","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Poland","Warsaw","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Czechia","Prague","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005915-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005915-39/IT/",NA,"Argentina","Buenos Aires","2021-Mar",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Exposed","Mortality, Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",10000
"2020-005315-44","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005315-44/HU/",NA,"Japan","Tokyo","2021-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization","mAb, Standard of care",1700
"2020-005315-44","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005315-44/HU/",NA,"Mexico","Mexico","2021-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization","mAb, Standard of care",1700
"2020-005315-44","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005315-44/HU/",NA,"Russia","Moscow","2021-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization","mAb, Standard of care",1700
"2020-005315-44","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005315-44/HU/",NA,"United States","Washington, Dc","2021-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization","mAb, Standard of care",1700
"2020-005315-44","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005315-44/HU/",NA,"Germany","Berlin","2021-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization","mAb, Standard of care",1700
"2020-005315-44","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005315-44/HU/",NA,"Hungary","Budapest","2021-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization","mAb, Standard of care",1700
"2020-005315-44","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005315-44/HU/",NA,"Italy","Rome","2021-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization","mAb, Standard of care",1700
"2020-005315-44","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005315-44/HU/",NA,"Spain","Madrid","2021-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization","mAb, Standard of care",1700
"2020-005315-44","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005315-44/HU/",NA,"United Kingdom","London","2021-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization","mAb, Standard of care",1700
"2020-005227-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005227-37/NL/",NA,"United States","Washington, Dc","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Labor Absenteeism, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Granulocyte Stimulaiting Factor, IP-10, Platelet Count, Hemoglobin, D-Dimer, ALT, AST, Bilirubin, Glucose, LDH, Urine Sample, Blood Pressure, SpO2, Respiratory Rate","Other, Standard of care",80
"2020-005227-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005227-37/NL/",NA,"Italy","Rome","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Labor Absenteeism, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Granulocyte Stimulaiting Factor, IP-10, Platelet Count, Hemoglobin, D-Dimer, ALT, AST, Bilirubin, Glucose, LDH, Urine Sample, Blood Pressure, SpO2, Respiratory Rate","Other, Standard of care",80
"2020-005227-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005227-37/NL/",NA,"Netherlands","Amsterdam","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Labor Absenteeism, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Granulocyte Stimulaiting Factor, IP-10, Platelet Count, Hemoglobin, D-Dimer, ALT, AST, Bilirubin, Glucose, LDH, Urine Sample, Blood Pressure, SpO2, Respiratory Rate","Other, Standard of care",80
"2020-005227-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005227-37/NL/",NA,"Switzerland","Bern","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Labor Absenteeism, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Granulocyte Stimulaiting Factor, IP-10, Platelet Count, Hemoglobin, D-Dimer, ALT, AST, Bilirubin, Glucose, LDH, Urine Sample, Blood Pressure, SpO2, Respiratory Rate","Other, Standard of care",80
"NCT04663737","https://ClinicalTrials.gov/show/NCT04663737",NA,"United States","Georgia","2020-Dec","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Creatinine Phosphokinase, LDH, SpO2, Radiographic Findings, Quality of Life","Other, Standard of care",20
"NCT04464408","https://ClinicalTrials.gov/show/NCT04464408",NA,"Saudi Arabia","Al Madinah","2020-Jul","2021-Dec","Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"FPV, Standard of care",576
"NCT04464408","https://ClinicalTrials.gov/show/NCT04464408",NA,"Saudi Arabia","Riyadh","2020-Jul","2021-Dec","Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"FPV, Standard of care",576
"NCT04464408","https://ClinicalTrials.gov/show/NCT04464408",NA,"Saudi Arabia","Makkah","2020-Jul","2021-Dec","Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"FPV, Standard of care",576
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Arizona","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Arkansas","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","California","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Colorado","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Connecticut","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","District Of Columbia","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Florida","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Georgia","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Illinois","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Kentucky","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Louisiana","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Massachusetts","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Minnesota","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","New Jersey","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","New York","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","North Carolina","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Ohio","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Oregon","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Pennsylvania","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Rhode Island","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","South Dakota","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","Texas","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04583956","https://ClinicalTrials.gov/show/NCT04583956",NA,"United States","West Virginia","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + mAb",200
"NCT04465604","https://ClinicalTrials.gov/show/NCT04465604",NA,"Saudi Arabia","Riyadh","2020-Jul","2021-Nov","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO","Other",50
"NCT04353180","https://ClinicalTrials.gov/show/NCT04353180",NA,"Egypt","Cairo","2020-Apr","2021-Jun","Not Recruiting","Randomised","Open-Label",5,NA,"ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-1, IL-6, Interferon (Any), Erythrocyte Sedimentation Rate, D-Dimer","Other, Standard of care",100000
"NCT04710303","https://ClinicalTrials.gov/show/NCT04710303",NA,"South Africa","Pretoria","2021-Jan","2022-Apr","Recruiting","Non-Randomised","Open-Label",3,"Healthy","Healthy Unexposed","IgG, IgM or IgA, Antibodies, Blood Pressure, Heart Rate, Respiratory Rate","Vaccine",35
"NCT04732468","https://ClinicalTrials.gov/show/NCT04732468",NA,"United States","California","2021-Feb","2022-Apr","Recruiting","Non-Randomised","Open-Label",4,"Healthy","Healthy Unexposed","IgG, IgM or IgA, Antibodies, CD4, CD8, Blood Pressure, Heart Rate, Respiratory Rate","Vaccine",65
"NCT04765449","https://ClinicalTrials.gov/show/NCT04765449",NA,"United States","Pennsylvania","2021-Feb","2023-Aug","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Radiographic Findings","Other, Standard of care",24
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Alberta","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","LPV/r, Standard of care",2900
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","British Columbia","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","LPV/r, Standard of care",2900
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Manitoba","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","LPV/r, Standard of care",2900
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Newfoundland And Labrador","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","LPV/r, Standard of care",2900
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Ontario","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","LPV/r, Standard of care",2900
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Quebec","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","LPV/r, Standard of care",2900
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Saskatchewan","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","LPV/r, Standard of care",2900
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","California","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","Florida","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","Georgia","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","Idaho","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","Illinois","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","Massachusetts","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","Michigan","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","North Carolina","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","Ohio","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04583592","https://ClinicalTrials.gov/show/NCT04583592",NA,"United States","Texas","2020-Oct","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Fever, Serious Adverse Events, Platelet Count, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, SpO2","Other, Standard of care",300
"NCT04678830","https://ClinicalTrials.gov/show/NCT04678830",NA,"United States","Florida","2020-Dec","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Hospitalization, Other Mild Symptoms","mAb, Standard of care",102
"NCT04678830","https://ClinicalTrials.gov/show/NCT04678830",NA,"United States","Georgia","2020-Dec","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Hospitalization, Other Mild Symptoms","mAb, Standard of care",102
"NCT04375397","https://ClinicalTrials.gov/show/NCT04375397",NA,"United States","California","2020-May","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Other, Standard of care",46
"NCT04375397","https://ClinicalTrials.gov/show/NCT04375397",NA,"United States","District Of Columbia","2020-May","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Other, Standard of care",46
"NCT04375397","https://ClinicalTrials.gov/show/NCT04375397",NA,"United States","Florida","2020-May","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Other, Standard of care",46
"NCT04375397","https://ClinicalTrials.gov/show/NCT04375397",NA,"United States","Massachusetts","2020-May","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Other, Standard of care",46
"NCT04375397","https://ClinicalTrials.gov/show/NCT04375397",NA,"United States","Utah","2020-May","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Other, Standard of care",46
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","California","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Florida","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Georgia","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Illinois","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Louisiana","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Michigan","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Mississippi","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Nebraska","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","New Mexico","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","North Carolina","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","North Dakota","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Pennsylvania","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Texas","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United States","Washington","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Brazil","Distrito Federal","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Brazil","Minas Gerais","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Brazil","Parana","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Brazil","Rio Grande Do Sul","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Brazil","Sao Paulo","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Canada","Ontario","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Chile","Libertador General Bernardo O Higgins","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Chile","Santiago","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Colombia","Antioquia","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Colombia","Atlantico","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Colombia","Cordoba","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Colombia","Bogota","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Colombia","Santander","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Colombia","Valle Del Cauca","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"France","Gironde","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"France","Paris","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"France","Nord","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Israel","Haifa","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Israel","Jerusalem","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"South Korea","Daejeon","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"South Korea","Incheon","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"South Korea","Seoul","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Mexico","Guanajuato","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Mexico","Jalisco","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Mexico","Nuevo Leon","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Philippines","Quezon City","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Poland","Lodz","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Poland","Lublin","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Poland","Warsaw","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Russia","Moscow","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Russia","Moskva","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Russia","Smolensk","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Russia","Tatarstan","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"South Africa","Pretoria","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"South Africa","Gauteng","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"South Africa","Western Cape","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Spain","Barcelona","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Spain","Madrid","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Ukraine","Kyiv (Kiev)","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Ukraine","Kharkiv","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Ukraine","Rivne","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"Ukraine","Volyn","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United Kingdom","City","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04575584","https://ClinicalTrials.gov/show/NCT04575584",NA,"United Kingdom","Manchester","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Adverse Events","Antivirals, Standard of care",1300
"NCT04416919","https://ClinicalTrials.gov/show/NCT04416919",NA,"United States","Oklahoma","2020-Jun","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthcare Workers",NA,"Device",20
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Ancona","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Arezzo","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Bari","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Bergamo","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Bologna","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Catania","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Rome","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Fermo","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Ferrara","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Firenze","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Foggia","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Frosinone","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Genova","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Grosseto","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","La Spezia","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Lecco","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Livorno","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Lucca","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Mantova","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Milano","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Napoli","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Palermo","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Pavia","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Perugia","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Pisa","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Pistoia","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Prato","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Ravenna","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Reggio Emilia","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Rimini","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Roma","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Savona","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Siena","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Sondrio","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Terni","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Treviso","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04716556","https://ClinicalTrials.gov/show/NCT04716556",NA,"Italy","Verona","2021-Jan","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy + Standard of care, Standard of care",474
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"United States","California","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"United States","Florida","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"United States","Massachusetts","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"United States","Texas","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"Brazil","Brasilia","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"Mexico","Jalisco","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"Mexico","Mexico","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"Mexico","Morelos","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"Mexico","Sinaloa","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04511819","https://ClinicalTrials.gov/show/NCT04511819",NA,"Peru","Arequipa","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events","Other, Standard of care",410
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Arizona","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","California","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","District Of Columbia","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Florida","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Georgia","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Illinois","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Massachusetts","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Minnesota","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","New Jersey","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","New York","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","North Carolina","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Ohio","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Pennsylvania","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Rhode Island","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","Texas","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04583969","https://ClinicalTrials.gov/show/NCT04583969",NA,"United States","West Virginia","2020-Oct","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Bilirubin, LDH","Remdesivir, Remdesivir + mAb",200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"United States","New York","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Brazil","Brasilia","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Brazil","Rio De Janeiro","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Alberta","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","British Columbia","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Manitoba","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","New Brunswick","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Ontario","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Quebec","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Saskatchewan","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1200
"NCT04650087","https://ClinicalTrials.gov/show/NCT04650087",NA,"United States","Illinois","2020-Dec","2021-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Resolved Discharged","Mortality, Deep Vein Thrombosis or Pulmonary Embolism","Antithrombotics, Standard of care",5320
"NCT04650087","https://ClinicalTrials.gov/show/NCT04650087",NA,"United States","Pennsylvania","2020-Dec","2021-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Resolved Discharged","Mortality, Deep Vein Thrombosis or Pulmonary Embolism","Antithrombotics, Standard of care",5320
"NCT04619719","https://ClinicalTrials.gov/show/NCT04619719",NA,"United States","Connecticut","2020-Nov","2021-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, Standard of care",600
"NCT04619719","https://ClinicalTrials.gov/show/NCT04619719",NA,"United States","Montana","2020-Nov","2021-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, Standard of care",600
"NCT04619719","https://ClinicalTrials.gov/show/NCT04619719",NA,"United States","New York","2020-Nov","2021-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, Standard of care",600
"NCT04619719","https://ClinicalTrials.gov/show/NCT04619719",NA,"United States","Oregon","2020-Nov","2021-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, Standard of care",600
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"United States","Texas","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Argentina","Buenos Aires","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Brazil","Brasilia","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Colombia","Antioquia","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Colombia","Bogota","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"India","Andhra Pradesh","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"India","Gujarat","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"India","Karnataka","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"India","Maharashtra","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"India","Rajasthan","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"India","Tamil Nadu","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"India","New Delhi","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Mexico","Jalisco","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Mexico","Nuevo Leon","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Mexico","Mexico","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Peru","Lima","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Philippines","Cavite","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Philippines","Iloilo","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Philippines","Makati","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Philippines","Pasay","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Philippines","Quezon City","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Philippines","Quezon","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Ukraine","Chernihiv","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Ukraine","Kyiv (Kiev)","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04672564","https://ClinicalTrials.gov/show/NCT04672564",NA,"Ukraine","Volyn","2020-Dec","2021-Jun","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, ECG, Radiographic Findings","Carrimycin, Standard of care",300
"NCT04551911","https://ClinicalTrials.gov/show/NCT04551911",NA,"United States","Florida","2020-Sep","2021-May","Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear",NA,"Standard of care, Vitamins",160
"NCT04619706","https://ClinicalTrials.gov/show/NCT04619706",NA,"United States","Florida","2020-Nov","2021-Aug","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ECG, SpO2","Palmitoylethanolamide, Standard of care",350
"NCT04619706","https://ClinicalTrials.gov/show/NCT04619706",NA,"United States","Idaho","2020-Nov","2021-Aug","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ECG, SpO2","Palmitoylethanolamide, Standard of care",350
"NCT04619706","https://ClinicalTrials.gov/show/NCT04619706",NA,"United States","Illinois","2020-Nov","2021-Aug","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ECG, SpO2","Palmitoylethanolamide, Standard of care",350
"NCT04619706","https://ClinicalTrials.gov/show/NCT04619706",NA,"United States","Texas","2020-Nov","2021-Aug","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ECG, SpO2","Palmitoylethanolamide, Standard of care",350
"NCT04547127","https://ClinicalTrials.gov/show/NCT04547127",NA,"Spain","Alicante","2020-Sep","2021-Feb","Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Plasma based therapy + Standard of care, Standard of care",200
"NCT04547127","https://ClinicalTrials.gov/show/NCT04547127",NA,"Spain","Barcelona","2020-Sep","2021-Feb","Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Plasma based therapy + Standard of care, Standard of care",200
"NCT04547127","https://ClinicalTrials.gov/show/NCT04547127",NA,"Spain","Madrid","2020-Sep","2021-Feb","Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Plasma based therapy + Standard of care, Standard of care",200
"NCT04547127","https://ClinicalTrials.gov/show/NCT04547127",NA,"Spain","Santa Cruz De Tenerife","2020-Sep","2021-Feb","Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Plasma based therapy + Standard of care, Standard of care",200
"NCT04547127","https://ClinicalTrials.gov/show/NCT04547127",NA,"Spain","Tarragona","2020-Sep","2021-Feb","Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Plasma based therapy + Standard of care, Standard of care",200
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Alessandria","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Rome","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Catania","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Cosenza","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Modena","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Ravenna","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Reggio Calabria","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Rimini","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Varese","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Verona","2020-Mar","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings","TCZ",402
"NCT04732949","https://ClinicalTrials.gov/show/NCT04732949",NA,"United States","Texas","2021-Feb","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Cough, Other Mild Symptoms, Serious Adverse Events, Quality of Life, Anxiety","IFN, Standard of care",610
"NCT04732949","https://ClinicalTrials.gov/show/NCT04732949",NA,"United Kingdom","East Riding Of Yorkshire","2021-Feb","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Cough, Other Mild Symptoms, Serious Adverse Events, Quality of Life, Anxiety","IFN, Standard of care",610
"NCT04732949","https://ClinicalTrials.gov/show/NCT04732949",NA,"United Kingdom","London","2021-Feb","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Cough, Other Mild Symptoms, Serious Adverse Events, Quality of Life, Anxiety","IFN, Standard of care",610
"NCT04732949","https://ClinicalTrials.gov/show/NCT04732949",NA,"United Kingdom","Southampton","2021-Feb","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Cough, Other Mild Symptoms, Serious Adverse Events, Quality of Life, Anxiety","IFN, Standard of care",610
"NCT04732949","https://ClinicalTrials.gov/show/NCT04732949",NA,"United Kingdom","Birmingham","2021-Feb","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Cough, Other Mild Symptoms, Serious Adverse Events, Quality of Life, Anxiety","IFN, Standard of care",610
"NCT04732949","https://ClinicalTrials.gov/show/NCT04732949",NA,"United Kingdom","Bournemouth","2021-Feb","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Cough, Other Mild Symptoms, Serious Adverse Events, Quality of Life, Anxiety","IFN, Standard of care",610
"NCT04732949","https://ClinicalTrials.gov/show/NCT04732949",NA,"United Kingdom","Leicester","2021-Feb","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Cough, Other Mild Symptoms, Serious Adverse Events, Quality of Life, Anxiety","IFN, Standard of care",610
"NCT04732949","https://ClinicalTrials.gov/show/NCT04732949",NA,"United Kingdom","Plymouth","2021-Feb","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Cough, Other Mild Symptoms, Serious Adverse Events, Quality of Life, Anxiety","IFN, Standard of care",610
"NCT04732949","https://ClinicalTrials.gov/show/NCT04732949",NA,"United Kingdom","Swansea","2021-Feb","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Cough, Other Mild Symptoms, Serious Adverse Events, Quality of Life, Anxiety","IFN, Standard of care",610
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Arizona","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","California","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Colorado","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Florida","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Georgia","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Illinois","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Iowa","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Kentucky","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Maine","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Massachusetts","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Michigan","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Minnesota","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Missouri","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","New Jersey","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","New Mexico","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","New York","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","North Carolina","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Ohio","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Oregon","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Pennsylvania","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Texas","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Utah","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04355767","https://ClinicalTrials.gov/show/NCT04355767",NA,"United States","Wisconsin","2020-Apr","2021-Apr","Not Recruiting","Randomised","Double",2,NA,"Outpatient","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",511
"NCT04770740","https://ClinicalTrials.gov/show/NCT04770740",NA,"Netherlands","Gelderland","2021-Feb","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"Standard of care, Vitamins",40
"NCT04336410","https://ClinicalTrials.gov/show/NCT04336410",NA,"United States","Kentucky","2020-Apr","2022-Jan","Not Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Unexposed","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Vaccine",120
"NCT04336410","https://ClinicalTrials.gov/show/NCT04336410",NA,"United States","Missouri","2020-Apr","2022-Jan","Not Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Unexposed","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Vaccine",120
"NCT04336410","https://ClinicalTrials.gov/show/NCT04336410",NA,"United States","Pennsylvania","2020-Apr","2022-Jan","Not Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Unexposed","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Vaccine",120
"NCT04498247","https://ClinicalTrials.gov/show/NCT04498247",NA,"United States","Florida","2020-Aug","2021-Mar","Not Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",260
"NCT04498247","https://ClinicalTrials.gov/show/NCT04498247",NA,"United States","Kansas","2020-Aug","2021-Mar","Not Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",260
"NCT04498247","https://ClinicalTrials.gov/show/NCT04498247",NA,"United States","Kentucky","2020-Aug","2021-Mar","Not Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",260
"NCT04498247","https://ClinicalTrials.gov/show/NCT04498247",NA,"United States","Missouri","2020-Aug","2021-Mar","Not Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",260
"NCT04498247","https://ClinicalTrials.gov/show/NCT04498247",NA,"Austria","Salzburg","2020-Aug","2021-Mar","Not Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",260
"NCT04498247","https://ClinicalTrials.gov/show/NCT04498247",NA,"Austria","Wien","2020-Aug","2021-Mar","Not Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",260
"NCT04498247","https://ClinicalTrials.gov/show/NCT04498247",NA,"Belgium","Brussels","2020-Aug","2021-Mar","Not Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",260
"NCT04498247","https://ClinicalTrials.gov/show/NCT04498247",NA,"Belgium","Antwerp","2020-Aug","2021-Mar","Not Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",260
"NCT04498247","https://ClinicalTrials.gov/show/NCT04498247",NA,"Belgium","Liege","2020-Aug","2021-Mar","Not Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",260
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Arizona","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","California","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","District Of Columbia","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Florida","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Georgia","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Kentucky","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Minnesota","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","New Hampshire","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","New Jersey","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","New York","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","North Carolina","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","Texas","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"Brazil","Minas Gerais","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"Brazil","Rio Grande Do Norte","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"Brazil","Rio Grande Do Sul","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"Brazil","Santa Catarina","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"Brazil","Brasilia","2020-Apr","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","mAb, Standard of care",520
"NCT04668950","https://ClinicalTrials.gov/show/NCT04668950",NA,"United States","Illinois","2020-Dec","2021-Jul","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient",NA,"SSRIs, Standard of care",1100
"NCT04668950","https://ClinicalTrials.gov/show/NCT04668950",NA,"United States","Missouri","2020-Dec","2021-Jul","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient",NA,"SSRIs, Standard of care",1100
"NCT04668950","https://ClinicalTrials.gov/show/NCT04668950",NA,"United States","Utah","2020-Dec","2021-Jul","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient",NA,"SSRIs, Standard of care",1100
"NCT04668950","https://ClinicalTrials.gov/show/NCT04668950",NA,"United States","Washington","2020-Dec","2021-Jul","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient",NA,"SSRIs, Standard of care",1100
"NCT04668950","https://ClinicalTrials.gov/show/NCT04668950",NA,"Canada","Quebec","2020-Dec","2021-Jul","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient",NA,"SSRIs, Standard of care",1100
"NCT04382040","https://ClinicalTrials.gov/show/NCT04382040",NA,"India","Maharashtra","2020-May","2020-Nov","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2","Other, Standard of care",50
"NCT04382040","https://ClinicalTrials.gov/show/NCT04382040",NA,"Israel","Haifa","2020-May","2020-Nov","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2","Other, Standard of care",50
"NCT04382040","https://ClinicalTrials.gov/show/NCT04382040",NA,"Israel","Jerusalem","2020-May","2020-Nov","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2","Other, Standard of care",50
"NCT04555096","https://ClinicalTrials.gov/show/NCT04555096",NA,"United States","Iowa","2020-Sep","2021-Nov","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality","Other, Standard of care",50
"NCT04555096","https://ClinicalTrials.gov/show/NCT04555096",NA,"United States","Missouri","2020-Sep","2021-Nov","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality","Other, Standard of care",50
"NCT04747158","https://ClinicalTrials.gov/show/NCT04747158",NA,"Paraguay","Asuncion","2021-Feb","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Ferritin, D-Dimer, Antibodies","Plasma based therapy",350
"NCT04330638","https://ClinicalTrials.gov/show/NCT04330638",NA,"Belgium","Brussels","2020-Apr","2020-Dec","Not Recruiting","Randomised","Open-Label",6,"Confirmed Or Suspected","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Radiographic Findings, Hypoxia","Anakinra, Anakinra + Siltuximab, Anakinra + TCZ, Siltuximab, Standard of care, TCZ",342
"NCT04330638","https://ClinicalTrials.gov/show/NCT04330638",NA,"Belgium","Antwerp","2020-Apr","2020-Dec","Not Recruiting","Randomised","Open-Label",6,"Confirmed Or Suspected","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Radiographic Findings, Hypoxia","Anakinra, Anakinra + Siltuximab, Anakinra + TCZ, Siltuximab, Standard of care, TCZ",342
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Arizona","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","California","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Colorado","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","District Of Columbia","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Florida","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Georgia","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Indiana","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Kentucky","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Louisiana","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Maryland","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Massachusetts","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Michigan","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Minnesota","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Mississippi","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","New Hampshire","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","New York","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","North Carolina","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Ohio","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Oregon","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Pennsylvania","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Tennessee","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Texas","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Utah","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Virginia","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","Washington","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United States","West Virginia","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"Denmark","Copenhagen","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"India","Tamil Nadu","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"Poland","Warsaw","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"Singapore","Singapore","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"Spain","Barcelona","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"Spain","Madrid","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"Switzerland","Zurich","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04501978","https://ClinicalTrials.gov/show/NCT04501978",NA,"United Kingdom","London","2020-Aug","2022-Jul","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Remdesivir, Remdesivir + Other",10000
"NCT04600895","https://ClinicalTrials.gov/show/NCT04600895",NA,"United States","Florida","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, IgG, IgM or IgA, Distress","FPV, Standard of care",826
"NCT04326920","https://ClinicalTrials.gov/show/NCT04326920",NA,"Belgium","Brussels","2020-Mar","2020-Sep","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, Serious Adverse Events, PaO2-FiO2","Other",80
"NCT04382755","https://ClinicalTrials.gov/show/NCT04382755",NA,"Belgium","Brussels","2020-May","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, PaO2-FiO2, Radiographic Findings, Hypoxia, Distress","Other, Standard of care",81
"NCT04723537","https://ClinicalTrials.gov/show/NCT04723537",NA,"United States","Florida","2021-Jan","2021-Sep","Recruiting","Randomised","Quadruple",5,"Confirmed","Outpatient","Mortality, Hospitalization, Pneumonia or ARDS, Adverse Events","Other, Standard of care",310
"NCT04723537","https://ClinicalTrials.gov/show/NCT04723537",NA,"United States","Michigan","2021-Jan","2021-Sep","Recruiting","Randomised","Quadruple",5,"Confirmed","Outpatient","Mortality, Hospitalization, Pneumonia or ARDS, Adverse Events","Other, Standard of care",310
"NCT04723537","https://ClinicalTrials.gov/show/NCT04723537",NA,"United States","Nevada","2021-Jan","2021-Sep","Recruiting","Randomised","Quadruple",5,"Confirmed","Outpatient","Mortality, Hospitalization, Pneumonia or ARDS, Adverse Events","Other, Standard of care",310
"NCT04723537","https://ClinicalTrials.gov/show/NCT04723537",NA,"United States","Ohio","2021-Jan","2021-Sep","Recruiting","Randomised","Quadruple",5,"Confirmed","Outpatient","Mortality, Hospitalization, Pneumonia or ARDS, Adverse Events","Other, Standard of care",310
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Alabama","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","California","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Colorado","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Connecticut","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Florida","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Illinois","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Kansas","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Massachusetts","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Michigan","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Minnesota","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Mississippi","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Missouri","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","New Jersey","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","New York","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","North Carolina","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Ohio","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Oklahoma","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Oregon","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Pennsylvania","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Tennessee","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Texas","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Washington","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"United States","Wisconsin","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"Spain","Madrid","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04505774","https://ClinicalTrials.gov/show/NCT04505774",NA,"Spain","Salamanca","2020-Aug","2021-Sep","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization","Anticoagulants",2000
"NCT04351724","https://ClinicalTrials.gov/show/NCT04351724",NA,"Austria","Tirol","2020-Apr","2021-Dec","Recruiting","Randomised","Open-Label",12,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Anticoagulants, HCQ, LPV/r, mAb, RAS blockade, Standard of care",500
"NCT04351724","https://ClinicalTrials.gov/show/NCT04351724",NA,"Austria","Vienna","2020-Apr","2021-Dec","Recruiting","Randomised","Open-Label",12,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Anticoagulants, HCQ, LPV/r, mAb, RAS blockade, Standard of care",500
"NCT04411602","https://ClinicalTrials.gov/show/NCT04411602",NA,"United States","Michigan","2020-Jun","2021-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","Mortality, ICU Admission","Plasma based therapy",90
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Alabama","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","California","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Florida","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Illinois","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Kentucky","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Louisiana","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Maryland","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Massachusetts","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Michigan","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Minnesota","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Nebraska","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","New York","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","North Carolina","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Pennsylvania","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United States","Texas","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"Italy","Rome","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"Italy","Padova","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"Italy","Parma","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"Spain","Barcelona","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"Spain","Madrid","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United Kingdom","Birmingham","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United Kingdom","Liverpool","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04431453","https://ClinicalTrials.gov/show/NCT04431453",NA,"United Kingdom","London","2020-Jun","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Bilirubin","Remdesivir",52
"NCT04381936","https://ClinicalTrials.gov/show/NCT04381936",NA,"Indonesia","Jakarta","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",13,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)",NA,40000
"NCT04381936","https://ClinicalTrials.gov/show/NCT04381936",NA,"Nepal","Kathmandu","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",13,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)",NA,40000
"NCT04381936","https://ClinicalTrials.gov/show/NCT04381936",NA,"United Kingdom","London","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",13,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)",NA,40000
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"United States","Alabama","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"United States","California","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"United States","Florida","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"United States","Georgia","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"United States","Illinois","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"United States","Iowa","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"United States","Texas","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"Argentina","Buenos Aires","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"Brazil","Minas Gerais","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"Brazil","Rio Grande Do Sul","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"Brazil","Sao Paulo","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"South Africa","Gauteng","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"South Africa","Kwazulu-Natal","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"South Africa","Western Cape","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"Ukraine","Kyiv (Kiev)","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"Ukraine","Kharkiv","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04590586","https://ClinicalTrials.gov/show/NCT04590586",NA,"Ukraine","Rivne","2020-Oct","2022-Jan","Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","PDE4 + Standard of care, Standard of care",1400
"NCT04456413","https://ClinicalTrials.gov/show/NCT04456413",NA,"United States","New Jersey","2020-Jul","2021-Nov","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Plasma based therapy, Standard of care",306
"NCT04547140","https://ClinicalTrials.gov/show/NCT04547140",NA,"United States","Alabama","2020-Sep","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",100
"NCT04547140","https://ClinicalTrials.gov/show/NCT04547140",NA,"United States","Arizona","2020-Sep","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",100
"NCT04547140","https://ClinicalTrials.gov/show/NCT04547140",NA,"United States","Nebraska","2020-Sep","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",100
"NCT04547140","https://ClinicalTrials.gov/show/NCT04547140",NA,"United States","New York","2020-Sep","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",100
"NCT04547140","https://ClinicalTrials.gov/show/NCT04547140",NA,"United States","Utah","2020-Sep","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",100
"NCT04547140","https://ClinicalTrials.gov/show/NCT04547140",NA,"Brazil","Santa Catarina","2020-Sep","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",100
"NCT04547140","https://ClinicalTrials.gov/show/NCT04547140",NA,"Brazil","Brasilia","2020-Sep","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",100
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"Czechia","Prague","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"Romania","Bucharest","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"Romania","Cluj","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","Barnsley","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","Bolton","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","Bradford","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","Bristol","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","Darlington","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","Dudley","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","London","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","York","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","Salford","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","Sheffield","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04516759","https://ClinicalTrials.gov/show/NCT04516759",NA,"United Kingdom","Walsall","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Other, Standard of care",150
"NCT04771598","https://ClinicalTrials.gov/show/NCT04771598",NA,"Turkey","Tokat","2021-Feb","2021-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Resolved","Outpatient, Resolved Discharged","6-Minute Walking Distance","Respiratory support",52
"NCT04480424","https://ClinicalTrials.gov/show/NCT04480424",NA,"United States","Kentucky","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress","Igs, Standard of care",100
"NCT04480424","https://ClinicalTrials.gov/show/NCT04480424",NA,"United States","Michigan","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress","Igs, Standard of care",100
"NCT04480424","https://ClinicalTrials.gov/show/NCT04480424",NA,"United States","Nebraska","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress","Igs, Standard of care",100
"NCT04480424","https://ClinicalTrials.gov/show/NCT04480424",NA,"United States","New York","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress","Igs, Standard of care",100
"NCT04480424","https://ClinicalTrials.gov/show/NCT04480424",NA,"United States","North Carolina","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress","Igs, Standard of care",100
"NCT04480424","https://ClinicalTrials.gov/show/NCT04480424",NA,"United States","Ohio","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress","Igs, Standard of care",100
"NCT04480424","https://ClinicalTrials.gov/show/NCT04480424",NA,"United States","Pennsylvania","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress","Igs, Standard of care",100
"NCT04480424","https://ClinicalTrials.gov/show/NCT04480424",NA,"United States","Texas","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress","Igs, Standard of care",100
"NCT04480424","https://ClinicalTrials.gov/show/NCT04480424",NA,"United States","Washington","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress","Igs, Standard of care",100
"NCT04570501","https://ClinicalTrials.gov/show/NCT04570501",NA,"United States","California","2020-Sep","2021-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Antihypertensive, Standard of care",160
"NCT04738045","https://ClinicalTrials.gov/show/NCT04738045",NA,"Egypt","Cairo","2021-Feb","2021-Feb","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Adverse Events","Remdesivir, Remdesivir + LPV/r",90
"NCT04393311","https://ClinicalTrials.gov/show/NCT04393311",NA,"United States","California","2020-May","2021-Sep","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",160
"NCT04765371","https://ClinicalTrials.gov/show/NCT04765371",NA,"France","Paris","2021-Feb","2021-Oct","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Adverse Events, Quality of Life","Corticosteroids, Dexamethasone",220
"NCT04542850","https://ClinicalTrials.gov/show/NCT04542850",NA,"Bahrain","Manama","2020-Sep","2021-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Ferritin, IL-6, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, D-Dimer, Myoglobin, Procalcitonin, ALT, AST, Albumin, Bilirubin, Glucose, LDH, Urine Sample, CD4, CD8, Blood Urea Nitrogen, Heart Rate, ECG, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","Nutrition",40
"NCT04652518","https://ClinicalTrials.gov/show/NCT04652518",NA,"United States","California","2020-Dec","2021-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","6-Minute Walking Distance, Quality of Life","Other, Standard of care",168
"NCT04652518","https://ClinicalTrials.gov/show/NCT04652518",NA,"United States","Florida","2020-Dec","2021-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","6-Minute Walking Distance, Quality of Life","Other, Standard of care",168
"NCT04652518","https://ClinicalTrials.gov/show/NCT04652518",NA,"United States","North Carolina","2020-Dec","2021-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","6-Minute Walking Distance, Quality of Life","Other, Standard of care",168
"NCT04652518","https://ClinicalTrials.gov/show/NCT04652518",NA,"United States","Texas","2020-Dec","2021-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","6-Minute Walking Distance, Quality of Life","Other, Standard of care",168
"NCT04652518","https://ClinicalTrials.gov/show/NCT04652518",NA,"Romania","Bucharest","2020-Dec","2021-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","6-Minute Walking Distance, Quality of Life","Other, Standard of care",168
"NCT04652518","https://ClinicalTrials.gov/show/NCT04652518",NA,"Romania","Cluj","2020-Dec","2021-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","6-Minute Walking Distance, Quality of Life","Other, Standard of care",168
"NCT04652518","https://ClinicalTrials.gov/show/NCT04652518",NA,"Romania","Timis","2020-Dec","2021-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","6-Minute Walking Distance, Quality of Life","Other, Standard of care",168
"NCT04498273","https://ClinicalTrials.gov/show/NCT04498273",NA,"United States","Florida","2020-Aug","2021-Sep","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Hospitalization","Anticoagulants, Antihypertensive, Standard of care",7000
"NCT04498273","https://ClinicalTrials.gov/show/NCT04498273",NA,"United States","Illinois","2020-Aug","2021-Sep","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Hospitalization","Anticoagulants, Antihypertensive, Standard of care",7000
"NCT04498273","https://ClinicalTrials.gov/show/NCT04498273",NA,"United States","Massachusetts","2020-Aug","2021-Sep","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Hospitalization","Anticoagulants, Antihypertensive, Standard of care",7000
"NCT04498273","https://ClinicalTrials.gov/show/NCT04498273",NA,"United States","Pennsylvania","2020-Aug","2021-Sep","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Hospitalization","Anticoagulants, Antihypertensive, Standard of care",7000
"NCT04498273","https://ClinicalTrials.gov/show/NCT04498273",NA,"United States","Texas","2020-Aug","2021-Sep","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Hospitalization","Anticoagulants, Antihypertensive, Standard of care",7000
"NCT04498273","https://ClinicalTrials.gov/show/NCT04498273",NA,"United States","Utah","2020-Aug","2021-Sep","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Hospitalization","Anticoagulants, Antihypertensive, Standard of care",7000
"NCT04627584","https://ClinicalTrials.gov/show/NCT04627584",NA,"China","Shanghai","2020-Nov","2021-May","Recruiting","Randomised","Quadruple",3,"Confirmed","Unclear","Viral Load or Clearance","Other, Standard of care",150
"NCT04537949","https://ClinicalTrials.gov/show/NCT04537949",NA,"Germany","Berlin","2020-Sep","2021-Mar","Not Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Unexposed","Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Antibodies","Vaccine",96
"NCT04712110","https://ClinicalTrials.gov/show/NCT04712110",NA,"Japan","Tokyo","2021-Jan","2022-Apr","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",200
"NCT04712110","https://ClinicalTrials.gov/show/NCT04712110",NA,"Japan","Kumamoto","2021-Jan","2022-Apr","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",200
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","California","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, Standard of care",196
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","Florida","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, Standard of care",196
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","Kentucky","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, Standard of care",196
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","Missouri","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, Standard of care",196
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","Texas","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Inhaled solution, Standard of care",196
"CHICTR2100043682","http://www.chictr.org.cn/showproj.aspx?proj=122412",NA,"China","Beijing","2021-Feb","2023-Sep","Not Recruiting","Non-Randomised","Unspecified",2,"Resolved","Resolved Discharged","6-Minute Walking Distance, Quality of Life","Rehabilitation, Standard of care",100
"NCT04771351","https://ClinicalTrials.gov/show/NCT04771351",NA,"United States","Washington, Dc","2021-Feb","2021-Jul","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance","mAb, Standard of care",280
"NCT04345679","https://ClinicalTrials.gov/show/NCT04345679",NA,"Hungary","Budapest","2020-Apr","2021-Jun","Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Other Mild Symptoms, Bilirubin","Plasma based therapy",20
"NCT04757857","https://ClinicalTrials.gov/show/NCT04757857",NA,"Brazil","Bahia","2021-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",1000
"NCT04757857","https://ClinicalTrials.gov/show/NCT04757857",NA,"Brazil","Brasilia","2021-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",1000
"NCT04757857","https://ClinicalTrials.gov/show/NCT04757857",NA,"Brazil","Distrito Federal","2021-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",1000
"NCT04757857","https://ClinicalTrials.gov/show/NCT04757857",NA,"Brazil","Goias","2021-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",1000
"NCT04757857","https://ClinicalTrials.gov/show/NCT04757857",NA,"Brazil","Minas Gerais","2021-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",1000
"NCT04757857","https://ClinicalTrials.gov/show/NCT04757857",NA,"Brazil","Para","2021-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",1000
"NCT04757857","https://ClinicalTrials.gov/show/NCT04757857",NA,"Brazil","Rio Grande Do Sul","2021-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",1000
"NCT04757857","https://ClinicalTrials.gov/show/NCT04757857",NA,"Brazil","Santa Catarina","2021-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",1000
"NCT04770467","https://ClinicalTrials.gov/show/NCT04770467",NA,"China","Hong Kong","2021-Feb","2022-Oct","Not Recruiting","Randomised","Single",4,"Confirmed","Unclear","Serious Adverse Events, Platelet Count, Hemoglobin, Weight, Height or BMI, ALT","mAb, Standard of care",56
"NCT04325633","https://ClinicalTrials.gov/show/NCT04325633",NA,"France","Paris","2020-Mar","2020-Dec","Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","NSAIDs, Standard of care",30
"NCT04771013","https://ClinicalTrials.gov/show/NCT04771013",NA,"Honduras","Tegucigalpa","2021-Feb","2021-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Adverse Events, Radiographic Findings","Other",20
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Berlin","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Bayern","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Brandenburg","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Hessen","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Mecklenburg-Vorpommern","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Niedersachsen","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Nordrhein-Westfalen","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Rheinland-Pfalz","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Sachsen-Anhalt","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Sachsen","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04416048","https://ClinicalTrials.gov/show/NCT04416048",NA,"Germany","Schleswig-Holstein","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants, Standard of care",400
"NCT04541979","https://ClinicalTrials.gov/show/NCT04541979",NA,"Sweden","Stockholm","2020-Sep","2021-May","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, SpO2","Other, Standard of care",100
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","Arizona","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","California","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","District Of Columbia","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","Florida","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","Georgia","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","Illinois","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","Nebraska","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","New Mexico","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","Texas","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United States","Washington","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Brazil","Distrito Federal","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Brazil","Minas Gerais","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Brazil","Parana","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Brazil","Rio Grande Do Sul","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Brazil","Sao Paulo","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Canada","Ontario","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Chile","Santiago","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Colombia","Antioquia","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Colombia","Atlantico","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Colombia","Cordoba","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Colombia","Cundinamarca","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Colombia","Santander","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Colombia","Valle Del Cauca","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"France","Gironde","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"France","Paris","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"France","Nord","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Germany","Baden-Wurttemberg","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Germany","Hessen","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Germany","Berlin","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Israel","Jerusalem","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Philippines","Quezon City","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Russia","Moskva","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Russia","Moscow","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Russia","Smolensk","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"South Africa","Pretoria","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"South Africa","Mpumalanga","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"South Africa","Gauteng","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"South Africa","Kwazulu-Natal","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"South Africa","Limpopo","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"South Africa","Western Cape","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Spain","Madrid","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Spain","Barcelona","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Ukraine","Kyiv (Kiev)","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"Ukraine","Kharkiv","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United Kingdom","Lancashire","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United Kingdom","City","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04575597","https://ClinicalTrials.gov/show/NCT04575597",NA,"United Kingdom","Newcastle Upon Tyne","2020-Oct","2021-Jun","Recruiting","Randomised","Double",6,"Confirmed","Outpatient","Hospitalization, Adverse Events","Antivirals, Standard of care",1450
"NCT04771611","https://ClinicalTrials.gov/show/NCT04771611",NA,"United States","Minnesota","2021-Feb","2022-Dec","Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Serious Adverse Events","Nutrition, Standard of care",150
"NCT04677660","https://ClinicalTrials.gov/show/NCT04677660",NA,"Japan","Tokyo","2020-Dec","2022-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Adverse Events, Antibodies","Standard of care, Vaccine",200
"NCT04677660","https://ClinicalTrials.gov/show/NCT04677660",NA,"Japan","Fukuoka","2020-Dec","2022-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Adverse Events, Antibodies","Standard of care, Vaccine",200
"NCT04349631","https://ClinicalTrials.gov/show/NCT04349631",NA,"United States","Texas","2020-Apr","2020-Nov","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthcare Workers","Hospitalization, Cough, Fever, Dyspnea, Serious or Seconday Infections, C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Albumin, Bilirubin, Glucose, Blood Urea Nitrogen, Blood Gas, Quality of Life, Depression, Renal Outcome (Unspecified)","Stem cells",56
"NCT04708236","https://ClinicalTrials.gov/show/NCT04708236",NA,"United States","California","2021-Jan","2021-May","Recruiting","Randomised","Quadruple",4,"Confirmed","Hospital","Non-invasive Ventilation, Adverse Events, Antibodies","Antirheumatic, Other",18
"NCT04768179","https://ClinicalTrials.gov/show/NCT04768179",NA,"Uganda","Kampala","2021-Feb","2021-Jun","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Viral Load or Clearance, Adverse Events","Antihypertensive + Ivermectin + Standard of care, Standard of care",490
"NCT04681053","https://ClinicalTrials.gov/show/NCT04681053",NA,"Egypt","Cairo","2020-Dec","2021-Apr","Recruiting","Non-Randomised","Open-Label",4,"Confirmed","Unclear","Pneumonia or ARDS","Ivermectin, Standard of care",80
"NCT04695652","https://ClinicalTrials.gov/show/NCT04695652",NA,"Taiwan","Changhua","2021-Jan","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",3700
"NCT04695652","https://ClinicalTrials.gov/show/NCT04695652",NA,"Taiwan","Taipei","2021-Jan","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",3700
"NCT04695652","https://ClinicalTrials.gov/show/NCT04695652",NA,"Taiwan","Taoyuan","2021-Jan","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",3700
"NCT04695652","https://ClinicalTrials.gov/show/NCT04695652",NA,"Vietnam","Hanoi","2021-Jan","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",3700
"NCT04535869","https://ClinicalTrials.gov/show/NCT04535869",NA,"Egypt","Cairo","2020-Sep","2021-Apr","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Pneumonia or ARDS","DAA, Standard of care",50
"NCT04365699","https://ClinicalTrials.gov/show/NCT04365699",NA,"United States","New York","2020-Apr","2021-Jan","Completed","Single-Arm","Open-Label",2,NA,"Hospital","Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Cardiac Outcome (Unspecified)","Other, Standard of care",10
"NCT04762628","https://ClinicalTrials.gov/show/NCT04762628",NA,"Ukraine","Kyiv (Kiev)","2021-Feb","2021-Nov","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose","Nutrition, Standard of care",600
"NCT04762628","https://ClinicalTrials.gov/show/NCT04762628",NA,"Ukraine","Kharkiv","2021-Feb","2021-Nov","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose","Nutrition, Standard of care",600
"NCT04415151","https://ClinicalTrials.gov/show/NCT04415151",NA,"United States","Connecticut","2020-Jun","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events","JAKi, Standard of care",60
"NCT04504734","https://ClinicalTrials.gov/show/NCT04504734",NA,"United States","California","2020-Aug","2021-May","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, Hospitalization, Adverse Events","Antirheumatic, Standard of care",1000
"NCT04504734","https://ClinicalTrials.gov/show/NCT04504734",NA,"United States","Florida","2020-Aug","2021-May","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, Hospitalization, Adverse Events","Antirheumatic, Standard of care",1000
"NCT04504734","https://ClinicalTrials.gov/show/NCT04504734",NA,"United States","Illinois","2020-Aug","2021-May","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, Hospitalization, Adverse Events","Antirheumatic, Standard of care",1000
"NCT04504734","https://ClinicalTrials.gov/show/NCT04504734",NA,"United States","Nevada","2020-Aug","2021-May","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, Hospitalization, Adverse Events","Antirheumatic, Standard of care",1000
"NCT04504734","https://ClinicalTrials.gov/show/NCT04504734",NA,"United States","North Carolina","2020-Aug","2021-May","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, Hospitalization, Adverse Events","Antirheumatic, Standard of care",1000
"NCT04504734","https://ClinicalTrials.gov/show/NCT04504734",NA,"United States","Texas","2020-Aug","2021-May","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, Hospitalization, Adverse Events","Antirheumatic, Standard of care",1000
"NCT04539873","https://ClinicalTrials.gov/show/NCT04539873",NA,"Colombia","Cundinamarca","2020-Sep","2021-Jul","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital",NA,"Colchicine + Standard of care, Standard of care",128
"NCT04494646","https://ClinicalTrials.gov/show/NCT04494646",NA,"United States","Illinois","2020-Jul","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified)","Standard of care, Triterpenes",40
"NCT04494646","https://ClinicalTrials.gov/show/NCT04494646",NA,"United States","New York","2020-Jul","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified)","Standard of care, Triterpenes",40
"NCT04333472","https://ClinicalTrials.gov/show/NCT04333472",NA,"Israel","Jerusalem","2020-Apr","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2","Other, Standard of care",40
"NCT04379518","https://ClinicalTrials.gov/show/NCT04379518",NA,"United States","New York","2020-May","2021-Sep","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Adverse Events","IFN + Rintatolimod",44
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Alabama","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Arizona","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Arkansas","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","California","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Colorado","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","District Of Columbia","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Florida","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Georgia","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Idaho","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Illinois","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Indiana","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Iowa","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Kansas","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Louisiana","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Maryland","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Massachusetts","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Michigan","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Minnesota","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Mississippi","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Missouri","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Nebraska","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Nevada","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","New York","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","North Carolina","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Ohio","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Oklahoma","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Oregon","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Rhode Island","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","South Carolina","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","South Dakota","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Tennessee","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Texas","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Utah","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Virginia","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"United States","Washington","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"Mexico","Queretaro","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"Mexico","Yucatan","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"Mexico","Mexico","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"Mexico","Veracruz","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04611802","https://ClinicalTrials.gov/show/NCT04611802",NA,"Puerto Rico","Puerto Rico","2020-Nov","2021-Mar","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Angiotensins, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30000
"NCT04766931","https://ClinicalTrials.gov/show/NCT04766931",NA,"United States","New Jersey","2021-Feb","2021-Aug","Not Recruiting","Randomised","Quadruple",4,"Confirmed Or Healthy","Healthy Unexposed","Adverse Events, Radiographic Findings","Other",32
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Alabama","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Arizona","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Arkansas","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","California","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Colorado","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Connecticut","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Florida","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Georgia","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Hawaii","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Idaho","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Illinois","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Indiana","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Iowa","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Kansas","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Kentucky","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Louisiana","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Maine","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Maryland","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Massachusetts","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Michigan","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Minnesota","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Mississippi","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Missouri","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Montana","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Nevada","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","New Hampshire","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","New Jersey","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","New Mexico","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","New York","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","North Carolina","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","North Dakota","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Ohio","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Oklahoma","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Oregon","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Pennsylvania","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Rhode Island","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","South Carolina","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Tennessee","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Texas","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Utah","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Vermont","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Virginia","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Washington","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","West Virginia","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"United States","Wisconsin","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"Argentina","Buenos Aires","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"Chile","Santiago","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"Colombia","Bogota","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"France","Paris","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"Peru","Callao","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04516746","https://ClinicalTrials.gov/show/NCT04516746",NA,"Peru","Lima","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",32459
"NCT04527575","https://ClinicalTrials.gov/show/NCT04527575",NA,"Russia","Novosibirsk","2020-Aug","2021-May","Not Recruiting","Randomised","Double",3,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","Standard of care, Vaccine",100
"NCT04767087","https://ClinicalTrials.gov/show/NCT04767087",NA,"Pakistan","Islamabad","2021-Feb","2021-Jun","Recruiting","Randomised","Triple",3,"Suspected","Healthcare Workers",NA,"Other, Standard of care",1000
"NCT04724720","https://ClinicalTrials.gov/show/NCT04724720",NA,"United States","New York","2021-Jan","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Serious Adverse Events, SpO2","Other, Standard of care",84
"NCT04349592","https://ClinicalTrials.gov/show/NCT04349592",NA,"Qatar","Doha","2020-Apr","2020-Aug","Completed","Randomised","Quadruple",4,"Confirmed","Hospital","Viral Load or Clearance","HCQ, HCQ + AZT, Standard of care",456
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"United States","California","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"United States","Louisiana","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"United States","Massachusetts","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"United States","Ohio","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"United States","Washington","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"Brazil","Brasilia","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"Brazil","Santa Catarina","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"Chile","Santiago","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"Mexico","Aguascalientes","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"Mexico","Mexico","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"Puerto Rico","Puerto Rico","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"Spain","Madrid","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04604184","https://ClinicalTrials.gov/show/NCT04604184",NA,"Spain","Alicante","2020-Oct","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Standard of care, Trpc6 inhibitor",130
"NCT04500626","https://ClinicalTrials.gov/show/NCT04500626",NA,"Canada","Ontario","2020-Aug","2022-Aug","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events","Non-invasive respiratory support, Standard of care",234
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Bahia","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Brasilia","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Espirito Santo","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Minas Gerais","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Para","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Pernambuco","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Rio Grande Do Sul","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Santa Catarina","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Brazil","Rio De Janeiro","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04394377","https://ClinicalTrials.gov/show/NCT04394377",NA,"Israel","Jerusalem","2020-May","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, D-Dimer, Troponin","Anticoagulants",600
"NCT04579393","https://ClinicalTrials.gov/show/NCT04579393",NA,"United States","Maryland","2020-Oct","2022-Jan","Recruiting","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, Ferritin, IL-6, Lymphocyte Count, Platelet Count, D-Dimer, Fibrinogen, PaO2-FiO2, SpO2, Renal Outcome (Unspecified)","Standard of care, SYKi + Standard of care",80
"NCT04579393","https://ClinicalTrials.gov/show/NCT04579393",NA,"United States","Virginia","2020-Oct","2022-Jan","Recruiting","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, Ferritin, IL-6, Lymphocyte Count, Platelet Count, D-Dimer, Fibrinogen, PaO2-FiO2, SpO2, Renal Outcome (Unspecified)","Standard of care, SYKi + Standard of care",80
"NCT04358783","https://ClinicalTrials.gov/show/NCT04358783",NA,"Mexico","Nuevo Leon","2020-Apr","2021-May","Not Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Viral Load or Clearance, Anti SARS-COV-2 Titers","Plasma based therapy, Standard of care",30
"NCT04355962","https://ClinicalTrials.gov/show/NCT04355962",NA,"Switzerland","Bern","2020-Apr","2022-Mar","Recruiting","Randomised","Double",2,NA,"ICU","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, MCP-1, Procalcitonin, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anesthetic, Standard of care",64
"NCT04355962","https://ClinicalTrials.gov/show/NCT04355962",NA,"Switzerland","Sankt Gallen","2020-Apr","2022-Mar","Recruiting","Randomised","Double",2,NA,"ICU","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, MCP-1, Procalcitonin, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anesthetic, Standard of care",64
"NCT04355962","https://ClinicalTrials.gov/show/NCT04355962",NA,"Switzerland","Zurich","2020-Apr","2022-Mar","Recruiting","Randomised","Double",2,NA,"ICU","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, MCP-1, Procalcitonin, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anesthetic, Standard of care",64
"NCT04384445","https://ClinicalTrials.gov/show/NCT04384445",NA,"United States","Florida","2020-May","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, D-Dimer, Radiographic Findings","Other, Standard of care",20
"NCT04452435","https://ClinicalTrials.gov/show/NCT04452435",NA,"India","Gujarat","2020-Jun","2020-Oct","Completed","Randomised","Triple",2,"Confirmed","Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any)","Other, Standard of care",106
"NCT04452435","https://ClinicalTrials.gov/show/NCT04452435",NA,"India","Maharashtra","2020-Jun","2020-Oct","Completed","Randomised","Triple",2,"Confirmed","Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any)","Other, Standard of care",106
"NCT04452435","https://ClinicalTrials.gov/show/NCT04452435",NA,"United Kingdom","London","2020-Jun","2020-Oct","Completed","Randomised","Triple",2,"Confirmed","Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any)","Other, Standard of care",106
"NCT04623671","https://ClinicalTrials.gov/show/NCT04623671",NA,"United States","California","2020-Nov","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Cardiosphere-Derived Cells, Standard of care",60
"NCT04623671","https://ClinicalTrials.gov/show/NCT04623671",NA,"United States","Michigan","2020-Nov","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Cardiosphere-Derived Cells, Standard of care",60
"NCT04623671","https://ClinicalTrials.gov/show/NCT04623671",NA,"United States","Texas","2020-Nov","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Cardiosphere-Derived Cells, Standard of care",60
"NCT04600141","https://ClinicalTrials.gov/show/NCT04600141",NA,"Brazil","Minas Gerais","2020-Oct","2021-Oct","Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","Anticoagulants, Anticoagulants + TCZ",308
"NCT04600141","https://ClinicalTrials.gov/show/NCT04600141",NA,"Brazil","Sergipe","2020-Oct","2021-Oct","Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","Anticoagulants, Anticoagulants + TCZ",308
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Arizona","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","California","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Colorado","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","District Of Columbia","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Florida","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Georgia","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Illinois","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Iowa","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Louisiana","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Maryland","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Michigan","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Mississippi","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Nevada","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","New Jersey","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","New Mexico","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","New York","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","North Carolina","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Ohio","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Pennsylvania","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Rhode Island","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","South Carolina","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","South Dakota","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Tennessee","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Texas","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Virginia","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Washington","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"United States","Wisconsin","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"Chile","Santiago","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"Mexico","Nuevo Leon","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"Mexico","Yucatan","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"Mexico","Mexico","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"Mexico","Durango","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"Mexico","Veracruz","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04425629","https://ClinicalTrials.gov/show/NCT04425629",NA,"Romania","Bucharest","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAb, Standard of care",6420
"NCT04495101","https://ClinicalTrials.gov/show/NCT04495101",NA,"Spain","Madrid","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress","Other, Standard of care",100
"NCT04495101","https://ClinicalTrials.gov/show/NCT04495101",NA,"Spain","Barcelona","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress","Other, Standard of care",100
"NCT04495101","https://ClinicalTrials.gov/show/NCT04495101",NA,"Spain","Asturias","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress","Other, Standard of care",100
"NCT04533347","https://ClinicalTrials.gov/show/NCT04533347",NA,"United States","Texas","2020-Aug","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Hospitalization, Labor Absenteeism","Antimalarial, Standard of care",275
"NCT04456153","https://ClinicalTrials.gov/show/NCT04456153",NA,"United States","Texas","2020-Jul","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance","Antibiotics, Standard of care",61
"NCT04483635","https://ClinicalTrials.gov/show/NCT04483635",NA,"Canada","Quebec","2020-Jul","2021-Sep","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Exposed, Healthcare Workers","Labor Absenteeism, IgG, IgM or IgA","Standard of care, Vitamins",2414
"NCT04591717","https://ClinicalTrials.gov/show/NCT04591717",NA,"United States","California","2020-Oct","2021-Nov","Recruiting","Non-Randomised","Open-Label",3,"Healthy","Healthy Unexposed","Fever, IgG, IgM or IgA, Antibodies, CD4, CD8, Respiratory Rate","Vaccine",60
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Arizona","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","California","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Florida","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Kentucky","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Maryland","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Michigan","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Missouri","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Nevada","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Pennsylvania","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Texas","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04642638","https://ClinicalTrials.gov/show/NCT04642638",NA,"United States","Utah","2020-Nov","2022-Sep","Not Recruiting","Randomised","Quadruple",6,"Healthy","Healthy Exposed","Mortality, Serious Adverse Events, Interferon (Any), Antibodies","Standard of care, Vaccine",401
"NCT04701658","https://ClinicalTrials.gov/show/NCT04701658",NA,"United States","New Mexico","2021-Jan","2021-Jun","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Monoclonal antibody, Standard of care",3000
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Arizona","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","California","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Colorado","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Connecticut","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Florida","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Georgia","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Illinois","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Louisiana","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Maryland","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Massachusetts","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Michigan","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Mississippi","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Missouri","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Nebraska","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Nevada","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","New Mexico","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","New York","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","North Carolina","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Ohio","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Oklahoma","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Oregon","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","South Dakota","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Tennessee","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Texas","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Utah","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Virginia","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Washington","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United States","Wisconsin","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"Denmark","Copenhagen","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"Spain","Madrid","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"Spain","Barcelona","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04501952","https://ClinicalTrials.gov/show/NCT04501952",NA,"United Kingdom","London","2020-Aug","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, Weight, Height or BMI","Remdesivir, Standard of care",1264
"NCT04425538","https://ClinicalTrials.gov/show/NCT04425538",NA,"United States","Massachusetts","2020-Jun","2021-Jan","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections","mAB",17
"NCT04655625","https://ClinicalTrials.gov/show/NCT04655625",NA,"Japan","Chiba","2020-Dec","2021-May","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",500
"NCT04655625","https://ClinicalTrials.gov/show/NCT04655625",NA,"Japan","Osaka","2020-Dec","2021-May","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",500
"NCT04655625","https://ClinicalTrials.gov/show/NCT04655625",NA,"Japan","Tokyo","2020-Dec","2021-May","Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",500
"NCT04760730","https://ClinicalTrials.gov/show/NCT04760730",NA,"United States","Washington","2021-Feb","2021-May","Not Recruiting","Randomised","Single",2,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","Vaccine",100
"NCT04412291","https://ClinicalTrials.gov/show/NCT04412291",NA,"Sweden","Stockholm","2020-Jun","2021-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Respiratory Rate","Anakinra + Non-invasive respiratory support + Anticoagulants + Antibiotics + Other, Non-invasive respiratory support + Anticoagulants + Antibiotics + Other, TCZ + Non-invasive respiratory support + Anticoagulants + Antibiotics + Other",120
"NCT04756128","https://ClinicalTrials.gov/show/NCT04756128",NA,"United States","Minnesota","2021-Feb","2021-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Fever, Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, D-Dimer, Troponin, Procalcitonin, ALT, AST, Albumin, Bilirubin","Colchicine, Colchicine + Opiate antagonists, Opiate antagonists, Standard of care",164
"NCT04377789","https://ClinicalTrials.gov/show/NCT04377789",NA,"Turkey","Istanbul","2020-May","2020-Jul","Completed","Randomised","Open-Label",3,"Healthy","Healthy Unexposed","Mortality","Alternative therapy, Standard of care",447
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Arizona","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","California","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Florida","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Georgia","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Illinois","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Indiana","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Massachusetts","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Michigan","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Nevada","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","New York","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","North Carolina","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Oklahoma","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Oregon","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Pennsylvania","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United States","Washington","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Argentina","Ciudad De Buenos Aires","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Argentina","Buenos Aires","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Argentina","Rio Negro","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Argentina","Cordoba","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Brazil","Minas Gerais","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Brazil","Parana","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Brazil","Para","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Brazil","Rio Grande Do Norte","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Brazil","Brasilia","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Brazil","Sao Paulo","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Germany","Bayern","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Germany","Schleswig-Holstein","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Germany","Berlin","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"India","Delhi","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"India","Gujarat","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"India","Haryana","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"India","Maharashtra","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"India","West Bengal","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Italy","Chieti","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Italy","Roma","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Italy","Milano","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Italy","Prato","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Japan","Kanagawa","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Japan","Tokyo","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"South Korea","Gyeonggi","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"South Korea","Seoul","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Mexico","Mexico","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Mexico","Yucatan","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Mexico","Nuevo Leon","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Puerto Rico","Puerto Rico","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Russia","Moscow","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Spain","Alava","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Spain","Madrid","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"Spain","Valencia","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United Kingdom","Cornwall","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United Kingdom","Barnet","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04421027","https://ClinicalTrials.gov/show/NCT04421027",NA,"United Kingdom","London","2020-Jun","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate","JAKi, Standard of care",1400
"NCT04456439","https://ClinicalTrials.gov/show/NCT04456439",NA,"United States","New York","2020-Jul",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Hospital",NA,"Stem cells + Corticosteroids + Other",NA
"NCT04760561","https://ClinicalTrials.gov/show/NCT04760561",NA,"Egypt","Cairo","2021-Feb","2021-Mar","Not Recruiting","Randomised","Triple",2,"Confirmed","ICU","Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Patient Positioning, Blood pH","Respiratory support, Standard of care",82
"NCT04473898","https://ClinicalTrials.gov/show/NCT04473898",NA,"Turkey","Konya","2020-Jul","2020-Oct","Completed","Randomised","Single",3,"Confirmed","Hospital","Other Mild Symptoms, Quality of Life, Depression, Anxiety","Education, Exercise, Respiratory support",35
"NCT04703608","https://ClinicalTrials.gov/show/NCT04703608",NA,"Gambia","Banjul","2021-Jan","2022-Mar","Recruiting","Randomised","Single",5,"Confirmed Or Suspected","Outpatient, Hospital","Mortality, Hospitalization, Hospital Discharge, Pneumonia or ARDS, C-Reactive Protein, D-Dimer, IgG, IgM or IgA","Antihypertensive, Ivermectin, Standard of care",1200
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Ankara","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Adana","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Antalya","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Bursa","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Gaziantep","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Istanbul","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Izmir","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Kayseri","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Kocaeli","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Malatya","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04582344","https://ClinicalTrials.gov/show/NCT04582344",NA,"Turkey","Trabzon","2020-Oct","2021-Feb","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",13000
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","California","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Florida","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Georgia","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Illinois","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Louisiana","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Michigan","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Missouri","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Montana","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","New Jersey","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","New York","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","North Carolina","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04380961","https://ClinicalTrials.gov/show/NCT04380961",NA,"United States","Texas","2020-May","2021-Sep","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin","mAb, Standard of care",270
"NCT04414631","https://ClinicalTrials.gov/show/NCT04414631",NA,"Brazil","Brasilia","2020-Jun","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Non-invasive Ventilation, PaO2-FiO2","Other, Standard of care",120
"NCT04414631","https://ClinicalTrials.gov/show/NCT04414631",NA,"Mexico","Nuevo Leon","2020-Jun","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Non-invasive Ventilation, PaO2-FiO2","Other, Standard of care",120
"NCT04414631","https://ClinicalTrials.gov/show/NCT04414631",NA,"Switzerland","Bern","2020-Jun","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Non-invasive Ventilation, PaO2-FiO2","Other, Standard of care",120
"NCT04472585","https://ClinicalTrials.gov/show/NCT04472585",NA,"Pakistan","Islamabad","2020-Jul","2021-Aug","Recruiting","Randomised","Quadruple",5,"Confirmed","Unclear",NA,"Ivermectin, Ivermectin + Alternative therapy, Ivermectin + Zinc, Standard of care",180
"NCT04472585","https://ClinicalTrials.gov/show/NCT04472585",NA,"Pakistan","Punjab","2020-Jul","2021-Aug","Recruiting","Randomised","Quadruple",5,"Confirmed","Unclear",NA,"Ivermectin, Ivermectin + Alternative therapy, Ivermectin + Zinc, Standard of care",180
"NCT04583410","https://ClinicalTrials.gov/show/NCT04583410",NA,"France","Paris","2020-Oct","2021-Dec","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Healthcare Workers","Other Mild Symptoms, Weight, Height or BMI, Urine Sample, Depression, Anxiety","Nicotine, Standard of care",1633
"NCT04550338","https://ClinicalTrials.gov/show/NCT04550338",NA,"United Kingdom","Birmingham","2020-Sep","2022-Dec","Not Recruiting","Randomised","Quadruple",2,"Suspected","Outpatient",NA,"Other, Standard of care",100
"NCT04542434","https://ClinicalTrials.gov/show/NCT04542434",NA,"United States","New York","2020-Sep","2021-Oct","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Fever, Treatment-emergent Adverse Events, Blood Pressure, Heart Rate, ECG","Other, Standard of care",148
"NCT04529525","https://ClinicalTrials.gov/show/NCT04529525",NA,"Argentina","Corrientes","2020-Aug","2021-Feb","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Renal Outcome (Unspecified)","Ivermectin, Standard of care",500
"NCT04655586","https://ClinicalTrials.gov/show/NCT04655586",NA,"United States","Colorado","2020-Dec","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, C-Reactive Protein, IL-6, D-Dimer, Coagulation Test","Anticoagulants, Other",100
"NCT04655586","https://ClinicalTrials.gov/show/NCT04655586",NA,"United States","Florida","2020-Dec","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, C-Reactive Protein, IL-6, D-Dimer, Coagulation Test","Anticoagulants, Other",100
"NCT04655586","https://ClinicalTrials.gov/show/NCT04655586",NA,"United States","Louisiana","2020-Dec","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, C-Reactive Protein, IL-6, D-Dimer, Coagulation Test","Anticoagulants, Other",100
"NCT04655586","https://ClinicalTrials.gov/show/NCT04655586",NA,"United States","Washington","2020-Dec","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, C-Reactive Protein, IL-6, D-Dimer, Coagulation Test","Anticoagulants, Other",100
"NCT04338828","https://ClinicalTrials.gov/show/NCT04338828",NA,"United States","Massachusetts","2020-Apr","2021-Apr","Not Recruiting","Randomised","Triple",2,"Suspected","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events",NA,47
"NCT04381377","https://ClinicalTrials.gov/show/NCT04381377",NA,"Russia","Moscow","2020-May","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Immunomodulators, Standard of care",394
"NCT04381377","https://ClinicalTrials.gov/show/NCT04381377",NA,"Russia","Novgorod","2020-May","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Immunomodulators, Standard of care",394
"NCT04381377","https://ClinicalTrials.gov/show/NCT04381377",NA,"Russia","Orenburg","2020-May","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Immunomodulators, Standard of care",394
"NCT04381377","https://ClinicalTrials.gov/show/NCT04381377",NA,"Russia","Vladimir","2020-May","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Immunomodulators, Standard of care",394
"NCT04381377","https://ClinicalTrials.gov/show/NCT04381377",NA,"Slovakia","Bratislava","2020-May","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Immunomodulators, Standard of care",394
"NCT04342728","https://ClinicalTrials.gov/show/NCT04342728",NA,"United States","Florida","2020-Apr","2020-Dec","Completed","Single-Arm","Open-Label",4,"Confirmed","Outpatient","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms","Standard of care, Vitamins, Vitamins + Zinc, Zinc",214
"NCT04342728","https://ClinicalTrials.gov/show/NCT04342728",NA,"United States","Ohio","2020-Apr","2020-Dec","Completed","Single-Arm","Open-Label",4,"Confirmed","Outpatient","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms","Standard of care, Vitamins, Vitamins + Zinc, Zinc",214
"NCT04755972","https://ClinicalTrials.gov/show/NCT04755972",NA,"Croatia","Zagreb","2021-Feb","2021-Jul","Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, Pneumonia or ARDS","Other, Standard of care",40
"NCT04373733","https://ClinicalTrials.gov/show/NCT04373733",NA,"United Kingdom","Westminster","2020-May","2021-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital","ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2, Respiratory Rate","FPV, HCQ + AZT + Zinc, Standard of care",500
"NCT04373733","https://ClinicalTrials.gov/show/NCT04373733",NA,"United Kingdom","London","2020-May","2021-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital","ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2, Respiratory Rate","FPV, HCQ + AZT + Zinc, Standard of care",500
"NCT04540419","https://ClinicalTrials.gov/show/NCT04540419",NA,"Russia","Moscow","2020-Sep","2021-May","Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Mortality, Hospitalization, Serious Adverse Events, Platelet Count, Hemoglobin, Erythrocyte Sedimentation Rate, Fibrinogen, Glucose, IgG, IgM or IgA, Antibodies, Blood Pressure, Heart Rate, ECG, Respiratory Rate, Blood pH","Standard of care, Vaccine",500
"NCT04419025","https://ClinicalTrials.gov/show/NCT04419025",NA,"United States","Massachusetts","2020-Jun","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient, Hospital","Hospitalization, Invasive Mechanical Ventilation or ECMO, Respiratory Rate","Other, Standard of care",200
"NCT04338074","https://ClinicalTrials.gov/show/NCT04338074",NA,"United States","Alabama","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Viral Load or Clearance, Treatment-emergent Adverse Events",NA,100
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Arkansas","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","California","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","District Of Columbia","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Illinois","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Iowa","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Kansas","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Kentucky","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Louisiana","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Maryland","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Massachusetts","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Michigan","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Mississippi","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Missouri","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","New Jersey","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","New York","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","North Carolina","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Oregon","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","South Dakota","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Texas","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Utah","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Virginia","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Washington","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","West Virginia","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04593940","https://ClinicalTrials.gov/show/NCT04593940",NA,"United States","Wisconsin","2020-Oct","2021-Aug","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir + Costimulation blocker, Remdesivir + mAb, Remdesivir + Other",2160
"NCT04754113","https://ClinicalTrials.gov/show/NCT04754113",NA,"China","Jiangsu","2021-Feb","2021-Feb","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU",NA,"Positioning",10
"NCT04750317","https://ClinicalTrials.gov/show/NCT04750317",NA,"Russia","Moscow","2021-Feb","2020-Aug","Completed","Non-Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","JAKi, Standard of care",414
"NCT04638634","https://ClinicalTrials.gov/show/NCT04638634",NA,"Australia","Canberra","2020-Nov","2021-May","Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, Serious Adverse Events, IgG, IgM or IgA","Igs",24
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","Colorado","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","District Of Columbia","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","Georgia","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","Maryland","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","Massachusetts","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","Minnesota","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","Missouri","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","North Carolina","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","Ohio","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","Texas","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United States","Virginia","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"Denmark","Copenhagen","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"Greece","Athens","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"Japan","Tokyo","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"Nigeria","Niger","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"Spain","Barcelona","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04546581","https://ClinicalTrials.gov/show/NCT04546581",NA,"United Kingdom","London","2020-Sep","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Igs + Standard of care, Standard of care",593
"NCT04312009","https://ClinicalTrials.gov/show/NCT04312009",NA,"United States","Florida","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","ARBs",200
"NCT04312009","https://ClinicalTrials.gov/show/NCT04312009",NA,"United States","Georgia","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","ARBs",200
"NCT04312009","https://ClinicalTrials.gov/show/NCT04312009",NA,"United States","Michigan","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","ARBs",200
"NCT04312009","https://ClinicalTrials.gov/show/NCT04312009",NA,"United States","Minnesota","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","ARBs",200
"NCT04312009","https://ClinicalTrials.gov/show/NCT04312009",NA,"United States","Mississippi","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","ARBs",200
"NCT04312009","https://ClinicalTrials.gov/show/NCT04312009",NA,"United States","New Jersey","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","ARBs",200
"NCT04312009","https://ClinicalTrials.gov/show/NCT04312009",NA,"United States","Ohio","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","ARBs",200
"NCT04311177","https://ClinicalTrials.gov/show/NCT04311177",NA,"United States","Minnesota","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",2,"Confirmed","Outpatient","Visits or Returns to Emergency Department","ARBs, Standard of care",580
"NCT04748783","https://ClinicalTrials.gov/show/NCT04748783",NA,"United States","North Carolina","2021-Feb","2022-Mar","Not Recruiting","Randomised","Triple",5,"Confirmed","Outpatient",NA,"Hygiene, Standard of care",180
"NCT04366908","https://ClinicalTrials.gov/show/NCT04366908",NA,"Spain","Cordoba","2020-Apr","2021-Jun","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Dyspnea, Adverse Events","Standard of care, Vitamins",1008
"NCT04322396","https://ClinicalTrials.gov/show/NCT04322396",NA,"Denmark","Copenhagen","2020-Mar","2021-Feb","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Blood Gas, Blood pH","HCQ + AZT, Standard of care",117
"NCT04680949","https://ClinicalTrials.gov/show/NCT04680949",NA,"Greece","Athens","2020-Dec","2021-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer","Anakinra, Standard of care",600
"NCT04680949","https://ClinicalTrials.gov/show/NCT04680949",NA,"Italy","Brescia","2020-Dec","2021-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer","Anakinra, Standard of care",600
"NCT04680949","https://ClinicalTrials.gov/show/NCT04680949",NA,"Italy","Genova","2020-Dec","2021-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer","Anakinra, Standard of care",600
"NCT04680949","https://ClinicalTrials.gov/show/NCT04680949",NA,"Italy","Milano","2020-Dec","2021-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer","Anakinra, Standard of care",600
"NCT04680949","https://ClinicalTrials.gov/show/NCT04680949",NA,"Italy","Rome","2020-Dec","2021-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer","Anakinra, Standard of care",600
"NCT04680949","https://ClinicalTrials.gov/show/NCT04680949",NA,"Italy","Roma","2020-Dec","2021-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer","Anakinra, Standard of care",600
"NCT04680949","https://ClinicalTrials.gov/show/NCT04680949",NA,"Italy","Varese","2020-Dec","2021-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer","Anakinra, Standard of care",600
"NCT04603924","https://ClinicalTrials.gov/show/NCT04603924",NA,"United States","Alabama","2020-Oct","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Treatment-emergent Adverse Events","Other, Standard of care",436
"NCT04603924","https://ClinicalTrials.gov/show/NCT04603924",NA,"United States","Florida","2020-Oct","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Treatment-emergent Adverse Events","Other, Standard of care",436
"NCT04603924","https://ClinicalTrials.gov/show/NCT04603924",NA,"United States","Texas","2020-Oct","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Treatment-emergent Adverse Events","Other, Standard of care",436
"NCT04521309","https://ClinicalTrials.gov/show/NCT04521309",NA,"Pakistan","Sind","2020-Aug","2021-Jan","Completed","Randomised","Single",5,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Fever, Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, LDH, Antibodies, Radiographic Findings, Bicarbonates","Igs, Standard of care",50
"NCT04751617","https://ClinicalTrials.gov/show/NCT04751617",NA,"Poland","Warsaw","2021-Feb","2021-Jan","Recruiting","Single-Arm","Open-Label",1,"Resolved","Resolved Discharged","C-Reactive Protein, D-Dimer, Weight, Height or BMI, Quality of Life","Respiratory support",60
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Arizona","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","California","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","District Of Columbia","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Georgia","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Illinois","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Iowa","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Massachusetts","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","New Jersey","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Texas","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04382586","https://ClinicalTrials.gov/show/NCT04382586",NA,"United States","Wisconsin","2020-May","2021-Feb","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",93
"NCT04751604","https://ClinicalTrials.gov/show/NCT04751604",NA,"Germany","Schleswig-Holstein","2021-Feb","2021-Sep","Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, ICU Admission, Visits or Returns to Emergency Department, Other Mild Symptoms","Nutrition, Standard of care",840
"NCT04363827","https://ClinicalTrials.gov/show/NCT04363827",NA,"Italy","Rome","2020-Apr","2021-Jun","Not Recruiting","Randomised","Open-Label",4,NA,"Healthy Exposed, Outpatient","Serious Adverse Events, Quality of Life","HCQ, Standard of care",2300
"NCT04540393","https://ClinicalTrials.gov/show/NCT04540393",NA,"Russia","Moscow","2020-Sep","2021-May","Suspended","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed","Antibodies","Vaccine",100
"NCT04449588","https://ClinicalTrials.gov/show/NCT04449588",NA,"Bangladesh","Dhaka","2020-Jun","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, PaO2-FiO2, SpO2","Other, Standard of care",368
"NCT04449588","https://ClinicalTrials.gov/show/NCT04449588",NA,"China","Chongqing","2020-Jun","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, PaO2-FiO2, SpO2","Other, Standard of care",368
"NCT04449588","https://ClinicalTrials.gov/show/NCT04449588",NA,"India","New Delhi","2020-Jun","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, PaO2-FiO2, SpO2","Other, Standard of care",368
"NCT04449588","https://ClinicalTrials.gov/show/NCT04449588",NA,"Indonesia","Jakarta","2020-Jun","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, PaO2-FiO2, SpO2","Other, Standard of care",368
"NCT04449588","https://ClinicalTrials.gov/show/NCT04449588",NA,"Spain","Madrid","2020-Jun","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, PaO2-FiO2, SpO2","Other, Standard of care",368
"NCT04357808","https://ClinicalTrials.gov/show/NCT04357808",NA,"Spain","Madrid","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Sarilumab, Standard of care",30
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Florida","2020-Mar","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count, D-Dimer","Immunomodulators, Standard of care",243
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Maryland","2020-Mar","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count, D-Dimer","Immunomodulators, Standard of care",243
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","New Jersey","2020-Mar","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count, D-Dimer","Immunomodulators, Standard of care",243
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Ohio","2020-Mar","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count, D-Dimer","Immunomodulators, Standard of care",243
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Texas","2020-Mar","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count, D-Dimer","Immunomodulators, Standard of care",243
"NCT04621461","https://ClinicalTrials.gov/show/NCT04621461",NA,"United States","New York","2020-Nov","2021-Feb","Completed","Single-Arm","Double",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department","Standard of care, Zinc",3
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","California","2020-May","2021-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",300
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","Florida","2020-May","2021-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",300
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","Georgia","2020-May","2021-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",300
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","Louisiana","2020-May","2021-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",300
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","Maryland","2020-May","2021-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",300
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","Massachusetts","2020-May","2021-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",300
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","Ohio","2020-May","2021-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",300
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","Pennsylvania","2020-May","2021-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",300
"NCT04391309","https://ClinicalTrials.gov/show/NCT04391309",NA,"United States","Washington","2020-May","2021-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",300
"NCT04750278","https://ClinicalTrials.gov/show/NCT04750278",NA,"Taiwan","Taipei","2021-Feb","2022-Apr","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Other, Standard of care",403
"NCT04652765","https://ClinicalTrials.gov/show/NCT04652765",NA,"United States","Maryland","2020-Dec","2023-Jan","Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, Hospitalization, Serious Adverse Events","Standard of care, Standard of care + Other, Standard of care + Other + Other",60
"NCT04331600","https://ClinicalTrials.gov/show/NCT04331600",NA,"Poland","Warsaw","2020-Apr","2020-Dec","Completed","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Serious or Seconday Infections","HCQ, Standard of care",16
"CHICTR2000039715","http://www.chictr.org.cn/showproj.aspx?proj=63754",NA,"China","Jiangsu","2020-Nov","2021-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthy Unexposed","Serious Adverse Events, Anti SARS-COV-2 Titers, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",720
"NCT04372602","https://ClinicalTrials.gov/show/NCT04372602",NA,"United States","Missouri","2020-May","2021-Nov","Recruiting","Single-Arm","Triple",1,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified)","Other",28
"NCT04747821","https://ClinicalTrials.gov/show/NCT04747821",NA,"Brazil","Brasilia","2021-Feb","2021-May","Recruiting","Randomised","Open-Label",4,"Healthy","Healthy Unexposed","Mortality, Hospitalization, Adverse Events, Antibodies","Vaccine",30000
"NCT04432324","https://ClinicalTrials.gov/show/NCT04432324",NA,"Spain","Madrid","2020-Jun","2021-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","Igs",100
"NCT04432324","https://ClinicalTrials.gov/show/NCT04432324",NA,"Spain","Barcelona","2020-Jun","2021-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","Igs",100
"NCT04333355","https://ClinicalTrials.gov/show/NCT04333355",NA,"Mexico","Nuevo Leon","2020-Apr","2020-Aug","Status Unclear","Single-Arm","Open-Label",1,"Confirmed","Hospital","Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma based therapy",12
"NCT04742946","https://ClinicalTrials.gov/show/NCT04742946",NA,"Spain","Melilla","2021-Feb","2021-May","Not Recruiting","Randomised","Single",2,"Confirmed","Resolved Discharged","Quality of Life","Other, Standard of care",237
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United States","Arkansas","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United States","California","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United States","Florida","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United States","Illinois","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United States","Minnesota","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United States","Nevada","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United States","New Jersey","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United States","New York","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United States","Texas","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United Kingdom","London","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04504032","https://ClinicalTrials.gov/show/NCT04504032",NA,"United Kingdom","City","2020-Aug","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Hospitalization, Serious Adverse Events","Anticoagulants, Standard of care",600
"NCT04641195","https://ClinicalTrials.gov/show/NCT04641195",NA,"India","Maharashtra","2020-Nov","2021-Nov","Not Recruiting","Randomised","Quadruple",4,"Confirmed","Hospital","Mortality, IL-6, IgG, IgM or IgA","Standard of care, Vitamins, Vitamins + Zinc, Zinc",700
"NCT04743011","https://ClinicalTrials.gov/show/NCT04743011",NA,"Brazil","Brasilia","2021-Feb","2021-Jul","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, White Blood Cell Count, Blood Gas, Renal Outcome (Unspecified)","Anticoagulants, Standard of care",50
"NCT04526717","https://ClinicalTrials.gov/show/NCT04526717",NA,"South Korea","Seoul","2020-Aug","2022-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance","Other",15
"NCT04349371","https://ClinicalTrials.gov/show/NCT04349371",NA,"United States","New York","2020-Apr","2021-Jan","Status Unclear","Randomised","Quadruple",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Serious Adverse Events","HCQ, Standard of care",8
"NCT04337918","https://ClinicalTrials.gov/show/NCT04337918",NA,"Canada","British Columbia","2020-Apr","2021-Jan","Completed","Randomised","Single",2,"Confirmed","Healthy Unexposed, Outpatient","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Non-invasive respiratory support",143
"NCT04337918","https://ClinicalTrials.gov/show/NCT04337918",NA,"Canada","Quebec","2020-Apr","2021-Jan","Completed","Randomised","Single",2,"Confirmed","Healthy Unexposed, Outpatient","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Non-invasive respiratory support",143
"NCT04748757","https://ClinicalTrials.gov/show/NCT04748757",NA,"Canada","Ontario","2021-Feb","2022-Mar","Not Recruiting","Randomised","Quadruple",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","Other, Standard of care",60
"NCT04642950","https://ClinicalTrials.gov/show/NCT04642950",NA,"Japan","Chiba","2020-Nov","2021-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge","Other, Standard of care",60
"NCT04642950","https://ClinicalTrials.gov/show/NCT04642950",NA,"Japan","Kanagawa","2020-Nov","2021-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge","Other, Standard of care",60
"NCT04642950","https://ClinicalTrials.gov/show/NCT04642950",NA,"Japan","Saitama","2020-Nov","2021-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge","Other, Standard of care",60
"NCT04642950","https://ClinicalTrials.gov/show/NCT04642950",NA,"Japan","Tokyo","2020-Nov","2021-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge","Other, Standard of care",60
"NCT04627519","https://ClinicalTrials.gov/show/NCT04627519",NA,"Indonesia","Jakarta","2020-Nov","2021-Jan","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Radiographic Findings","Nutrition + Standard of care, Standard of care",85
"NCT04348071","https://ClinicalTrials.gov/show/NCT04348071",NA,"United States","Colorado","2020-Apr","2021-Aug","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Hemoglobin, Creatinine Phosphokinase, Prothrombin, ALT, Bilirubin, Glucose","JAKi",80
"NCT04340232","https://ClinicalTrials.gov/show/NCT04340232",NA,"United States","Colorado","2020-Apr","2021-Aug","Not Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)",NA,80
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Alabama","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","California","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Colorado","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Florida","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Georgia","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Hawaii","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Illinois","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Iowa","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Louisiana","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Maryland","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Massachusetts","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Minnesota","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Missouri","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Nebraska","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","New Mexico","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","New York","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","North Carolina","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Oregon","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Pennsylvania","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Texas","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Utah","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Virginia","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"United States","Washington","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"Japan","Tokyo","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"South Korea","Gyeonggi","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"South Korea","Seoul","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"Mexico","Mexico","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04492475","https://ClinicalTrials.gov/show/NCT04492475",NA,"Singapore","Singapore","2020-Jul","2020-Dec","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, INR, ALT, AST, Bilirubin","Remdesivir, Remdesivir + IFN",969
"NCT04746183","https://ClinicalTrials.gov/show/NCT04746183",NA,"United Kingdom","Liverpool","2021-Feb","2021-Jun","Recruiting","Randomised","Quadruple",3,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Platelet Count, ALT, SpO2","Other, Standard of care",200
"NCT04742725","https://ClinicalTrials.gov/show/NCT04742725",NA,"United States","Tennessee","2021-Feb","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, C-Reactive Protein, Lymphocyte Count, SpO2","Other, Standard of care",200
"NCT04475991","https://ClinicalTrials.gov/show/NCT04475991",NA,"Mexico","Mexico","2020-Jul","2021-Apr","Not Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO","Anticoagulants + HCQ + AZT + Other, FPV + Anticoagulants + HCQ + AZT + Other, Immunomodulators + Anticoagulants + HCQ + AZT + Other, Immunomodulators + FPV + Anticoagulants + HCQ + AZT + Other",100
"NCT04547660","https://ClinicalTrials.gov/show/NCT04547660",NA,"Brazil","Rio Grande Do Sul","2020-Sep","2021-Jan","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Troponin, Prothrombin, Fibrinogen, PaO2-FiO2","Plasma based therapy, Standard of care",160
"NCT04723459","https://ClinicalTrials.gov/show/NCT04723459",NA,"Egypt","Qina","2021-Jan","2021-Feb","Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Device, Standard of care",150
"NCT04584710","https://ClinicalTrials.gov/show/NCT04584710",NA,"United States","Connecticut","2020-Oct","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Hospitalization","Other, Standard of care",60
"NCT04584710","https://ClinicalTrials.gov/show/NCT04584710",NA,"United States","Massachusetts","2020-Oct","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Hospitalization","Other, Standard of care",60
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"United States","California","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"United States","Florida","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"United States","Illinois","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"United States","Kentucky","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"United States","Michigan","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"United States","New Jersey","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"United States","Ohio","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"United States","South Carolina","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"United States","Texas","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"Israel","Jerusalem","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"Netherlands","Utrecht","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04644120","https://ClinicalTrials.gov/show/NCT04644120",NA,"Puerto Rico","Puerto Rico","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",6,"Confirmed","Hospital","Adverse Events, Antibodies","Monoclonal antibody, Standard of care",24
"NCT04636697","https://ClinicalTrials.gov/show/NCT04636697",NA,"United States","Florida","2020-Nov","2021-Dec","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Mortality, Serious Adverse Events, Urine Sample, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30918
"NCT04636697","https://ClinicalTrials.gov/show/NCT04636697",NA,"United States","Nebraska","2020-Nov","2021-Dec","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Mortality, Serious Adverse Events, Urine Sample, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30918
"NCT04636697","https://ClinicalTrials.gov/show/NCT04636697",NA,"United States","Texas","2020-Nov","2021-Dec","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Mortality, Serious Adverse Events, Urine Sample, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30918
"NCT04636697","https://ClinicalTrials.gov/show/NCT04636697",NA,"Canada","Nova Scotia","2020-Nov","2021-Dec","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Mortality, Serious Adverse Events, Urine Sample, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30918
"NCT04636697","https://ClinicalTrials.gov/show/NCT04636697",NA,"Canada","Ontario","2020-Nov","2021-Dec","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Mortality, Serious Adverse Events, Urine Sample, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30918
"NCT04636697","https://ClinicalTrials.gov/show/NCT04636697",NA,"Canada","Quebec","2020-Nov","2021-Dec","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Mortality, Serious Adverse Events, Urine Sample, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",30918
"NCT04746430","https://ClinicalTrials.gov/show/NCT04746430",NA,"Netherlands","Groningen","2021-Feb","2022-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization","Dexamethasone, Standard of care",2000
"NCT04344184","https://ClinicalTrials.gov/show/NCT04344184",NA,"United States","Virginia","2020-Apr","2021-May","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Clinical Improvement Score (Any), Fever","Standard of care, Vitamins",60
"NCT04745351","https://ClinicalTrials.gov/show/NCT04745351",NA,"United States","California","2021-Feb","2021-Jul","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified)","Remdesivir + Standard of care, Standard of care",1116
"CHICTR2100042004","http://www.chictr.org.cn/showproj.aspx?proj=65719",NA,"China","Sichuan","2021-Jan","2020-Dec","Suspended","Single-Arm","Unspecified",1,"Confirmed","Unclear","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Other",20
"NCT04359095","https://ClinicalTrials.gov/show/NCT04359095",NA,"Colombia","Bogota","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",4,NA,"Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events","AZT, HCQ, LPV/r, Standard of care",1200
"NCT04359095","https://ClinicalTrials.gov/show/NCT04359095",NA,"Colombia","Huila","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",4,NA,"Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events","AZT, HCQ, LPV/r, Standard of care",1200
"NCT04662086","https://ClinicalTrials.gov/show/NCT04662086",NA,"United States","California","2020-Dec","2022-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Antibodies","Other",240
"NCT04662073","https://ClinicalTrials.gov/show/NCT04662073",NA,"United States","California","2020-Dec","2022-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Antibodies","Other, Standard of care",120
"NCT04662060","https://ClinicalTrials.gov/show/NCT04662060",NA,"United States","California","2020-Dec","2022-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Antibodies","Other, Standard of care",120
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Arizona","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","California","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Colorado","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Florida","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Georgia","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Illinois","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Maryland","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Massachusetts","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Michigan","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","New York","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Tennessee","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04508023","https://ClinicalTrials.gov/show/NCT04508023",NA,"United States","Texas","2020-Aug","2021-Mar","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department","Anticoagulants, Standard of care",4000
"NCT04416399","https://ClinicalTrials.gov/show/NCT04416399",NA,"United Kingdom","Oxfordshire","2020-Jun","2021-Jan","Status Unclear","Randomised","Open-Label",2,"Suspected","Outpatient","Visits or Returns to Emergency Department, Viral Load or Clearance, Fever, SpO2","Corticosteroids, Standard of care",146
"NCT04743349","https://ClinicalTrials.gov/show/NCT04743349",NA,"Italy","Rome","2021-Feb","2021-Oct","Recruiting","Randomised","Single",2,"Confirmed","Unclear",NA,"Respiratory support, Standard of care",200
"NCT04330586","https://ClinicalTrials.gov/show/NCT04330586",NA,"South Korea","Seoul","2020-Apr","2021-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Outpatient","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Corticosteroids, HCQ + Corticosteroids, Standard of care",66
"NCT04584567","https://ClinicalTrials.gov/show/NCT04584567",NA,"Tunisia","Tunis","2020-Oct","2021-Feb","Recruiting","Randomised","Double",3,"Healthy","Healthcare Workers","IgG, IgM or IgA","Antibiotics + Zinc, Standard of care",1100
"NCT04733651","https://ClinicalTrials.gov/show/NCT04733651",NA,"Nepal","Bagmati","2021-Feb","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Standard of care, Standard of care + Other",250
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","New South Wales","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","South Australia","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","Victoria","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","Western Australia","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Brazil","Amazonas","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Brazil","Mato Grosso Do Sul","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Brazil","Rio De Janeiro","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Netherlands","Amsterdam","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Netherlands","Utrecht","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Spain","Barcelona","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Spain","Bizkaia","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Spain","Madrid","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Spain","Sevilla","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"United Kingdom","London","2020-Mar","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events","Vaccine",10078
"NCT04490486","https://ClinicalTrials.gov/show/NCT04490486",NA,"United States","Florida","2020-Jul","2024-Jun","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Pneumonia or ARDS, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Electrolytes, LDH","Standard of care, Stem cells",21
"NCT04738175","https://ClinicalTrials.gov/show/NCT04738175",NA,"United States","California","2021-Feb","2021-Nov","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Adverse Events","mAb, Standard of care",209
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Alabama","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Arizona","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","California","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Colorado","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Connecticut","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Florida","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Georgia","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Illinois","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Indiana","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Iowa","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Kentucky","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Louisiana","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Maryland","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Massachusetts","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Michigan","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Minnesota","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Missouri","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Nebraska","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Nevada","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","New Jersey","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","New Mexico","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","New York","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","North Carolina","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Ohio","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Oregon","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Pennsylvania","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Rhode Island","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","South Dakota","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Texas","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Utah","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Virginia","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Washington","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"United States","Wisconsin","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Brazil","Bahia","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Brazil","Ceara","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Brazil","Para","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Brazil","Rio Grande Do Sul","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Brazil","Brasilia","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Brazil","Santa Catarina","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Chile","Santiago","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Mexico","Jalisco","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Mexico","Nuevo Leon","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Mexico","Mexico","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Mexico","Veracruz","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Moldova","Chisinau","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04426695","https://ClinicalTrials.gov/show/NCT04426695",NA,"Romania","Bucharest","2020-Jun","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies","mAB",6900
"NCT04739410","https://ClinicalTrials.gov/show/NCT04739410",NA,"Pakistan","Punjab","2021-Feb","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Outpatient",NA,"Ivermectin, Standard of care",50
"NCT04703036","https://ClinicalTrials.gov/show/NCT04703036",NA,"United States","Texas","2021-Jan","2021-Dec","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Other Mild Symptoms","Nutrition + Other, Standard of care",64
"NCT04466241","https://ClinicalTrials.gov/show/NCT04466241",NA,"France","Paris","2020-Jul","2021-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Fibrinogen, IgG, IgM or IgA, CD4, CD8","LPV/r + ARBs + Statins",294
"CHICTR2100043045","http://www.chictr.org.cn/showproj.aspx?proj=121511",NA,"China","Beijing","2021-Feb","2022-Mar","Not Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Cough, Dyspnea, Other Mild Symptoms, SpO2, Radiographic Findings, Depression, Anxiety","TCM",300
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Asturias","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Barcelona","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Bizkaia","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Cantabria","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Ciudad Real","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Madrid","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Baleares","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Navarra","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Toledo","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Albacete","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Badajoz","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Burgos","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Gerona","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Granada","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Murcia","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Orense","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Salamanca","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Sevilla","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Valencia","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04445272","https://ClinicalTrials.gov/show/NCT04445272",NA,"Spain","Zaragoza","2020-Jun","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","TCZ",495
"NCT04578158","https://ClinicalTrials.gov/show/NCT04578158",NA,"Pakistan","Sind","2020-Oct","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",200
"NCT04529499","https://ClinicalTrials.gov/show/NCT04529499",NA,"Kuwait","Kuwait City","2020-Aug","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient, Hospital","ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Radiographic Findings, Hypoxia","FPV, Standard of care",780
"NCT04700163","https://ClinicalTrials.gov/show/NCT04700163",NA,"United States","New York","2021-Jan","2021-Jun","Recruiting","Non-Randomised","Open-Label",5,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","mAb",15
"NCT04678700","https://ClinicalTrials.gov/show/NCT04678700",NA,"Spain","Madrid","2020-Dec","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital, Resolved Discharged","Respiratory Rate, Quality of Life, Anxiety","Rehabilitation",40
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"Austria","Vienna","2020-Mar","2023-Mar","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"Austria","Salzburg","2020-Mar","2023-Mar","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"Belgium","Brussels","2020-Mar","2023-Mar","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"France","Paris","2020-Mar","2023-Mar","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"France","Martinique","2020-Mar","2023-Mar","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"Luxembourg","Luxembourg","2020-Mar","2023-Mar","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"Portugal","Lisbon","2020-Mar","2023-Mar","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"Portugal","Lisboa","2020-Mar","2023-Mar","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",3100
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"Portugal","Porto","2020-Mar","2023-Mar","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",3100
"NCT04734860","https://ClinicalTrials.gov/show/NCT04734860",NA,"United States","California","2021-Feb","2021-Sep","Not Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Visits or Returns to Emergency Department, Viral Load or Clearance, Fever","Monoclonal antibody, Standard of care",500
"NCT04388683","https://ClinicalTrials.gov/show/NCT04388683",NA,"United States","Massachusetts","2020-May","2021-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Fibrinogen, PaO2-FiO2","Non-invasive respiratory support, Standard of care",42
"NCT04363346","https://ClinicalTrials.gov/show/NCT04363346",NA,"United States","Minnesota","2020-Apr","2022-Jan","Not Recruiting","Non-Randomised","Open-Label",3,NA,"Hospital","Hospital Discharge, Non-invasive Ventilation, Stool Sample","Natural Killer Cells",5
"NCT04716426","https://ClinicalTrials.gov/show/NCT04716426",NA,"Brazil","Rio Grande Do Sul","2021-Jan","2021-Feb","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Adverse Events","Antibiotics, Standard of care",100
"NCT04459286","https://ClinicalTrials.gov/show/NCT04459286",NA,"Nigeria","Niger","2020-Jul","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any)","Antivirals, Standard of care",98
"NCT04733833","https://ClinicalTrials.gov/show/NCT04733833",NA,"Israel","Jerusalem","2021-Feb","2022-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Other, Standard of care",30
"NCT04729140","https://ClinicalTrials.gov/show/NCT04729140",NA,"United States","Florida","2021-Jan","2021-Dec","Recruiting","Randomised","Triple",3,"Confirmed","Outpatient","Mortality, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, Prothrombin, Fibrinogen, AST, Albumin, Bilirubin, Glucose, Blood Urea Nitrogen, Depression, Anxiety","Ivermectin + Antibiotics, Ivermectin + Standard of care, Standard of care + Standard of care",150
"NCT04486001","https://ClinicalTrials.gov/show/NCT04486001",NA,"United States","California","2020-Jul","2022-Jan","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Serious Adverse Events","Stem cells",20
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Argentina","Ciudad De Buenos Aires","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Argentina","Buenos Aires","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Brazil","Brasilia","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Brazil","Sao Paulo","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Chile","Santiago","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"France","Paris","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Germany","Berlin","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Germany","Hamburg","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"India","New Delhi","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"India","Delhi","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Italy","Milano","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Italy","Roma","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Japan","Tokyo","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Mexico","Mexico","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Peru","Lima","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Russia","Moscow","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Russia","Murmansk","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"South Africa","Pretoria","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Turkey","Ankara","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Turkey","Istanbul","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2","Acalabrutinib, Standard of care",177
"NCT04469114","https://ClinicalTrials.gov/show/NCT04469114",NA,"Brazil","Brasilia","2020-Jul","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","JAKi, Standard of care",260
"NCT04469114","https://ClinicalTrials.gov/show/NCT04469114",NA,"Israel","Jerusalem","2020-Jul","2021-Mar","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","JAKi, Standard of care",260
"NCT04364737","https://ClinicalTrials.gov/show/NCT04364737",NA,"United States","Connecticut","2020-Apr","2023-Jan","Recruiting","Randomised","Double",2,NA,"Hospital","Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",1000
"NCT04364737","https://ClinicalTrials.gov/show/NCT04364737",NA,"United States","Florida","2020-Apr","2023-Jan","Recruiting","Randomised","Double",2,NA,"Hospital","Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",1000
"NCT04364737","https://ClinicalTrials.gov/show/NCT04364737",NA,"United States","New York","2020-Apr","2023-Jan","Recruiting","Randomised","Double",2,NA,"Hospital","Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",1000
"NCT04364737","https://ClinicalTrials.gov/show/NCT04364737",NA,"United States","Texas","2020-Apr","2023-Jan","Recruiting","Randomised","Double",2,NA,"Hospital","Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",1000
"NCT04364737","https://ClinicalTrials.gov/show/NCT04364737",NA,"United States","Wisconsin","2020-Apr","2023-Jan","Recruiting","Randomised","Double",2,NA,"Hospital","Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",1000
"NCT04639375","https://ClinicalTrials.gov/show/NCT04639375",NA,"United States","California","2020-Nov","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Healthy","Unclear","Antibodies","Vaccine",300
"NCT04334044","https://ClinicalTrials.gov/show/NCT04334044",NA,"Mexico","Mexico","2020-Apr","2021-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Mortality, ICU Admission, Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","JAKi",20
"NCT04388826","https://ClinicalTrials.gov/show/NCT04388826",NA,"United States","Arizona","2020-May","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Fever","Other, Standard of care",40
"NCT04388826","https://ClinicalTrials.gov/show/NCT04388826",NA,"United States","Minnesota","2020-May","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Fever","Other, Standard of care",40
"NCT04388826","https://ClinicalTrials.gov/show/NCT04388826",NA,"United States","New Jersey","2020-May","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Fever","Other, Standard of care",40
"NCT04388826","https://ClinicalTrials.gov/show/NCT04388826",NA,"United States","Texas","2020-May","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Fever","Other, Standard of care",40
"NCT04528667","https://ClinicalTrials.gov/show/NCT04528667",NA,"Brazil","Brasilia","2020-Aug","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Adverse Events, C-Reactive Protein","Other, Standard of care",400
"NCT04452669","https://ClinicalTrials.gov/show/NCT04452669",NA,"United States","Ohio","2020-Jun","2021-May","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Cardiac Outcome (Unspecified)","Other",20
"NCT04610138","https://ClinicalTrials.gov/show/NCT04610138",NA,"United States","Washington","2020-Oct","2021-Jul","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Hospitalization","Polymer compound, Standard of care",276
"NCT04528368","https://ClinicalTrials.gov/show/NCT04528368",NA,"Brazil","Rio De Janeiro","2020-Aug","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Antibodies, PaO2-FiO2, SpO2, Respiratory Rate","Plasma based therapy, Standard of care",60
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"United States","Missouri","2020-Apr","2021-Aug","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",30000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Ghana","Greater Accra","2020-Apr","2021-Aug","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",30000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"South Africa","Pretoria","2020-Apr","2021-Aug","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",30000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"South Africa","Western Cape","2020-Apr","2021-Aug","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",30000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"United Kingdom","London","2020-Apr","2021-Aug","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",30000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Zambia","Lusaka","2020-Apr","2021-Aug","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",30000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Zimbabwe","Harare","2020-Apr","2021-Aug","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",30000
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Zaragoza","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Barcelona","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Madrid","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Asturias","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Albacete","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Ciudad Real","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Las Palmas","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Navarra","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Salamanca","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Toledo","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Valencia","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Valladolid","2020-Apr","2021-Feb","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma based therapy, Standard of care",278
"NCT04388527","https://ClinicalTrials.gov/show/NCT04388527",NA,"United States","Pennsylvania","2020-May","2021-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose","Plasma based therapy",50
"NCT04391179","https://ClinicalTrials.gov/show/NCT04391179",NA,"United States","Illinois","2020-May","2021-Feb","Not Recruiting","Randomised","Single",2,"Confirmed","Outpatient, Hospital","D-Dimer","Other, Standard of care",160
"NCT04391179","https://ClinicalTrials.gov/show/NCT04391179",NA,"United States","Michigan","2020-May","2021-Feb","Not Recruiting","Randomised","Single",2,"Confirmed","Outpatient, Hospital","D-Dimer","Other, Standard of care",160
"NCT04731051","https://ClinicalTrials.gov/show/NCT04731051",NA,"Jordan","Amman","2021-Jan","2021-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2, Cardiac Outcome (Unspecified)","Inhaled solution + Standard of care, Standard of care",28
"NCT04341584","https://ClinicalTrials.gov/show/NCT04341584",NA,"France","Paris","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Anakinra",161
"NCT04681430","https://ClinicalTrials.gov/show/NCT04681430",NA,"Germany","Berlin","2020-Dec","2021-May","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA, Antibodies","Other, Plasma based therapy, Standard of care",1094
"NCT04681430","https://ClinicalTrials.gov/show/NCT04681430",NA,"Germany","Hessen","2020-Dec","2021-May","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA, Antibodies","Other, Plasma based therapy, Standard of care",1094
"CHICTR2000032457","http://www.chictr.org.cn/showproj.aspx?proj=52925",NA,"China","Hubei","2020-Apr","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear",NA,"Rehabilitation, Standard of care",60
"CHICTR2100042069","http://www.chictr.org.cn/showproj.aspx?proj=120071",NA,"China","Hebei","2021-Jan","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Cough, Fever, Dyspnea, Radiographic Findings","Standard of care, TCM",120
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Alabama","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Arizona","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Arkansas","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","California","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Connecticut","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Florida","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Georgia","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Illinois","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Indiana","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Kansas","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Minnesota","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Missouri","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Nebraska","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Nevada","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","New Mexico","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","New York","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","North Carolina","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Ohio","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Oklahoma","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","South Carolina","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","South Dakota","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Texas","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Utah","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United States","Virginia","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"Belgium","Brussels","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"Belgium","Namur","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"France","Paris","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"Spain","Madrid","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"Spain","Barcelona","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United Kingdom","Enfield","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United Kingdom","London","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United Kingdom","Manchester","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United Kingdom","Rochdale","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United Kingdom","Southampton","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04625725","https://ClinicalTrials.gov/show/NCT04625725",NA,"United Kingdom","Wakefield","2020-Nov","2021-Aug","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Visits or Returns to Emergency Department, Antibodies","mAb, Standard of care",5000
"NCT04730323","https://ClinicalTrials.gov/show/NCT04730323",NA,"Pakistan","Punjab","2021-Jan","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission","Corticosteroids, TCZ",93
"NCT04464395","https://ClinicalTrials.gov/show/NCT04464395",NA,"United States","California","2020-Jul","2021-Mar","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Treatment-emergent Adverse Events, IgG, IgM or IgA","Other",70
"NCT04464395","https://ClinicalTrials.gov/show/NCT04464395",NA,"United States","New York","2020-Jul","2021-Mar","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Treatment-emergent Adverse Events, IgG, IgM or IgA","Other",70
"NCT04464395","https://ClinicalTrials.gov/show/NCT04464395",NA,"United States","Pennsylvania","2020-Jul","2021-Mar","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Treatment-emergent Adverse Events, IgG, IgM or IgA","Other",70
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Alabama","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Arizona","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","California","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Florida","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Georgia","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Idaho","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Indiana","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Louisiana","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Maryland","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Michigan","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Missouri","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Nevada","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","New Mexico","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","New York","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","North Carolina","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Ohio","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Pennsylvania","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Tennessee","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Texas","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United States","Washington","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Austria","Vienna","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Brazil","Minas Gerais","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Brazil","Parana","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Brazil","Rio Grande Do Norte","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Brazil","Rio Grande Do Sul","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Brazil","Santa Catarina","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Brazil","Sao Paulo","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Brazil","Brasilia","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Canada","Ontario","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Canada","Quebec","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Chile","Santiago","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"France","Paris","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Peru","Callao","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Peru","Lima","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Spain","Barcelona","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Spain","Albacete","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Spain","Madrid","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"Spain","Granada","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04545060","https://ClinicalTrials.gov/show/NCT04545060",NA,"United Kingdom","Belfast","2020-Sep","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Non-invasive Ventilation, Serious Adverse Events","Monoclonal antibody, Standard of care",1360
"NCT04730401","https://ClinicalTrials.gov/show/NCT04730401",NA,"Finland","Uusimaa","2021-Jan","2021-Aug","Recruiting","Randomised","Triple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Antibodies","Plasma based therapy, Standard of care",390
"NCT04730427","https://ClinicalTrials.gov/show/NCT04730427",NA,"South Korea","Seoul","2021-Jan","2021-May","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Other, Standard of care",40
"NCT04731116","https://ClinicalTrials.gov/show/NCT04731116",NA,"Israel","Jerusalem","2021-Jan","2021-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), IP-10, Interferon (Any), PaO2-FiO2","TCM",40
"NCT04723524","https://ClinicalTrials.gov/show/NCT04723524",NA,"Pakistan","Islamabad","2021-Jan","2021-Jun","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Cough, Fever, C-Reactive Protein, Ferritin, Quality of Life","Standard of care, TCM",300
"NCT04362085","https://ClinicalTrials.gov/show/NCT04362085",NA,"Canada","Ontario","2020-Apr","2022-Mar","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Platelet Count, D-Dimer, Prothrombin, Fibrinogen, Renal Outcome (Unspecified)","Anticoagulants, Standard of care",462
"NCT04448756","https://ClinicalTrials.gov/show/NCT04448756",NA,"United States","Alabama","2020-Jun","2021-Jun","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2","Other, Standard of care",150
"NCT04448756","https://ClinicalTrials.gov/show/NCT04448756",NA,"United States","California","2020-Jun","2021-Jun","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2","Other, Standard of care",150
"NCT04448756","https://ClinicalTrials.gov/show/NCT04448756",NA,"United States","Michigan","2020-Jun","2021-Jun","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2","Other, Standard of care",150
"NCT04448756","https://ClinicalTrials.gov/show/NCT04448756",NA,"United States","Missouri","2020-Jun","2021-Jun","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2","Other, Standard of care",150
"NCT04448756","https://ClinicalTrials.gov/show/NCT04448756",NA,"United States","New Jersey","2020-Jun","2021-Jun","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2","Other, Standard of care",150
"NCT04448756","https://ClinicalTrials.gov/show/NCT04448756",NA,"United States","Texas","2020-Jun","2021-Jun","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2","Other, Standard of care",150
"NCT04448756","https://ClinicalTrials.gov/show/NCT04448756",NA,"Brazil","Brasilia","2020-Jun","2021-Jun","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2","Other, Standard of care",150
"NCT04448756","https://ClinicalTrials.gov/show/NCT04448756",NA,"Brazil","Sao Paulo","2020-Jun","2021-Jun","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2","Other, Standard of care",150
"NCT04414618","https://ClinicalTrials.gov/show/NCT04414618",NA,"United States","Arizona","2020-Jun","2020-Nov","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",42
"NCT04414618","https://ClinicalTrials.gov/show/NCT04414618",NA,"United States","Florida","2020-Jun","2020-Nov","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",42
"NCT04414618","https://ClinicalTrials.gov/show/NCT04414618",NA,"United States","Michigan","2020-Jun","2020-Nov","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",42
"NCT04414618","https://ClinicalTrials.gov/show/NCT04414618",NA,"United States","New York","2020-Jun","2020-Nov","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",42
"NCT04414618","https://ClinicalTrials.gov/show/NCT04414618",NA,"United States","Oregon","2020-Jun","2020-Nov","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",42
"NCT04414618","https://ClinicalTrials.gov/show/NCT04414618",NA,"United States","Texas","2020-Jun","2020-Nov","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",42
"NCT04414618","https://ClinicalTrials.gov/show/NCT04414618",NA,"Israel","Jerusalem","2020-Jun","2020-Nov","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",42
"NCT04730284","https://ClinicalTrials.gov/show/NCT04730284",NA,"China","Hong Kong","2021-Jan","2021-Sep","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Adverse Events, IL-6, Tumor Necrosis Factor (Any), Quality of Life","Nutrition",20
"NCT04640233","https://ClinicalTrials.gov/show/NCT04640233",NA,"India","New Delhi","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",1600
"NCT04640233","https://ClinicalTrials.gov/show/NCT04640233",NA,"India","Delhi","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",1600
"NCT04640233","https://ClinicalTrials.gov/show/NCT04640233",NA,"India","Puducherry","2020-Nov","2021-Aug","Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",1600
"CHICTR2100042822","http://www.chictr.org.cn/showproj.aspx?proj=121247",NA,"China","Hebei","2021-Jan","2022-Jan","Not Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Cough","Rehabilitation, TCM + Rehabilitation",200
"CHICTR2000040146","http://www.chictr.org.cn/showproj.aspx?proj=64452",NA,"China","Jiangsu","2020-Nov","2021-Jan","Completed","Randomised","Double",4,"Healthy","Unclear","Adverse Events, Antibodies","Vaccine",640
"NCT04707534","https://ClinicalTrials.gov/show/NCT04707534",NA,"United States","Oklahoma","2021-Jan","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Dexamethasone",300
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Alabama","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Florida","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Illinois","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Indiana","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Massachusetts","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Michigan","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Mississippi","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Missouri","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","New York","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","North Carolina","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Pennsylvania","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Rhode Island","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Tennessee","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Texas","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Virginia","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Argentina","Buenos Aires","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Alagoas","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Bahia","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Brasilia","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Distrito Federal","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Goias","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Minas Gerais","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Pernambuco","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Rio Grande Do Norte","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Rio Grande Do Sul","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Santa Catarina","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Sergipe","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Brazil","Rio De Janeiro","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Canada","Ontario","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"India","New Delhi","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"India","Delhi","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"India","Maharashtra","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"India","Punjab","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Mexico","Mexico","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Mexico","Chihuahua","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Mexico","Durango","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Mexico","Guanajuato","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Mexico","Jalisco","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Mexico","Puebla","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Mexico","Queretaro","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"Mexico","Sonora","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United Kingdom","London","2020-Apr","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","SGLT2, Standard of care",1250
"NCT04682041","https://ClinicalTrials.gov/show/NCT04682041",NA,"Spain","Barcelona","2020-Dec","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Fever, Dyspnea, C-Reactive Protein, Ferritin, IL-6, Lymphocyte Count, Platelet Count, D-Dimer, ALT, AST","Nutrition + Standard of care, Standard of care",420
"NCT04480138","https://ClinicalTrials.gov/show/NCT04480138",NA,"Mexico","Mexico","2020-Jul","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), D-Dimer","IFN, Standard of care",40
"NCT04347915","https://ClinicalTrials.gov/show/NCT04347915",NA,"South Korea","Seoul","2020-Apr","2021-Jan","Recruiting","Randomised","Single",2,"Confirmed","Unclear","Viral Load or Clearance, Non-invasive Ventilation","Antivirals, Standard of care",60
"NCT04646109","https://ClinicalTrials.gov/show/NCT04646109",NA,"Turkey","Afyonkarahisar","2020-Nov","2020-Sep","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Fever, Adverse Events, Ferritin, Lymphocyte Count, D-Dimer, Heart Rate, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Ivermectin, Standard of care",66
"NCT04646109","https://ClinicalTrials.gov/show/NCT04646109",NA,"Turkey","Ankara","2020-Nov","2020-Sep","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Fever, Adverse Events, Ferritin, Lymphocyte Count, D-Dimer, Heart Rate, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Ivermectin, Standard of care",66
"NCT04509999","https://ClinicalTrials.gov/show/NCT04509999",NA,"United States","Florida","2020-Aug","2022-Sep","Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Other, Standard of care",100
"NCT04550351","https://ClinicalTrials.gov/show/NCT04550351",NA,"China","Beijing","2020-Sep","2020-Dec","Not Recruiting","Randomised","Quadruple",3,"Healthy","Healthy Unexposed","Adverse Events","Vaccine",50
"NCT04596839","https://ClinicalTrials.gov/show/NCT04596839",NA,"Bangladesh","Dhaka","2020-Oct","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Remdesivir, Standard of care",60
"NCT04727424","https://ClinicalTrials.gov/show/NCT04727424",NA,"Brazil","Brasilia","2021-Jan","2022-Feb","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","Ivermectin, Metformin, SSRIs, Standard of care",2724
"NCT04727424","https://ClinicalTrials.gov/show/NCT04727424",NA,"Brazil","Minas Gerais","2021-Jan","2022-Feb","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","Ivermectin, Metformin, SSRIs, Standard of care",2724
"NCT04390477","https://ClinicalTrials.gov/show/NCT04390477",NA,"Spain","Alicante","2020-May","2021-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Adverse Events","Nutrition, Standard of care",40
"NCT04535856","https://ClinicalTrials.gov/show/NCT04535856",NA,"Indonesia","Jakarta","2020-Sep","2021-Jan","Completed","Randomised","Quadruple",3,"Confirmed","Unclear","Hospitalization, Clinical Improvement Score (Any), Treatment-emergent Adverse Events","Standard of care, Stem cells",9
"NCT04406389","https://ClinicalTrials.gov/show/NCT04406389",NA,"United States","New York","2020-May","2021-Jun","Recruiting","Randomised","Open-Label",4,"Confirmed","ICU","Mortality, ICU Admission","Anticoagulants",186
"NCT04342689","https://ClinicalTrials.gov/show/NCT04342689",NA,"United States","Connecticut","2020-Apr","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Nutrition, Standard of care",1500
"NCT04342689","https://ClinicalTrials.gov/show/NCT04342689",NA,"United States","Michigan","2020-Apr","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Nutrition, Standard of care",1500
"NCT04724629","https://ClinicalTrials.gov/show/NCT04724629",NA,"Brazil","Brasilia","2021-Jan","2021-Mar","Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, Hospitalization, Labor Absenteeism, Invasive Mechanical Ventilation or ECMO, IL-2, IL-6, IL-17","Colchicine, Other, Standard of care",60
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","California","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Colorado","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Connecticut","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Hawaii","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Illinois","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Indiana","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Iowa","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Louisiana","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Maine","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Maryland","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Massachusetts","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Michigan","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Minnesota","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Montana","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","New Hampshire","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","New Jersey","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","New York","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","North Carolina","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Ohio","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Oregon","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Pennsylvania","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Rhode Island","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","South Carolina","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Texas","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Utah","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Virginia","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Washington","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"China","Beijing","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"France","Paris","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Germany","Berlin","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Germany","Hamburg","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Germany","Schleswig-Holstein","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"China","Hong Kong","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Bergamo","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Brescia","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Cremona","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Milano","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Rome","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Padova","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Parma","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Pavia","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Piacenza","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Roma","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Japan","Kanagawa","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Japan","Tokyo","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"South Korea","Daegu","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"South Korea","Seoul","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Netherlands","Amsterdam","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Singapore","Singapore","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Asturias","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Madrid","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Barcelona","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Bizkaia","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Sevilla","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Valencia","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Sweden","Stockholm","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Switzerland","Bern","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Taiwan","Taipei","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Taiwan","Taipei City","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","London","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Edinburgh","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Glasgow","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Liverpool","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Manchester","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Plymouth","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Sheffield","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir, Standard of care",1113
"NCT04572412","https://ClinicalTrials.gov/show/NCT04572412",NA,"United Kingdom","London","2020-Oct","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Adverse Events","Radiation therapy",13
"NCT04718467","https://ClinicalTrials.gov/show/NCT04718467",NA,"China","Jiangsu","2021-Jan","2021-May","Not Recruiting","Randomised","Triple",4,"Healthy","Unclear","Adverse Events, Antibodies","Standard of care, Vaccine",4000
"NCT04485130","https://ClinicalTrials.gov/show/NCT04485130",NA,"United States","California","2020-Jul","2021-Aug","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Adverse Events, IL-1, IL-6, Radiographic Findings","Other, Standard of care",60
"NCT04723589","https://ClinicalTrials.gov/show/NCT04723589",NA,"United States","Alabama","2021-Jan","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), von Wildebrandt Factor, D-Dimer, Prothrombin, Fibrinogen","Standard of care, Standard of care + Standard of care",40
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","Arizona","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","Arkansas","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","California","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","Florida","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","Minnesota","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","Mississippi","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","New York","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","North Carolina","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","South Carolina","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","Texas","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"Brazil","Sao Paulo","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"Canada","Quebec","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"South Africa","Pretoria","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"Spain","Madrid","2020-Mar","2021-Jan","Completed","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine, Standard of care",4506
"NCT04723446","https://ClinicalTrials.gov/show/NCT04723446",NA,"United Kingdom","London","2021-Jan","2021-Jul","Not Recruiting","Randomised","Single",4,"Confirmed","Outpatient, Hospital","Viral Load or Clearance","Hygiene, Standard of care",40
"CHICTR2000032573","http://www.chictr.org.cn/showproj.aspx?proj=53225",NA,"China","Beijing","2020-May","2021-May","Recruiting","Randomised","Double",2,"Resolved","Resolved Discharged","Clinical Improvement Score (Any), 6-Minute Walking Distance, Quality of Life","Standard of care, TCM",120
"NCT04718480","https://ClinicalTrials.gov/show/NCT04718480",NA,"Hungary","Budapest","2021-Jan","2021-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"SSRIs, Standard of care",100
"NCT04718480","https://ClinicalTrials.gov/show/NCT04718480",NA,"Hungary","Debrecen","2021-Jan","2021-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"SSRIs, Standard of care",100
"NCT04720612","https://ClinicalTrials.gov/show/NCT04720612",NA,"Canada","Quebec","2021-Jan","2021-Jul","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Monoclonal antibody, Standard of care",200
"NCT04523181","https://ClinicalTrials.gov/show/NCT04523181",NA,"United States","Michigan","2020-Aug","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospitalization","Other, Standard of care",174
"NCT04523181","https://ClinicalTrials.gov/show/NCT04523181",NA,"United States","Kansas","2020-Aug","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospitalization","Other, Standard of care",174
"NCT04523181","https://ClinicalTrials.gov/show/NCT04523181",NA,"United States","New Jersey","2020-Aug","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospitalization","Other, Standard of care",174
"NCT04523181","https://ClinicalTrials.gov/show/NCT04523181",NA,"Argentina","Buenos Aires","2020-Aug","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospitalization","Other, Standard of care",174
"NCT04523181","https://ClinicalTrials.gov/show/NCT04523181",NA,"Argentina","Cordoba","2020-Aug","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospitalization","Other, Standard of care",174
"NCT04523181","https://ClinicalTrials.gov/show/NCT04523181",NA,"Peru","Lima","2020-Aug","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospitalization","Other, Standard of care",174
"NCT04576728","https://ClinicalTrials.gov/show/NCT04576728",NA,"Brazil","Brasilia","2020-Oct","2021-May","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Treatment-emergent Adverse Events, ECG","Standard of care, Trimodulin",164
"NCT04576728","https://ClinicalTrials.gov/show/NCT04576728",NA,"France","Paris","2020-Oct","2021-May","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Treatment-emergent Adverse Events, ECG","Standard of care, Trimodulin",164
"NCT04576728","https://ClinicalTrials.gov/show/NCT04576728",NA,"Russia","Moscow","2020-Oct","2021-May","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Treatment-emergent Adverse Events, ECG","Standard of care, Trimodulin",164
"NCT04576728","https://ClinicalTrials.gov/show/NCT04576728",NA,"Spain","Barcelona","2020-Oct","2021-May","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Treatment-emergent Adverse Events, ECG","Standard of care, Trimodulin",164
"NCT04576728","https://ClinicalTrials.gov/show/NCT04576728",NA,"Spain","Madrid","2020-Oct","2021-May","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Treatment-emergent Adverse Events, ECG","Standard of care, Trimodulin",164
"NCT04536298","https://ClinicalTrials.gov/show/NCT04536298",NA,"United States","Massachusetts","2020-Sep","2021-Apr","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization","Standard of care, Vitamins",2700
"NCT04721236","https://ClinicalTrials.gov/show/NCT04721236",NA,"Italy","Pavia","2021-Jan","2021-Nov","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Troponin, Procalcitonin, Albumin, LDH, PaO2-FiO2, Radiographic Findings, Renal Outcome (Unspecified)","Plasma based therapy",300
"NCT04634799","https://ClinicalTrials.gov/show/NCT04634799",NA,"United States","Illinois","2020-Nov","2021-Nov","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), PAI-1","Other, Standard of care",80
"NCT04397757","https://ClinicalTrials.gov/show/NCT04397757",NA,"United States","Pennsylvania","2020-May","2021-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose","Plasma based therapy",80
"NCT04716998","https://ClinicalTrials.gov/show/NCT04716998",NA,"Israel","Haifa","2021-Jan","2022-Jan","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospitalization, C-Reactive Protein, Lymphocyte Count","Other",35
"NCT04668209","https://ClinicalTrials.gov/show/NCT04668209",NA,"United States","Arizona","2020-Dec","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Creatinine Phosphokinase, LDH, SpO2","Other, Standard of care",40
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","Florida","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","Iowa","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","Massachusetts","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","Mississippi","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","New Jersey","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","New York","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","North Carolina","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","South Dakota","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","Texas","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04409509","https://ClinicalTrials.gov/show/NCT04409509",NA,"United States","Virginia","2020-Jun","2021-Jan","Completed","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies","mAb, Standard of care",124
"NCT04587219","https://ClinicalTrials.gov/show/NCT04587219",NA,"Russia","Moscow","2020-Oct","2021-Mar","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed","Adverse Events, Antibodies","Vaccine",110
"NCT04356495","https://ClinicalTrials.gov/show/NCT04356495",NA,"France","Paris","2020-Apr","2021-Aug","Recruiting","Randomised","Open-Label",5,NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Creatinine Phosphokinase, Procalcitonin, Prothrombin, ALT, LDH, Bicarbonates, Quality of Life","Antihypertensive, FPV, HCQ, Other, Standard of care",820
"NCT04468009","https://ClinicalTrials.gov/show/NCT04468009",NA,"Argentina","Buenos Aires","2020-Jul","2021-Jan","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Plasma-based therapy, Standard of care",36
"NCT04517396","https://ClinicalTrials.gov/show/NCT04517396",NA,"United States","Pennsylvania","2020-Aug","2021-Aug","Recruiting","Randomised","Quadruple",3,"Confirmed Or Suspected","Outpatient, Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",700
"NCT04605887","https://ClinicalTrials.gov/show/NCT04605887",NA,"Israel","Haifa","2020-Oct","2023-Nov","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Antihypertensive, Standard of care",120
"CHICTR2100042374","http://www.chictr.org.cn/showproj.aspx?proj=120494",NA,"China","Sichuan","2021-Jan","2022-Apr","Not Recruiting","Randomised","Double",3,"Healthy","Unclear","Serious Adverse Events, Antibodies","Vaccine",4800
"NCT04476888","https://ClinicalTrials.gov/show/NCT04476888",NA,"Pakistan","Sind","2020-Jul","2020-Sep","Completed","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, D-Dimer, Procalcitonin, Radiographic Findings","Plasma based therapy, Standard of care",110
"NCT04470622","https://ClinicalTrials.gov/show/NCT04470622",NA,"United States","Alabama","2020-Jul","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6","Other, Standard of care",100
"NCT04470622","https://ClinicalTrials.gov/show/NCT04470622",NA,"United States","California","2020-Jul","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6","Other, Standard of care",100
"NCT04470622","https://ClinicalTrials.gov/show/NCT04470622",NA,"United States","Connecticut","2020-Jul","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6","Other, Standard of care",100
"NCT04470622","https://ClinicalTrials.gov/show/NCT04470622",NA,"United States","New York","2020-Jul","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6","Other, Standard of care",100
"NCT04470622","https://ClinicalTrials.gov/show/NCT04470622",NA,"United States","Texas","2020-Jul","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6","Other, Standard of care",100
"NCT04470622","https://ClinicalTrials.gov/show/NCT04470622",NA,"Puerto Rico","Puerto Rico","2020-Jul","2021-Jun","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6","Other, Standard of care",100
"NCT04715295","https://ClinicalTrials.gov/show/NCT04715295",NA,"Cameroon","Centre","2021-Jan","2021-May","Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Mortality","Antibiotics +  Anticoagulants, HCQ + AZT",200
"NCT04678739","https://ClinicalTrials.gov/show/NCT04678739",NA,"Bangladesh","Chittagong","2020-Dec","2021-Jan","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation","Remdesivir + TCZ, Standard of care",150
"NCT04678739","https://ClinicalTrials.gov/show/NCT04678739",NA,"Bangladesh","Dhaka","2020-Dec","2021-Jan","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation","Remdesivir + TCZ, Standard of care",150
"NCT04701606","https://ClinicalTrials.gov/show/NCT04701606",NA,"Philippines","Manila","2021-Jan","2021-Sep","Not Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious Adverse Events, SpO2, Respiratory Rate","Other, Standard of care",402
"NCT04709172","https://ClinicalTrials.gov/show/NCT04709172",NA,"Spain","Madrid","2021-Jan","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Outpatient","Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Adverse Events","Antibiotics",30
"NCT04498325","https://ClinicalTrials.gov/show/NCT04498325",NA,"United States","Missouri","2020-Aug","2021-Nov","Not Recruiting","Randomised","Triple",6,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Treatment-emergent Adverse Events, Lymphocyte Count","Other, Standard of care",42
"NCT04386239","https://ClinicalTrials.gov/show/NCT04386239",NA,"Italy","Milano","2020-May","2021-Jan","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Viral Load or Clearance, Fever, Tumor Necrosis Factor (Any)","Sarilumab",40
"NCT04366050","https://ClinicalTrials.gov/show/NCT04366050",NA,"United States","California","2020-Apr","2021-May","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission","ACEi, Standard of care",560
"NCT04716647","https://ClinicalTrials.gov/show/NCT04716647",NA,"United Kingdom","Leicestershire","2021-Jan","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Unclear","Viral Load or Clearance","Alternative therapy",28
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Alabama","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","California","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Colorado","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Florida","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Georgia","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Idaho","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Illinois","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Maryland","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Kansas","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Louisiana","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Massachusetts","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Mississippi","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Missouri","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Montana","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Nebraska","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Nevada","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","New York","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Washington","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","North Carolina","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","North Dakota","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Ohio","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Oklahoma","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Oregon","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Pennsylvania","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","South Carolina","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","South Dakota","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Tennessee","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Texas","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Virginia","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"United States","Wisconsin","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04518410","https://ClinicalTrials.gov/show/NCT04518410",NA,"Puerto Rico","Puerto Rico","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Fever, Adverse Events, Antibodies, SpO2","Other, Standard of care",2000
"NCT04711863","https://ClinicalTrials.gov/show/NCT04711863",NA,"South Korea","Seoul","2021-Jan","2021-May","Recruiting","Randomised","Single",2,"Confirmed","Outpatient","Adverse Events","SSRIs, Standard of care",400
"NCT04713878","https://ClinicalTrials.gov/show/NCT04713878",NA,"Turkey","Istanbul","2021-Jan","2020-Jun","Completed","Randomised","Open-Label",3,"Confirmed","ICU","Distress","Stem cells",21
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Brasilia","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Goias","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Minas Gerais","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Para","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Parana","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Rio Grande Do Norte","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Rio Grande Do Sul","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Rio De Janeiro","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Santa Catarina","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Israel","Jerusalem","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life","HCQ, HCQ + AZT",440
"NCT04609865","https://ClinicalTrials.gov/show/NCT04609865",NA,"France","Bas-Rhin","2020-Oct","2021-Dec","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","ICU Admission, Cough, C-Reactive Protein, Ferritin, IL-6, Lymphocyte Count, Platelet Count, D-Dimer, Fibrinogen, Triglycerides, Albumin, LDH, Blood Pressure, ECG, Bicarbonates, Cardiac Outcome (Unspecified)","Anesthetic, Standard of care",100
"NCT04455815","https://ClinicalTrials.gov/show/NCT04455815",NA,"United Kingdom","Edinburgh","2020-Jul","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, Non-invasive Ventilation","Other, Standard of care",389
"NCT04455815","https://ClinicalTrials.gov/show/NCT04455815",NA,"United Kingdom","London","2020-Jul","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality, Non-invasive Ventilation","Other, Standard of care",389
"NCT04676867","https://ClinicalTrials.gov/show/NCT04676867",NA,"Canada","Quebec","2020-Dec","2021-Feb","Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient",NA,"CETP inhibitor, Standard of care",208
"NCT04621071","https://ClinicalTrials.gov/show/NCT04621071",NA,"Canada","Quebec","2020-Nov","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient",NA,"Nutrition, Standard of care",84
"NCT04425252","https://ClinicalTrials.gov/show/NCT04425252",NA,"United States","Connecticut","2020-Jun","2020-Dec","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Adverse Events","DHODH inhibitor, Standard of care",23
"NCT04425252","https://ClinicalTrials.gov/show/NCT04425252",NA,"United States","Florida","2020-Jun","2020-Dec","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Adverse Events","DHODH inhibitor, Standard of care",23
"NCT04425252","https://ClinicalTrials.gov/show/NCT04425252",NA,"United States","New Mexico","2020-Jun","2020-Dec","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Adverse Events","DHODH inhibitor, Standard of care",23
"NCT04425252","https://ClinicalTrials.gov/show/NCT04425252",NA,"United States","Pennsylvania","2020-Jun","2020-Dec","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Adverse Events","DHODH inhibitor, Standard of care",23
"NCT04347954","https://ClinicalTrials.gov/show/NCT04347954",NA,"United States","California","2020-Apr","2020-Dec","Completed","Randomised","Double",3,NA,"Unclear","Viral Load or Clearance, Fever, Adverse Events, Anti SARS-COV-2 Titers","Hygiene",40
"NCT04435184","https://ClinicalTrials.gov/show/NCT04435184",NA,"United States","Maryland","2020-Jun","2020-Nov","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Adverse Events, C-Reactive Protein, von Wildebrandt Factor, D-Dimer","mAb, Standard of care",50
"NCT04347538","https://ClinicalTrials.gov/show/NCT04347538",NA,"United States","Tennessee","2020-Apr","2021-Jun","Not Recruiting","Randomised","Open-Label",3,NA,"Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms","Hygiene, Standard of care",90
"NCT04565392","https://ClinicalTrials.gov/show/NCT04565392",NA,"United States","Connecticut","2020-Sep","2021-Nov","Not Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Serious Adverse Events","Other, Standard of care",150
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","California","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Colorado","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Florida","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Georgia","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Hawaii","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Mississippi","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Nevada","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","North Carolina","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Ohio","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Texas","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Virginia","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"United States","Washington","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"Afghanistan","Kabul","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"Djibouti","Djibouti","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"Guam","Guam","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"Iraq","Baghdad","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"Japan","Aomori","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"Japan","Tokyo","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"Japan","Okinawa","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04360486","https://ClinicalTrials.gov/show/NCT04360486",NA,"Kuwait","Kuwait City","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"Plasma based therapy",NA
"NCT04321096","https://ClinicalTrials.gov/show/NCT04321096",NA,"Denmark","Copenhagen","2020-Mar","2021-Jan","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",580
"NCT04321096","https://ClinicalTrials.gov/show/NCT04321096",NA,"Sweden","Stockholm","2020-Mar","2021-Jan","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",580
"CHICTR2000039212","http://www.chictr.org.cn/showproj.aspx?proj=63183",NA,"China","Yunnan","2020-Oct","2021-Dec","Recruiting","Randomised","Double",5,"Healthy","Healthy Unexposed","IgG, IgM or IgA, Antibodies","Vaccine",120
"CHICTR2000034780","http://www.chictr.org.cn/showproj.aspx?proj=56651",NA,"China","Beijing","2020-Jul","2021-Jul","Completed","Randomised","Double",3,"Healthy","Unclear","Mortality, Pneumonia or ARDS, Serious Adverse Events, Antibodies","Standard of care, Vaccine",45000
"NCT04712279","https://ClinicalTrials.gov/show/NCT04712279",NA,"Brazil","Brasilia","2021-Jan","2021-Mar","Not Recruiting","Randomised","Triple",4,"Confirmed","Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, D-Dimer","Ivermectin, Standard of care",294
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","California","2020-Apr","2020-Jul","Completed","Randomised","Quadruple",3,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, Standard of care",20
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Illinois","2020-Apr","2020-Jul","Completed","Randomised","Quadruple",3,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, Standard of care",20
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Louisiana","2020-Apr","2020-Jul","Completed","Randomised","Quadruple",3,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, Standard of care",20
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Maryland","2020-Apr","2020-Jul","Completed","Randomised","Quadruple",3,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, Standard of care",20
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","North Carolina","2020-Apr","2020-Jul","Completed","Randomised","Quadruple",3,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, Standard of care",20
"NCT04358081","https://ClinicalTrials.gov/show/NCT04358081",NA,"United States","Washington","2020-Apr","2020-Jul","Completed","Randomised","Quadruple",3,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, HCQ + AZT, Standard of care",20
"NCT04712357","https://ClinicalTrials.gov/show/NCT04712357",NA,"Brazil","Brasilia","2021-Jan","2022-Jan","Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Viral Load or Clearance, C-Reactive Protein, IL-2, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, MCP-1, MIP-1, D-Dimer, Troponin, Procalcitonin, IgG, IgM or IgA","NRTIs, NRTIs + NRTIs, Standard of care",219
"NCT04527471","https://ClinicalTrials.gov/show/NCT04527471",NA,"United States","Alabama","2020-Aug","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",45
"NCT04473690","https://ClinicalTrials.gov/show/NCT04473690",NA,"United States","Texas","2020-Jul","2021-May","Recruiting","Randomised","Quadruple",3,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","Standard of care, Vaccine",180
"NCT04710381","https://ClinicalTrials.gov/show/NCT04710381",NA,"Czechia","Prague","2021-Jan","2021-May","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthcare Workers",NA,"Immunomodulation",100
"NCT04686773","https://ClinicalTrials.gov/show/NCT04686773",NA,"Azerbaijan","Baku","2020-Dec","2021-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","Vaccine",100
"NCT04441996","https://ClinicalTrials.gov/show/NCT04441996",NA,"United States","Georgia","2020-Jun","2021-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, Fibrinogen, INR, Albumin, Bilirubin, Blood Urea Nitrogen, Blood Pressure, Heart Rate, Respiratory Rate","Plasma based therapy, Standard of care",20
"NCT04610567","https://ClinicalTrials.gov/show/NCT04610567",NA,"Brazil","Brasilia","2020-Oct","2021-Mar","Recruiting","Randomised","Triple",3,"Confirmed","Hospital","Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, Radiographic Findings, Renal Outcome (Unspecified)","Other, Standard of care",100
"NCT04710199","https://ClinicalTrials.gov/show/NCT04710199",NA,"Spain","Sevilla","2021-Jan","2021-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Adverse Events, C-Reactive Protein, Monocyte Count, Lymphocyte Count, Dendritic Cell Count, Neutrophils, Platelet Count, LDH, SpO2, Radiographic Findings","Antiretrovirals, Standard of care",40
"NCT04674189","https://ClinicalTrials.gov/show/NCT04674189",NA,"Germany","Berlin","2020-Dec","2021-Jun","Recruiting","Randomised","Double",3,"Healthy","Healthcare Workers","Mortality, Serious Adverse Events, Antibodies","Standard of care, Vaccine",2520
"NCT04366960","https://ClinicalTrials.gov/show/NCT04366960",NA,"Italy","Milano","2020-Apr","2021-Aug","Recruiting","Randomised","Open-Label",2,NA,"Hospital","ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, IL-6, D-Dimer, Radiographic Findings, Cardiac Outcome (Unspecified)","Anticoagulants",2712
"NCT04428008","https://ClinicalTrials.gov/show/NCT04428008",NA,"United States","Kansas","2020-Jun","2021-Apr","Recruiting","Randomised","Open-Label",2,"Healthy","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Lymphocyte Count, CD4, CD8","Other, Standard of care",240
"NCT04707742","https://ClinicalTrials.gov/show/NCT04707742",NA,"Spain","Valencia","2021-Jan","2020-Nov","Completed","Randomised","Triple",5,"Confirmed","Unclear","Viral Load or Clearance","Hygiene, Standard of care",84
"NCT04341688","https://ClinicalTrials.gov/show/NCT04341688",NA,"Pakistan","Sind","2020-Apr","2021-Jun","Not Recruiting","Randomised","Quadruple",6,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein","Hygiene, Standard of care",50
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","Alabama","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","California","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","District Of Columbia","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","Hawaii","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","Iowa","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","Louisiana","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","Michigan","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","Nevada","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","North Dakota","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","South Carolina","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"United States","Texas","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"Russia","Ivanovo","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"Russia","Moscow","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"Ukraine","Kyiv (Kiev)","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04400058","https://ClinicalTrials.gov/show/NCT04400058",NA,"Ukraine","Kharkiv","2020-May","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings","Plasma based therapy, Standard of care",208
"NCT04708327","https://ClinicalTrials.gov/show/NCT04708327",NA,"United States","Colorado","2021-Jan","2022-Apr","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Unclear",NA,"Opiate antagonists, Standard of care",75
"NCT04598594","https://ClinicalTrials.gov/show/NCT04598594",NA,"France","Paris","2020-Oct","2021-Sep","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Blood Gas, Respiratory Rate, Depression, Anxiety","Patch, Standard of care",220
"NCT04707703","https://ClinicalTrials.gov/show/NCT04707703",NA,"United States","California","2021-Jan","2022-Jan","Not Recruiting","Randomised","Triple",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events","Standard of care, Standard of care + Antifungal",162
"NCT04705597","https://ClinicalTrials.gov/show/NCT04705597",NA,"United States","Maryland","2021-Jan","2022-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, SpO2, Renal Outcome (Unspecified)","Other, Standard of care",132
"NCT04405908","https://ClinicalTrials.gov/show/NCT04405908",NA,"Australia","Western Australia","2020-May","2020-Oct","Not Recruiting","Randomised","Triple",3,"Healthy","Healthy Unexposed","Adverse Events, ACE, ACE-II, Antibodies","Vaccine",150
"NCT04350320","https://ClinicalTrials.gov/show/NCT04350320",NA,"Spain","Murcia","2020-Apr","2020-Oct","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, White Blood Cell Count, D-Dimer, LDH","Colchicine, Standard of care",102
"NCT04706416","https://ClinicalTrials.gov/show/NCT04706416",NA,"United States","Texas","2021-Jan","2021-Jan","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Outpatient","Mortality, ICU Admission, Non-invasive Ventilation","Nutrition",50
"NCT04421508","https://ClinicalTrials.gov/show/NCT04421508",NA,"United States","Arizona","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance","Non-invasive respiratory support, Standard of care",500
"NCT04421508","https://ClinicalTrials.gov/show/NCT04421508",NA,"United States","California","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance","Non-invasive respiratory support, Standard of care",500
"NCT04421508","https://ClinicalTrials.gov/show/NCT04421508",NA,"United States","Florida","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance","Non-invasive respiratory support, Standard of care",500
"NCT04421508","https://ClinicalTrials.gov/show/NCT04421508",NA,"United States","Missouri","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance","Non-invasive respiratory support, Standard of care",500
"NCT04421508","https://ClinicalTrials.gov/show/NCT04421508",NA,"United States","New Mexico","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance","Non-invasive respiratory support, Standard of care",500
"NCT04421508","https://ClinicalTrials.gov/show/NCT04421508",NA,"United States","Ohio","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance","Non-invasive respiratory support, Standard of care",500
"NCT04421508","https://ClinicalTrials.gov/show/NCT04421508",NA,"United States","Pennsylvania","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance","Non-invasive respiratory support, Standard of care",500
"NCT04421508","https://ClinicalTrials.gov/show/NCT04421508",NA,"United States","Texas","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance","Non-invasive respiratory support, Standard of care",500
"NCT04421508","https://ClinicalTrials.gov/show/NCT04421508",NA,"United States","Virginia","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance","Non-invasive respiratory support, Standard of care",500
"NCT04483375","https://ClinicalTrials.gov/show/NCT04483375",NA,"China","Beijing","2020-Jul","2020-Dec","Completed","Randomised","Triple",2,"Healthy","Healthy Unexposed","Adverse Events, Antibodies","mAb, Standard of care",33
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"United States","California","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"United States","Georgia","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"United States","Maryland","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"United States","North Carolina","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"United States","Ohio","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"United States","South Carolina","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"Australia","New South Wales","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"Australia","Victoria","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"Brazil","Brasilia","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"Spain","Barcelona","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04439071","https://ClinicalTrials.gov/show/NCT04439071",NA,"Spain","Madrid","2020-Jun","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","Other, Standard of care",380
"NCT04355637","https://ClinicalTrials.gov/show/NCT04355637",NA,"Argentina","Buenos Aires","2020-Apr","2021-Aug","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, LDH, Cardiac Outcome (Unspecified)","Corticosteroids, Standard of care",300
"NCT04355637","https://ClinicalTrials.gov/show/NCT04355637",NA,"Argentina","San Juan","2020-Apr","2021-Aug","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, LDH, Cardiac Outcome (Unspecified)","Corticosteroids, Standard of care",300
"NCT04355637","https://ClinicalTrials.gov/show/NCT04355637",NA,"Spain","Barcelona","2020-Apr","2021-Aug","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, LDH, Cardiac Outcome (Unspecified)","Corticosteroids, Standard of care",300
"NCT04341935","https://ClinicalTrials.gov/show/NCT04341935",NA,"United States","Florida","2020-Apr","2021-Dec","Not Recruiting","Randomised","Open-Label",2,NA,"Outpatient, Unclear","IL-6, Glucose, SpO2","DPP-4i, Standard of care",20
"NCT04649775","https://ClinicalTrials.gov/show/NCT04649775",NA,"United States","Washington, Dc","2020-Dec","2021-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Cough, Dyspnea, Hypoxia","Device, Standard of care",50
"NCT04527562","https://ClinicalTrials.gov/show/NCT04527562",NA,"Bangladesh","Dhaka","2020-Aug","2020-Nov","Completed","Randomised","Triple",2,"Confirmed","Unclear","Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Colchicine, Standard of care",299
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Alabama","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Arizona","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Arkansas","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","California","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Florida","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Georgia","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Hawaii","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Illinois","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Indiana","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Iowa","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Kansas","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Kentucky","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Maryland","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Missouri","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Nebraska","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","North Carolina","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","South Carolina","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","South Dakota","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Texas","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Utah","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Virginia","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United States","Washington","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United Kingdom","London","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United Kingdom","Manchester","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United Kingdom","Southampton","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04625972","https://ClinicalTrials.gov/show/NCT04625972",NA,"United Kingdom","Wakefield","2020-Nov","2022-Jan","Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody, Standard of care",1125
"NCT04342663","https://ClinicalTrials.gov/show/NCT04342663",NA,"United States","Illinois","2020-Apr","2020-Aug","Completed","Randomised","Triple",2,NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Troponin","SSRIs, Standard of care",152
"NCT04342663","https://ClinicalTrials.gov/show/NCT04342663",NA,"United States","Missouri","2020-Apr","2020-Aug","Completed","Randomised","Triple",2,NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Troponin","SSRIs, Standard of care",152
"NCT04473261","https://ClinicalTrials.gov/show/NCT04473261",NA,"Pakistan","Islamabad","2020-Jul","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Unclear",NA,"Other, Standard of care",200
"NCT04584684","https://ClinicalTrials.gov/show/NCT04584684",NA,"United States","North Carolina","2020-Oct","2022-Sep","Recruiting","Randomised","Triple",6,"Confirmed","Unclear",NA,"Hygiene, Standard of care",480
"NCT04398004","https://ClinicalTrials.gov/show/NCT04398004",NA,"Greece","Athens","2020-May","2020-Nov","Completed","Single-Arm","Open-Label",1,"Confirmed","Unclear","Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Monocyte Count","Antibiotics",90
"NCT04339712","https://ClinicalTrials.gov/show/NCT04339712",NA,"Greece","Athens","2020-Apr","2020-Dec","Completed","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Organ Failure or Dysfunction (SOFA)","Anakinra, TCZ",102
"CHICTR2000039000","http://www.chictr.org.cn/showproj.aspx?proj=62581",NA,"China","Beijing","2020-Oct","2020-Dec","Recruiting","Randomised","Double",2,"Healthy","Unclear","Serious Adverse Events, Antibodies","Standard of care, Vaccine",600
"NCT04354831","https://ClinicalTrials.gov/show/NCT04354831",NA,"United States","Wisconsin","2020-Apr","2022-May","Not Recruiting","Non-Randomised","Open-Label",2,NA,"Hospital, ICU","Mortality, ICU Admission","Plasma based therapy",131
"NCT04631536","https://ClinicalTrials.gov/show/NCT04631536",NA,"Lebanon","Beirut","2020-Nov","2021-Jan","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO","Other + Standard of care, Standard of care",80
"NCT04676971","https://ClinicalTrials.gov/show/NCT04676971",NA,"Italy","Bergamo","2020-Dec","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events, Radiographic Findings","Monoclonal IgG4 + Standard of care, Standard of care",105
"NCT04676971","https://ClinicalTrials.gov/show/NCT04676971",NA,"Italy","Milano","2020-Dec","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events, Radiographic Findings","Monoclonal IgG4 + Standard of care, Standard of care",105
"NCT04676971","https://ClinicalTrials.gov/show/NCT04676971",NA,"Russia","Krasnoyarsk","2020-Dec","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events, Radiographic Findings","Monoclonal IgG4 + Standard of care, Standard of care",105
"NCT04676971","https://ClinicalTrials.gov/show/NCT04676971",NA,"Russia","Moscow","2020-Dec","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events, Radiographic Findings","Monoclonal IgG4 + Standard of care, Standard of care",105
"NCT04676971","https://ClinicalTrials.gov/show/NCT04676971",NA,"Russia","Saratov","2020-Dec","2021-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events, Radiographic Findings","Monoclonal IgG4 + Standard of care, Standard of care",105
"NCT04432272","https://ClinicalTrials.gov/show/NCT04432272",NA,"United States","Michigan","2020-Jun","2021-Jun","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, IgG, IgM or IgA, Renal Outcome (Unspecified)","Plasma based therapy",500
"CHICTR2100041855","http://www.chictr.org.cn/showproj.aspx?proj=119719",NA,"China","Yunnan","2021-Jan","2022-Mar","Not Recruiting","Unspecified","Unspecified",4,"Healthy","Healthy Unexposed","IgG, IgM or IgA, Antibodies","Vaccine",420
"NCT04656691","https://ClinicalTrials.gov/show/NCT04656691",NA,"United States","Minnesota","2020-Dec","2021-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Outpatient","Hospitalization, Adverse Events","Monoclonal antibody",7500
"NCT04604678","https://ClinicalTrials.gov/show/NCT04604678",NA,"United States","Michigan","2020-Oct","2021-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization","Metformin + Opiate antagonists, Standard of care",80
"NCT04547257","https://ClinicalTrials.gov/show/NCT04547257",NA,"Netherlands","Limburg","2020-Sep","2021-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA)","Broad- spectrum sorbent hemoperfusion device, Standard of care",42
"NCT04696562","https://ClinicalTrials.gov/show/NCT04696562",NA,"Turkey","Ankara","2021-Jan","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Dyspnea, SpO2, Respiratory Rate, Quality of Life, Anxiety","Respiratory support, Standard of care",44
"NCT04691947","https://ClinicalTrials.gov/show/NCT04691947",NA,"Turkey","Kayseri","2020-Dec","2021-Mar","Recruiting","Randomised","Double",3,"Healthy","Healthy Unexposed","Tumor Necrosis Factor (Any), Interferon (Any), IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",44
"NCT04684446","https://ClinicalTrials.gov/show/NCT04684446",NA,"United Kingdom","Cambridgeshire","2020-Dec","2021-Nov","Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed","Antibodies","Vaccine",100
"NCT04356690","https://ClinicalTrials.gov/show/NCT04356690",NA,"United States","Massachusetts","2020-Apr","2021-Dec","Recruiting","Randomised","Open-Label",3,NA,"Hospital, ICU","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, PaO2-FiO2","Other, Standard of care",64
"NCT04647669","https://ClinicalTrials.gov/show/NCT04647669",NA,"Jamaica","Kingston","2020-Dec","2021-Nov","Not Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Acalabrutinib, IFN, Remdesivir, Standard of care",100
"NCT04694612","https://ClinicalTrials.gov/show/NCT04694612",NA,"Nepal","Bagmati","2021-Jan","2021-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance","FPV, FPV + Remdesivir",676
"NCT04694612","https://ClinicalTrials.gov/show/NCT04694612",NA,"Nepal","Gandaki","2021-Jan","2021-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance","FPV, FPV + Remdesivir",676
"NCT04598581","https://ClinicalTrials.gov/show/NCT04598581",NA,"Switzerland","Bern","2020-Oct","2021-Oct","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, C-Reactive Protein, Ferritin, White Blood Cell Count, PaO2-FiO2","Radiation therapy",22
"NCT04657406","https://ClinicalTrials.gov/show/NCT04657406",NA,"United States","Florida","2020-Dec",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Outpatient",NA,"Other",NA
"CHICTR2100041704","http://www.chictr.org.cn/showproj.aspx?proj=66464",NA,"China","Shanxi","2021-Jan","2021-Mar","Completed","Randomised","Unspecified",3,"Healthy","Healthcare Workers","Serious Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",360
"CHICTR2100041705","http://www.chictr.org.cn/showproj.aspx?proj=66407",NA,"China","Shanxi","2021-Jan","2021-Mar","Recruiting","Randomised","Unspecified",3,"Healthy","Unclear","Serious Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",360
"CHICTR2100041706","http://www.chictr.org.cn/showproj.aspx?proj=66405",NA,"China","Shanxi","2021-Jan","2021-Mar","Recruiting","Randomised","Unspecified",3,"Healthy","Unclear","Serious Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",360
"NCT04359797","https://ClinicalTrials.gov/show/NCT04359797",NA,"United States","Illinois","2020-Apr","2020-Dec","Not Recruiting","Randomised","Single",2,NA,"Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Positioning",503
"NCT04359797","https://ClinicalTrials.gov/show/NCT04359797",NA,"United States","Tennessee","2020-Apr","2020-Dec","Not Recruiting","Randomised","Single",2,NA,"Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Positioning",503
"NCT04690920","https://ClinicalTrials.gov/show/NCT04690920",NA,"Pakistan","Punjab","2020-Dec","2020-Dec","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance","Remdesivir, Standard of care, TCZ",200
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","California","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Colorado","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Connecticut","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Hawaii","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Illinois","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Indiana","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Iowa","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Louisiana","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Maine","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Maryland","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Massachusetts","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Michigan","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Minnesota","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Montana","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","New Hampshire","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","New Jersey","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","New York","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","North Carolina","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Ohio","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Oregon","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Pennsylvania","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Rhode Island","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","South Carolina","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Texas","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Utah","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Virginia","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Washington","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"China","Beijing","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"France","Paris","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Germany","Berlin","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Germany","Hamburg","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Germany","Schleswig-Holstein","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"China","Hong Kong","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Bergamo","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Brescia","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Cremona","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Milano","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Rome","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Padova","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Parma","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Pavia","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Piacenza","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Roma","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Japan","Kanagawa","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Japan","Tokyo","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"South Korea","Daegu","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"South Korea","Seoul","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Netherlands","Amsterdam","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Singapore","Singapore","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Asturias","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Madrid","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Barcelona","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Bizkaia","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Sevilla","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Sweden","Stockholm","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Switzerland","Bern","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Taiwan","Taipei","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Taiwan","Taipei City","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","London","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Edinburgh","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Glasgow","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Liverpool","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Manchester","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Plymouth","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Sheffield","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Remdesivir",4891
"NCT04572399","https://ClinicalTrials.gov/show/NCT04572399",NA,"United States","California","2020-Oct","2020-Dec","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Viral Load or Clearance, Pneumonia or ARDS, C-Reactive Protein","Device",5
"NCT04475107","https://ClinicalTrials.gov/show/NCT04475107",NA,"South Korea","Seoul","2020-Jul","2021-Apr","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, SpO2, Respiratory Rate","Other, Standard of care",76
"NCT04475107","https://ClinicalTrials.gov/show/NCT04475107",NA,"South Korea","Incheon","2020-Jul","2021-Apr","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, SpO2, Respiratory Rate","Other, Standard of care",76
"NCT04686760","https://ClinicalTrials.gov/show/NCT04686760",NA,"Pakistan","Punjab","2020-Dec","2021-Jan","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Inhaled solution, Standard of care",30
"NCT04305457","https://ClinicalTrials.gov/show/NCT04305457",NA,"United States","Alaska","2020-Mar","2021-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Non-invasive respiratory support, Standard of care",70
"NCT04305457","https://ClinicalTrials.gov/show/NCT04305457",NA,"United States","Louisiana","2020-Mar","2021-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Non-invasive respiratory support, Standard of care",70
"NCT04305457","https://ClinicalTrials.gov/show/NCT04305457",NA,"United States","Massachusetts","2020-Mar","2021-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Non-invasive respiratory support, Standard of care",70
"NCT04382066","https://ClinicalTrials.gov/show/NCT04382066",NA,"Spain","Madrid","2020-May","2020-Dec","Completed","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Creatinine Phosphokinase, ALT, AST, Bilirubin, ECG","Other",46
"NCT04382066","https://ClinicalTrials.gov/show/NCT04382066",NA,"Spain","Barcelona","2020-May","2020-Dec","Completed","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Creatinine Phosphokinase, ALT, AST, Bilirubin, ECG","Other",46
"NCT04382066","https://ClinicalTrials.gov/show/NCT04382066",NA,"Spain","Ciudad Real","2020-May","2020-Dec","Completed","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Creatinine Phosphokinase, ALT, AST, Bilirubin, ECG","Other",46
"NCT04382066","https://ClinicalTrials.gov/show/NCT04382066",NA,"Spain","Guadalajara","2020-May","2020-Dec","Completed","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Creatinine Phosphokinase, ALT, AST, Bilirubin, ECG","Other",46
"NCT04328285","https://ClinicalTrials.gov/show/NCT04328285",NA,"France","Paris","2020-Mar","2021-Mar","Not Recruiting","Randomised","Triple",4,"Healthy","Healthcare Workers","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Treatment-emergent Adverse Events","HCQ, LPV/r, Standard of care",1200
"NCT04340050","https://ClinicalTrials.gov/show/NCT04340050",NA,"United States","Illinois","2020-Apr","2020-Dec","Completed","Single-Arm","Open-Label",1,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Plasma based therapy",10
"NCT04682574","https://ClinicalTrials.gov/show/NCT04682574",NA,"Pakistan","Punjab","2020-Dec","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Hospitalization, PaO2-FiO2","Standard of care, Vitamins",15
"NCT04651374","https://ClinicalTrials.gov/show/NCT04651374",NA,"Canada","Ontario","2020-Dec","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality","Device, Standard of care",40
"NCT04355936","https://ClinicalTrials.gov/show/NCT04355936",NA,"Argentina","Ciudad De Buenos Aires","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,NA,"Unclear","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Troponin, LDH, Urine Sample","Antihypertensive, Standard of care",400
"NCT04355936","https://ClinicalTrials.gov/show/NCT04355936",NA,"Argentina","Buenos Aires","2020-Apr","2020-Nov","Completed","Randomised","Open-Label",2,NA,"Unclear","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Troponin, LDH, Urine Sample","Antihypertensive, Standard of care",400
"NCT04394117","https://ClinicalTrials.gov/show/NCT04394117",NA,"Australia","New South Wales","2020-May","2021-Jun","Recruiting","Randomised","Single",2,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Renal Outcome (Unspecified)","ARBs, Standard of care",1500
"NCT04394117","https://ClinicalTrials.gov/show/NCT04394117",NA,"Australia","Victoria","2020-May","2021-Jun","Recruiting","Randomised","Single",2,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Renal Outcome (Unspecified)","ARBs, Standard of care",1500
"NCT04394117","https://ClinicalTrials.gov/show/NCT04394117",NA,"India","Delhi","2020-May","2021-Jun","Recruiting","Randomised","Single",2,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Renal Outcome (Unspecified)","ARBs, Standard of care",1500
"NCT04394117","https://ClinicalTrials.gov/show/NCT04394117",NA,"India","New Delhi","2020-May","2021-Jun","Recruiting","Randomised","Single",2,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Renal Outcome (Unspecified)","ARBs, Standard of care",1500
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","California","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Florida","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Georgia","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Illinois","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Kansas","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Kentucky","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Massachusetts","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Michigan","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","New York","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","North Carolina","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Pennsylvania","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Texas","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Washington","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Austria","Vienna","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"France","Paris","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Israel","Jerusalem","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Spain","Barcelona","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Spain","Salamanca","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United Kingdom","Kent","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United Kingdom","London","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United Kingdom","Plymouth","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other, Standard of care",202
"NCT04532931","https://ClinicalTrials.gov/show/NCT04532931",NA,"South Africa","Pretoria","2020-Aug","2021-Jun","Recruiting","Randomised","Open-Label",5,"Confirmed","Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Fever, Serious Adverse Events","Antimalarial, DAA, FPV + Antivirals, Standard of care",250
"NCT04357782","https://ClinicalTrials.gov/show/NCT04357782",NA,"United States","Virginia","2020-Apr","2020-Oct","Completed","Single-Arm","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Neutrophils, D-Dimer, LDH","Vitamins",20
"NCT04403646","https://ClinicalTrials.gov/show/NCT04403646",NA,"Argentina","Buenos Aires","2020-May","2020-Oct","Status Unclear","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospital Discharge","Other, Standard of care",124
"NCT04449276","https://ClinicalTrials.gov/show/NCT04449276",NA,"Belgium","Brussels","2020-Jun","2021-Dec","Not Recruiting","Randomised","Single",2,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","Standard of care, Vaccine",280
"NCT04449276","https://ClinicalTrials.gov/show/NCT04449276",NA,"Germany","Berlin","2020-Jun","2021-Dec","Not Recruiting","Randomised","Single",2,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","Standard of care, Vaccine",280
"NCT04657484","https://ClinicalTrials.gov/show/NCT04657484",NA,"India","Chandigarh","2020-Dec","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Dyspnea, SpO2, Quality of Life","Corticosteroids",100
"NCT04525820","https://ClinicalTrials.gov/show/NCT04525820",NA,"Switzerland","Bern","2020-Aug","2021-May","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Vitamins",80
"NCT04531748","https://ClinicalTrials.gov/show/NCT04531748",NA,"United States","Washington, Dc","2020-Aug","2021-Sep","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Outpatient","Heart Rate, SpO2","Hormone therapy + Melatonin, Melatonin, Standard of care",390
"NCT04372979","https://ClinicalTrials.gov/show/NCT04372979",NA,"France","Paris","2020-May","2021-May","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, Quality of Life","Plasma based therapy, Standard of care",80
"NCT04325906","https://ClinicalTrials.gov/show/NCT04325906",NA,"United States","Illinois","2020-Mar","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU",NA,"Non-invasive respiratory support, Positioning + Non-invasive respiratory support",346
"CHICTR2000038804","http://www.chictr.org.cn/showproj.aspx?proj=62350",NA,"China","Jiangsu","2020-Oct","2022-Apr","Not Recruiting","Randomised","Double",6,"Healthy","Healthy Unexposed","Serious Adverse Events, Coagulation Test, Urine Sample, IgG, IgM or IgA, Antibodies","Vaccine",180
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Arizona","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","California","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","District Of Columbia","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Florida","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Illinois","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Indiana","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Louisiana","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Maryland","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Massachusetts","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Minnesota","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Missouri","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","New Jersey","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","New York","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","North Carolina","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Ohio","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Pennsylvania","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Texas","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Washington","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"United States","Wisconsin","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04377620","https://ClinicalTrials.gov/show/NCT04377620",NA,"Russia","Moscow","2020-May","2021-Apr","Recruiting","Randomised","Double",3,"Confirmed","ICU","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events","JAKi, Standard of care",500
"NCT04366791","https://ClinicalTrials.gov/show/NCT04366791",NA,"United States","Georgia","2020-Apr","2021-Apr","Suspended","Single-Arm","Open-Label",1,NA,"Hospital","C-Reactive Protein, Ferritin, IL-6, Hemoglobin, D-Dimer, eGFR, Myoglobin, Troponin, Procalcitonin, Fibrinogen, Triglycerides, ALT, AST, Albumin, Bilirubin, LDH, Blood Gas, Blood Pressure, Heart Rate, Radiographic Findings, Blood pH","Radiation therapy",10
"NCT04673162","https://ClinicalTrials.gov/show/NCT04673162",NA,"Italy","Reggio Emilia","2020-Dec","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospitalization","Standard of care, Standard of care + Corticosteroids",260
"NCT04669015","https://ClinicalTrials.gov/show/NCT04669015",NA,"United States","Michigan","2020-Dec","2021-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Adverse Events","Other + Standard of care, Standard of care",914
"NCT04619628","https://ClinicalTrials.gov/show/NCT04619628",NA,"United Kingdom","London","2020-Nov","2021-Jun","Recruiting","Randomised","Quadruple",7,"Healthy","Healthy Unexposed","Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",48
"NCT04402879","https://ClinicalTrials.gov/show/NCT04402879",NA,"Canada","Alberta","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",2,"Suspected","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, SpO2","Positioning, Standard of care",596
"NCT04390022","https://ClinicalTrials.gov/show/NCT04390022",NA,"Spain","Navarra","2020-May","2020-Sep","Completed","Randomised","Double",2,"Confirmed","Outpatient","Viral Load or Clearance, Cough, Fever, Adverse Events, IgG, IgM or IgA, CD4, CD8","Ivermectin, Standard of care",24
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Arizona","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","California","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","District Of Columbia","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Florida","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Georgia","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Illinois","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Massachusetts","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Montana","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","North Carolina","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","Ohio","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"United States","South Carolina","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"Belgium","Brussels","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"Brazil","Brasilia","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"Moldova","Chisinau","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"Romania","Bucharest","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"South Africa","Pretoria","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04396106","https://ClinicalTrials.gov/show/NCT04396106",NA,"Ukraine","Kyiv (Kiev)","2020-May","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","Other, Standard of care",190
"NCT04666116","https://ClinicalTrials.gov/show/NCT04666116",NA,"Spain","Valencia","2020-Dec","2020-Dec","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Viral Load or Clearance","Nutrition, Standard of care",96
"NCT04668469","https://ClinicalTrials.gov/show/NCT04668469",NA,"Egypt","Cairo","2020-Dec","2020-Sep","Completed","Randomised","Triple",6,"Confirmed","Unclear","Mortality, Hospitalization","HCQ + Standard of care, HCQ + Standard of care + Corticosteroids, Ivermectin + Personal protective measures, Ivermectin + Standard of care, Ivermectin + Standard of care + Corticosteroids, Personal protective measures",600
"NCT04668235","https://ClinicalTrials.gov/show/NCT04668235",NA,"Brazil","Brasilia","2020-Dec","2021-Jun","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Serious Adverse Events","DAA, Standard of care",342
"NCT04366232","https://ClinicalTrials.gov/show/NCT04366232",NA,"France","Paris","2020-Apr","2020-Oct","Status Unclear","Randomised","Open-Label",3,NA,"Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA)","Anakinra with/without JAKi, Standard of care",2
"NCT04366232","https://ClinicalTrials.gov/show/NCT04366232",NA,"France","Var","2020-Apr","2020-Oct","Status Unclear","Randomised","Open-Label",3,NA,"Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA)","Anakinra with/without JAKi, Standard of care",2
"NCT04530435","https://ClinicalTrials.gov/show/NCT04530435",NA,"Denmark","Copenhagen","2020-Aug","2021-Apr","Recruiting","Randomised","Single",2,"Confirmed","Outpatient",NA,"Respiratory support, Standard of care",400
"NCT04635241","https://ClinicalTrials.gov/show/NCT04635241",NA,"Argentina","Buenos Aires","2020-Nov","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Anticoagulants, Standard of care",712
"NCT04635241","https://ClinicalTrials.gov/show/NCT04635241",NA,"Egypt","Cairo","2020-Nov","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Anticoagulants, Standard of care",712
"NCT04667780","https://ClinicalTrials.gov/show/NCT04667780",NA,"Pakistan","Islamabad","2020-Dec","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-6","Colchicine + Standard of care, Standard of care",102
"NCT04372628","https://ClinicalTrials.gov/show/NCT04372628",NA,"United States","Colorado","2020-May","2021-Apr","Recruiting","Randomised","Triple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life","HCQ, LPV/r, Standard of care",600
"NCT04372628","https://ClinicalTrials.gov/show/NCT04372628",NA,"United States","Massachusetts","2020-May","2021-Apr","Recruiting","Randomised","Triple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life","HCQ, LPV/r, Standard of care",600
"NCT04372628","https://ClinicalTrials.gov/show/NCT04372628",NA,"United States","Mississippi","2020-May","2021-Apr","Recruiting","Randomised","Triple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life","HCQ, LPV/r, Standard of care",600
"NCT04372628","https://ClinicalTrials.gov/show/NCT04372628",NA,"United States","Oregon","2020-May","2021-Apr","Recruiting","Randomised","Triple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life","HCQ, LPV/r, Standard of care",600
"NCT04372628","https://ClinicalTrials.gov/show/NCT04372628",NA,"United States","Tennessee","2020-May","2021-Apr","Recruiting","Randomised","Triple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life","HCQ, LPV/r, Standard of care",600
"NCT04372628","https://ClinicalTrials.gov/show/NCT04372628",NA,"United States","Wisconsin","2020-May","2021-Apr","Recruiting","Randomised","Triple",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life","HCQ, LPV/r, Standard of care",600
"NCT04487886","https://ClinicalTrials.gov/show/NCT04487886",NA,"United States","Georgia","2020-Jul","2022-Feb","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, Interferon (Any), PD-1, MCP-1, MIP-1, Monocyte Count, IgG, IgM or IgA, Antibodies, CD8","Other, Standard of care",80
"NCT04667247","https://ClinicalTrials.gov/show/NCT04667247",NA,"United States","California","2020-Dec","2021-Apr","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","ICU Admission, Hospitalization, Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Troponin, Prothrombin, ALT","Other, Standard of care",66
"NCT04549922","https://ClinicalTrials.gov/show/NCT04549922",NA,"Brazil","Rio De Janeiro","2020-Sep","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Antisense therapy, Standard of care",111
"NCT04549922","https://ClinicalTrials.gov/show/NCT04549922",NA,"Brazil","Brasilia","2020-Sep","2021-Feb","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Antisense therapy, Standard of care",111
"NCT04463602","https://ClinicalTrials.gov/show/NCT04463602",NA,"Mexico","Mexico","2020-Jul","2021-Jan","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, D-Dimer","Other + Standard of care, Standard of care",24
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","California","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","District Of Columbia","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Illinois","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Indiana","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Louisiana","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Maryland","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Massachusetts","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Michigan","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Mississippi","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Nevada","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","New Mexico","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Oregon","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Pennsylvania","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Texas","2020-Apr","2021-Dec","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","mAb, Standard of care",384
"NCT04442230","https://ClinicalTrials.gov/show/NCT04442230",NA,"United States","Florida","2020-Jun","2021-Feb","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Outpatient","Mortality","Standard of care, Vaccine",96
"NCT04442230","https://ClinicalTrials.gov/show/NCT04442230",NA,"United States","Georgia","2020-Jun","2021-Feb","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Outpatient","Mortality","Standard of care, Vaccine",96
"NCT04442230","https://ClinicalTrials.gov/show/NCT04442230",NA,"United States","Illinois","2020-Jun","2021-Feb","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Outpatient","Mortality","Standard of care, Vaccine",96
"NCT04442230","https://ClinicalTrials.gov/show/NCT04442230",NA,"United States","Louisiana","2020-Jun","2021-Feb","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Outpatient","Mortality","Standard of care, Vaccine",96
"NCT04442230","https://ClinicalTrials.gov/show/NCT04442230",NA,"United States","New York","2020-Jun","2021-Feb","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Outpatient","Mortality","Standard of care, Vaccine",96
"NCT04442230","https://ClinicalTrials.gov/show/NCT04442230",NA,"United States","North Carolina","2020-Jun","2021-Feb","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Outpatient","Mortality","Standard of care, Vaccine",96
"NCT04442230","https://ClinicalTrials.gov/show/NCT04442230",NA,"United States","Texas","2020-Jun","2021-Feb","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Outpatient","Mortality","Standard of care, Vaccine",96
"NCT04649515","https://ClinicalTrials.gov/show/NCT04649515",NA,"Singapore","Singapore","2020-Dec","2021-Aug","Recruiting","Randomised","Double",3,"Confirmed","Unclear","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Weight, Height or BMI","Monoclonal antibody, Standard of care",1305
"CHICTR2000038333","http://www.chictr.org.cn/showproj.aspx?proj=61769",NA,"China","Beijing","2020-Sep","2021-Sep","Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","ECG","TCM",120
"CHICTR2000038343","http://www.chictr.org.cn/showproj.aspx?proj=61668",NA,"China","Beijing","2020-Sep","2021-Aug","Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","ECG","TCM",120
"NCT04370262","https://ClinicalTrials.gov/show/NCT04370262",NA,"United States","New York","2020-Apr","2020-Sep","Completed","Randomised","Triple",3,NA,"Hospital","Mortality","HCQ, HCQ + Other, Standard of care",233
"NCT04664010","https://ClinicalTrials.gov/show/NCT04664010",NA,"China","Shaanxi","2020-Dec","2021-Jan","Not Recruiting","Randomised","Single",6,"Confirmed","Unclear","Cough, Fever, C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), Erythrocyte Sedimentation Rate, Procalcitonin, SpO2, Respiratory Rate, Radiographic Findings","TCM + Western Medicine, TCM + Western Medicine + Vitamins, Western Medicine",60
"NCT04343976","https://ClinicalTrials.gov/show/NCT04343976",NA,"United States","Massachusetts","2020-Apr","2021-Apr","Recruiting","Randomised","Single",2,NA,"Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Respiratory Rate","IFN",20
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Arizona","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Arkansas","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","California","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Colorado","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","District Of Columbia","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Illinois","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Kansas","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Louisiana","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Maryland","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Massachusetts","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Michigan","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Minnesota","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Mississippi","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","New Mexico","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","New York","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Ohio","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Tennessee","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Utah","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Virginia","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04362176","https://ClinicalTrials.gov/show/NCT04362176",NA,"United States","Washington","2020-Apr","2021-Apr","Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",1000
"NCT04365257","https://ClinicalTrials.gov/show/NCT04365257",NA,"United States","Maryland","2020-Apr","2021-Jun","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Other, Standard of care",220
"NCT04647695","https://ClinicalTrials.gov/show/NCT04647695",NA,"China","Hong Kong","2020-Dec","2021-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","IFN + Remdesivir, Remdesivir",100
"NCT04329923","https://ClinicalTrials.gov/show/NCT04329923",NA,"United States","Pennsylvania","2020-Apr","2020-Nov","Status Unclear","Randomised","Triple",6,"Confirmed Or Healthy","Healthcare Workers, Outpatient, Hospital","Hospitalization, Hospital Discharge","HCQ, Standard of care",173
"NCT04530136","https://ClinicalTrials.gov/show/NCT04530136",NA,"United States","New Jersey","2020-Aug","2021-Aug","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Non-invasive Ventilation","Other, Standard of care",120
"NCT04661930","https://ClinicalTrials.gov/show/NCT04661930",NA,"Israel","Jerusalem","2020-Dec","2021-Apr","Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2, Renal Outcome (Unspecified)","Other + Standard of care, Standard of care",50
"NCT04659941","https://ClinicalTrials.gov/show/NCT04659941",NA,"Brazil","Rio De Janeiro","2020-Dec","2021-Oct","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers",NA,"Standard of care, Vaccine",1000
"NCT04659122","https://ClinicalTrials.gov/show/NCT04659122",NA,"United States","Ohio","2020-Dec","2021-Jun","Not Recruiting","Non-Randomised","Open-Label",3,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Other",9
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Alabama","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","California","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Colorado","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Georgia","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Illinois","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Louisiana","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Maryland","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Massachusetts","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Minnesota","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Missouri","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Nebraska","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","New York","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","North Carolina","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Pennsylvania","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Tennessee","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Texas","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Virginia","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Washington","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Denmark","Copenhagen","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Germany","Nordrhein-Westfalen","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Germany","Berlin","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Macedonia","Skopje","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Greece","Athens","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Japan","Tokyo","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"South Korea","Gyeonggi","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"South Korea","Seoul","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Mexico","Mexico","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Singapore","Singapore","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Spain","Barcelona","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","East Sussex","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","City","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","Newcastle Upon Tyne","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","Leeds","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","London","2020-Feb","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Standard of care",1062
"NCT04659486","https://ClinicalTrials.gov/show/NCT04659486",NA,"Brazil","Sao Paulo","2020-Dec","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed","Resolved Discharged","Pneumonia or ARDS, C-Reactive Protein, Ferritin, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, Triglycerides, Glucose, IgG, IgM or IgA, Antibodies, 6-Minute Walking Distance, Radiographic Findings, Quality of Life, Depression, Anxiety","Rehabilitation, Standard of care",100
"NCT04410354","https://ClinicalTrials.gov/show/NCT04410354",NA,"United States","Arizona","2020-Jun","2020-Dec","Status Unclear","Randomised","Triple",3,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2","Merimepodib + Remdesivir, Remdesivir",44
"NCT04410354","https://ClinicalTrials.gov/show/NCT04410354",NA,"United States","Florida","2020-Jun","2020-Dec","Status Unclear","Randomised","Triple",3,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2","Merimepodib + Remdesivir, Remdesivir",44
"NCT04410354","https://ClinicalTrials.gov/show/NCT04410354",NA,"United States","Minnesota","2020-Jun","2020-Dec","Status Unclear","Randomised","Triple",3,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2","Merimepodib + Remdesivir, Remdesivir",44
"NCT04410354","https://ClinicalTrials.gov/show/NCT04410354",NA,"United States","New Jersey","2020-Jun","2020-Dec","Status Unclear","Randomised","Triple",3,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2","Merimepodib + Remdesivir, Remdesivir",44
"NCT04410354","https://ClinicalTrials.gov/show/NCT04410354",NA,"United States","Texas","2020-Jun","2020-Dec","Status Unclear","Randomised","Triple",3,"Confirmed","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2","Merimepodib + Remdesivir, Remdesivir",44
"NCT04527081","https://ClinicalTrials.gov/show/NCT04527081",NA,"Japan","Osaka","2020-Aug","2020-Nov","Not Recruiting","Randomised","Open-Label",3,"Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, ACE, ACE-II, IgG, IgM or IgA, Antibodies","Vaccine",30
"NCT04552366","https://ClinicalTrials.gov/show/NCT04552366",NA,"China","Hubei","2020-Sep","2020-Dec","Not Recruiting","Non-Randomised","Open-Label",6,"Healthy","Healthy Unexposed","Serious Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",149
"NCT04333420","https://ClinicalTrials.gov/show/NCT04333420",NA,"Germany","Berlin","2020-Apr","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance, PaO2-FiO2","IFN, Standard of care",390
"NCT04333420","https://ClinicalTrials.gov/show/NCT04333420",NA,"Netherlands","Amsterdam","2020-Apr","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance, PaO2-FiO2","IFN, Standard of care",390
"NCT04605588","https://ClinicalTrials.gov/show/NCT04605588",NA,"United States","New Jersey","2020-Oct","2021-Apr","Recruiting","Randomised","Quadruple",6,"Confirmed","Outpatient","Viral Load or Clearance","HCQ + Antivirals, Standard of care",70
"NCT04638673","https://ClinicalTrials.gov/show/NCT04638673",NA,"United States","South Carolina","2020-Nov","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient",NA,"Device",30
"NCT04524715","https://ClinicalTrials.gov/show/NCT04524715",NA,"United States","Delaware","2020-Aug","2022-Mar","Not Recruiting","Randomised","Single",2,"Confirmed","Unclear","C-Reactive Protein, IL-6","Other, Standard of care",64
"NCT04473274","https://ClinicalTrials.gov/show/NCT04473274",NA,"United States","Oregon","2020-Jul","2020-Nov","Completed","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events, Ferritin, D-Dimer","Other, Standard of care",10
"NCT04382846","https://ClinicalTrials.gov/show/NCT04382846",NA,"Egypt","Cairo","2020-May","2030-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Unclear",NA,"Antivirals + AZT, Ivermectin + Antivirals, Ivermectin + Antivirals + AZT, Ivermectin + HCQ",160
"NCT04333368","https://ClinicalTrials.gov/show/NCT04333368",NA,"France","Paris","2020-Apr","2021-Jan","Not Recruiting","Randomised","Triple",2,"Confirmed","ICU","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Antibodies, SRAGE, PaO2-FiO2, Quality of Life","Standard of care, Stem cells",47
"NCT04345419","https://ClinicalTrials.gov/show/NCT04345419",NA,"Egypt","Cairo","2020-Apr","2029-Dec","Recruiting","Randomised","Single",2,NA,"Unclear","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events",NA,120
"CHICTR2000040632","http://www.chictr.org.cn/showproj.aspx?proj=65372",NA,"China","Beijing","2020-Dec","2020-Jun","Completed","Single-Arm","Unspecified",1,"Confirmed","Unclear","Cough, Fever, Other Mild Symptoms, Radiographic Findings","Other",34
"NCT04568031","https://ClinicalTrials.gov/show/NCT04568031",NA,"Japan","Fukuoka","2020-Sep","2021-Nov","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Serious Adverse Events","Vaccine",256
"NCT04568031","https://ClinicalTrials.gov/show/NCT04568031",NA,"Japan","Tokyo","2020-Sep","2021-Nov","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Serious Adverse Events","Vaccine",256
"NCT04575610","https://ClinicalTrials.gov/show/NCT04575610",NA,"United States","Connecticut","2020-Oct","2021-Mar","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, PaO2-FiO2, Radiographic Findings","Other + Standard of care, Standard of care",68
"NCT04445194","https://ClinicalTrials.gov/show/NCT04445194",NA,"China","Chongqing","2020-Jun","2020-Oct","Not Recruiting","Randomised","Double",3,"Healthy","Unclear","Adverse Events","Standard of care, Vaccine",50
"NCT04466085","https://ClinicalTrials.gov/show/NCT04466085",NA,"China","Hunan","2020-Jul","2020-Oct","Not Recruiting","Randomised","Double",6,"Healthy","Healthy Unexposed","Adverse Events, IL-2, IL-4, IL-6, Antibodies","Standard of care, Vaccine",900
"NCT04353336","https://ClinicalTrials.gov/show/NCT04353336",NA,"Egypt","Cairo","2020-Apr","2030-Sep","Recruiting","Randomised","Open-Label",2,NA,"Unclear","Viral Load or Clearance","HCQ",200
"NCT04652648","https://ClinicalTrials.gov/show/NCT04652648",NA,"United States","Pennsylvania","2020-Dec","2020-Oct","Completed","Randomised","Open-Label",2,"Suspected","Outpatient","Mortality, ECG","HCQ, Standard of care",54
"NCT04355364","https://ClinicalTrials.gov/show/NCT04355364",NA,"France","Paris","2020-Apr","2020-Nov","Recruiting","Randomised","Single",2,NA,"ICU","Clinical Improvement Score (Any)","Inhaled solution, Standard of care",100
"NCT04649879","https://ClinicalTrials.gov/show/NCT04649879",NA,"Sweden","Stockholm","2020-Dec","2022-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Adverse Events, PaO2-FiO2","Plasma based therapy, Standard of care",920
"NCT04432298","https://ClinicalTrials.gov/show/NCT04432298",NA,"United States","Michigan","2020-Jun","2020-Dec","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","mAb, Standard of care",130
"NCT04432298","https://ClinicalTrials.gov/show/NCT04432298",NA,"United States","North Carolina","2020-Jun","2020-Dec","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","mAb, Standard of care",130
"NCT04432298","https://ClinicalTrials.gov/show/NCT04432298",NA,"United States","Pennsylvania","2020-Jun","2020-Dec","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","mAb, Standard of care",130
"NCT04497948","https://ClinicalTrials.gov/show/NCT04497948",NA,"United States","Maryland","2020-Aug","2020-Nov","Status Unclear","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), C-Reactive Protein","Acalabrutinib",8
"NCT04497948","https://ClinicalTrials.gov/show/NCT04497948",NA,"United States","Minnesota","2020-Aug","2020-Nov","Status Unclear","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), C-Reactive Protein","Acalabrutinib",8
"NCT04497948","https://ClinicalTrials.gov/show/NCT04497948",NA,"United States","North Carolina","2020-Aug","2020-Nov","Status Unclear","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), C-Reactive Protein","Acalabrutinib",8
"NCT04497948","https://ClinicalTrials.gov/show/NCT04497948",NA,"United States","Pennsylvania","2020-Aug","2020-Nov","Status Unclear","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), C-Reactive Protein","Acalabrutinib",8
"NCT04497948","https://ClinicalTrials.gov/show/NCT04497948",NA,"Brazil","Brasilia","2020-Aug","2020-Nov","Status Unclear","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), C-Reactive Protein","Acalabrutinib",8
"NCT04497948","https://ClinicalTrials.gov/show/NCT04497948",NA,"Brazil","Sao Paulo","2020-Aug","2020-Nov","Status Unclear","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), C-Reactive Protein","Acalabrutinib",8
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Alabama","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","California","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","District Of Columbia","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Florida","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Illinois","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Indiana","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Kentucky","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Maryland","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","New Jersey","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","New York","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Pennsylvania","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Tennessee","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Texas","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Virginia","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04380688","https://ClinicalTrials.gov/show/NCT04380688",NA,"United States","Washington","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2","Acalabrutinib, Standard of care",62
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Alabama","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","California","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Colorado","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","District Of Columbia","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Florida","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Georgia","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Illinois","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Indiana","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Louisiana","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Maryland","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Massachusetts","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Minnesota","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Missouri","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Nebraska","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","New Mexico","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","New York","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","North Carolina","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Oregon","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Pennsylvania","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Tennessee","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Texas","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Utah","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Virginia","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United States","Washington","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"Denmark","Copenhagen","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"Japan","Tokyo","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"South Korea","Seoul","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"Mexico","Mexico","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"Singapore","Singapore","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"Spain","Barcelona","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"Spain","Madrid","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United Kingdom","London","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United Kingdom","City","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United Kingdom","Leeds","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04401579","https://ClinicalTrials.gov/show/NCT04401579",NA,"United Kingdom","Newcastle Upon Tyne","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose","Remdesivir, Remdesivir + JAKi",1034
"NCT04564716","https://ClinicalTrials.gov/show/NCT04564716",NA,"Belarus","Minsk","2020-Sep","2021-Mar","Not Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events, Antibodies","Standard of care, Vaccine",100
"NCT04564716","https://ClinicalTrials.gov/show/NCT04564716",NA,"Belarus","Vitebsk","2020-Sep","2021-Mar","Not Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events, Antibodies","Standard of care, Vaccine",100
"NCT04339426","https://ClinicalTrials.gov/show/NCT04339426",NA,"United States","Arizona","2020-Apr","2021-Jul","Recruiting","Single-Arm","Open-Label",1,NA,"Unclear","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","AZT + Antibiotics",25
"NCT04552379","https://ClinicalTrials.gov/show/NCT04552379",NA,"Chile","Santiago","2020-Sep","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Adverse Events, Interferon (Any)","IFN, Standard of care",1240
"NCT04343755","https://ClinicalTrials.gov/show/NCT04343755",NA,"United States","New Jersey","2020-Apr","2021-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation","Plasma based therapy",52
"NCT04546841","https://ClinicalTrials.gov/show/NCT04546841",NA,"Germany","Berlin","2020-Sep","2021-Sep","Recruiting","Unspecified","Open-Label",1,"Healthy","Healthy Unexposed","Coagulation Test","Vaccine",36
"NCT04647604","https://ClinicalTrials.gov/show/NCT04647604",NA,"Sweden","Stockholm","2020-Dec","2021-Apr","Recruiting","Randomised","Single",2,"Confirmed Or Suspected","Hospital","Hospitalization, Coagulation Test, Cardiac Outcome (Unspecified)","Nutrition, Standard of care",40
"NCT04646031","https://ClinicalTrials.gov/show/NCT04646031",NA,"United States","Washington","2020-Nov",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Hospital",NA,"Botanical drug",NA
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Brazil","Alagoas","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Brazil","Bahia","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Brazil","Brasilia","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Brazil","Minas Gerais","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Brazil","Para","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Brazil","Pernambuco","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Brazil","Rio De Janeiro","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Brazil","Rio Grande Do Sul","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Brazil","Santa Catarina","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04466540","https://ClinicalTrials.gov/show/NCT04466540",NA,"Israel","Jerusalem","2020-Jul","2021-Jan","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever","HCQ, Standard of care",1300
"NCT04374461","https://ClinicalTrials.gov/show/NCT04374461",NA,"United States","New York","2020-May","2022-May","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital, ICU","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any)","Other",84
"NCT04332835","https://ClinicalTrials.gov/show/NCT04332835",NA,"Colombia","Cundinamarca","2020-Apr","2020-Oct","Completed","Randomised","Single",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA","HCQ + AZT, Plasma based therapy + HCQ + AZT",92
"NCT04536051","https://ClinicalTrials.gov/show/NCT04536051",NA,"Brazil","Bahia","2020-Sep","2021-Sep","Recruiting","Randomised","Single",4,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, Antibodies","Vaccine",10300
"NCT04536051","https://ClinicalTrials.gov/show/NCT04536051",NA,"Brazil","Rio Grande Do Norte","2020-Sep","2021-Sep","Recruiting","Randomised","Single",4,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, Antibodies","Vaccine",10300
"NCT04536051","https://ClinicalTrials.gov/show/NCT04536051",NA,"Brazil","Rio Grande Do Sul","2020-Sep","2021-Sep","Recruiting","Randomised","Single",4,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, Antibodies","Vaccine",10300
"NCT04536051","https://ClinicalTrials.gov/show/NCT04536051",NA,"Brazil","Rio De Janeiro","2020-Sep","2021-Sep","Recruiting","Randomised","Single",4,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, Antibodies","Vaccine",10300
"NCT04536051","https://ClinicalTrials.gov/show/NCT04536051",NA,"Brazil","Brasilia","2020-Sep","2021-Sep","Recruiting","Randomised","Single",4,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Serious Adverse Events, Antibodies","Vaccine",10300
"NCT04444674","https://ClinicalTrials.gov/show/NCT04444674",NA,"South Africa","Gauteng","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Adverse Events","Standard of care, Vaccine",2130
"NCT04444674","https://ClinicalTrials.gov/show/NCT04444674",NA,"South Africa","Western Cape","2020-Jun","2020-Dec","Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Adverse Events","Standard of care, Vaccine",2130
"NCT04646044","https://ClinicalTrials.gov/show/NCT04646044",NA,"United States","Florida","2020-Nov","2021-Jan","Recruiting","Randomised","Double",3,"Confirmed","Unclear","Non-invasive Ventilation, Treatment-emergent Adverse Events, Serious Adverse Events, Lymphocyte Count, Antibodies","CD122-preferential IL2 pathway, Standard of care",30
"NCT04646044","https://ClinicalTrials.gov/show/NCT04646044",NA,"United States","Texas","2020-Nov","2021-Jan","Recruiting","Randomised","Double",3,"Confirmed","Unclear","Non-invasive Ventilation, Treatment-emergent Adverse Events, Serious Adverse Events, Lymphocyte Count, Antibodies","CD122-preferential IL2 pathway, Standard of care",30
"NCT04645407","https://ClinicalTrials.gov/show/NCT04645407",NA,"China","Shanghai","2020-Nov","2020-Apr","Completed","Non-Randomised","Open-Label",2,"Confirmed","Hospital","C-Reactive Protein, Procalcitonin, SpO2, Radiographic Findings","Standard of care, TCM",66
"NCT04532294","https://ClinicalTrials.gov/show/NCT04532294",NA,"Australia","Queensland","2020-Aug","2021-Feb","Recruiting","Randomised","Triple",6,"Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies","Igs, Standard of care",30
"NCT04353284","https://ClinicalTrials.gov/show/NCT04353284",NA,"United States","Connecticut","2020-Apr","2021-May","Recruiting","Randomised","Quadruple",2,NA,"Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms","Other, Standard of care",114
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Alabama","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Arizona","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Colorado","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Florida","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Georgia","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Michigan","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Nevada","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","New York","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Ohio","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Oklahoma","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Oregon","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","South Carolina","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Texas","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Virginia","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04539275","https://ClinicalTrials.gov/show/NCT04539275",NA,"United States","Wisconsin","2020-Sep","2022-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose","Plasma based therapy, Standard of care",702
"NCT04633772","https://ClinicalTrials.gov/show/NCT04633772",NA,"Brazil","Minas Gerais","2020-Nov","2021-Feb","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","ICU","ICU Admission, Non-invasive Ventilation, Serious or Seconday Infections, D-Dimer, Troponin, Radiographic Findings","Antihypertensive, Standard of care",130
"NCT04357444","https://ClinicalTrials.gov/show/NCT04357444",NA,"France","Paris","2020-Apr","2020-Nov","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, C-Reactive Protein, IL-2, CD4, CD8, PaO2-FiO2, Patient Positioning","Immunomodulators, Standard of care",30
"NCT04416334","https://ClinicalTrials.gov/show/NCT04416334",NA,"Spain","Cantabria","2020-Jun","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Hospitalization","Colchicine, Standard of care",954
"NCT04338126","https://ClinicalTrials.gov/show/NCT04338126",NA,"United States","Alabama","2020-Apr","2021-Dec","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms",NA,60
"NCT04458298","https://ClinicalTrials.gov/show/NCT04458298",NA,"United States","California","2020-Jul","2021-Jan","Recruiting","Randomised","Double",4,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Fever, Serious Adverse Events, Respiratory Rate, Radiographic Findings, Hypoxemia","Other, Standard of care",24
"NCT04458298","https://ClinicalTrials.gov/show/NCT04458298",NA,"United States","Florida","2020-Jul","2021-Jan","Recruiting","Randomised","Double",4,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Fever, Serious Adverse Events, Respiratory Rate, Radiographic Findings, Hypoxemia","Other, Standard of care",24
"NCT04458298","https://ClinicalTrials.gov/show/NCT04458298",NA,"United States","Georgia","2020-Jul","2021-Jan","Recruiting","Randomised","Double",4,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Fever, Serious Adverse Events, Respiratory Rate, Radiographic Findings, Hypoxemia","Other, Standard of care",24
"NCT04458298","https://ClinicalTrials.gov/show/NCT04458298",NA,"United States","Maryland","2020-Jul","2021-Jan","Recruiting","Randomised","Double",4,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Fever, Serious Adverse Events, Respiratory Rate, Radiographic Findings, Hypoxemia","Other, Standard of care",24
"NCT04458298","https://ClinicalTrials.gov/show/NCT04458298",NA,"United States","Texas","2020-Jul","2021-Jan","Recruiting","Randomised","Double",4,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Fever, Serious Adverse Events, Respiratory Rate, Radiographic Findings, Hypoxemia","Other, Standard of care",24
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Alberta","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","British Columbia","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Manitoba","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Nova Scotia","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Ontario","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Quebec","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",100
"NCT04377568","https://ClinicalTrials.gov/show/NCT04377568",NA,"Canada","Saskatchewan","2020-May","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",100
"NCT04542408","https://ClinicalTrials.gov/show/NCT04542408",NA,"Germany","Berlin","2020-Sep","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anticoagulants",172
"NCT04542408","https://ClinicalTrials.gov/show/NCT04542408",NA,"Germany","Hamburg","2020-Sep","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anticoagulants",172
"NCT04324606","https://ClinicalTrials.gov/show/NCT04324606",NA,"United Kingdom","Southampton","2020-Mar","2021-Oct","Not Recruiting","Randomised","Single",7,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",1090
"NCT04324606","https://ClinicalTrials.gov/show/NCT04324606",NA,"United Kingdom","Bristol","2020-Mar","2021-Oct","Not Recruiting","Randomised","Single",7,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",1090
"NCT04324606","https://ClinicalTrials.gov/show/NCT04324606",NA,"United Kingdom","London","2020-Mar","2021-Oct","Not Recruiting","Randomised","Single",7,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",1090
"NCT04449718","https://ClinicalTrials.gov/show/NCT04449718",NA,"Brazil","Sao Paulo","2020-Jun","2020-Oct","Completed","Randomised","Quadruple",2,"Suspected","Hospital","Mortality, ICU Admission, Hospitalization, C-Reactive Protein","Standard of care, Vitamins",240
"NCT04324996","https://ClinicalTrials.gov/show/NCT04324996",NA,"China","Chongqing","2020-Mar","2022-Feb","Recruiting","Randomised","Quadruple",5,"Confirmed","Unclear","Clinical Improvement Score (Any), Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events","Natural Killer Cells",90
"NCT04472494","https://ClinicalTrials.gov/show/NCT04472494",NA,"United States","Kentucky","2020-Jul","2021-Jan","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Serious Adverse Events","Immunomodulators, Standard of care",129
"NCT04472494","https://ClinicalTrials.gov/show/NCT04472494",NA,"United States","Massachusetts","2020-Jul","2021-Jan","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Serious Adverse Events","Immunomodulators, Standard of care",129
"NCT04472494","https://ClinicalTrials.gov/show/NCT04472494",NA,"United States","New Jersey","2020-Jul","2021-Jan","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Serious Adverse Events","Immunomodulators, Standard of care",129
"NCT04472494","https://ClinicalTrials.gov/show/NCT04472494",NA,"United States","Texas","2020-Jul","2021-Jan","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Serious Adverse Events","Immunomodulators, Standard of care",129
"NCT04472494","https://ClinicalTrials.gov/show/NCT04472494",NA,"Puerto Rico","Puerto Rico","2020-Jul","2021-Jan","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Serious Adverse Events","Immunomodulators, Standard of care",129
"NCT04412772","https://ClinicalTrials.gov/show/NCT04412772",NA,"United States","Hawaii","2020-Jun","2021-Dec","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",300
"NCT04586153","https://ClinicalTrials.gov/show/NCT04586153",NA,"China","Jiangsu","2020-Oct","2021-Apr","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Adverse Events, Weight, Height or BMI, Antibodies, Blood Pressure, ECG","mAb, Standard of care",456
"NCT04511650","https://ClinicalTrials.gov/show/NCT04511650",NA,"United States","California","2020-Aug","2021-Feb","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events","Razuprotafib, Standard of care",180
"NCT04511650","https://ClinicalTrials.gov/show/NCT04511650",NA,"United States","District Of Columbia","2020-Aug","2021-Feb","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events","Razuprotafib, Standard of care",180
"NCT04511650","https://ClinicalTrials.gov/show/NCT04511650",NA,"United States","Idaho","2020-Aug","2021-Feb","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events","Razuprotafib, Standard of care",180
"NCT04511650","https://ClinicalTrials.gov/show/NCT04511650",NA,"United States","Minnesota","2020-Aug","2021-Feb","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events","Razuprotafib, Standard of care",180
"NCT04511650","https://ClinicalTrials.gov/show/NCT04511650",NA,"United States","Ohio","2020-Aug","2021-Feb","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events","Razuprotafib, Standard of care",180
"NCT04511650","https://ClinicalTrials.gov/show/NCT04511650",NA,"United States","Rhode Island","2020-Aug","2021-Feb","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Adverse Events","Razuprotafib, Standard of care",180
"NCT04581954","https://ClinicalTrials.gov/show/NCT04581954",NA,"United Kingdom","London","2020-Oct","2021-Jun","Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified)","Immunomodulators, JAKi, Standard of care",456
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"United States","California","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"United States","Illinois","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"United States","Louisiana","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"United States","Minnesota","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"United States","Missouri","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"United States","Ohio","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"United States","Texas","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"Brazil","Brasilia","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"Chile","Santiago","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"Peru","Lima","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04447469","https://ClinicalTrials.gov/show/NCT04447469",NA,"South Africa","Pretoria","2020-Jun","2021-Feb","Recruiting","Randomised","Double",6,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","mAb, Standard of care",573
"NCT04463472","https://ClinicalTrials.gov/show/NCT04463472",NA,"Japan","Osaka","2020-Jul","2020-Sep","Not Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",30
"NCT04610502","https://ClinicalTrials.gov/show/NCT04610502",NA,"Costa Rica","San Jose","2020-Oct","2020-Oct","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Adverse Events, IgG, IgM or IgA, Radiographic Findings","Igs",26
"NCT04468087","https://ClinicalTrials.gov/show/NCT04468087",NA,"Brazil","Sao Paulo","2020-Jul","2021-Feb","Not Recruiting","Randomised","Quadruple",7,"Confirmed","Hospital","Viral Load or Clearance","Antiretrovirals, DAA, FPV, Other, Standard of care",1005
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Alabama","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","California","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Florida","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Georgia","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Massachusetts","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","New Jersey","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","New York","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","North Carolina","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Ohio","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Oregon","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04347239","https://ClinicalTrials.gov/show/NCT04347239",NA,"United States","Texas","2020-Apr","2020-Dec","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",390
"NCT04469621","https://ClinicalTrials.gov/show/NCT04469621",NA,"Argentina","Buenos Aires","2020-Jul","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Lymphocyte Count, D-Dimer","Other, Standard of care",68
"NCT04469621","https://ClinicalTrials.gov/show/NCT04469621",NA,"Brazil","Brasilia","2020-Jul","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Lymphocyte Count, D-Dimer","Other, Standard of care",68
"NCT04469621","https://ClinicalTrials.gov/show/NCT04469621",NA,"Chile","Santiago","2020-Jul","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Lymphocyte Count, D-Dimer","Other, Standard of care",68
"NCT04469621","https://ClinicalTrials.gov/show/NCT04469621",NA,"Mexico","Mexico","2020-Jul","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Lymphocyte Count, D-Dimer","Other, Standard of care",68
"NCT04469621","https://ClinicalTrials.gov/show/NCT04469621",NA,"Russia","Moscow","2020-Jul","2020-Oct","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Lymphocyte Count, D-Dimer","Other, Standard of care",68
"NCT04342169","https://ClinicalTrials.gov/show/NCT04342169",NA,"United States","Utah","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","ICU Admission, Depression, Anxiety","HCQ, Standard of care",400
"NCT04461379","https://ClinicalTrials.gov/show/NCT04461379",NA,"Mexico","Mexico","2020-Jul","2021-Jan","Not Recruiting","Randomised","Triple",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Antibodies","Standard of care, Vaccine",908
"NCT04513184","https://ClinicalTrials.gov/show/NCT04513184",NA,"Mexico","Mexico","2020-Aug","2021-Mar","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Dexamethasone",60
"NCT04399356","https://ClinicalTrials.gov/show/NCT04399356",NA,"United States","Massachusetts","2020-May","2021-Jan","Recruiting","Randomised","Triple",3,"Confirmed","Outpatient","Viral Load or Clearance, Fever","Other, Standard of care",100
"NCT04347382","https://ClinicalTrials.gov/show/NCT04347382",NA,"Pakistan","Punjab","2020-Apr","2020-Aug","Completed","Randomised","Triple",3,NA,"Hospital","Mortality, Fever, SpO2","Alternative therapy, Standard of care",313
"NCT04474483","https://ClinicalTrials.gov/show/NCT04474483",NA,"United States","New York","2020-Jul","2021-Mar","Recruiting","Randomised","Quadruple",2,"Suspected","Outpatient","Mortality, Hospitalization, Treatment-emergent Adverse Events","Melatonin, Standard of care",30
"NCT04622865","https://ClinicalTrials.gov/show/NCT04622865",NA,"France","Paris","2020-Nov","2021-Jun","Recruiting","Randomised","Triple",3,"Confirmed","Hospital",NA,"Alternative therapy + Other, HCQ",200
"NCT04622865","https://ClinicalTrials.gov/show/NCT04622865",NA,"France","Nord","2020-Nov","2021-Jun","Recruiting","Randomised","Triple",3,"Confirmed","Hospital",NA,"Alternative therapy + Other, HCQ",200
"NCT04523246","https://ClinicalTrials.gov/show/NCT04523246",NA,"United States","Oklahoma","2020-Aug","2021-Jul","Recruiting","Randomised","Triple",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",250
"NCT04483973","https://ClinicalTrials.gov/show/NCT04483973",NA,"United States","Washington","2020-Jul","2021-Apr","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Non-invasive Ventilation, Adverse Events, SpO2","Other, Standard of care",60
"NCT04484025","https://ClinicalTrials.gov/show/NCT04484025",NA,"United States","Washington","2020-Jul","2021-Apr","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Non-invasive Ventilation, Adverse Events, SpO2","Other, Standard of care",60
"NCT04381923","https://ClinicalTrials.gov/show/NCT04381923",NA,"United States","Pennsylvania","2020-May","2022-Feb","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Dyspnea, Renal Outcome (Unspecified)","Non-invasive respiratory support",200
"NCT04428801","https://ClinicalTrials.gov/show/NCT04428801",NA,"United States","Texas","2020-Jun","2022-Jan","Not Recruiting","Randomised","Double",2,"Healthy","Unclear","Mortality, Pneumonia or ARDS, C-Reactive Protein, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, D-Dimer, Procalcitonin, Bilirubin, Stool Sample, IgG, IgM or IgA, Antibodies, Blood Gas","Standard of care, Stem cells",200
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Alabama","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Arizona","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","California","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Connecticut","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","District Of Columbia","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Florida","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Illinois","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Louisiana","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Maryland","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Massachusetts","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Michigan","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","New Mexico","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","New York","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Ohio","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Rhode Island","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Texas","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Utah","2020-Mar","2022-Dec","Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Plasma based therapy, Standard of care",500
"NCT04536350","https://ClinicalTrials.gov/show/NCT04536350",NA,"Switzerland","Bern","2020-Sep","2021-Dec","Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Lymphocyte Count, Procalcitonin","Inhaled solution",80
"NCT04375202","https://ClinicalTrials.gov/show/NCT04375202",NA,"Italy","Rome","2020-May","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Organ Failure or Dysfunction (SOFA), Ferritin, White Blood Cell Count, ALT","Colchicine, Standard of care",308
"NCT04542694","https://ClinicalTrials.gov/show/NCT04542694",NA,"Russia","Moscow","2020-Sep","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Radiographic Findings","FPV, Standard of care",200
"NCT04542694","https://ClinicalTrials.gov/show/NCT04542694",NA,"Russia","Mordovia","2020-Sep","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Radiographic Findings","FPV, Standard of care",200
"NCT04542694","https://ClinicalTrials.gov/show/NCT04542694",NA,"Russia","Smolensk","2020-Sep","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Radiographic Findings","FPV, Standard of care",200
"NCT04446377","https://ClinicalTrials.gov/show/NCT04446377",NA,"United States","Connecticut","2020-Jun","2021-Mar","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Viral Load or Clearance, SpO2","Other, Standard of care",142
"NCT04343092","https://ClinicalTrials.gov/show/NCT04343092",NA,"Iraq","Baghdad","2020-Apr","2020-May","Completed","Single-Arm","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ + AZT, HCQ + AZT + Other",16
"NCT04510493","https://ClinicalTrials.gov/show/NCT04510493",NA,"Switzerland","Bern","2020-Aug","2023-Sep","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Hemoglobin, D-Dimer, eGFR, Glucose, Renal Outcome (Unspecified)","mAb, Standard of care",116
"NCT04510493","https://ClinicalTrials.gov/show/NCT04510493",NA,"Switzerland","Lucerne","2020-Aug","2023-Sep","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Hemoglobin, D-Dimer, eGFR, Glucose, Renal Outcome (Unspecified)","mAb, Standard of care",116
"NCT04335123","https://ClinicalTrials.gov/show/NCT04335123",NA,"United States","Kansas","2020-Apr","2020-Jun","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Bicarbonates","ARBs",34
"NCT04489446","https://ClinicalTrials.gov/show/NCT04489446",NA,"Chile","Valparaiso","2020-Jul","2020-Dec","Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",40
"NCT04552483","https://ClinicalTrials.gov/show/NCT04552483",NA,"Brazil","Rio De Janeiro","2020-Sep","2020-Aug","Completed","Randomised","Double",2,"Confirmed","Unclear","Viral Load or Clearance, Cough, Fever, C-Reactive Protein, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), Interferon (Any), Monocyte Count, Platelet Count","Antivirals, Standard of care",392
"NCT04340544","https://ClinicalTrials.gov/show/NCT04340544",NA,"Germany","Berlin","2020-Apr","2020-Oct","Status Unclear","Randomised","Quadruple",2,NA,"Outpatient","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,17
"NCT04554992","https://ClinicalTrials.gov/show/NCT04554992",NA,"United States","Texas","2020-Sep","2022-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Plasma-based therapy",350
"NCT04596085","https://ClinicalTrials.gov/show/NCT04596085",NA,"India","Andhra Pradesh","2020-Oct","2020-Nov","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","ICU Admission, Invasive Mechanical Ventilation or ECMO","Nutrition, Standard of care",124
"NCT04596085","https://ClinicalTrials.gov/show/NCT04596085",NA,"India","Maharashtra","2020-Oct","2020-Nov","Recruiting","Randomised","Double",2,"Confirmed","Outpatient","ICU Admission, Invasive Mechanical Ventilation or ECMO","Nutrition, Standard of care",124
"NCT04415086","https://ClinicalTrials.gov/show/NCT04415086",NA,"Brazil","Sao Paulo","2020-Jun","2022-Apr","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Adverse Events, IgG, IgM or IgA, Antibodies","Plasma-based therapy, Standard of care",120
"NCT04361214","https://ClinicalTrials.gov/show/NCT04361214",NA,"United States","Illinois","2020-Apr","2021-Feb","Recruiting","Single-Arm","Open-Label",1,NA,"Outpatient","Hospitalization, Clinical Improvement Score (Any), Fever, Other Mild Symptoms, Adverse Events","DMARD",20
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","California","2020-Apr","2020-Sep","Completed","Randomised","Double",2,"Healthy","Healthy Exposed",NA,"HCQ, Vitamins",829
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Louisiana","2020-Apr","2020-Sep","Completed","Randomised","Double",2,"Healthy","Healthy Exposed",NA,"HCQ, Vitamins",829
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Maryland","2020-Apr","2020-Sep","Completed","Randomised","Double",2,"Healthy","Healthy Exposed",NA,"HCQ, Vitamins",829
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Massachusetts","2020-Apr","2020-Sep","Completed","Randomised","Double",2,"Healthy","Healthy Exposed",NA,"HCQ, Vitamins",829
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","New York","2020-Apr","2020-Sep","Completed","Randomised","Double",2,"Healthy","Healthy Exposed",NA,"HCQ, Vitamins",829
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Washington","2020-Apr","2020-Sep","Completed","Randomised","Double",2,"Healthy","Healthy Exposed",NA,"HCQ, Vitamins",829
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"United States","Nebraska","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"United States","Rhode Island","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"United States","Tennessee","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"Belgium","Brussels","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"Canada","Alberta","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"Canada","British Columbia","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"Canada","Ontario","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"Canada","Quebec","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"France","Paris","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"Japan","Chiba","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04606563","https://ClinicalTrials.gov/show/NCT04606563",NA,"Spain","Madrid","2020-Oct","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","ARBs, Standard of care",1372
"NCT04561219","https://ClinicalTrials.gov/show/NCT04561219",NA,"Brazil","Rio De Janeiro","2020-Sep","2020-Oct","Completed","Randomised","Double",2,"Suspected","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, C-Reactive Protein, Ferritin, D-Dimer, Troponin, Electrolytes, Glucose, LDH, Renal Outcome (Unspecified)","Antivirals, Standard of care",500
"NCT04603794","https://ClinicalTrials.gov/show/NCT04603794",NA,"United States","Ohio","2020-Oct","2020-Nov","Recruiting","Randomised","Triple",4,"Confirmed","Hospital",NA,"Hygiene, Standard of care",60
"NCT04344431","https://ClinicalTrials.gov/show/NCT04344431",NA,"France","Paris","2020-Apr","2022-Apr","Recruiting","Randomised","Single",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation","Non-invasive respiratory support, Standard of care",100
"NCT04604327","https://ClinicalTrials.gov/show/NCT04604327",NA,"Spain","Madrid","2020-Oct","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Anticoagulants",164
"NCT04604327","https://ClinicalTrials.gov/show/NCT04604327",NA,"Spain","Navarra","2020-Oct","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Anticoagulants",164
"NCT04604327","https://ClinicalTrials.gov/show/NCT04604327",NA,"Spain","Barcelona","2020-Oct","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Anticoagulants",164
"NCT04604327","https://ClinicalTrials.gov/show/NCT04604327",NA,"Spain","Salamanca","2020-Oct","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Anticoagulants",164
"NCT04604327","https://ClinicalTrials.gov/show/NCT04604327",NA,"Spain","Toledo","2020-Oct","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Anticoagulants",164
"NCT04604327","https://ClinicalTrials.gov/show/NCT04604327",NA,"Spain","Valladolid","2020-Oct","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Anticoagulants",164
"NCT04420247","https://ClinicalTrials.gov/show/NCT04420247",NA,"Brazil","Parana","2020-Jun","2020-Aug","Completed","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Lymphocyte Count, Neutrophils, Renal Outcome (Unspecified)","HCQ, Standard of care",142
"NCT04299152","https://ClinicalTrials.gov/show/NCT04299152",NA,"China","Beijing","2020-Mar","2021-Oct","Not Recruiting","Randomised","Single",2,"Confirmed","Unclear","Viral Load or Clearance, Other Mild Symptoms, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Natural Killer Cell Count, Radiographic Findings","Standard of care, Stem cells",20
"NCT04371965","https://ClinicalTrials.gov/show/NCT04371965",NA,"France","Paris","2020-May","2020-Oct","Completed","Randomised","Open-Label",2,NA,"Unclear","ICU Admission, Hospitalization, Viral Load or Clearance, Cough, Other Mild Symptoms, Distress","Hygiene, Standard of care",24
"NCT04344288","https://ClinicalTrials.gov/show/NCT04344288",NA,"France","Paris","2020-Apr","2020-Aug","Status Unclear","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Corticosteroids, Standard of care",11
"NCT04344288","https://ClinicalTrials.gov/show/NCT04344288",NA,"France","Nord","2020-Apr","2020-Aug","Status Unclear","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Corticosteroids, Standard of care",11
"NCT04344288","https://ClinicalTrials.gov/show/NCT04344288",NA,"France","Vienne","2020-Apr","2020-Aug","Status Unclear","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Corticosteroids, Standard of care",11
"CHICTR2000037524","http://www.chictr.org.cn/showproj.aspx?proj=60034",NA,"China","Beijing","2020-Aug","2020-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear",NA,"Psychological therapy",1600
"NCT04448119","https://ClinicalTrials.gov/show/NCT04448119",NA,"Canada","Ontario","2020-Jun","2021-Mar","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Exposed","Mortality, Hospitalization","FPV, Standard of care",760
"NCT04462757","https://ClinicalTrials.gov/show/NCT04462757",NA,"United Kingdom","Manchester","2020-Jul","2020-Aug","Suspended","Randomised","Open-Label",2,"Confirmed Or Suspected","ICU","IL-1, IL-6","Anakinra",5
"NCT04462757","https://ClinicalTrials.gov/show/NCT04462757",NA,"United Kingdom","Salford","2020-Jul","2020-Aug","Suspended","Randomised","Open-Label",2,"Confirmed Or Suspected","ICU","IL-1, IL-6","Anakinra",5
"NCT04412785","https://ClinicalTrials.gov/show/NCT04412785",NA,"United States","Pennsylvania","2020-Jun","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","ICU Admission, Ferritin, IL-6, Lymphocyte Count, D-Dimer","Cyclosporine",20
"NCT04334629","https://ClinicalTrials.gov/show/NCT04334629",NA,"United Kingdom","London","2020-Apr","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","NSAIDs, Standard of care",230
"NCT04421404","https://ClinicalTrials.gov/show/NCT04421404",NA,"United States","California","2020-Jun","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Plasma based therapy, Standard of care",50
"NCT04590053","https://ClinicalTrials.gov/show/NCT04590053",NA,"Israel","Jerusalem","2020-Oct","2021-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Serious Adverse Events, Platelet Count, PaO2-FiO2","Cell-based therapeutic",24
"NCT04590053","https://ClinicalTrials.gov/show/NCT04590053",NA,"Israel","Tel Aviv","2020-Oct","2021-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Serious Adverse Events, Platelet Count, PaO2-FiO2","Cell-based therapeutic",24
"NCT04594460","https://ClinicalTrials.gov/show/NCT04594460",NA,"China","Guangdong","2020-Oct","2021-Oct","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","SpO2","Non-invasive respiratory support",198
"NCT04451174","https://ClinicalTrials.gov/show/NCT04451174",NA,"Chile","Santiago","2020-Jun","2020-Nov","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Corticosteroids, Standard of care",184
"NCT04594330","https://ClinicalTrials.gov/show/NCT04594330",NA,"Indonesia","Yogyakarta","2020-Oct","2020-Dec","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Clinical Improvement Score (Any), C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), Lymphocyte Count, D-Dimer, Procalcitonin","Oil + Standard of care, Standard of care",60
"NCT04593641","https://ClinicalTrials.gov/show/NCT04593641",NA,"South Korea","Incheon","2020-Oct","2020-Oct","Not Recruiting","Randomised","Quadruple",3,"Confirmed","Unclear","Radiographic Findings","Monoclonal antibody",18
"NCT04513158","https://ClinicalTrials.gov/show/NCT04513158",NA,"United States","Kentucky","2020-Aug","2021-Aug","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, C-Reactive Protein, Ferritin, IL-6, Lymphocyte Count, D-Dimer","Plasma based therapy",100
"NCT04591600","https://ClinicalTrials.gov/show/NCT04591600",NA,"Iraq","Baghdad","2020-Oct","2020-Sep","Completed","Randomised","Single",2,"Confirmed","Outpatient, Hospital","Mortality","Ivermectin + Antibiotics, Standard of care",140
"NCT04513470","https://ClinicalTrials.gov/show/NCT04513470",NA,"Israel","Jerusalem","2020-Aug","2021-Jan","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Serious Adverse Events, Platelet Count, PaO2-FiO2","Apoptotic cells",5
"NCT04446104","https://ClinicalTrials.gov/show/NCT04446104",NA,"Singapore","Singapore","2020-Jun","2020-Aug","Completed","Randomised","Open-Label",5,"Healthy","Unclear","Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","HCQ, Hygeine, Ivermectin, Vitamins, Vitamins + Zinc",4257
"NCT04589949","https://ClinicalTrials.gov/show/NCT04589949",NA,"Netherlands","Zuid-Holland","2020-Oct","2022-Nov","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, ICU Admission","Plasma-based therapy",690
"NCT04589949","https://ClinicalTrials.gov/show/NCT04589949",NA,"Netherlands","Amsterdam","2020-Oct","2022-Nov","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, ICU Admission","Plasma-based therapy",690
"NCT04589949","https://ClinicalTrials.gov/show/NCT04589949",NA,"Netherlands","Groningen","2020-Oct","2022-Nov","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, ICU Admission","Plasma-based therapy",690
"NCT04578210","https://ClinicalTrials.gov/show/NCT04578210",NA,"Spain","Madrid","2020-Oct","2021-Jan","Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Natural Killer Cells, Other",58
"NCT04530448","https://ClinicalTrials.gov/show/NCT04530448",NA,"United States","West Virginia","2020-Aug","2021-Jan","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Blood pH","Other, Standard of care",40
"NCT04590274","https://ClinicalTrials.gov/show/NCT04590274",NA,"United States","New Jersey","2020-Oct","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected","Unclear",NA,"HCQ + Vitamins + AZT + Zinc",5000
"NCT04361942","https://ClinicalTrials.gov/show/NCT04361942",NA,"Spain","Valladolid","2020-Apr","2020-Nov","Recruiting","Randomised","Triple",2,NA,"ICU","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Standard of care, Stem cells",24
"NCT04333628","https://ClinicalTrials.gov/show/NCT04333628",NA,"Israel","Jerusalem","2020-Apr","2020-Sep","Status Unclear","Randomised","Open-Label",3,"Confirmed","Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance","HCQ, Standard of care",5
"NCT04335071","https://ClinicalTrials.gov/show/NCT04335071",NA,"Switzerland","Bern","2020-Apr","2020-Sep","Status Unclear","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism","Standard of care, TCZ",5
"NCT04335071","https://ClinicalTrials.gov/show/NCT04335071",NA,"Switzerland","Vaud","2020-Apr","2020-Sep","Status Unclear","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism","Standard of care, TCZ",5
"NCT04335071","https://ClinicalTrials.gov/show/NCT04335071",NA,"Switzerland","Zurich","2020-Apr","2020-Sep","Status Unclear","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism","Standard of care, TCZ",5
"NCT04459325","https://ClinicalTrials.gov/show/NCT04459325",NA,"Russia","Moscow","2020-Jul","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, SpO2","Other, Standard of care",100
"NCT04584580","https://ClinicalTrials.gov/show/NCT04584580",NA,"Egypt","Cairo","2020-Oct","2020-Oct","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress","Anticoagulants",50
"NCT04453774","https://ClinicalTrials.gov/show/NCT04453774",NA,"Canada","Ontario","2020-Jul","2021-Feb","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected","Outpatient","Visits or Returns to Emergency Department","Other",1000
"NCT04558021","https://ClinicalTrials.gov/show/NCT04558021",NA,"Turkey","Antalya","2020-Sep","2021-Jan","Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Hospital","Clinical Improvement Score (Any)","Other, Standard of care",200
"NCT04558021","https://ClinicalTrials.gov/show/NCT04558021",NA,"Turkey","Gaziantep","2020-Sep","2021-Jan","Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Hospital","Clinical Improvement Score (Any)","Other, Standard of care",200
"NCT04558021","https://ClinicalTrials.gov/show/NCT04558021",NA,"Turkey","Istanbul","2020-Sep","2021-Jan","Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Hospital","Clinical Improvement Score (Any)","Other, Standard of care",200
"NCT04558021","https://ClinicalTrials.gov/show/NCT04558021",NA,"Turkey","Ankara","2020-Sep","2021-Jan","Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Hospital","Clinical Improvement Score (Any)","Other, Standard of care",200
"NCT04523831","https://ClinicalTrials.gov/show/NCT04523831",NA,"Bangladesh","Dhaka","2020-Aug","2020-Aug","Completed","Randomised","Double",2,"Confirmed","Unclear","Clinical Improvement Score (Any)","Ivermectin + Antibiotics, Standard of care",400
"NCT04322773","https://ClinicalTrials.gov/show/NCT04322773",NA,"Denmark","Copenhagen","2020-Mar","2020-Oct","Status Unclear","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Sarilumab, Standard of care, TCZ",20
"NCT04577534","https://ClinicalTrials.gov/show/NCT04577534",NA,"Finland","Helsinki","2020-Oct","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA)","Standard of care, TCZ",90
"NCT04359277","https://ClinicalTrials.gov/show/NCT04359277",NA,"United States","New York","2020-Apr","2020-Sep","Status Unclear","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, D-Dimer, Troponin, Fibrinogen, Lung Inflamation, Hypoxemia, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anticoagulants",77
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Brazil","Brasilia","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Brazil","Goias","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Brazil","Rio De Janeiro","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Canada","Ontario","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Chile","Santiago","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Colombia","Atlantico","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Colombia","Bolivar","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Colombia","Cundinamarca","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Colombia","Narino","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Colombia","Quindio","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Colombia","Santander","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Colombia","Tolima","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Colombia","Bogota","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Ecuador","Guayas","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Ecuador","Pichincha","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Egypt","Cairo","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"India","Gujarat","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"India","Haryana","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"India","Karnataka","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"India","Maharashtra","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"India","Punjab","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"India","Tamil Nadu","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"India","New Delhi","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Pakistan","Islamabad","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Philippines","Manila","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Russia","Moscow","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Russia","Novgorod","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Russia","Rostov","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Saudi Arabia","Riyadh","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"United Arab Emirates","Abu Dhabi","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, Standard of care",4000
"NCT04461353","https://ClinicalTrials.gov/show/NCT04461353",NA,"United States","New York","2020-Jul","2020-Aug","Completed","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, Platelet Count, Glucose, Blood Pressure, Heart Rate, ECG, Respiratory Rate, Radiographic Findings","HCQ, SPC",12
"NCT04325893","https://ClinicalTrials.gov/show/NCT04325893",NA,"France","Paris","2020-Mar","2020-Jun","Status Unclear","Randomised","Double",2,"Confirmed","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, CK-MB, Procalcitonin, Radiographic Findings","HCQ, Standard of care",259
"NCT04325893","https://ClinicalTrials.gov/show/NCT04325893",NA,"France","Cher","2020-Mar","2020-Jun","Status Unclear","Randomised","Double",2,"Confirmed","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, CK-MB, Procalcitonin, Radiographic Findings","HCQ, Standard of care",259
"NCT04325893","https://ClinicalTrials.gov/show/NCT04325893",NA,"Monaco","Monaco","2020-Mar","2020-Jun","Status Unclear","Randomised","Double",2,"Confirmed","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, CK-MB, Procalcitonin, Radiographic Findings","HCQ, Standard of care",259
"NCT04384458","https://ClinicalTrials.gov/show/NCT04384458",NA,"Brazil","Brasilia","2020-May","2020-Sep","Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers","Invasive Mechanical Ventilation or ECMO, Adverse Events, Heart Rate, ECG","HCQ, Standard of care",400
"NCT04326452","https://ClinicalTrials.gov/show/NCT04326452",NA,"United States","Arizona","2020-Mar","2021-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate","Non-invasive respiratory support",30
"NCT04326452","https://ClinicalTrials.gov/show/NCT04326452",NA,"United States","California","2020-Mar","2021-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate","Non-invasive respiratory support",30
"NCT04326452","https://ClinicalTrials.gov/show/NCT04326452",NA,"United States","Georgia","2020-Mar","2021-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate","Non-invasive respiratory support",30
"NCT04374526","https://ClinicalTrials.gov/show/NCT04374526",NA,"Italy","Roma","2020-May","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Plasma based therapy, Standard of care",182
"NCT04374526","https://ClinicalTrials.gov/show/NCT04374526",NA,"Italy","Chieti","2020-May","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Plasma based therapy, Standard of care",182
"NCT04374526","https://ClinicalTrials.gov/show/NCT04374526",NA,"Italy","Rome","2020-May","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Plasma based therapy, Standard of care",182
"NCT04381884","https://ClinicalTrials.gov/show/NCT04381884",NA,"Argentina","Buenos Aires","2020-May","2020-Sep","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance, Adverse Events, Antibodies","Ivermectin, Standard of care",45
"NCT04381884","https://ClinicalTrials.gov/show/NCT04381884",NA,"Argentina","Ciudad De Buenos Aires","2020-May","2020-Sep","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance, Adverse Events, Antibodies","Ivermectin, Standard of care",45
"NCT04524507","https://ClinicalTrials.gov/show/NCT04524507",NA,"United States","North Carolina","2020-Aug","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospital Discharge, Serious Adverse Events","Plasma based therapy",56
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"Indonesia","Jakarta","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"Italy","Rome","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Oxfordshire","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"Pakistan","Islamabad","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"Thailand","Nan","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Cumbria","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Devon","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Essex","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Hertfordshire","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Greenwich","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Nottinghamshire","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Dudley","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Leeds","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","London","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Warwickshire","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ, Standard of care",40000
"NCT04344041","https://ClinicalTrials.gov/show/NCT04344041",NA,"France","Paris","2020-Apr","2021-May","Recruiting","Randomised","Open-Label",2,NA,"Unclear","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Vitamins",260
"NCT04410510","https://ClinicalTrials.gov/show/NCT04410510",NA,"Colombia","Bogota","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Hospital","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Treatment-emergent Adverse Events","HCQ + LPV/r, HCQ + LPV/r + Alternative therapy",100
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","California","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Colorado","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Connecticut","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","District Of Columbia","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Florida","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Georgia","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Illinois","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Louisiana","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Massachusetts","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Michigan","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Minnesota","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","New Jersey","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","New York","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Oklahoma","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Oregon","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Pennsylvania","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Texas","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Utah","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Virginia","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Washington","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",1912
"NCT04405102","https://ClinicalTrials.gov/show/NCT04405102",NA,"Canada","Ottawa","2020-May","2023-Jan","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, SpO2","Immunomodulators, Standard of care",48
"NCT04375046","https://ClinicalTrials.gov/show/NCT04375046",NA,"Egypt","Cairo","2020-May","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any), PAI-1, von Wildebrandt Factor, Lymphocyte Count, Angiotensins, ACE, ACE-II, Surfactant Factor Protein, SRAGE, PaO2-FiO2, Radiographic Findings","Other, Standard of care",24
"NCT04480593","https://ClinicalTrials.gov/show/NCT04480593",NA,"Brazil","Brasilia","2020-Jul","2020-Aug","Completed","Randomised","Single",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Adverse Events, C-Reactive Protein, Renal Outcome (Unspecified)","Alternative therapy, Standard of care",120
"NCT04488081","https://ClinicalTrials.gov/show/NCT04488081",NA,"United States","Alabama","2020-Jul","2022-Jul","Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality","Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir",1500
"NCT04488081","https://ClinicalTrials.gov/show/NCT04488081",NA,"United States","California","2020-Jul","2022-Jul","Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality","Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir",1500
"NCT04488081","https://ClinicalTrials.gov/show/NCT04488081",NA,"United States","Colorado","2020-Jul","2022-Jul","Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality","Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir",1500
"NCT04488081","https://ClinicalTrials.gov/show/NCT04488081",NA,"United States","Connecticut","2020-Jul","2022-Jul","Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality","Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir",1500
"NCT04488081","https://ClinicalTrials.gov/show/NCT04488081",NA,"United States","New York","2020-Jul","2022-Jul","Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality","Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir",1500
"NCT04488081","https://ClinicalTrials.gov/show/NCT04488081",NA,"United States","North Carolina","2020-Jul","2022-Jul","Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality","Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir",1500
"NCT04488081","https://ClinicalTrials.gov/show/NCT04488081",NA,"United States","Pennsylvania","2020-Jul","2022-Jul","Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality","Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir",1500
"NCT04488081","https://ClinicalTrials.gov/show/NCT04488081",NA,"United States","South Dakota","2020-Jul","2022-Jul","Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality","Icatibant + Remdesivir, Other + Remdesivir, PDE4 inhibitor + Remdesivir, Remdesivir, VE-PTP inhibitor + Remdesivir",1500
"NCT04380519","https://ClinicalTrials.gov/show/NCT04380519",NA,"Russia","Moscow","2020-May","2020-Jul","Completed","Randomised","Double",3,"Confirmed","ICU","Mortality, Labor Absenteeism","mAb, Other, Standard of care",372
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Argentina","Buenos Aires","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Brazil","Brasilia","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Brazil","Sao Paulo","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Canada","Ottawa","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Chile","Santiago","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"France","Paris","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Germany","Berlin","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Israel","Jerusalem","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Milano","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Modena","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Parma","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Rome","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Japan","Tokyo","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Russia","Moscow","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Spain","Barcelona","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Spain","Madrid","2020-Mar","2020-Jul","Completed","Randomised","Quadruple",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia","Sarilumab, Standard of care",420
"NCT04400019","https://ClinicalTrials.gov/show/NCT04400019",NA,"Spain","Malaga","2020-May","2020-Dec","Not Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed, Healthcare Workers","Mortality, Hospitalization, Adverse Events","HCQ, Standard of care",1930
"NCT04497298","https://ClinicalTrials.gov/show/NCT04497298",NA,"Belgium","Antwerp","2020-Aug","2020-Nov","Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Unexposed","Urine Sample, Antibodies","Standard of care, Vaccine",90
"NCT04497298","https://ClinicalTrials.gov/show/NCT04497298",NA,"France","Paris","2020-Aug","2020-Nov","Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Unexposed","Urine Sample, Antibodies","Standard of care, Vaccine",90
"NCT04485169","https://ClinicalTrials.gov/show/NCT04485169",NA,"Pakistan","Punjab","2020-Jul","2020-Jul","Completed","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Plasma based therapy, Standard of care",280
"NCT04482621","https://ClinicalTrials.gov/show/NCT04482621",NA,"United States","Maryland","2020-Jul","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Adverse Events","Chemotherapy, Standard of care",40
"NCT04392414","https://ClinicalTrials.gov/show/NCT04392414",NA,"Russia","Moscow","2020-May","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Antibodies","Plasma based therapy, Standard of care",60
"NCT04516811","https://ClinicalTrials.gov/show/NCT04516811",NA,"South Africa","Pretoria","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Antibodies, Radiographic Findings, Hypoxia","Plasma based therapy + Standard of care, Standard of care",600
"NCT04516811","https://ClinicalTrials.gov/show/NCT04516811",NA,"South Africa","Western Cape","2020-Aug","2021-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Antibodies, Radiographic Findings, Hypoxia","Plasma based therapy + Standard of care, Standard of care",600
"NCT04400890","https://ClinicalTrials.gov/show/NCT04400890",NA,"United States","Ohio","2020-May","2020-Nov","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","ICU Admission, Hospitalization","Vitamins, Vitamins + Polyphenols",200
"NCT04497623","https://ClinicalTrials.gov/show/NCT04497623",NA,"Colombia","Bogota","2020-Aug","2020-Aug","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Weight, Height or BMI, Blood Urea Nitrogen, PaO2-FiO2, Respiratory Rate, Blood pH, Cardiac Outcome (Unspecified)","Device",5
"NCT04497623","https://ClinicalTrials.gov/show/NCT04497623",NA,"Colombia","Cundinamarca","2020-Aug","2020-Aug","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Weight, Height or BMI, Blood Urea Nitrogen, PaO2-FiO2, Respiratory Rate, Blood pH, Cardiac Outcome (Unspecified)","Device",5
"NCT04429529","https://ClinicalTrials.gov/show/NCT04429529",NA,"Singapore","Singapore","2020-Jun","2020-Nov","Not Recruiting","Randomised","Double",7,"Healthy","Healthy Unexposed","Adverse Events, Radiographic Findings","Other, Standard of care",32
"NCT04343261","https://ClinicalTrials.gov/show/NCT04343261",NA,"United States","Connecticut","2020-Apr","2020-Jul","Completed","Single-Arm","Open-Label",1,NA,"Hospital","Mortality, Viral Load or Clearance, Antibodies","Plasma based therapy",48
"NCT04361422","https://ClinicalTrials.gov/show/NCT04361422",NA,"Egypt","Cairo","2020-Apr","2021-Aug","Not Recruiting","Randomised","Open-Label",3,NA,"Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Other Mild Symptoms","Other, Standard of care",300
"NCT04479358","https://ClinicalTrials.gov/show/NCT04479358",NA,"United States","Illinois","2020-Jul","2020-Dec","Recruiting","Randomised","Open-Label",6,"Confirmed","Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, C-Reactive Protein","Standard of care, TCZ",332
"NCT04323228","https://ClinicalTrials.gov/show/NCT04323228",NA,"Saudi Arabia","Riyadh","2020-Mar","2020-Dec","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Non-invasive Ventilation, Fever, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), MCP-1, White Blood Cell Count, Neutrophils, Weight, Height or BMI","Nutrition, Standard of care",40
"NCT04421664","https://ClinicalTrials.gov/show/NCT04421664",NA,"United States","Minnesota","2020-Jun","2020-Aug","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization","HCQ, Standard of care",70
"NCT04421664","https://ClinicalTrials.gov/show/NCT04421664",NA,"Canada","Alberta","2020-Jun","2020-Aug","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization","HCQ, Standard of care",70
"NCT04421664","https://ClinicalTrials.gov/show/NCT04421664",NA,"Canada","British Columbia","2020-Jun","2020-Aug","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization","HCQ, Standard of care",70
"NCT04421664","https://ClinicalTrials.gov/show/NCT04421664",NA,"Canada","Manitoba","2020-Jun","2020-Aug","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization","HCQ, Standard of care",70
"NCT04421664","https://ClinicalTrials.gov/show/NCT04421664",NA,"Canada","Newfoundland And Labrador","2020-Jun","2020-Aug","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization","HCQ, Standard of care",70
"NCT04421664","https://ClinicalTrials.gov/show/NCT04421664",NA,"Canada","Ontario","2020-Jun","2020-Aug","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization","HCQ, Standard of care",70
"NCT04421664","https://ClinicalTrials.gov/show/NCT04421664",NA,"Canada","Quebec","2020-Jun","2020-Aug","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization","HCQ, Standard of care",70
"NCT04558476","https://ClinicalTrials.gov/show/NCT04558476",NA,"Belgium","Brussels","2020-Sep","2022-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, Quality of Life, Depression, Anxiety, Renal Outcome (Unspecified)","Plasma based therapy, Standard of care",500
"NCT04558476","https://ClinicalTrials.gov/show/NCT04558476",NA,"Belgium","Antwerp","2020-Sep","2022-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, Quality of Life, Depression, Anxiety, Renal Outcome (Unspecified)","Plasma based therapy, Standard of care",500
"NCT04558476","https://ClinicalTrials.gov/show/NCT04558476",NA,"Belgium","Namur","2020-Sep","2022-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, Quality of Life, Depression, Anxiety, Renal Outcome (Unspecified)","Plasma based therapy, Standard of care",500
"NCT04516564","https://ClinicalTrials.gov/show/NCT04516564",NA,"New Zealand","Wellington","2020-Aug","2021-Mar","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Antibodies","mAb, Standard of care",32
"CHICTR2000036871","http://www.chictr.org.cn/showproj.aspx?proj=55984",NA,"China","Beijing","2020-Aug","2021-Apr","Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Fever, C-Reactive Protein, Ferritin, Radiographic Findings, Quality of Life","Standard of care, TCM",300
"NCT04357990","https://ClinicalTrials.gov/show/NCT04357990",NA,"Iceland","Reykjavik","2020-Apr","2021-Mar","Recruiting","Randomised","Triple",3,NA,"Outpatient","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events","Alternative therapy, Standard of care",128
"NCT04387240","https://ClinicalTrials.gov/show/NCT04387240",NA,"Saudi Arabia","Riyadh","2020-May","2021-Apr","Not Recruiting","Randomised","Triple",2,"Confirmed","Unclear","ICU Admission","Other, Standard of care",22
"NCT04375098","https://ClinicalTrials.gov/show/NCT04375098",NA,"Chile","Santiago","2020-May","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever","Plasma based therapy",58
"NCT04322344","https://ClinicalTrials.gov/show/NCT04322344",NA,"Italy","Catanzaro","2020-Mar","2020-Jun","Recruiting","Non-Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Alternative therapy, Standard of care",120
"NCT04334967","https://ClinicalTrials.gov/show/NCT04334967",NA,"United States","Oregon","2020-Apr","2021-May","Suspended","Randomised","Single",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea",NA,13
"NCT04476992","https://ClinicalTrials.gov/show/NCT04476992",NA,"Russia","Tomsk","2020-Jul","2021-Jul","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Renal Outcome (Unspecified)","Non-invasive respiratory support",20
"NCT04418505","https://ClinicalTrials.gov/show/NCT04418505",NA,"United States","Florida","2020-Jun","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, SpO2","Alternative therapy, Standard of care",280
"NCT04418505","https://ClinicalTrials.gov/show/NCT04418505",NA,"Canada","Ontario","2020-Jun","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, SpO2","Alternative therapy, Standard of care",280
"NCT04422509","https://ClinicalTrials.gov/show/NCT04422509",NA,"Netherlands","Amsterdam","2020-Jun","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Adverse Events","mAB, Standard of care",80
"NCT04422509","https://ClinicalTrials.gov/show/NCT04422509",NA,"Netherlands","Utrecht","2020-Jun","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Adverse Events","mAB, Standard of care",80
"NCT04487444","https://ClinicalTrials.gov/show/NCT04487444",NA,"United States","Rhode Island","2020-Jul","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO","Immunomodulators, Standard of care",80
"NCT04275414","https://ClinicalTrials.gov/show/NCT04275414",NA,"China","Hubei","2020-Feb","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Dyspnea, C-Reactive Protein, PaO2-FiO2, SpO2, Radiographic Findings","mAb",27
"NCT04275414","https://ClinicalTrials.gov/show/NCT04275414",NA,"China","Shandong","2020-Feb","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Dyspnea, C-Reactive Protein, PaO2-FiO2, SpO2, Radiographic Findings","mAb",27
"NCT04275414","https://ClinicalTrials.gov/show/NCT04275414",NA,"Italy","Rome","2020-Feb","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Dyspnea, C-Reactive Protein, PaO2-FiO2, SpO2, Radiographic Findings","mAb",27
"NCT04395768","https://ClinicalTrials.gov/show/NCT04395768",NA,"Australia","Victoria","2020-May","2021-Sep","Recruiting","Randomised","Double",6,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","HCQ + AZT + Zinc + Vitamins",200
"NCT04383002","https://ClinicalTrials.gov/show/NCT04383002",NA,"Canada","Ontario","2020-May","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU",NA,"Non-invasive respiratory support, Standard of care",20
"NCT04478071","https://ClinicalTrials.gov/show/NCT04478071",NA,"United States","Texas","2020-Jul","2022-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Other, Standard of care",300
"CHICTR2000034825","http://www.chictr.org.cn/showproj.aspx?proj=56834",NA,"China","Jiangsu","2020-Jul","2020-Dec","Completed","Randomised","Unspecified",6,"Healthy","Healthy Unexposed","Urine Sample, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",144
"NCT04461340","https://ClinicalTrials.gov/show/NCT04461340",NA,"Egypt","Cairo","2020-Jul","2020-Oct","Recruiting","Randomised","Single",2,"Confirmed","Hospital, Unclear","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Adverse Events","Other, Standard of care",40
"NCT04483830","https://ClinicalTrials.gov/show/NCT04483830",NA,"Mexico","Sonora","2020-Jul","2020-Aug","Completed","Randomised","Single",2,"Suspected","Outpatient","Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",243
"NCT04390594","https://ClinicalTrials.gov/show/NCT04390594",NA,"Senegal","Dakar","2020-May","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events","HCQ, HCQ + AZT",186
"NCT04276987","https://ClinicalTrials.gov/show/NCT04276987",NA,"China","Shanghai","2020-Feb","2020-May","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-6, IL-8, D-Dimer, LDH, Radiographic Findings","Stem cells",24
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","California","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","District Of Columbia","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","Florida","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","Illinois","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","Maryland","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","Massachusetts","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","Michigan","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","New Jersey","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","New York","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","North Carolina","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","Pennsylvania","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","Texas","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04452565","https://ClinicalTrials.gov/show/NCT04452565",NA,"United States","Washington","2020-Jun","2020-Dec","Recruiting","Randomised","Triple",4,"Confirmed","Hospital","Fever","Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone",525
"NCT04537962","https://ClinicalTrials.gov/show/NCT04537962",NA,"Israel","Jerusalem","2020-Sep","2020-Sep","Recruiting","Randomised","Single",7,"Confirmed","Hospital, ICU","Hospitalization, Viral Load or Clearance","Hygiene",70
"NCT04405999","https://ClinicalTrials.gov/show/NCT04405999",NA,"Russia","Moscow","2020-May","2020-Aug","Completed","Randomised","Open-Label",2,"Healthy","Healthcare Workers",NA,"Other, Standard of care",50
"NCT04466657","https://ClinicalTrials.gov/show/NCT04466657",NA,"Nigeria","Niger","2020-Jul","2021-Feb","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any)","Nutrition, Standard of care",90
"NCT04466657","https://ClinicalTrials.gov/show/NCT04466657",NA,"Nigeria","Cross River","2020-Jul","2021-Feb","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any)","Nutrition, Standard of care",90
"NCT04466657","https://ClinicalTrials.gov/show/NCT04466657",NA,"Nigeria","Sokoto","2020-Jul","2021-Feb","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any)","Nutrition, Standard of care",90
"NCT04364022","https://ClinicalTrials.gov/show/NCT04364022",NA,"Switzerland","Bern","2020-Apr","2021-Mar","Recruiting","Randomised","Open-Label",2,NA,"Healthy Exposed",NA,"HCQ, LPV/r",300
"NCT04329832","https://ClinicalTrials.gov/show/NCT04329832",NA,"United States","Utah","2020-Apr","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","AZT, HCQ",85
"NCT04431466","https://ClinicalTrials.gov/show/NCT04431466",NA,"Brazil","Brasilia","2020-Jun","2020-Dec","Recruiting","Randomised","Open-Label",5,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance","Ivermectin, Standard of care",64
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Arizona","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","California","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Colorado","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Florida","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Kentucky","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Louisiana","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Maine","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Massachusetts","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Michigan","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Mississippi","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","New York","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","North Carolina","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Ohio","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Oregon","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Pennsylvania","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","South Carolina","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Tennessee","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Texas","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Utah","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Virginia","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Washington","2020-Apr","2020-Jun","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",479
"NCT04363450","https://ClinicalTrials.gov/show/NCT04363450",NA,"United States","Louisiana","2020-Apr","2021-Mar","Recruiting","Randomised","Quadruple",2,NA,"Healthcare Workers","Labor Absenteeism","HCQ, Standard of care",1700
"NCT04523090","https://ClinicalTrials.gov/show/NCT04523090",NA,"South Africa","Western Cape","2020-Aug","2021-Apr","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Cough","Antivirals, Standard of care",960
"NCT04534673","https://ClinicalTrials.gov/show/NCT04534673",NA,"Israel","Jerusalem","2020-Sep","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","IFN, Standard of care",40
"NCT04472572","https://ClinicalTrials.gov/show/NCT04472572",NA,"United States","New Jersey","2020-Jul",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Hospital",NA,"Plasma based therapy",NA
"NCT04521036","https://ClinicalTrials.gov/show/NCT04521036",NA,"Vietnam","Hanoi","2020-Aug","2021-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Plasma based therapy, Standard of care",44
"NCT04528641","https://ClinicalTrials.gov/show/NCT04528641",NA,"Italy","Rome","2020-Aug","2021-Jul","Recruiting","Non-Randomised","Open-Label",6,"Healthy","Healthy Unexposed","Albumin, LDH, Renal Outcome (Unspecified)","Vaccine",90
"NCT04528641","https://ClinicalTrials.gov/show/NCT04528641",NA,"Italy","Verona","2020-Aug","2021-Jul","Recruiting","Non-Randomised","Open-Label",6,"Healthy","Healthy Unexposed","Albumin, LDH, Renal Outcome (Unspecified)","Vaccine",90
"CHICTR2000032165","http://www.chictr.org.cn/showproj.aspx?proj=52679",NA,"China","Hubei","2020-Apr","2021-Mar","Completed","Randomised","Double",2,NA,"Unclear","6-Minute Walking Distance, Radiographic Findings, Quality of Life","Education, TCM + Education",160
"NCT04530474","https://ClinicalTrials.gov/show/NCT04530474",NA,"United States","Pennsylvania","2020-Aug","2021-Jun","Not Recruiting","Randomised","Triple",2,"Suspected","Outpatient","Clinical Improvement Score (Any)","Ivermectin, Standard of care",200
"NCT04530422","https://ClinicalTrials.gov/show/NCT04530422",NA,"Egypt","Cairo","2020-Aug","2020-Jul","Completed","Randomised","Single",2,"Confirmed","Unclear","Mortality, Hospitalization","DAA, Oseltamivir + HCQ + AZT",250
"NCT04500418","https://ClinicalTrials.gov/show/NCT04500418",NA,"Germany","Berlin","2020-Aug","2021-Sep","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Monocyte Count, Neutrophils, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, ECG","Other, Standard of care",183
"NCT04527133","https://ClinicalTrials.gov/show/NCT04527133",NA,"Russia","Smolensk","2020-Aug","2020-Aug","Not Recruiting","Non-Randomised","Open-Label",3,"Confirmed","Hospital","Hospital Discharge, Fever, C-Reactive Protein, D-Dimer, Fibrinogen, INR, Radiographic Findings","FPV + Other, Other",30
"NCT04388410","https://ClinicalTrials.gov/show/NCT04388410",NA,"Mexico","Mexico","2020-May","2020-Nov","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Antibodies","Plasma based therapy, Standard of care",410
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Madrid","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Alicante","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Asturias","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Barcelona","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Las Palmas","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","La Rioja","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Murcia","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Navarra","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Valencia","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Alava","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Albacete","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Burgos","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Cuenca","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Granada","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Palencia","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Salamanca","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Segovia","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Sevilla","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Valladolid","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Zaragoza","2020-Apr","2020-Dec","Recruiting","Randomised","Double",4,"Healthy","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, HCQ + NRTIs, NRTIs, Standard of care",4000
"NCT04505761","https://ClinicalTrials.gov/show/NCT04505761",NA,"Netherlands","Gelderland","2020-Aug","2021-Jan","Recruiting","Single-Arm","Open-Label",1,"Resolved","Resolved Discharged","Other Mild Symptoms, 6-Minute Walking Distance","Rehabilitation",40
"NCT04522986","https://ClinicalTrials.gov/show/NCT04522986",NA,"Japan","Osaka","2020-Aug","2021-Dec","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Adverse Events","Stem cells",6
"CHICTR2000036333","http://www.chictr.org.cn/showproj.aspx?proj=57115",NA,"China","Hunan","2020-Aug","2020-Apr","Completed","Non-Randomised","Unspecified",2,"Suspected","Hospital","Anxiety","Psychological therapy, Standard of care",51
"NCT04445285","https://ClinicalTrials.gov/show/NCT04445285",NA,"United States","Alabama","2020-Jun","2020-Nov","Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospitalization","Inhaled solution + Other, Standard of care",44
"NCT04473053","https://ClinicalTrials.gov/show/NCT04473053",NA,"United Kingdom","Edinburgh","2020-Jul","2021-Jul","Recruiting","Randomised","Single",3,"Confirmed","Outpatient, Hospital","Hospital Discharge, Viral Load or Clearance, Adverse Events, Coagulation Test, SpO2, Renal Outcome (Unspecified)","Anticoagulants, Other, Standard of care",60
"NCT04516915","https://ClinicalTrials.gov/show/NCT04516915",NA,"United Kingdom","Warwickshire","2020-Aug","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified)","Oseltamivir, Other + Oseltamivir",120
"NCT04438057","https://ClinicalTrials.gov/show/NCT04438057",NA,"United States","Illinois","2020-Jun","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Hospitalization","Plasma based therapy, Standard of care",150
"NCT04374565","https://ClinicalTrials.gov/show/NCT04374565",NA,"United States","Virginia","2020-May","2021-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies, Renal Outcome (Unspecified)","Plasma based therapy",29
"NCT04481685","https://ClinicalTrials.gov/show/NCT04481685",NA,"United States","Kansas","2020-Jul","2021-Jul","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, Fever, Serious Adverse Events, IL-1, IL-8, Tumor Necrosis Factor (Any), SpO2, Distress","Other, Standard of care",36
"NCT04401423","https://ClinicalTrials.gov/show/NCT04401423",NA,"United States","New York","2020-May","2021-Jun","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Non-invasive Ventilation, Renal Outcome (Unspecified)","Antihypertensive, Standard of care",100
"NCT04516954","https://ClinicalTrials.gov/show/NCT04516954",NA,"Vietnam","Hanoi","2020-Aug","2020-Nov","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital",NA,"Plasma based therapy",10
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","California","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, Standard of care",86
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","Connecticut","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, Standard of care",86
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","Georgia","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, Standard of care",86
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","Massachusetts","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, Standard of care",86
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","New Jersey","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, Standard of care",86
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","New York","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, Standard of care",86
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","North Carolina","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, Standard of care",86
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","Ohio","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, Standard of care",86
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","Oregon","2020-Apr","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Natural Killer Cell Count, CD4, CD8, SpO2, Radiographic Findings","mAb, Standard of care",86
"NCT04353271","https://ClinicalTrials.gov/show/NCT04353271",NA,"United States","Alabama","2020-Apr","2020-Jul","Status Unclear","Randomised","Quadruple",2,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Anti SARS-COV-2 Titers, Antibodies","HCQ, Standard of care",58
"NCT04514627","https://ClinicalTrials.gov/show/NCT04514627",NA,"United States","California","2020-Aug","2021-Jul","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Platelet Count, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, Troponin, Procalcitonin, LDH, SpO2, Respiratory Rate, Hypoxemia","Other, Standard of care",100
"NCT04288102","https://ClinicalTrials.gov/show/NCT04288102",NA,"China","Hubei","2020-Feb","2020-May","Completed","Randomised","Quadruple",2,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, Radiographic Findings","Standard of care, Stem cells",100
"NCT04447781","https://ClinicalTrials.gov/show/NCT04447781",NA,"South Korea","Gyeonggi","2020-Jun","2022-Feb","Recruiting","Randomised","Triple",4,"Healthy","Healthy Unexposed",NA,"Device, Vaccine + Device",160
"NCT04447781","https://ClinicalTrials.gov/show/NCT04447781",NA,"South Korea","Seoul","2020-Jun","2022-Feb","Recruiting","Randomised","Triple",4,"Healthy","Healthy Unexposed",NA,"Device, Vaccine + Device",160
"NCT04519125","https://ClinicalTrials.gov/show/NCT04519125",NA,"Colombia","Bogota","2020-Aug","2020-Dec","Not Recruiting","Randomised","Triple",2,"Healthy","Healthcare Workers","Serious Adverse Events","NRTIs, Standard of care",950
"NCT04332666","https://ClinicalTrials.gov/show/NCT04332666",NA,"Belgium","Brussels","2020-Apr","2020-Dec","Not Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","ICU","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Serious Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), Angiotensins, PaO2-FiO2, Radiographic Findings","Antihypertensive, Standard of care",60
"NCT04508985","https://ClinicalTrials.gov/show/NCT04508985",NA,"Canada","Quebec","2020-Aug","2021-Jan","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Other, Standard of care",40
"NCT04394208","https://ClinicalTrials.gov/show/NCT04394208",NA,"Egypt","Cairo","2020-May","2021-Jan","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events","Alternative therapy, Standard of care",50
"NCT04355494","https://ClinicalTrials.gov/show/NCT04355494",NA,"United States","California","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"mAb",NA
"NCT04355494","https://ClinicalTrials.gov/show/NCT04355494",NA,"United States","Massachusetts","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"mAb",NA
"NCT04355494","https://ClinicalTrials.gov/show/NCT04355494",NA,"United States","Minnesota","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"mAb",NA
"NCT04355494","https://ClinicalTrials.gov/show/NCT04355494",NA,"United States","New Jersey","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"mAb",NA
"NCT04355494","https://ClinicalTrials.gov/show/NCT04355494",NA,"United States","New York","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"mAb",NA
"NCT04355494","https://ClinicalTrials.gov/show/NCT04355494",NA,"United States","Ohio","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"mAb",NA
"NCT04355494","https://ClinicalTrials.gov/show/NCT04355494",NA,"France","Paris","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"Hospital",NA,"mAb",NA
"NCT04392219","https://ClinicalTrials.gov/show/NCT04392219",NA,"United Kingdom","Leeds","2020-May","2020-Aug","Completed","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events","Antivirals, Standard of care",130
"NCT04332380","https://ClinicalTrials.gov/show/NCT04332380",NA,"Colombia","Cundinamarca","2020-Apr","2020-Jul","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA","Plasma based therapy",10
"NCT04504240","https://ClinicalTrials.gov/show/NCT04504240",NA,"Bangladesh","Chittagong","2020-Aug","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Other",200
"NCT04504240","https://ClinicalTrials.gov/show/NCT04504240",NA,"Bangladesh","Dhaka","2020-Aug","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Other",200
"NCT04437693","https://ClinicalTrials.gov/show/NCT04437693",NA,"Qatar","Doha","2020-Jun","2021-Aug","Not Recruiting","Randomised","Single",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"HCQ, Standard of care",500
"NCT04415073","https://ClinicalTrials.gov/show/NCT04415073",NA,"United States","Arizona","2020-Jun","2020-Nov","Suspended","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any)","mAb, Standard of care",186
"NCT04415073","https://ClinicalTrials.gov/show/NCT04415073",NA,"United States","New York","2020-Jun","2020-Nov","Suspended","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any)","mAb, Standard of care",186
"CHICTR2000029822","http://www.chictr.org.cn/showproj.aspx?proj=49502",NA,"China","Hebei","2020-Feb","2020-Apr","Suspended","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Fever, Respiratory Rate","Standard of care, TCM",110
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Bahia","2020-Mar","2020-Jul","Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Dexamethasone, Standard of care",299
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Distrito Federal","2020-Mar","2020-Jul","Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Dexamethasone, Standard of care",299
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Brasilia","2020-Mar","2020-Jul","Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Dexamethasone, Standard of care",299
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Minas Gerais","2020-Mar","2020-Jul","Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Dexamethasone, Standard of care",299
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Para","2020-Mar","2020-Jul","Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Dexamethasone, Standard of care",299
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Rio Grande Do Norte","2020-Mar","2020-Jul","Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Dexamethasone, Standard of care",299
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Rio Grande Do Sul","2020-Mar","2020-Jul","Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Dexamethasone, Standard of care",299
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Santa Catarina","2020-Mar","2020-Jul","Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Dexamethasone, Standard of care",299
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Israel","Jerusalem","2020-Mar","2020-Jul","Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Dexamethasone, Standard of care",299
"NCT04501796","https://ClinicalTrials.gov/show/NCT04501796",NA,"United States","Maryland","2020-Aug","2021-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Lymphocyte Count","Other, Standard of care",30
"NCT04501796","https://ClinicalTrials.gov/show/NCT04501796",NA,"United States","Nebraska","2020-Aug","2021-Oct","Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Lymphocyte Count","Other, Standard of care",30
"NCT04501783","https://ClinicalTrials.gov/show/NCT04501783",NA,"Russia","Moscow","2020-Aug","2020-Jul","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Radiographic Findings","FPV, Standard of care",168
"NCT04501783","https://ClinicalTrials.gov/show/NCT04501783",NA,"Russia","Voronezh","2020-Aug","2020-Jul","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Radiographic Findings","FPV, Standard of care",168
"NCT04391712","https://ClinicalTrials.gov/show/NCT04391712",NA,"United States","Massachusetts","2020-May","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","C-Reactive Protein, IL-6, Radiographic Findings","Other, Standard of care",10
"NCT04408456","https://ClinicalTrials.gov/show/NCT04408456",NA,"India","Chandigarh","2020-May","2020-Jul","Completed","Non-Randomised","Open-Label",2,"Healthy","Healthy Unexposed",NA,"HCQ, Standard of care",325
"NCT04477655","https://ClinicalTrials.gov/show/NCT04477655",NA,"Mexico","Jalisco","2020-Jul","2020-Nov","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Patient Positioning","Positioning, Standard of care",200
"NCT04384380","https://ClinicalTrials.gov/show/NCT04384380",NA,"Taiwan","Taoyuan","2020-May","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Adverse Events, Radiographic Findings","HCQ, Standard of care",33
"NCT04389944","https://ClinicalTrials.gov/show/NCT04389944",NA,"Switzerland","Bern","2020-May","2020-Jun","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Serious Adverse Events","Plasma based therapy",15
"CHICTR2000030259","http://www.chictr.org.cn/showproj.aspx?proj=49918",NA,"China","Shanghai","2020-Feb","2020-Apr","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Viral Load or Clearance, PaO2-FiO2, Respiratory Rate","DAA, Standard of care",60
"NCT04337541","https://ClinicalTrials.gov/show/NCT04337541",NA,"Denmark","Copenhagen","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,"Healthy","Healthcare Workers, Outpatient","Viral Load or Clearance, Antibodies",NA,6000
"NCT04329611","https://ClinicalTrials.gov/show/NCT04329611",NA,"Canada","Alberta","2020-Apr","2020-Jul","Status Unclear","Single-Arm","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",148
"NCT04361643","https://ClinicalTrials.gov/show/NCT04361643",NA,"Spain","Madrid","2020-Apr","2021-Aug","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Neutrophils","Immunomodulators, Standard of care",120
"NCT04345289","https://ClinicalTrials.gov/show/NCT04345289",NA,"Denmark","Copenhagen","2020-Apr","2021-Jun","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO",NA,1100
"NCT04447235","https://ClinicalTrials.gov/show/NCT04447235",NA,"Brazil","Sao Paulo","2020-Jun","2020-Dec","Recruiting","Randomised","Double",3,"Confirmed Or Suspected","Unclear","Adverse Events","Ivermectin + ARBs, Standard of care",176
"NCT04359953","https://ClinicalTrials.gov/show/NCT04359953",NA,"France","Paris","2020-Apr","2021-Jun","Recruiting","Randomised","Open-Label",3,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","ARBs, AZT, HCQ",1600
"NCT04321993","https://ClinicalTrials.gov/show/NCT04321993",NA,"Canada","Nova Scotia","2020-Mar","2022-Feb","Recruiting","Non-Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, SpO2","HCQ, JAKi, LPV/r, Sarilumab",800
"NCT04485429","https://ClinicalTrials.gov/show/NCT04485429",NA,"Brazil","Rio De Janeiro","2020-Jul","2020-Dec","Recruiting","Randomised","Open-Label",4,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Anticoagulants, Anticoagulants + Corticosteroids, Corticosteroids, Standard of care",268
"NCT04438837","https://ClinicalTrials.gov/show/NCT04438837",NA,"Israel","Haifa","2020-Jun","2022-Jun","Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Adverse Events","HCQ, Standard of care",582
"NCT04480632","https://ClinicalTrials.gov/show/NCT04480632",NA,"Colombia","Santander","2020-Jul","2021-Aug","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","ICU","Mortality, Adverse Events, Renal Outcome (Unspecified)","Plasma based therapy, Standard of care",44
"NCT04377477","https://ClinicalTrials.gov/show/NCT04377477",NA,"Italy","Brescia","2020-May","2021-Aug","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","ICU Admission, Hospitalization, Adverse Events, Radiographic Findings","Radiation therapy",30
"NCT04423042","https://ClinicalTrials.gov/show/NCT04423042",NA,"Canada","Alberta","2020-Jun","2021-Jun","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality","TCZ",30
"NCT04455243","https://ClinicalTrials.gov/show/NCT04455243",NA,"Saudi Arabia","Riyadh","2020-Jul","2021-Aug","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"Other, Standard of care",1180
"NCT04410159","https://ClinicalTrials.gov/show/NCT04410159",NA,"Malaysia","Kuala Lumpur","2020-Jun","2020-Jun","Completed","Randomised","Open-Label",4,"Confirmed","Unclear","Viral Load or Clearance","Hygiene, Standard of care",20
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Belgium","Brussels","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Brazil","Amazonas","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Brazil","Roraima","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Brazil","Sao Paulo","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Brazil","Rio De Janeiro","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"France","Nord","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"France","Paris","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Germany","Berlin","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Germany","Nordrhein-Westfalen","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Germany","Hamburg","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Italy","Milano","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Italy","Treviso","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Italy","Lecco","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Mexico","Yucatan","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Mexico","Mexico","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Spain","Barcelona","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Spain","Alicante","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"Spain","Madrid","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04393038","https://ClinicalTrials.gov/show/NCT04393038",NA,"United Kingdom","London","2020-May","2020-Dec","Recruiting","Randomised","Triple",2,"Confirmed","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"NCT04478539","https://ClinicalTrials.gov/show/NCT04478539",NA,"Macedonia","Skopje","2020-Jul","2021-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","ICU Admission, C-Reactive Protein, IL-8, Tumor Necrosis Factor (Any), Lymphocyte Count, D-Dimer, Fibrinogen, Coagulation Test","Dialysis",35
"NCT04476680","https://ClinicalTrials.gov/show/NCT04476680",NA,"United Kingdom","Leeds","2020-Jul","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","IgG, IgM or IgA","Standard of care, Vitamins",4400
"NCT04477993","https://ClinicalTrials.gov/show/NCT04477993",NA,"Brazil","Sao Paulo","2020-Jul","2021-Feb","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Ferritin, IL-6, PAI-1, von Wildebrandt Factor, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, Troponin, Prothrombin, Fibrinogen, AST, Bilirubin, Glucose, PaO2-FiO2","JAKi, Standard of care",200
"NCT04334512","https://ClinicalTrials.gov/show/NCT04334512",NA,"United States","California","2020-Apr","2021-Jun","Recruiting","Randomised","Double",5,"Confirmed","Unclear","Viral Load or Clearance, Radiographic Findings",NA,600
"CHICTR2000034794","http://www.chictr.org.cn/showproj.aspx?proj=56771",NA,"China","Hubei","2020-Jul","2021-Apr","Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Antibodies, 6-Minute Walking Distance, Radiographic Findings, Renal Outcome (Unspecified)","Other, Standard of care",60
"CHICTR2000034795","http://www.chictr.org.cn/showproj.aspx?proj=56756",NA,"China","Hubei","2020-Jul","2020-Feb","Completed","Non-Randomised","Unspecified",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",42
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"United States","Minnesota","2020-Mar","2020-May","Completed","Randomised","Quadruple",2,"Confirmed, Suspected Or Healthy","Healthy Exposed, Healthcare Workers, Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ, Standard of care",1309
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"Canada","Alberta","2020-Mar","2020-May","Completed","Randomised","Quadruple",2,"Confirmed, Suspected Or Healthy","Healthy Exposed, Healthcare Workers, Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ, Standard of care",1309
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"Canada","Manitoba","2020-Mar","2020-May","Completed","Randomised","Quadruple",2,"Confirmed, Suspected Or Healthy","Healthy Exposed, Healthcare Workers, Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ, Standard of care",1309
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"Canada","Quebec","2020-Mar","2020-May","Completed","Randomised","Quadruple",2,"Confirmed, Suspected Or Healthy","Healthy Exposed, Healthcare Workers, Outpatient","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ, Standard of care",1309
"NCT04475601","https://ClinicalTrials.gov/show/NCT04475601",NA,"Sweden","Stockholm","2020-Jul","2021-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Adverse Events, C-Reactive Protein, IL-6, Platelet Count, Hemoglobin, D-Dimer","Hormone therapy, Standard of care",500
"NCT04424797","https://ClinicalTrials.gov/show/NCT04424797",NA,"United States","Colorado","2020-Jun","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, SpO2, Patient Positioning","Positioning",100
"NCT04473170","https://ClinicalTrials.gov/show/NCT04473170",NA,"United Arab Emirates","Abu Dhabi","2020-Jul","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","Standard of care, Stem cells",146
"NCT04400799","https://ClinicalTrials.gov/show/NCT04400799",NA,"Switzerland","Bern","2020-May","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, Coagulation Test","Anticoagulants, Standard of care",1000
"NCT04400799","https://ClinicalTrials.gov/show/NCT04400799",NA,"Switzerland","Vaud","2020-May","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, Coagulation Test","Anticoagulants, Standard of care",1000
"NCT04400799","https://ClinicalTrials.gov/show/NCT04400799",NA,"Switzerland","Zurich","2020-May","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, Coagulation Test","Anticoagulants, Standard of care",1000
"NCT04465695","https://ClinicalTrials.gov/show/NCT04465695",NA,"China","Hong Kong","2020-Jul","2021-Jun","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Viral Load or Clearance, Adverse Events","Antibiotics, IFN + Antibiotics, Standard of care",81
"NCT04353206","https://ClinicalTrials.gov/show/NCT04353206",NA,"United States","California","2020-Apr","2021-May","Recruiting","Single-Arm","Open-Label",1,NA,"ICU","Mortality","Plasma based therapy",60
"NCT04353206","https://ClinicalTrials.gov/show/NCT04353206",NA,"United States","Maryland","2020-Apr","2021-May","Recruiting","Single-Arm","Open-Label",1,NA,"ICU","Mortality","Plasma based therapy",60
"NCT04338698","https://ClinicalTrials.gov/show/NCT04338698",NA,"Pakistan","Islamabad","2020-Apr","2020-Sep","Recruiting","Randomised","Double",3,"Confirmed","Unclear","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO",NA,500
"NCT04443270","https://ClinicalTrials.gov/show/NCT04443270",NA,"Mexico","Mexico","2020-Jun","2020-Oct","Not Recruiting","Non-Randomised","Single",2,"Healthy","Healthy Exposed, Healthcare Workers","Clinical Improvement Score (Any), Adverse Events","HCQ, Standard of care",200
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"United States","Massachusetts","2020-Apr","2020-May","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, Standard of care",8
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"Belgium","Brussels","2020-Apr","2020-May","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, Standard of care",8
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"France","Paris","2020-Apr","2020-May","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, Standard of care",8
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"Netherlands","Groningen","2020-Apr","2020-May","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, Standard of care",8
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"Netherlands","Amsterdam","2020-Apr","2020-May","Status Unclear","Randomised","Quadruple",2,"Confirmed","Outpatient","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2","HCQ, Standard of care",8
"NCT04306393","https://ClinicalTrials.gov/show/NCT04306393",NA,"United States","Alabama","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","ICU",NA,"Non-invasive respiratory support, Standard of care",200
"NCT04306393","https://ClinicalTrials.gov/show/NCT04306393",NA,"United States","Louisiana","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","ICU",NA,"Non-invasive respiratory support, Standard of care",200
"NCT04306393","https://ClinicalTrials.gov/show/NCT04306393",NA,"United States","Massachusetts","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","ICU",NA,"Non-invasive respiratory support, Standard of care",200
"NCT04389359","https://ClinicalTrials.gov/show/NCT04389359",NA,"United Kingdom","Cambridgeshire","2020-May","2021-Aug","Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed","Mortality","HCQ, Standard of care",1500
"NCT04468646","https://ClinicalTrials.gov/show/NCT04468646",NA,"Pakistan","Punjab","2020-Jul","2020-Jul","Recruiting","Randomised","Triple",2,"Confirmed","Hospital, ICU","Viral Load or Clearance, Cough, Fever, IL-6","Other, Standard of care",100
"NCT04467047","https://ClinicalTrials.gov/show/NCT04467047",NA,"Brazil","Rio Grande Do Sul","2020-Jul","2020-Oct","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital, Unclear","Hospitalization, C-Reactive Protein, PaO2-FiO2","Stem cells",10
"NCT04466670","https://ClinicalTrials.gov/show/NCT04466670",NA,"Brazil","Sao Paulo","2020-Jul","2020-Dec","Recruiting","Non-Randomised","Open-Label",4,"Confirmed","Unclear","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","Anticoagulants, Antihypertensive",310
"NCT04395170","https://ClinicalTrials.gov/show/NCT04395170",NA,"Colombia","Antioquia","2020-May","2020-Dec","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, IgG, IgM or IgA, Antibodies","Igs, Plasma based therapy, Standard of care",75
"NCT04322565","https://ClinicalTrials.gov/show/NCT04322565",NA,"Italy","Parma","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever","Colchicine, Standard of care",310
"NCT04376788","https://ClinicalTrials.gov/show/NCT04376788",NA,"Egypt","Cairo","2020-May","2020-Jul","Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear",NA,"Plasma based therapy, Plasma based therapy + Other, Standard of care",15
"NCT04441385","https://ClinicalTrials.gov/show/NCT04441385",NA,"Spain","Barcelona","2020-Jun","2020-Nov","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, ECG","Antivirals, Standard of care",200
"NCT04441385","https://ClinicalTrials.gov/show/NCT04441385",NA,"Spain","Madrid","2020-Jun","2020-Nov","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, ECG","Antivirals, Standard of care",200
"CHICTR2000034112","http://www.chictr.org.cn/showproj.aspx?proj=55524",NA,"China","Yunnan","2020-Jun","2021-Dec","Not Recruiting","Randomised","Unspecified",3,"Healthy","Healthy Unexposed","IgG, IgM or IgA, Antibodies","Vaccine",168
"CHICTR2000033627","http://www.chictr.org.cn/showproj.aspx?proj=54707",NA,"China","Beijing","2020-Jun","2020-Jul","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Viral Load or Clearance","Ivermectin, Standard of care",60
"CHICTR2000032919","http://www.chictr.org.cn/showproj.aspx?proj=53274",NA,"China","Hubei","2020-May","2021-May","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Other Mild Symptoms, Stool Sample","Standard of care, TCM",200
"CHICTR2000032367","http://www.chictr.org.cn/showproj.aspx?proj=52972",NA,"China","Shanghai","2020-Apr","2020-Jul","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Hospitalization, Dyspnea, Other Mild Symptoms","Exercise, Standard of care",186
"NCT04354805","https://ClinicalTrials.gov/show/NCT04354805",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Randomised","Single",2,NA,"Hospital","LDH","Other, Standard of care",100
"NCT04462848","https://ClinicalTrials.gov/show/NCT04462848",NA,"United States","California","2020-Jul","2024-Sep","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Healthy","Healthy Exposed, Unclear","Serious Adverse Events, Antibodies","Plasma based therapy",30
"NCT04461925","https://ClinicalTrials.gov/show/NCT04461925",NA,"Ukraine","Kyiv (Kiev)","2020-Jul","2021-May","Recruiting","Non-Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Cough, Fever, C-Reactive Protein, PaO2-FiO2","Antibiotics + AZT + Corticosteroids + Anticoagulants + Other, Stem cells + Antibiotics + AZT + Corticosteroids + Anticoagulants + Other",30
"NCT04418518","https://ClinicalTrials.gov/show/NCT04418518",NA,"United States","New York","2020-Jun","2021-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified)","Plasma-based therapy, Standard of care",1200
"NCT04374539","https://ClinicalTrials.gov/show/NCT04374539",NA,"Spain","Barcelona","2020-May","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, Invasive Mechanical Ventilation or ECMO","Plasma based therapy, Standard of care",116
"NCT04379037","https://ClinicalTrials.gov/show/NCT04379037",NA,"Argentina","Buenos Aires","2020-May","2020-Sep","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Device",50
"NCT04342650","https://ClinicalTrials.gov/show/NCT04342650",NA,"Brazil","Amazonas","2020-Apr","2020-May","Completed","Randomised","Quadruple",2,NA,"Unclear","Adverse Events, Natural Killer Cell Count",NA,152
"NCT04454307","https://ClinicalTrials.gov/show/NCT04454307",NA,"Egypt","Cairo","2020-Jul","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Other, Standard of care",100
"NCT04412486","https://ClinicalTrials.gov/show/NCT04412486",NA,"United States","Mississippi","2020-Jun","2022-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","ICU Admission, Hospitalization, Organ Failure or Dysfunction (SOFA), IgG, IgM or IgA, PaO2-FiO2, Respiratory Rate","Plasma based therapy",100
"NCT04369742","https://ClinicalTrials.gov/show/NCT04369742",NA,"United States","New York","2020-Apr","2021-Jun","Suspended","Randomised","Double",2,NA,"Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, LDH","HCQ, Standard of care",626
"NCT04364893","https://ClinicalTrials.gov/show/NCT04364893",NA,"Brazil","Brasilia","2020-Apr","2020-Oct","Recruiting","Randomised","Open-Label",2,NA,"Hospital",NA,"ARBs + ACEi, Standard of care",700
"NCT04398147","https://ClinicalTrials.gov/show/NCT04398147",NA,"Canada","Ottawa","2020-May","2021-Dec","Not Recruiting","Randomised","Quadruple",3,"Healthy","Healthy Unexposed","Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, IL-2, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",696
"NCT04365985","https://ClinicalTrials.gov/show/NCT04365985",NA,"United States","Michigan","2020-Apr","2021-May","Recruiting","Randomised","Triple",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Renal Outcome (Unspecified)","Opiate antagonists, Opiate antagonists + Anesthetic, Standard of care",500
"NCT04363372","https://ClinicalTrials.gov/show/NCT04363372",NA,"United Kingdom","Plymouth","2020-Apr","2020-Aug","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Other, Standard of care",90
"NCT04252885","https://ClinicalTrials.gov/show/NCT04252885","https://www.medrxiv.org/content/medrxiv/early/2020/03/23/2020.03.19.20038984.full.pdf","China","Guangdong","2020-Feb","2020-Apr","Completed w. Results","Randomised","Open-Label",3,"Confirmed","Unclear","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, ALT, Bilirubin, Blood Pressure, Heart Rate, PaO2-FiO2, Respiratory Rate, Radiographic Findings","LPV/r, Standard of care, Umifenovir",86
"NCT04379271","https://ClinicalTrials.gov/show/NCT04379271",NA,"Bulgaria","Sofia","2020-May","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), D-Dimer, Weight, Height or BMI, Troponin, Procalcitonin, LDH, IgG, IgM or IgA, Antibodies, Blood Pressure, Heart Rate, ECG, SpO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Immunomodulators, Standard of care",230
"NCT04379271","https://ClinicalTrials.gov/show/NCT04379271",NA,"Germany","Berlin","2020-May","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), D-Dimer, Weight, Height or BMI, Troponin, Procalcitonin, LDH, IgG, IgM or IgA, Antibodies, Blood Pressure, Heart Rate, ECG, SpO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Immunomodulators, Standard of care",230
"NCT04453852","https://ClinicalTrials.gov/show/NCT04453852",NA,"Australia","South Australia","2020-Jul","2021-Jul","Recruiting","Randomised","Triple",2,"Healthy","Unclear","Adverse Events, Antibodies","Standard of care, Vaccine",40
"NCT04343729","https://ClinicalTrials.gov/show/NCT04343729",NA,"Brazil","Amazonas","2020-Apr","2020-Jun","Not Recruiting","Randomised","Quadruple",2,NA,"Unclear","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Corticosteroids, Standard of care",416
"NCT04269525","https://ClinicalTrials.gov/show/NCT04269525",NA,"China","Hubei","2020-Feb","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Procalcitonin, PaO2-FiO2, Radiographic Findings","Stem cells",16
"NCT04452474","https://ClinicalTrials.gov/show/NCT04452474",NA,"United States","District Of Columbia","2020-Jun","2020-Nov","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Hospitalization","mAb, Standard of care",376
"NCT04452474","https://ClinicalTrials.gov/show/NCT04452474",NA,"United States","Georgia","2020-Jun","2020-Nov","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Hospitalization","mAb, Standard of care",376
"NCT04452474","https://ClinicalTrials.gov/show/NCT04452474",NA,"United States","Illinois","2020-Jun","2020-Nov","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Hospitalization","mAb, Standard of care",376
"NCT04452474","https://ClinicalTrials.gov/show/NCT04452474",NA,"United States","Indiana","2020-Jun","2020-Nov","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Hospitalization","mAb, Standard of care",376
"NCT04452474","https://ClinicalTrials.gov/show/NCT04452474",NA,"United States","Massachusetts","2020-Jun","2020-Nov","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Hospitalization","mAb, Standard of care",376
"NCT04452474","https://ClinicalTrials.gov/show/NCT04452474",NA,"United States","North Carolina","2020-Jun","2020-Nov","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Hospitalization","mAb, Standard of care",376
"NCT04444271","https://ClinicalTrials.gov/show/NCT04444271",NA,"Pakistan","Punjab","2020-Jun","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital Discharge, Clinical Improvement Score (Any)","Standard of care, Stem cells",20
"NCT04304053","https://ClinicalTrials.gov/show/NCT04304053",NA,"Spain","Barcelona","2020-Mar","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Outpatient","Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, Radiographic Findings","HCQ + Antivirals, Standard of care",2300
"NCT04452799","https://ClinicalTrials.gov/show/NCT04452799",NA,"Egypt","Cairo","2020-Jun","2020-Oct","Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, IL-1, Tumor Necrosis Factor (Any), Respiratory Rate","Alternative therapy, Standard of care",100
"NCT04330300","https://ClinicalTrials.gov/show/NCT04330300",NA,"Ireland","Galway","2020-Apr","2021-Jul","Suspended","Randomised","Open-Label",4,"Healthy","Healthy Unexposed","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Troponin","Antihypertensive",2414
"NCT04407208","https://ClinicalTrials.gov/show/NCT04407208",NA,"Indonesia","Jakarta","2020-May","2020-Jun","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Adverse Events, C-Reactive Protein, D-Dimer, INR, Radiographic Findings","Plasma based therapy",10
"NCT04449965","https://ClinicalTrials.gov/show/NCT04449965",NA,"Canada","British Columbia","2020-Jun","2020-Nov","Not Recruiting","Randomised","Double",3,"Confirmed Or Suspected","Outpatient","Viral Load or Clearance","Hygeine, Standard of care",81
"NCT04377334","https://ClinicalTrials.gov/show/NCT04377334",NA,"Germany","Berlin","2020-May","2021-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Lymphocyte Count, D-Dimer, Antibodies","Standard of care, Stem cells",40
"CHICTR2000029589","http://www.chictr.org.cn/showproj.aspx?proj=49104",NA,"China","Beijing","2020-Feb","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Viral Load or Clearance, Cough, Fever, Dyspnea","Standard of care, TCM",120
"NCT04389710","https://ClinicalTrials.gov/show/NCT04389710",NA,"United States","Pennsylvania","2020-May","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","ICU Admission, Hospitalization, Hospital Discharge, Adverse Events, C-Reactive Protein, Platelet Count, D-Dimer, Prothrombin, Fibrinogen","Plasma based therapy",100
"NCT04399317","https://ClinicalTrials.gov/show/NCT04399317",NA,"Qatar","Doha","2020-May","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","ICU",NA,"Device, Standard of care",20
"NCT04443725","https://ClinicalTrials.gov/show/NCT04443725",NA,"Egypt","Cairo","2020-Jun","2020-Oct","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"HCQ + Antivirals, Standard of care",100
"NCT04349241","https://ClinicalTrials.gov/show/NCT04349241",NA,"Egypt","Cairo","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Outpatient","Viral Load or Clearance, Fever, Radiographic Findings","FPV, Standard of care",100
"NCT04445935","https://ClinicalTrials.gov/show/NCT04445935",NA,"Qatar","Doha","2020-Jun","2020-Sep","Recruiting","Randomised","Triple",2,"Confirmed","Unclear","PaO2-FiO2, Renal Outcome (Unspecified)","Anticoagulants, Standard of care",100
"NCT04371822","https://ClinicalTrials.gov/show/NCT04371822",NA,"Egypt","Cairo","2020-May","2020-Oct","Not Recruiting","Non-Randomised","Open-Label",7,NA,"Healthy Unexposed, ICU","Mortality, ICU Admission, C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer","Other",56
"NCT04445454","https://ClinicalTrials.gov/show/NCT04445454",NA,"Belgium","Brussels","2020-Jun","2022-Sep","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Pneumonia or ARDS","Stem cells",20
"NCT04445207","https://ClinicalTrials.gov/show/NCT04445207",NA,"United States","Massachusetts","2020-Jun",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Unclear",NA,"Plasma based therapy",NA
"NCT04441424","https://ClinicalTrials.gov/show/NCT04441424",NA,"Iraq","Baghdad","2020-Jun","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","HCQ + AZT, HCQ + Plasma based therapy + AZT",49
"NCT04359303","https://ClinicalTrials.gov/show/NCT04359303",NA,"Spain","Valencia","2020-Apr","2020-Nov","Not Recruiting","Randomised","Double",2,NA,"Hospital","Hospitalization, Clinical Improvement Score (Any), Serious or Seconday Infections, Radiographic Findings","Non-invasive respiratory support, Standard of care",50
"NCT04438980","https://ClinicalTrials.gov/show/NCT04438980",NA,"Spain","Barcelona","2020-Jun","2020-Dec","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Adverse Events","Corticosteroids, Standard of care",72
"NCT04438980","https://ClinicalTrials.gov/show/NCT04438980",NA,"Spain","Navarra","2020-Jun","2020-Dec","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Adverse Events","Corticosteroids, Standard of care",72
"NCT04442191","https://ClinicalTrials.gov/show/NCT04442191",NA,"United States","Illinois","2020-Jun","2021-May","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, LDH","Plasma based therapy, Standard of care",50
"NCT04399889","https://ClinicalTrials.gov/show/NCT04399889",NA,"United States","North Carolina","2020-May","2021-Apr","Recruiting","Single-Arm","Quadruple",3,"Confirmed","Unclear",NA,"Standard of care, Stem cells",30
"CHICTR2000034076","http://www.chictr.org.cn/showproj.aspx?proj=55582",NA,"China","Shandong","2020-Jun","2022-Apr","Recruiting","Single-Arm","Unspecified",1,"Healthy","Unclear",NA,"Other",25
"NCT04437823","https://ClinicalTrials.gov/show/NCT04437823",NA,"Pakistan","Punjab","2020-Jun","2021-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Organ Failure or Dysfunction (SOFA), Adverse Events, Radiographic Findings","Standard of care, Stem cells",20
"NCT04432103","https://ClinicalTrials.gov/show/NCT04432103",NA,"Mexico","Morelos","2020-Jun","2020-Jul","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Plasma based therapy",36
"NCT04433013","https://ClinicalTrials.gov/show/NCT04433013",NA,"Singapore","Singapore","2020-Jun","2020-Dec","Not Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Other Mild Symptoms","Standard of care, TCM",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Bologna","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Parma","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Foggia","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Brescia","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Catania","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Cremona","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Rome","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Mantova","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Potenza","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Milano","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"NCT04427098","https://ClinicalTrials.gov/show/NCT04427098",NA,"Italy","Verona","2020-Jun","2020-Oct","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Anticoagulants",300
"CHICTR2000030001","http://www.chictr.org.cn/showproj.aspx?proj=49723",NA,"China","Heilongjiang","2020-Feb","2020-May","Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Viral Load or Clearance, Fever, Radiographic Findings, Lung Inflamation","Other, Standard of care",240
"NCT04432987","https://ClinicalTrials.gov/show/NCT04432987",NA,"Turkey","Istanbul","2020-Jun","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital",NA,"Inhaled solution, Standard of care",60
"NCT04434248","https://ClinicalTrials.gov/show/NCT04434248",NA,"Russia","Moscow","2020-Jun","2020-Jul","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Radiographic Findings","FPV, Standard of care",330
"NCT04434248","https://ClinicalTrials.gov/show/NCT04434248",NA,"Russia","Novgorod","2020-Jun","2020-Jul","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Radiographic Findings","FPV, Standard of care",330
"NCT04434248","https://ClinicalTrials.gov/show/NCT04434248",NA,"Russia","Kirov","2020-Jun","2020-Jul","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Radiographic Findings","FPV, Standard of care",330
"NCT04434248","https://ClinicalTrials.gov/show/NCT04434248",NA,"Russia","Saratov","2020-Jun","2020-Jul","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Radiographic Findings","FPV, Standard of care",330
"NCT04434248","https://ClinicalTrials.gov/show/NCT04434248",NA,"Russia","Smolensk","2020-Jun","2020-Jul","Not Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Radiographic Findings","FPV, Standard of care",330
"NCT04427865","https://ClinicalTrials.gov/show/NCT04427865",NA,"Egypt","Cairo","2020-Jun","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers",NA,"Other",200
"NCT04353128","https://ClinicalTrials.gov/show/NCT04353128",NA,"Spain","Madrid","2020-Apr","2020-Oct","Recruiting","Randomised","Quadruple",2,NA,"Healthcare Workers","Viral Load or Clearance","Melatonin, Standard of care",450
"NCT04312243","https://ClinicalTrials.gov/show/NCT04312243",NA,"United States","Massachusetts","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Labor Absenteeism","Non-invasive respiratory support, Standard of care",470
"NCT04386850","https://ClinicalTrials.gov/show/NCT04386850",NA,"Iran","Tehran","2020-May","2020-Nov","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Viral Load or Clearance, Dyspnea","Standard of care, Vitamins",1500
"NCT04429763","https://ClinicalTrials.gov/show/NCT04429763",NA,"United States","Illinois","2020-Jun","2020-Sep","Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality","Standard of care, Stem cells",30
"NCT04420299","https://ClinicalTrials.gov/show/NCT04420299",NA,"Spain","Madrid","2020-Jun","2021-Mar","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Ferritin, D-Dimer, Radiographic Findings","Other",120
"NCT04425837","https://ClinicalTrials.gov/show/NCT04425837",NA,"Colombia","Cundinamarca","2020-Jun","2021-Feb","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Troponin, Procalcitonin, LDH, PaO2-FiO2","Plasma based therapy, Standard of care",236
"NCT04409886","https://ClinicalTrials.gov/show/NCT04409886",NA,"United States","New York","2020-Jun","2020-Dec","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","SpO2","Non-invasive respiratory support",30
"NCT04345861","https://ClinicalTrials.gov/show/NCT04345861",NA,"France","Paris","2020-Apr","2020-Jun","Status Unclear","Randomised","Double",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Radiographic Findings","HCQ, HCQ + AZT",7
"NCT04425772","https://ClinicalTrials.gov/show/NCT04425772",NA,"China","Beijing","2020-Jun","2020-Aug","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Viral Load or Clearance, Non-invasive Ventilation, Cough, Other Mild Symptoms, Adverse Events, Radiographic Findings","Antivirals, Standard of care",342
"NCT04382768","https://ClinicalTrials.gov/show/NCT04382768",NA,"Argentina","Buenos Aires","2020-May","2021-Jan","Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Organ Failure or Dysfunction (SOFA), Adverse Events, Lymphocyte Count","NSAIDs",40
"NCT04428073","https://ClinicalTrials.gov/show/NCT04428073",NA,"United States","Georgia","2020-Jun","2021-Jul","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Outpatient","Adverse Events, CD8","Vaccine",32
"CHICTR2000033774","http://www.chictr.org.cn/showproj.aspx?proj=55097",NA,"China","Zhejiang","2020-Jun","2020-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Unclear","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea","Other, Standard of care",30
"NCT04421534","https://ClinicalTrials.gov/show/NCT04421534",NA,"Egypt","Cairo","2020-Jun","2020-Sep","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Clinical Improvement Score (Any)","Other, Standard of care",150
"NCT04370223","https://ClinicalTrials.gov/show/NCT04370223",NA,"Spain","Madrid","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils","Non-invasive respiratory support, Standard of care",208
"NCT04370223","https://ClinicalTrials.gov/show/NCT04370223",NA,"Spain","Asturias","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils","Non-invasive respiratory support, Standard of care",208
"NCT04370223","https://ClinicalTrials.gov/show/NCT04370223",NA,"Spain","Valencia","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils","Non-invasive respiratory support, Standard of care",208
"NCT04370223","https://ClinicalTrials.gov/show/NCT04370223",NA,"Spain","Valladolid","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils","Non-invasive respiratory support, Standard of care",208
"NCT04420390","https://ClinicalTrials.gov/show/NCT04420390",NA,"Spain","Madrid","2020-Jun","2020-Jul","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospitalization, Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, LDH, PaO2-FiO2","Radiation therapy",41
"NCT04346589","https://ClinicalTrials.gov/show/NCT04346589",NA,"Italy","Rome","2020-Apr","2020-Aug","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Non-invasive Ventilation","Plasma based therapy",10
"NCT04346589","https://ClinicalTrials.gov/show/NCT04346589",NA,"Italy","Bergamo","2020-Apr","2020-Aug","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Non-invasive Ventilation","Plasma based therapy",10
"NCT04424134","https://ClinicalTrials.gov/show/NCT04424134",NA,"Russia","Moscow","2020-Jun","2020-Jul","Recruiting","Randomised","Single",2,"Confirmed","Hospital","C-Reactive Protein, D-Dimer","Other, Standard of care",80
"NCT04321928","https://ClinicalTrials.gov/show/NCT04321928",NA,"Hungary","Budapest","2020-Mar","2021-Apr","Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","ICU Admission, Hospitalization, Other Mild Symptoms","Education, Psychological therapy",7576
"NCT04418128","https://ClinicalTrials.gov/show/NCT04418128",NA,"South Korea","Seoul","2020-Jun","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Anticoagulants, Standard of care",84
"NCT04421391","https://ClinicalTrials.gov/show/NCT04421391",NA,"United States","California","2020-Jun","2020-Nov","Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthcare Workers","Labor Absenteeism, Serious Adverse Events","Nutrition",500
"NCT04385940","https://ClinicalTrials.gov/show/NCT04385940",NA,"Canada","Alberta","2020-May","2020-Aug","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count","Vitamins",64
"NCT04316377","https://ClinicalTrials.gov/show/NCT04316377",NA,"Norway","Oslo","2020-Mar","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance","HCQ, Standard of care",53
"NCT04418531","https://ClinicalTrials.gov/show/NCT04418531",NA,"Italy","Bergamo","2020-Jun","2020-Sep","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected","Unclear","IL-1, IL-2, IL-6, IL-7, IL-10, Tumor Necrosis Factor (Any), MCP-1, IgG, IgM or IgA, Antibodies, Radiographic Findings","Igs",10
"NCT04418531","https://ClinicalTrials.gov/show/NCT04418531",NA,"Italy","Rome","2020-Jun","2020-Sep","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected","Unclear","IL-1, IL-2, IL-6, IL-7, IL-10, Tumor Necrosis Factor (Any), MCP-1, IgG, IgM or IgA, Antibodies, Radiographic Findings","Igs",10
"NCT04332081","https://ClinicalTrials.gov/show/NCT04332081",NA,"United States","New York","2020-Apr","2020-May","Status Unclear","Single-Arm","Open-Label",1,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,20
"NCT04394416","https://ClinicalTrials.gov/show/NCT04394416",NA,"United States","Maryland","2020-May","2022-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Imatinib, Standard of care",204
"NCT04389580","https://ClinicalTrials.gov/show/NCT04389580",NA,"Egypt","Cairo","2020-May","2020-Aug","Not Recruiting","Randomised","Open-Label",3,"Confirmed","ICU","Mortality, ICU Admission, C-Reactive Protein, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer","Hormone therapy, Hormone therapy + Other, Standard of care",160
"NCT04341727","https://ClinicalTrials.gov/show/NCT04341727",NA,"United States","Missouri","2020-Apr","2021-Apr","Suspended","Randomised","Open-Label",3,NA,"Hospital",NA,NA,500
"NCT04413838","https://ClinicalTrials.gov/show/NCT04413838",NA,"France","Paris","2020-Jun","2021-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Adverse Events, IL-1, IL-6, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), PD-1, Lymphocyte Count, CD4, CD8","mAb, Standard of care",120
"NCT04377672","https://ClinicalTrials.gov/show/NCT04377672",NA,"United States","Maryland","2020-May","2021-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Healthy","Healthy Exposed, Unclear","Adverse Events, Antibodies","Plasma based therapy",30
"NCT04385186","https://ClinicalTrials.gov/show/NCT04385186",NA,"Colombia","Bogota","2020-May","2020-Nov","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-6, Hemoglobin, D-Dimer, Procalcitonin, AST, Bilirubin, Antibodies, Radiographic Findings","Plasma based therapy, Standard of care",60
"NCT04385186","https://ClinicalTrials.gov/show/NCT04385186",NA,"Colombia","Cundinamarca","2020-May","2020-Nov","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-6, Hemoglobin, D-Dimer, Procalcitonin, AST, Bilirubin, Antibodies, Radiographic Findings","Plasma based therapy, Standard of care",60
"NCT04385186","https://ClinicalTrials.gov/show/NCT04385186",NA,"Colombia","Risaralda","2020-May","2020-Nov","Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-6, Hemoglobin, D-Dimer, Procalcitonin, AST, Bilirubin, Antibodies, Radiographic Findings","Plasma based therapy, Standard of care",60
"NCT04344951","https://ClinicalTrials.gov/show/NCT04344951",NA,"Greece","Athens","2020-Apr","2021-Apr","Recruiting","Single-Arm","Open-Label",1,NA,"Outpatient, Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2",NA,60
"NCT04322123","https://ClinicalTrials.gov/show/NCT04322123",NA,"Brazil","Brasilia","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2","HCQ, Standard of care",630
"NCT04322123","https://ClinicalTrials.gov/show/NCT04322123",NA,"Brazil","Distrito Federal","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2","HCQ, Standard of care",630
"NCT04322123","https://ClinicalTrials.gov/show/NCT04322123",NA,"Brazil","Rio De Janeiro","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2","HCQ, Standard of care",630
"CHICTR2000033284","http://www.chictr.org.cn/showproj.aspx?proj=49590",NA,"China","Guangdong","2020-May","2025-May","Not Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Dyspnea, Weight, Height or BMI","Other, TCM + Other",150
"CHICTR2000029479","http://www.chictr.org.cn/showproj.aspx?proj=48773",NA,"China","Sichuan","2020-Feb","2020-May","Completed","Randomised","Open-Label",2,"Healthy","Healthy Unexposed","Pneumonia or ARDS","Standard of care, TCM",20000
"NCT04328493","https://ClinicalTrials.gov/show/NCT04328493",NA,"Vietnam","Hanoi","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events","HCQ, Standard of care",250
"NCT04328493","https://ClinicalTrials.gov/show/NCT04328493",NA,"Vietnam","Ho Chi Minh City","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events","HCQ, Standard of care",250
"CHICTR2000033372","http://www.chictr.org.cn/showproj.aspx?proj=54408",NA,"China","Shandong","2020-May","2020-May","Completed","Non-Randomised","Unspecified",2,"Confirmed","Hospital",NA,"DMARD, Standard of care",30
"NCT04321421","https://ClinicalTrials.gov/show/NCT04321421",NA,"Italy","Pavia","2020-Mar","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","ICU","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Antibodies","Plasma based therapy",49
"NCT04321421","https://ClinicalTrials.gov/show/NCT04321421",NA,"Italy","Mantova","2020-Mar","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","ICU","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Antibodies","Plasma based therapy",49
"NCT04406246","https://ClinicalTrials.gov/show/NCT04406246",NA,"Mexico","Mexico","2020-May","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Healthcare Workers, Outpatient","Hospitalization","Antivirals",150
"NCT04367168","https://ClinicalTrials.gov/show/NCT04367168",NA,"Mexico","Mexico","2020-Apr","2021-Apr","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Fever, Other Mild Symptoms, Ferritin, D-Dimer, Fibrinogen, PaO2-FiO2, Respiratory Rate","Colchicine, Standard of care",174
"CHICTR2000033320","http://www.chictr.org.cn/showproj.aspx?proj=54321",NA,"China","Shanghai","2020-May","2020-Dec","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear",NA,"Standard of care, TCM",300
"CHICTR2000033318","http://www.chictr.org.cn/showproj.aspx?proj=54326",NA,"China","Shanghai","2020-May","2020-Dec","Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient, Hospital","Dyspnea, Other Mild Symptoms","Exercise, Standard of care",104
"NCT04380532","https://ClinicalTrials.gov/show/NCT04380532",NA,"Canada","British Columbia","2020-May","2021-May","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed","Adverse Events, Platelet Count, Radiographic Findings","Vaccine",20
"NCT04380532","https://ClinicalTrials.gov/show/NCT04380532",NA,"Mongolia","Ulaanbaatar","2020-May","2021-May","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed","Adverse Events, Platelet Count, Radiographic Findings","Vaccine",20
"NCT04384497","https://ClinicalTrials.gov/show/NCT04384497",NA,"Sweden","Stockholm","2020-May","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Fever, Adverse Events, Antibodies","Plasma based therapy",50
"NCT04328467","https://ClinicalTrials.gov/show/NCT04328467",NA,"United States","Minnesota","2020-Mar","2020-Aug","Not Recruiting","Randomised","Quadruple",3,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",1500
"NCT04307693","https://ClinicalTrials.gov/show/NCT04307693",NA,"South Korea","Seoul","2020-Mar","2020-Apr","Status Unclear","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate","HCQ, LPV/r, Standard of care",65
"NCT04348370","https://ClinicalTrials.gov/show/NCT04348370",NA,"United States","California","2020-Apr","2021-May","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance","Standard of care, Vaccine",1800
"NCT04348370","https://ClinicalTrials.gov/show/NCT04348370",NA,"United States","Texas","2020-Apr","2021-May","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance","Standard of care, Vaccine",1800
"CHICTR2000033286","http://www.chictr.org.cn/showproj.aspx?proj=54176",NA,"China","Hubei","2020-May","2020-Mar","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, PaO2-FiO2","Alternative therapy, Standard of care",60
"CHICTR2000033133","http://www.chictr.org.cn/showproj.aspx?proj=53925",NA,"China","Zhejiang","2020-May","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","Standard of care, TCM",60
"NCT04380402","https://ClinicalTrials.gov/show/NCT04380402",NA,"United States","Massachusetts","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Suspected","Hospital","Mortality, ICU Admission, Visits or Returns to Emergency Department, Clinical Improvement Score (Any)","Standard of care, Statins",300
"NCT04399798","https://ClinicalTrials.gov/show/NCT04399798",NA,"Italy","Pavia","2020-May","2020-Sep","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Adverse Events, IL-2, IL-6, IL-8, IL-10, IL-17, Tumor Necrosis Factor (Any), Interferon (Any), PaO2-FiO2, SpO2","JAKi",13
"NCT04397328","https://ClinicalTrials.gov/show/NCT04397328",NA,"Canada","Ontario","2020-May","2021-Apr","Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed, Healthy Exposed, Hospital","Mortality, ICU Admission, Cough, Fever, Dyspnea","HCQ, Standard of care",336
"NCT04398303","https://ClinicalTrials.gov/show/NCT04398303",NA,"United States","Florida","2020-May","2020-Oct","Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission","Standard of care, Stem cells",70
"NCT04355143","https://ClinicalTrials.gov/show/NCT04355143",NA,"United States","California","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",2,NA,"Unclear","Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, D-Dimer, Troponin, Cardiac Outcome (Unspecified)","Colchicine, Standard of care",150
"NCT04360837","https://ClinicalTrials.gov/show/NCT04360837",NA,"Hungary","Szeged","2020-Apr","2021-Jun","Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","Clinical Improvement Score (Any), PaO2-FiO2","Respiratory support",10
"NCT04345991","https://ClinicalTrials.gov/show/NCT04345991",NA,"France","Paris","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,NA,"Outpatient","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Creatinine Phosphokinase, Myoglobin, Troponin, Procalcitonin, Fibrinogen, Coagulation Test, Triglycerides, Electrolytes, Albumin, LDH, Urine Sample, PaO2-FiO2, Respiratory Rate","Plasma based therapy, Standard of care",120
"NCT04355897","https://ClinicalTrials.gov/show/NCT04355897",NA,"United States","Ohio","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy",100
"NCT04341675","https://ClinicalTrials.gov/show/NCT04341675",NA,"United States","Illinois","2020-Apr","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Fever, Ferritin, Lymphocyte Count, D-Dimer, LDH","Other, Standard of care",30
"NCT04341675","https://ClinicalTrials.gov/show/NCT04341675",NA,"United States","Ohio","2020-Apr","2020-Jul","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Fever, Ferritin, Lymphocyte Count, D-Dimer, LDH","Other, Standard of care",30
"NCT04392232","https://ClinicalTrials.gov/show/NCT04392232",NA,"United States","Ohio","2020-May","2020-Dec","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital",NA,"Plasma based therapy",100
"NCT04394442","https://ClinicalTrials.gov/show/NCT04394442",NA,"Saudi Arabia","Riyadh","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",200
"NCT04393792","https://ClinicalTrials.gov/show/NCT04393792",NA,"United Kingdom","Hampshire","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed, Suspected Or Healthy","Healthy Exposed, Healthcare Workers","Viral Load or Clearance","Hygiene, Standard of care",40
"NCT04392778","https://ClinicalTrials.gov/show/NCT04392778",NA,"Turkey","Istanbul","2020-May","2020-Jul","Recruiting","Randomised","Quadruple",3,"Confirmed","ICU","Clinical Improvement Score (Any)","Standard of care, Stem cells",30
"NCT04313127","https://ClinicalTrials.gov/show/NCT04313127",NA,"China","Hubei","2020-Mar","2020-Dec","Not Recruiting","Non-Randomised","Open-Label",3,"Healthy","Healthy Unexposed","Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies","Vaccine",108
"CHICTR2000033057","http://www.chictr.org.cn/showproj.aspx?proj=53529",NA,"China","Liaoning","2020-May","2020-Sep","Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient","Depression, Anxiety","Rehabilitation",160
"NCT04371952","https://ClinicalTrials.gov/show/NCT04371952",NA,"France","Paris","2020-May","2020-Dec","Not Recruiting","Randomised","Double",2,NA,"Outpatient","Mortality, ICU Admission, Hospitalization","Antibiotics, Standard of care",330
"CHICTR2000033003","http://www.chictr.org.cn/showproj.aspx?proj=53790",NA,"China","Beijing","2020-May","2022-Apr","Not Recruiting","Single-Arm","Unspecified",1,"Healthy","Healthy Unexposed","Adverse Events","Other",25
"NCT04390178","https://ClinicalTrials.gov/show/NCT04390178",NA,"Sweden","Stockholm","2020-May","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Fever, Adverse Events, Antibodies","Plasma based therapy",10
"NCT04390503","https://ClinicalTrials.gov/show/NCT04390503",NA,"United States","New York","2020-May","2021-Apr","Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Healthy Exposed, Outpatient",NA,"Plasma based therapy, Standard of care",200
"NCT04375124","https://ClinicalTrials.gov/show/NCT04375124",NA,"Turkey","Istanbul","2020-May","2020-Aug","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Antihypertensive, Standard of care",20
"NCT04389385","https://ClinicalTrials.gov/show/NCT04389385",NA,"Turkey","Kayseri","2020-May","2020-Sep","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear",NA,"Other",60
"NCT04390191","https://ClinicalTrials.gov/show/NCT04390191",NA,"United States","New York","2020-May","2021-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient, Hospital","Mortality, ICU Admission, Household Members with CoViD-19, Invasive Mechanical Ventilation or ECMO, SpO2","Non-invasive respiratory support, Standard of care",200
"NCT04378712","https://ClinicalTrials.gov/show/NCT04378712",NA,"China","Guangdong","2020-May","2020-Mar","Completed","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Cough, Dyspnea, SpO2, Distress","Non-invasive respiratory support, Standard of care",90
"CHICTR2000029605","http://www.chictr.org.cn/showproj.aspx?proj=49051",NA,"China","Hubei","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",4,"Confirmed","Unclear","ICU Admission, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","Standard of care, TCM",400
"CHICTR2000032915","http://www.chictr.org.cn/showproj.aspx?proj=53658",NA,"China","Heilongjiang","2020-May","2020-Dec","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Viral Load or Clearance, Fever, Urine Sample, Blood Pressure, ECG, Radiographic Findings, Renal Outcome (Unspecified)","Other, Standard of care",240
"NCT04384900","https://ClinicalTrials.gov/show/NCT04384900",NA,"Denmark","Copenhagen","2020-May","2020-Nov","Recruiting","Randomised","Single",2,"Confirmed Or Suspected","ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","Positioning",150
"NCT04352933","https://ClinicalTrials.gov/show/NCT04352933",NA,"United Kingdom","London","2020-Apr","2020-Oct","Recruiting","Randomised","Quadruple",3,NA,"Healthcare Workers","Hospitalization, Viral Load or Clearance, Other Mild Symptoms","HCQ, Standard of care",1000
"NCT04385836","https://ClinicalTrials.gov/show/NCT04385836",NA,"Saudi Arabia","Riyadh","2020-May","2020-Sep","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","Other, Standard of care",150
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Catanzaro","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, Standard of care",400
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Cosenza","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, Standard of care",400
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Rome","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, Standard of care",400
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Reggio Calabria","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, Standard of care",400
"NCT04385043","https://ClinicalTrials.gov/show/NCT04385043",NA,"Italy","Vibo Valentia","2020-May","2020-Oct","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Lymphocyte Count","Plasma based therapy, Standard of care",400
"NCT04385199","https://ClinicalTrials.gov/show/NCT04385199",NA,"United States","Michigan","2020-May","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","ICU Admission, Radiographic Findings","Plasma based therapy, Standard of care",30
"NCT04380376","https://ClinicalTrials.gov/show/NCT04380376",NA,"Russia","Moscow","2020-May","2020-Oct","Recruiting","Non-Randomised","Single",2,"Confirmed Or Suspected","Unclear","C-Reactive Protein, IL-6, Lymphocyte Count, D-Dimer","Chemotherapy, Standard of care",60
"NCT04273321","https://ClinicalTrials.gov/show/NCT04273321",NA,"China","Hubei","2020-Feb","2020-Apr","Completed","Single-Arm","Open-Label",2,"Confirmed","Hospital",NA,"Corticosteroids, Standard of care",86
"NCT04273321","https://ClinicalTrials.gov/show/NCT04273321",NA,"China","Beijing","2020-Feb","2020-Apr","Completed","Single-Arm","Open-Label",2,"Confirmed","Hospital",NA,"Corticosteroids, Standard of care",86
"CHICTR2000032717","http://www.chictr.org.cn/showproj.aspx?proj=53322",NA,"China","Shaanxi","2020-May","2021-Jan","Completed","Randomised","Unspecified",6,"Confirmed","Hospital","Viral Load or Clearance, Other Mild Symptoms, Blood Gas, Radiographic Findings","Standard of care, TCM, TCM + Vitamins",60
"CHICTR2000032635","http://www.chictr.org.cn/showproj.aspx?proj=52671",NA,"China","Hubei","2020-May","2021-Mar","Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, White Blood Cell Count, Lymphocyte Count, Neutrophils, Antibodies, Radiographic Findings","TCM",60
"CHICTR2000032769","http://www.chictr.org.cn/showproj.aspx?proj=53368",NA,"China","Beijing","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Radiographic Findings","DAA, Standard of care",342
"NCT04381052","https://ClinicalTrials.gov/show/NCT04381052",NA,"United States","New York","2020-May","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed","ICU","ICU Admission, Serious Adverse Events, C-Reactive Protein, Renal Outcome (Unspecified)","mAb, Standard of care",30
"NCT04374942","https://ClinicalTrials.gov/show/NCT04374942",NA,"Canada","Ontario","2020-May","2020-Aug","Recruiting","Randomised","Quadruple",2,NA,"Healthcare Workers","Mortality, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Quality of Life, Distress","HCQ, Standard of care",988
"NCT04363437","https://ClinicalTrials.gov/show/NCT04363437",NA,"United States","New York","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Non-invasive Ventilation, C-Reactive Protein, Troponin","Colchicine, Standard of care",70
"NCT04326790","https://ClinicalTrials.gov/show/NCT04326790",NA,"Gibraltar","Gibraltar","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Clinical Improvement Score (Any), C-Reactive Protein, Troponin","Colchicine, Standard of care",180
"NCT04381338","https://ClinicalTrials.gov/show/NCT04381338",NA,"Italy","Padova","2020-May","2020-Sep","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","ICU","ICU Admission, Hospitalization","Rehabilitation, Standard of care",92
"NCT04381338","https://ClinicalTrials.gov/show/NCT04381338",NA,"Italy","Verona","2020-May","2020-Sep","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","ICU","ICU Admission, Hospitalization","Rehabilitation, Standard of care",92
"CHICTR2000032737","http://www.chictr.org.cn/showproj.aspx?proj=53458",NA,"China","Guangdong","2020-May","2021-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Pneumonia or ARDS, C-Reactive Protein, IL-2, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer, Myoglobin, Procalcitonin, Electrolytes, Glucose, Blood Gas, Renal Outcome (Unspecified)","Other, Standard of care",60
"CHICTR2000032716","http://www.chictr.org.cn/showproj.aspx?proj=53389",NA,"China","Shanghai","2020-May","2020-Apr","Completed","Unspecified","Unspecified",2,"Confirmed","Hospital","C-Reactive Protein, Lymphocyte Count, CD4, PaO2-FiO2","Vitamins",12
"NCT04379479","https://ClinicalTrials.gov/show/NCT04379479",NA,"Mexico","Mexico","2020-May","2020-Aug","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Unclear",NA,"Other, Standard of care",562
"NCT04377750","https://ClinicalTrials.gov/show/NCT04377750",NA,"Israel","Jerusalem","2020-May","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","ICU",NA,"Standard of care, TCZ",500
"NCT04376034","https://ClinicalTrials.gov/show/NCT04376034",NA,"United States","West Virginia","2020-May","2021-Mar","Recruiting","Non-Randomised","Open-Label",3,"Confirmed","ICU",NA,"Plasma based therapy, Standard of care",240
"NCT04324489","https://ClinicalTrials.gov/show/NCT04324489",NA,"China","Hubei","2020-Mar","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation",NA,4
"NCT04343768","https://ClinicalTrials.gov/show/NCT04343768",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, SpO2","HCQ + LPV/r, HCQ + LPV/r + IFN",60
"NCT04374903","https://ClinicalTrials.gov/show/NCT04374903",NA,"Jordan","Amman","2020-May","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, HCQ + Other",58
"NCT04363216","https://ClinicalTrials.gov/show/NCT04363216",NA,"United States","Pennsylvania","2020-Apr","2021-May","Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Fever","Standard of care, Vitamins",66
"NCT04360122","https://ClinicalTrials.gov/show/NCT04360122",NA,"Egypt","Cairo","2020-Apr","2020-Nov","Not Recruiting","Randomised","Open-Label",3,NA,"Healthcare Workers","Viral Load or Clearance","Other",100
"NCT04251871","https://ClinicalTrials.gov/show/NCT04251871",NA,"China","Beijing","2020-Feb","2021-Jan","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Radiographic Findings","LPV/r + IFN + TCM + Non-invasive respiratory support, LPV/r + Non-invasive respiratory support + IFN",150
"NCT04333550","https://ClinicalTrials.gov/show/NCT04333550",NA,"Iran","Kermanshah","2020-Apr","2020-Sep","Recruiting","Randomised","Double",2,"Confirmed","Hospital, Unclear","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, PaO2-FiO2","Other, Standard of care",50
"CHICTR2000032456","http://www.chictr.org.cn/showproj.aspx?proj=53048",NA,"China","Shanghai","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Quality of Life, Depression, Anxiety","Education + Non-invasive respiratory support, Standard of care",100
"CHICTR2000031174","http://www.chictr.org.cn/showproj.aspx?proj=51437",NA,"China","Shanghai","2020-Mar","2020-Sep","Not Recruiting","Single-Arm","Unspecified",2,"Healthy","Healthy Unexposed",NA,"HCQ, Standard of care",1000
"NCT04273763","https://ClinicalTrials.gov/show/NCT04273763",NA,"China","Zhejiang","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, PaO2-FiO2, Respiratory Rate","IFN + Umifenovir, IFN + Umifenovir + Other",18
"NCT04371523","https://ClinicalTrials.gov/show/NCT04371523",NA,"Canada","Ontario","2020-May","2020-Jul","Not Recruiting","Randomised","Quadruple",2,NA,"Healthcare Workers","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events","HCQ, Standard of care",1100
"NCT04369365","https://ClinicalTrials.gov/show/NCT04369365",NA,"Austria","Vienna","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,NA,"Outpatient","Treatment-emergent Adverse Events","AZT, Standard of care",200
"NCT04346667","https://ClinicalTrials.gov/show/NCT04346667",NA,"Pakistan","Punjab","2020-Apr","2020-May","Recruiting","Randomised","Double",4,NA,"Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Adverse Events","HCQ, Standard of care",400
"NCT04371601","https://ClinicalTrials.gov/show/NCT04371601",NA,"China","Fujian","2020-May","2021-Dec","Not Recruiting","Randomised","Open-Label",4,NA,"Unclear","C-Reactive Protein, IL-10, Tumor Necrosis Factor (Any), CD4, CD8, Blood Gas, PaO2-FiO2","Oseltamivir + Non-invasive respiratory support + Hormone therapy, Stem cells + Oseltamivir + Non-invasive respiratory support + Hormone therapy",60
"NCT04366180","https://ClinicalTrials.gov/show/NCT04366180",NA,"Spain","Granada","2020-Apr","2020-Jun","Recruiting","Randomised","Quadruple",2,NA,"Healthcare Workers","ICU Admission, Pneumonia or ARDS, Cough, Other Mild Symptoms","Nutrition, Standard of care",314
"NCT04366063","https://ClinicalTrials.gov/show/NCT04366063",NA,"Iran","Tehran","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",3,NA,"Hospital","ICU Admission, Pneumonia or ARDS, Adverse Events, Serious Adverse Events","Standard of care, Stem cells",60
"NCT04366739","https://ClinicalTrials.gov/show/NCT04366739",NA,"France","Paris","2020-Apr","2020-Aug","Not Recruiting","Randomised","Single",2,NA,"Hospital","Mortality, Hospital Discharge, Viral Load or Clearance, Serious Adverse Events, C-Reactive Protein, Lymphocyte Count, Creatinine Phosphokinase, ECG, Radiographic Findings, Anxiety","Other, Standard of care",40
"NCT04363034","https://ClinicalTrials.gov/show/NCT04363034",NA,"United States","Arkansas","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,NA,"ICU",NA,"Plasma based therapy",NA
"NCT04368377","https://ClinicalTrials.gov/show/NCT04368377",NA,"Italy","Milano","2020-Apr","2020-Apr","Completed","Single-Arm","Open-Label",1,NA,"ICU","Hemoglobin, PaO2-FiO2","Other",5
"CHICTR2000032487","http://www.chictr.org.cn/showproj.aspx?proj=52394",NA,"China","Shanghai","2020-Apr","2020-Sep","Not Recruiting","Randomised","Unspecified",2,NA,"Healthy Unexposed","Antibodies","HCQ, Standard of care",2000
"NCT04359615","https://ClinicalTrials.gov/show/NCT04359615",NA,"Iran","Tehran","2020-Apr","2020-May","Not Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","FPV + HCQ",40
"NCT04365738","https://ClinicalTrials.gov/show/NCT04365738",NA,"Turkey","Istanbul","2020-Apr","2020-Apr","Completed","Randomised","Single",2,NA,"Outpatient","Dyspnea, Other Mild Symptoms, Depression, Anxiety","Education, Non-invasive respiratory support",270
"NCT04331808","https://ClinicalTrials.gov/show/NCT04331808",NA,"France","Paris","2020-Apr","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, PaO2-FiO2, Radiographic Findings, Blood pH","Standard of care, TCZ",228
"NCT04365309","https://ClinicalTrials.gov/show/NCT04365309",NA,"China","Shaanxi","2020-Apr","2020-Apr","Recruiting","Randomised","Open-Label",2,NA,"Unclear",NA,"Antihypertensive, Standard of care",128
"NCT04355429","https://ClinicalTrials.gov/show/NCT04355429",NA,"France","Paris","2020-Apr","2020-Jul","Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","ACEi, Standard of care",230
"NCT04366089","https://ClinicalTrials.gov/show/NCT04366089",NA,"Italy","Rome","2020-Apr","2020-Oct","Recruiting","Randomised","Single",4,NA,"Hospital","Mortality, IL-6, IL-10, Tumor Necrosis Factor (Any), CD8","HCQ + AZT, HCQ + AZT + Non-invasive respiratory support + Nutrition",152
"NCT04318444","https://ClinicalTrials.gov/show/NCT04318444",NA,"United States","New York","2020-Mar","2021-Mar","Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Exposed","Viral Load or Clearance","HCQ, Standard of care",1600
"CHICTR2000032400","http://www.chictr.org.cn/showproj.aspx?proj=52958",NA,"China","Shanghai","2020-Apr","2020-Jun","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","C-Reactive Protein, Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer, Bilirubin, LDH, Urine Sample, CD4, PaO2-FiO2","Standard of care, TCM",120
"CHICTR2000032399","http://www.chictr.org.cn/showproj.aspx?proj=52942",NA,"China","Hubei","2020-Apr","2020-Jul","Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"Standard of care, TCM",200
"CHICTR2000032135","http://www.chictr.org.cn/showproj.aspx?proj=52506",NA,"China","Shanghai","2020-Apr","2020-Dec","Not Recruiting","Randomised","Unspecified",4,NA,"Unclear","Viral Load or Clearance, Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, CD4, PaO2-FiO2, Radiographic Findings","Other, Standard of care",50
"CHICTR2000032313","http://www.chictr.org.cn/showproj.aspx?proj=52916",NA,"China","Beijing","2020-Apr","2020-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Radiographic Findings, Quality of Life","Standard of care, TCM",60
"NCT04360356","https://ClinicalTrials.gov/show/NCT04360356",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Randomised","Double",2,NA,"Unclear","Mortality, Ferritin, IL-6, Tumor Necrosis Factor (Any), Platelet Count, Prothrombin, INR, Respiratory Rate","Ivermectin + Antivirals, Non-invasive respiratory support",100
"NCT04361318","https://ClinicalTrials.gov/show/NCT04361318",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Randomised","Double",2,NA,"Hospital","Mortality, Viral Load or Clearance, Ferritin, IL-6, Tumor Necrosis Factor (Any), Prothrombin, PaO2-FiO2, Respiratory Rate","HCQ + Antivirals, Standard of care",100
"NCT04359316","https://ClinicalTrials.gov/show/NCT04359316",NA,"Iran","Tehran","2020-Apr","2020-May","Not Recruiting","Randomised","Triple",2,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","AZT, HCQ",40
"NCT04353037","https://ClinicalTrials.gov/show/NCT04353037",NA,"United States","New York","2020-Apr","2021-Apr","Recruiting","Randomised","Double",2,NA,"Healthcare Workers, Outpatient","Hospitalization, Viral Load or Clearance, Household Members with CoViD-19, Labor Absenteeism, Adverse Events","HCQ, Standard of care",850
"NCT04341493","https://ClinicalTrials.gov/show/NCT04341493",NA,"Mexico","Mexico","2020-Apr","2020-Aug","Recruiting","Randomised","Single",2,NA,"Unclear","Hospitalization","HCQ, HCQ + Antivirals",86
"NCT04333589","https://ClinicalTrials.gov/show/NCT04333589",NA,"China","Anhui","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","FPV, Standard of care",210
"NCT04333589","https://ClinicalTrials.gov/show/NCT04333589",NA,"China","Hubei","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","FPV, Standard of care",210
"NCT04333589","https://ClinicalTrials.gov/show/NCT04333589",NA,"China","Zhejiang","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","FPV, Standard of care",210
"NCT04334265","https://ClinicalTrials.gov/show/NCT04334265",NA,"China","Anhui","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",750
"NCT04334265","https://ClinicalTrials.gov/show/NCT04334265",NA,"China","Hubei","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",750
"NCT04334265","https://ClinicalTrials.gov/show/NCT04334265",NA,"China","Zhejiang","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",750
"NCT04361526","https://ClinicalTrials.gov/show/NCT04361526",NA,"Spain","Barcelona","2020-Apr","2020-Jul","Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Cytokine removal, Standard of care",40
"CHICTR2000032242","http://www.chictr.org.cn/showproj.aspx?proj=52824",NA,"China","Heilongjiang","2020-Apr","2021-May","Not Recruiting","Randomised","Open-Label",2,NA,"Unclear","Mortality, Hospitalization, Hospital Discharge, C-Reactive Protein, White Blood Cell Count, Coagulation Test, IgG, IgM or IgA, Antibodies","Other, Standard of care",350
"CHICTR2000032237","http://www.chictr.org.cn/showproj.aspx?proj=52699",NA,"China","Hubei","2020-Apr","2020-Jun","Recruiting","Randomised","Double",2,NA,"Unclear","Other Mild Symptoms","Standard of care, TCM",200
"CHICTR2000032214","http://www.chictr.org.cn/showproj.aspx?proj=52781",NA,"China","Hubei","2020-Apr","2020-Jul","Not Recruiting","Randomised","Double",2,NA,"Unclear","Other Mild Symptoms","Standard of care, TCM",200
"NCT04357106","https://ClinicalTrials.gov/show/NCT04357106",NA,"Mexico","Puebla","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,"ICU","Mortality, Adverse Events, PaO2-FiO2","Plasma based therapy",10
"NCT04355247","https://ClinicalTrials.gov/show/NCT04355247",NA,"Puerto Rico","Puerto Rico","2020-Apr","2020-Jul","Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, D-Dimer, LDH, Radiographic Findings","Corticosteroids",20
"NCT04355026","https://ClinicalTrials.gov/show/NCT04355026",NA,"Slovenia","Celje","2020-Apr","2020-Jun","Recruiting","Randomised","Open-Label",2,NA,"Hospital","ICU Admission, Hospitalization, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + Other",90
"NCT04323345","https://ClinicalTrials.gov/show/NCT04323345",NA,"Egypt","Cairo","2020-Mar","2020-Dec","Recruiting","Randomised","Single",2,"Confirmed","Unclear","Mortality, Viral Load or Clearance, Fever, Radiographic Findings","Nutrition, Standard of care",1000
"NCT04321174","https://ClinicalTrials.gov/show/NCT04321174",NA,"Canada","British Columbia","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Healthy","Healthy Exposed","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Quality of Life, Distress","LPV/r, Standard of care",1220
"NCT04321174","https://ClinicalTrials.gov/show/NCT04321174",NA,"Canada","Ontario","2020-Mar","2021-Mar","Recruiting","Randomised","Single",2,"Healthy","Healthy Exposed","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Quality of Life, Distress","LPV/r, Standard of care",1220
"NCT04320056","https://ClinicalTrials.gov/show/NCT04320056",NA,"Canada","Quebec","2020-Mar","2021-Apr","Recruiting","Randomised","Open-Label",2,"Suspected","Hospital","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, Standard of care",216
"NCT04350671","https://ClinicalTrials.gov/show/NCT04350671",NA,"Iran","Tehran","2020-Apr","2020-Apr","Recruiting","Randomised","Triple",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","LPV/r + HCQ, LPV/r + IFN + HCQ",40
"NCT04350684","https://ClinicalTrials.gov/show/NCT04350684",NA,"Iran","Tehran","2020-Apr","2020-Apr","Recruiting","Randomised","Triple",5,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","HCQ + LPV/r + IFN, HCQ + LPV/r + IFN + Umifenovir",40
"NCT04350931","https://ClinicalTrials.gov/show/NCT04350931",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Randomised","Single",2,"Healthy","Healthcare Workers","Viral Load or Clearance","Standard of care, Vaccine",900
"NCT04348877","https://ClinicalTrials.gov/show/NCT04348877",NA,"Egypt","Cairo","2020-Apr","2020-Oct","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Viral Load or Clearance, Fever, Radiographic Findings","Plasma based therapy",20
"NCT04326426","https://ClinicalTrials.gov/show/NCT04326426",NA,"United States","New York","2020-Mar","2020-Aug","Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, IL-6","Other, Standard of care",300
"CHICTR2000032098","http://www.chictr.org.cn/showproj.aspx?proj=52477",NA,"China","Hubei","2020-Apr","2020-Jul","Recruiting","Single-Arm","Unspecified",1,NA,"Unclear","Viral Load or Clearance, C-Reactive Protein, Radiographic Findings","TCM",300
"CHICTR2000029976","http://www.chictr.org.cn/showproj.aspx?proj=49631",NA,"China","Shanghai","2020-Feb","2022-Feb","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Non-invasive Ventilation, Cough, Dyspnea, Other Mild Symptoms, Radiographic Findings, Quality of Life","Psychological therapy, Standard of care",160
"NCT04351763","https://ClinicalTrials.gov/show/NCT04351763",NA,"Poland","Warsaw","2020-Apr","2021-Mar","Recruiting","Randomised","Single",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Fever, PaO2-FiO2, Cardiac Outcome (Unspecified)","CCB, Other, Standard of care",804
"NCT04351620","https://ClinicalTrials.gov/show/NCT04351620",NA,"United States","Illinois","2020-Apr","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Outpatient","Hospitalization, Fever, Other Mild Symptoms, Adverse Events","HCQ",20
"NCT04348695","https://ClinicalTrials.gov/show/NCT04348695",NA,"Spain","Madrid","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","JAKi + Statins, Standard of care",94
"CHICTR2000032011","http://www.chictr.org.cn/showproj.aspx?proj=52142",NA,"China","Beijing","2020-Apr","2020-May","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Hospital","C-Reactive Protein, IL-6, PaO2-FiO2, Radiographic Findings","Non-invasive respiratory support, Standard of care",45
"CHICTR2000029434","http://www.chictr.org.cn/showproj.aspx?proj=48889",NA,"China","Hebei","2020-Feb","2020-Dec","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings","Standard of care, TCM",240
"CHICTR2000029433","http://www.chictr.org.cn/showproj.aspx?proj=48898",NA,"China","Hebei","2020-Feb","2020-Dec","Completed","Randomised","Open-Label",2,"Suspected","Unclear","Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings","Standard of care, TCM",240
"NCT04252118","https://ClinicalTrials.gov/show/NCT04252118",NA,"China","Beijing","2020-Feb","2020-Dec","Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein, Creatinine Phosphokinase, ALT, CD4, CD8","Standard of care, Stem cells",20
"NCT04346368","https://ClinicalTrials.gov/show/NCT04346368",NA,"China","Guangdong","2020-Apr","2020-Dec","Not Recruiting","Randomised","Single",2,NA,"ICU","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Adverse Events, C-Reactive Protein, CD4, CD8, PaO2-FiO2, Radiographic Findings","Standard of care, Stem cells",20
"NCT04276688","https://ClinicalTrials.gov/show/NCT04276688",NA,"China","Hong Kong","2020-Feb","2020-Mar","Completed","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, IL-6, Tumor Necrosis Factor (Any)","LPV/r, LPV/r + IFN",127
"NCT04324073","https://ClinicalTrials.gov/show/NCT04324073",NA,"France","Paris","2020-Mar","2021-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Sarilumab, Standard of care",239
"CHICTR2000031944","http://www.chictr.org.cn/showproj.aspx?proj=52414",NA,"China","Beijing","2020-Apr","2020-Dec","Recruiting","Randomised","Unspecified",2,NA,"Healthy Exposed","Viral Load or Clearance, Fever, Other Mild Symptoms","Standard of care, TCM",2000
"NCT04345445","https://ClinicalTrials.gov/show/NCT04345445",NA,"Malaysia","Kuala Lumpur","2020-Apr","2020-Oct","Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation","Corticosteroids, TCZ",310
"NCT04280224","https://ClinicalTrials.gov/show/NCT04280224",NA,"China","Henan","2020-Feb","2020-Sep","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance, Treatment-emergent Adverse Events, CD4, CD8, Radiographic Findings","Natural Killer Cells, Standard of care",30
"NCT04273646","https://ClinicalTrials.gov/show/NCT04273646",NA,"China","Hubei","2020-Feb","2020-Jun","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, C-Reactive Protein, Procalcitonin, CD4, CD8, PaO2-FiO2","Standard of care, Stem cells",48
"NCT04344106","https://ClinicalTrials.gov/show/NCT04344106",NA,"France","Paris","2020-Apr","2020-Apr","Recruiting","Single-Arm","Open-Label",1,NA,"Hospital, ICU","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events",NA,25
"NCT04343183","https://ClinicalTrials.gov/show/NCT04343183",NA,"United States","Louisiana","2020-Apr","2020-Jun","Not Recruiting","Randomised","Single",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation",NA,48
"NCT04252274","https://ClinicalTrials.gov/show/NCT04252274",NA,"China","Shanghai","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","DAA, Standard of care",30
"NCT04261517","https://ClinicalTrials.gov/show/NCT04261517","http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03#1","China","Shanghai","2020-Feb","2020-Feb","Completed w. Results","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality","HCQ, Standard of care",30
"CHICTR2000031888","http://www.chictr.org.cn/showproj.aspx?proj=52106",NA,"China","Guangdong","2020-Apr","2020-Nov","Recruiting","Randomised","Unspecified",2,NA,"Unclear","Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, CD4, CD8, Renal Outcome (Unspecified)",NA,300
"CHICTR2000030750","http://www.chictr.org.cn/showproj.aspx?proj=50928",NA,"China","Guangdong","2020-Mar","2021-Feb","Not Recruiting","Randomised","Unspecified",4,"Confirmed","Unclear","C-Reactive Protein, IL-17, Lymphocyte Count, Blood Gas","Standard of care, Vaccine",120
"NCT04302766","https://ClinicalTrials.gov/show/NCT04302766",NA,"United States","Virginia","2020-Mar",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Unclear",NA,"Remdesivir",NA
"NCT04310228","https://ClinicalTrials.gov/show/NCT04310228",NA,"China","Beijing","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","FPV, FPV + TCZ, TCZ",150
"NCT04310228","https://ClinicalTrials.gov/show/NCT04310228",NA,"China","Hubei","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","FPV, FPV + TCZ, TCZ",150
"NCT04339660","https://ClinicalTrials.gov/show/NCT04339660",NA,"China","Hubei","2020-Apr","2020-Jun","Recruiting","Randomised","Triple",2,NA,"Unclear","Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, C-Reactive Protein, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), Procalcitonin, CD4, CD8, SpO2, Radiographic Findings",NA,30
"NCT04334382","https://ClinicalTrials.gov/show/NCT04334382",NA,"United States","Utah","2020-Apr","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,1550
"NCT04336904","https://ClinicalTrials.gov/show/NCT04336904",NA,"Italy","Milano","2020-Apr","2020-Jul","Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission",NA,100
"NCT04336462","https://ClinicalTrials.gov/show/NCT04336462",NA,"China","Guangdong","2020-Apr","2020-Feb","Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, Neutrophils, Hemoglobin, Urine Sample, IgG, IgM or IgA, Blood Urea Nitrogen",NA,100
"CHICTR2000031630","http://www.chictr.org.cn/showproj.aspx?proj=50474",NA,"China","Guangdong","2020-Apr","2020-Jun","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear",NA,NA,60
"NCT04328272","https://ClinicalTrials.gov/show/NCT04328272",NA,"Pakistan","Islamabad","2020-Mar","2020-May","Not Recruiting","Randomised","Single",3,"Confirmed","Hospital","Clinical Improvement Score (Any), C-Reactive Protein, D-Dimer","HCQ, HCQ + AZT, Standard of care",75
"CHICTR2000031494","http://www.chictr.org.cn/showproj.aspx?proj=51904",NA,"China","Hubei","2020-Apr","2020-Dec","Recruiting","Single-Arm","Unspecified",2,"Confirmed","Unclear","Radiographic Findings",NA,36
"NCT04320238","https://ClinicalTrials.gov/show/NCT04320238",NA,"China","Hubei","2020-Mar","2020-May","Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events","IFN, IFN + Other",2944
"NCT04327349","https://ClinicalTrials.gov/show/NCT04327349",NA,"Iran","Mazandaran","2020-Mar","2020-May","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Mortality, Hospitalization, Non-invasive Ventilation, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Creatinine Phosphokinase, CK-MB, ALT, LDH, IgG, IgM or IgA, CD4, CD8, PaO2-FiO2","Plasma based therapy",30
"CHICTR2000031430","http://www.chictr.org.cn/showproj.aspx?proj=49254",NA,"China","Beijing","2020-Mar","2021-Dec","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Hospital","Clinical Improvement Score (Any), C-Reactive Protein, Ferritin, IL-6, Interferon (Any), Lymphocyte Count, D-Dimer, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Coagulation Test, ALT, Albumin, Bilirubin, IgG, IgM or IgA, Blood Gas, ECG, SpO2, 6-Minute Walking Distance, Radiographic Findings, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Standard of care, Stem cells",200
"NCT04288713","https://ClinicalTrials.gov/show/NCT04288713",NA,"United States","New York","2020-Feb",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","ICU",NA,"mAb",NA
"CHICTR2000031203","http://www.chictr.org.cn/showproj.aspx?proj=51030",NA,"China","Henan","2020-Mar","2022-Feb","Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Anxiety","Standard of care, TCM",28
"CHICTR2000030198","http://www.chictr.org.cn/showproj.aspx?proj=50066",NA,"China","Sichuan","2020-Feb","2020-Aug","Not Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Clinical Improvement Score (Any), PaO2-FiO2, Respiratory Rate, 6-Minute Walking Distance, Quality of Life, Depression, Anxiety","Psychological therapy, Respiratory + Education",60
"CHICTR2000031319","http://www.chictr.org.cn/showproj.aspx?proj=51647",NA,"China","Hubei","2020-Mar","2020-Jul","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Viral Load or Clearance, Fever, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Neutrophils, Creatinine Phosphokinase, CK-MB, Troponin, Procalcitonin, ALT, LDH, CD4, CD8, Respiratory Rate, Radiographic Findings","Standard of care, Stem cells",20
"NCT04323332","https://ClinicalTrials.gov/show/NCT04323332",NA,"China","Beijing","2020-Mar","2020-Mar","Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, C-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Neutrophils, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, CK-MB, LDH, Antibodies, Radiographic Findings","Standard of care, TCM",50
"CHICTR2000031271","http://www.chictr.org.cn/showproj.aspx?proj=51194",NA,"China","Guangdong","2020-Mar","2021-Mar","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Organ Failure or Dysfunction (SOFA), Quality of Life","Nutrition, Standard of care",80
"CHICTR2000030704","http://www.chictr.org.cn/showproj.aspx?proj=50778",NA,"China","Jiangsu","2020-Mar","2020-Mar","Suspended","Randomised","Unspecified",2,"Confirmed","Hospital","Non-invasive Ventilation, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, ALT, PaO2-FiO2, Respiratory Rate","Standard of care, TCM",50
"NCT04319900","https://ClinicalTrials.gov/show/NCT04319900",NA,"China","Beijing","2020-Mar","2020-Apr","Recruiting","Randomised","Double",3,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Radiographic Findings","FPV, HCQ + FPV, Standard of care",150
"CHICTR2000030028","http://www.chictr.org.cn/showproj.aspx?proj=49840",NA,"China","Sichuan","2020-Feb","2020-Aug","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital, ICU","PD-1, Monocyte Count, Natural Killer Cell Count, Dendritic Cell Count, Neutrophils, CD4, CD8","mAb, Standard of care",40
"CHICTR2000031204","http://www.chictr.org.cn/showproj.aspx?proj=49420",NA,"China","Beijing","2020-Mar","2020-Apr","Recruiting","Randomised","Single",2,"Confirmed","Unclear","Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Radiographic Findings","HCQ, Standard of care",300
"CHICTR2000030940","http://www.chictr.org.cn/showproj.aspx?proj=51061",NA,"China","Shanghai","2020-Mar","2020-Jun","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Pneumonia or ARDS, Cough, Fever, Dyspnea","TCM",76
"CHICTR2000031138","http://www.chictr.org.cn/showproj.aspx?proj=51416",NA,"China","Hunan","2020-Mar","2020-Dec","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Pneumonia or ARDS, PaO2-FiO2, Respiratory Rate","Other",40
"CHICTR2000030937","http://www.chictr.org.cn/showproj.aspx?proj=51240",NA,"China","Guangdong","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Resolved","Resolved Discharged","Other Mild Symptoms","Standard of care, TCM",144
"CHICTR2000030988","http://www.chictr.org.cn/showproj.aspx?proj=51317",NA,"China","Guangdong","2020-Mar","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospitalization, Hospital Discharge, Pneumonia or ARDS, Treatment-emergent Adverse Events","Standard of care, TCM",204
"CHICTR2000030936","http://www.chictr.org.cn/showproj.aspx?proj=51100",NA,"China","Sichuan","2020-Mar","2020-May","Recruiting","Non-Randomised","Unspecified",2,"Confirmed Or Suspected","Outpatient, Hospital","Fever","Standard of care, TCM",2840
"CHICTR2000031139","http://www.chictr.org.cn/showproj.aspx?proj=51404",NA,"China","Hubei","2020-Mar","2021-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Pneumonia or ARDS, Radiographic Findings, Quality of Life, Depression, Anxiety, Distress","Stem cells",20
"CHICTR2000030923","http://www.chictr.org.cn/showproj.aspx?proj=51139",NA,"China","Shaanxi","2020-Mar","2020-Apr","Recruiting","Randomised","Open-Label",4,"Confirmed Or Suspected","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance","Standard of care, TCM",400
"CHICTR2000030920","http://www.chictr.org.cn/showproj.aspx?proj=50476",NA,"China","Zhejiang","2020-Mar","2021-May","Recruiting","Randomised","Unspecified",4,"Resolved","Resolved Discharged","Viral Load or Clearance, Secondary CoViD-19 Re-infection, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), Weight, Height or BMI, Albumin, IgG, IgM or IgA, Antibodies, CD4, CD8","Standard of care, TCM",100
"CHICTR2000031196","http://www.chictr.org.cn/showproj.aspx?proj=51112",NA,"China","Beijing","2020-Mar","2020-Dec","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Viral Load or Clearance, Adverse Events","LPV/r + IFN, Standard of care",90
"CHICTR2000031090","http://www.chictr.org.cn/showproj.aspx?proj=51148",NA,"China","Zhejiang","2020-Mar","2022-Mar","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Quality of Life, Depression, Anxiety, Distress","Psychological therapy",60
"CHICTR2000029868","http://www.chictr.org.cn/showproj.aspx?proj=49524",NA,"China","Shanghai","2020-Feb","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance, Adverse Events","HCQ, Standard of care",360
"CHICTR2000031089","http://www.chictr.org.cn/showproj.aspx?proj=51136",NA,"China","Guangdong","2020-Mar","2020-Apr","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, White Blood Cell Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, Albumin, Bilirubin, Radiographic Findings","Standard of care, TCM",300
"CHICTR2000029496","http://www.chictr.org.cn/showproj.aspx?proj=48809",NA,"China","Hunan","2020-Feb","2021-Jan","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Viral Load or Clearance, Adverse Events","LPV/r, LPV/r + Other, Other",90
"CHICTR2000030987","http://www.chictr.org.cn/showproj.aspx?proj=51329",NA,"China","Beijing","2020-Mar","2020-Jun","Recruiting","Randomised","Unspecified",3,"Resolved","Resolved Discharged","Viral Load or Clearance, Pneumonia or ARDS, Cough, Dyspnea","FPV, FPV + HCQ, Standard of care",150
"CHICTR2000030420","http://www.chictr.org.cn/showproj.aspx?proj=50286",NA,"China","Liaoning","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Depression, Anxiety, Distress","TCM",60
"CHICTR2000030539","http://www.chictr.org.cn/showproj.aspx?proj=50660",NA,"China","Guangdong","2020-Mar","2021-Mar","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Outpatient","Viral Load or Clearance","Hygiene, Standard of care",40
"NCT04276896","https://ClinicalTrials.gov/show/NCT04276896",NA,"China","Guangdong","2020-Feb","2023-Jul","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Radiographic Findings","Vaccine",100
"CHICTR2000030944","http://www.chictr.org.cn/showproj.aspx?proj=50199",NA,"China","Jiangxi","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, Treatment-emergent Adverse Events","Standard of care, Stem cells + Natural Killer Cells",20
"CHICTR2000030946","http://www.chictr.org.cn/showproj.aspx?proj=51265",NA,"China","Guangdong","2020-Mar","2020-Apr","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Hospital",NA,"Anticoagulants, Other",120
"NCT04313322","https://ClinicalTrials.gov/show/NCT04313322",NA,"Jordan","Amman","2020-Mar","2020-Jun","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings","Stem cells",5
"CHICTR2000030933","http://www.chictr.org.cn/showproj.aspx?proj=51184",NA,"China","Jiangxi","2020-Mar","2020-Dec","Not Recruiting","Randomised","Open-Label",3,"Resolved","Resolved Discharged","Fever, Respiratory Rate, 6-Minute Walking Distance, Quality of Life, Depression, Anxiety, Distress","Exercise, Exercise + Respiratory support, Respiratory support",108
"CHICTR2000030929","http://www.chictr.org.cn/showproj.aspx?proj=50696",NA,"China","Hubei","2020-Mar","2020-Jun","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Cough, Fever, Other Mild Symptoms","Plasma based therapy, Standard of care",60
"NCT04291053","https://ClinicalTrials.gov/show/NCT04291053",NA,"China","Beijing","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, PaO2-FiO2, Respiratory Rate","Standard of care, TCM",550
"NCT04304313","https://ClinicalTrials.gov/show/NCT04304313",NA,"China","Hubei","2020-Mar","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, CK-MB, ALT, PaO2-FiO2, Radiographic Findings","Other",10
"CHICTR2000030922","http://www.chictr.org.cn/showproj.aspx?proj=51141",NA,"China","Guangdong","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Viral Load or Clearance, Pneumonia or ARDS, ALT","IFN + Other, Umifenovir + IFN",30
"CHICTR2000029869","http://www.chictr.org.cn/showproj.aspx?proj=49486",NA,"China","Hubei","2020-Feb","2020-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, ICU Admission, Pneumonia or ARDS, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Radiographic Findings","Standard of care, TCM",300
"CHICTR2000029956","http://www.chictr.org.cn/showproj.aspx?proj=49618",NA,"China","Sichuan","2020-Feb","2020-Jul","Not Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Cough, Fever, Dyspnea, Other Mild Symptoms, Quality of Life, Depression, Anxiety, Distress","Standard of care, TCM",120
"CHICTR2000030469","http://www.chictr.org.cn/showproj.aspx?proj=50082",NA,"China","Shanghai","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Hospitalization, Pneumonia or ARDS, Fever, Radiographic Findings","Standard of care, TCM",96
"CHICTR2000029978","http://www.chictr.org.cn/showproj.aspx?proj=49702",NA,"China","Shanghai","2020-Feb","2020-Jul","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Hospitalization, Cough, Fever, Dyspnea, PD-1, Weight, Height or BMI, Creatinine Phosphokinase, CK-MB, ALT, CD4, CD8, Respiratory Rate, Radiographic Findings, Depression, Anxiety, Distress","Standard of care, TCM",186
"CHICTR2000030188","http://www.chictr.org.cn/showproj.aspx?proj=50025",NA,"China","Guangdong","2020-Feb","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate","Standard of care, TCM",120
"CHICTR2000029658","http://www.chictr.org.cn/showproj.aspx?proj=49074",NA,"China","Hubei","2020-Feb","2020-Apr","Suspended","Randomised","Unspecified",2,"Confirmed","ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Hypoxia","Non-invasive respiratory support",60
"CHICTR2000030166","http://www.chictr.org.cn/showproj.aspx?proj=49696",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Viral Load or Clearance, Fever, 3CL Mpro, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Dendritic Cell Count, Neutrophils, Creatinine Phosphokinase, CK-MB, ALT, Urine Sample, Stool Sample, Radiographic Findings","LPV/r + IFN, LPV/r + IFN + TCM",20
"NCT04308317","https://ClinicalTrials.gov/show/NCT04308317",NA,"China","Zhejiang","2020-Mar","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Fever","Other, Standard of care",60
"CHICTR2000030759","http://www.chictr.org.cn/showproj.aspx?proj=49284",NA,"China","Zhejiang","2020-Mar","2020-May","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Viral Load or Clearance, Pneumonia or ARDS, Fever, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), Myoglobin, Troponin, Procalcitonin, Prothrombin, Coagulation Test, Triglycerides, ALT, Albumin, Bilirubin, Glucose, Urine Sample, Radiographic Findings","Standard of care, TCM",70
"CHICTR2000030810","http://www.chictr.org.cn/showproj.aspx?proj=50986",NA,"China","Hubei","2020-Mar","2020-Mar","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Hospital Discharge, Creatinine Phosphokinase, CK-MB, ALT, Blood Urea Nitrogen","Standard of care, TCM",100
"CHICTR2000030804","http://www.chictr.org.cn/showproj.aspx?proj=51018",NA,"China","Guangdong","2020-Mar","2021-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient","Hospitalization, Cough, C-Reactive Protein","Standard of care, TCM",128
"CHICTR2000030896","http://www.chictr.org.cn/showproj.aspx?proj=51028",NA,"China","Henan","2020-Mar","2021-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings","TCM",24
"CHICTR2000030841","http://www.chictr.org.cn/showproj.aspx?proj=51072",NA,"China","Hubei","2020-Mar","2020-May","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","ICU","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, PaO2-FiO2, Respiratory Rate, Radiographic Findings","Igs, Standard of care",10
"CHICTR2000030853","http://www.chictr.org.cn/showproj.aspx?proj=51081",NA,"China","Guizhou","2020-Mar","2020-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","CK-MB, LDH","Other",200
"CHICTR2000030894","http://www.chictr.org.cn/showproj.aspx?proj=51126",NA,"China","Beijing","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",3,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Radiographic Findings","FPV, FPV + TCZ, TCZ",150
"CHICTR2000030855","http://www.chictr.org.cn/showproj.aspx?proj=51090",NA,"China","Guizhou","2020-Mar","2020-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","ICU Admission, PaO2-FiO2, Respiratory Rate","Respiratory support",200
"CHICTR2000030479","http://www.chictr.org.cn/showproj.aspx?proj=50450",NA,"China","Jiangsu","2020-Mar","2021-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance, Pneumonia or ARDS, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, Procalcitonin","Standard of care, TCM",100
"CHICTR2000030864","http://www.chictr.org.cn/showproj.aspx?proj=50662",NA,"China","Hubei","2020-Mar","2020-Jul","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Viral Load or Clearance, Pneumonia or ARDS, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Glucose, Radiographic Findings","TCM",50
"CHICTR2000030892","http://www.chictr.org.cn/showproj.aspx?proj=51118",NA,"China","Guangdong","2020-Mar","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospitalization, Hospital Discharge, Treatment-emergent Adverse Events, Radiographic Findings","Other, Standard of care",40
"CHICTR2000030703","http://www.chictr.org.cn/showproj.aspx?proj=50251",NA,"China","Hunan","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","PaO2-FiO2, Respiratory Rate, Radiographic Findings","Antivirals, Other + Antiviral",40
"CHICTR2000030836","http://www.chictr.org.cn/showproj.aspx?proj=51054",NA,"China","Shanghai","2020-Mar","2020-Jun","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Dyspnea, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Interferon (Any), eGFR, Coagulation Test, ALT, Albumin, Bilirubin, PaO2-FiO2, Respiratory Rate","Standard of care, TCM",300
"CHICTR2000030897","http://www.chictr.org.cn/showproj.aspx?proj=50462",NA,"China","Zhejiang","2020-Mar","2021-May","Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Hospitalization, Hospital Discharge, Viral Load or Clearance, Fever, C-Reactive Protein, IL-2, IL-4, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), White Blood Cell Count, Monocyte Count, Weight, Height or BMI, Albumin, IgG, IgM or IgA, Antibodies, CD4, Radiographic Findings","Nutrition, Standard of care",20
"CHICTR2000029991","http://www.chictr.org.cn/showproj.aspx?proj=49666",NA,"China","Jiangxi","2020-Feb","2020-Jul","Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever","Standard of care, TCM",72
"CHICTR2000030545","http://www.chictr.org.cn/showproj.aspx?proj=50126",NA,"China","Hubei","2020-Mar","2020-Apr","Recruiting","Randomised","Unspecified",3,"Confirmed","Hospital","ICU Admission, Hospitalization, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings","Standard of care, TCM",300
"CHICTR2000030187","http://www.chictr.org.cn/showproj.aspx?proj=50057",NA,"China","Hubei","2020-Feb","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Procalcitonin, ALT, Albumin, Bilirubin","LPV/r, Standard of care",60
"CHICTR2000030835","http://www.chictr.org.cn/showproj.aspx?proj=51050",NA,"China","Henan","2020-Mar","2021-Feb","Recruiting","Single-Arm","Open-Label",2,"Confirmed","Hospital","C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Procalcitonin, ALT, Albumin, Bilirubin, Glucose, Urine Sample, Radiographic Findings, Depression, Anxiety, Distress","Stem cells",20
"CHICTR2000030580","http://www.chictr.org.cn/showproj.aspx?proj=50693",NA,"China","Shanghai","2020-Mar","2020-Apr","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Viral Load or Clearance, IL-6, IL-10, Tumor Necrosis Factor (Any), Radiographic Findings","Standard of care, TCZ + Adalimumab",60
"CHICTR2000030388","http://www.chictr.org.cn/showproj.aspx?proj=50306",NA,"China","Hubei","2020-Mar",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any), White Blood Cell Count, Shock","Standard of care, TCM",60
"CHICTR2000030849","http://www.chictr.org.cn/showproj.aspx?proj=51086",NA,"China","Henan","2020-Mar","2021-Mar","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Outpatient","Depression, Anxiety","Psychological therapy",81
"CHICTR2000030761","http://www.chictr.org.cn/showproj.aspx?proj=50956",NA,"China","Shanghai","2020-Mar","2020-Apr","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","ICU","C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any)","Other",20
"CHICTR2000030779","http://www.chictr.org.cn/showproj.aspx?proj=50973",NA,"China","Shanghai","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events","Other, Standard of care",100
"CHICTR2000030773","http://www.chictr.org.cn/showproj.aspx?proj=50934",NA,"China","Shanghai","2020-Mar","2020-Jul","Recruiting","Single-Arm","Unspecified",1,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Other",20
"CHICTR2000030751","http://www.chictr.org.cn/showproj.aspx?proj=50941",NA,"China","Inner Mongol","2020-Mar","2020-Dec","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Viral Load or Clearance, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Neutrophils, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Urine Sample, Radiographic Findings","TCM",60
"CHICTR2000030744","http://www.chictr.org.cn/showproj.aspx?proj=50910",NA,"China","Shandong","2020-Mar","2020-Aug","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization","ECMO, Standard of care",30
"CHICTR2000030720","http://www.chictr.org.cn/showproj.aspx?proj=50793",NA,"China","Hubei","2020-Mar","2020-Aug","Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Clinical Improvement Score (Any), Fever, Antibodies, Radiographic Findings","Standard of care, TCM",120
"CHICTR2000030718","http://www.chictr.org.cn/showproj.aspx?proj=50843",NA,"China","Hubei","2020-Mar","2020-May","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Serious Adverse Events, Granulocyte Stimulaiting Factor, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Neutrophils, ALT, Albumin, Bilirubin, IgG, IgM or IgA","Cyclosporine, HCQ, Standard of care",80
"NCT04302519","https://ClinicalTrials.gov/show/NCT04302519",NA,"China","Beijing","2020-Mar","2021-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","PaO2-FiO2, Radiographic Findings, Hypoxia, Hypoxemia","Stem cells",24
"CHICTR2000030700","http://www.chictr.org.cn/showproj.aspx?proj=50786",NA,"China","Hubei","2020-Mar","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Respiratory Rate","Anticoagulants, Standard of care",60
"CHICTR2000030701","http://www.chictr.org.cn/showproj.aspx?proj=50795",NA,"China","Guangdong","2020-Mar","2020-Sep","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Respiratory Rate","Anticoagulants, Standard of care",60
"CHICTR2000030702","http://www.chictr.org.cn/showproj.aspx?proj=50537",NA,"China","Beijing","2020-Mar","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma based therapy, Standard of care",50
"NCT04299724","https://ClinicalTrials.gov/show/NCT04299724",NA,"China","Guangdong","2020-Mar","2023-Jul","Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Healthy","Healthy Unexposed, Healthy Exposed, Outpatient","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein","Vaccine",100
"CHICTR2000029308","http://www.chictr.org.cn/showproj.aspx?proj=48684","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true","China","Hubei","2020-Jan","2021-Jan","Completed w. Results","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","LPV/r, Standard of care",160
"CHICTR2000029580","http://www.chictr.org.cn/showproj.aspx?proj=49088",NA,"China","Hubei","2020-Feb","2020-Dec","Recruiting","Randomised","Single",2,"Confirmed","Hospital","Adverse Events","Standard of care, Stem cells",70
"CHICTR2000029549","http://www.chictr.org.cn/showproj.aspx?proj=49014",NA,"China","Sichuan","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Unclear","Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Radiographic Findings","Standard of care, TCM",400
"CHICTR2000029993","http://www.chictr.org.cn/showproj.aspx?proj=49435",NA,"China","Guangdong","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Standard of care, TCM + Umifenovir",40
"CHICTR2000029550","http://www.chictr.org.cn/showproj.aspx?proj=48775",NA,"China","Sichuan","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","C-Reactive Protein, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Erythrocyte Sedimentation Rate, D-Dimer, Weight, Height or BMI, Creatinine Phosphokinase, Troponin, Procalcitonin, Radiographic Findings","TCM",300
"CHICTR2000029757","http://www.chictr.org.cn/showproj.aspx?proj=49081",NA,"China","Beijing","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma based therapy, Standard of care",200
"CHICTR2000030471","http://www.chictr.org.cn/showproj.aspx?proj=50421",NA,"China","Guangdong","2020-Mar","2020-Apr","Recruiting","Randomised","Single",2,"Confirmed","Outpatient, Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Erythrocyte Sedimentation Rate","Nutrition, Standard of care",394
"CHICTR2000030578","http://www.chictr.org.cn/showproj.aspx?proj=50690",NA,"China","Shandong","2020-Mar","2021-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Quality of Life","Respiratory support, Standard of care",40
"CHICTR2000030627","http://www.chictr.org.cn/showproj.aspx?proj=50727",NA,"China","Henan","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma based therapy, Standard of care",30
"CHICTR2000030540","http://www.chictr.org.cn/showproj.aspx?proj=50658",NA,"China","Hubei","2020-Mar","2020-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed","ICU","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Erythrocyte Sedimentation Rate, Radiographic Findings","Other, Standard of care",152
"CHICTR2000030535","http://www.chictr.org.cn/showproj.aspx?proj=49790",NA,"China","Sichuan","2020-Mar","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","LPV/r + IFN, LPV/r + IFN + Other",100
"CHICTR2000030518","http://www.chictr.org.cn/showproj.aspx?proj=50586",NA,"China","Zhejiang","2020-Mar","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), CD4, CD8, Radiographic Findings","Standard of care, TCM",60
"NCT04295551","https://ClinicalTrials.gov/show/NCT04295551",NA,"China","Beijing","2020-Mar","2020-Jul","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient, Hospital","Cough, Fever, Dyspnea","LPV/r, LPV/r + TCM",80
"CHICTR2000030487","http://www.chictr.org.cn/showproj.aspx?proj=50507",NA,"China","Henan","2020-Mar","2020-May","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, CD4, CD8","DAA",10
"CHICTR2000030490","http://www.chictr.org.cn/showproj.aspx?proj=50487",NA,"China","Hubei","2020-Mar","2020-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected","Unclear","Viral Load or Clearance","TCM",100
"NCT04293887","https://ClinicalTrials.gov/show/NCT04293887",NA,"China","Hebei","2020-Mar","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate","IFN, Standard of care",328
"CHICTR2000030472","http://www.chictr.org.cn/showproj.aspx?proj=49753",NA,"China","Liaoning","2020-Mar","2020-Jun","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Hospital","Viral Load or Clearance, Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","DAA, Standard of care",20
"CHICTR2000030475","http://www.chictr.org.cn/showproj.aspx?proj=50452",NA,"China","Beijing","2020-Mar","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any)","Cytokine removal",19
"CHICTR2000030477","http://www.chictr.org.cn/showproj.aspx?proj=50458",NA,"China","Beijing","2020-Mar","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any)","Other",19
"CHICTR2000030484","http://www.chictr.org.cn/showproj.aspx?proj=50263",NA,"China","Hubei","2020-Mar","2021-Jan","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2, Radiographic Findings","Standard of care, Stem cells",90
"CHICTR2000030480","http://www.chictr.org.cn/showproj.aspx?proj=50470",NA,"China","Hubei","2020-Mar","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Treatment-emergent Adverse Events","IFN, Standard of care",328
"CHICTR2000030481","http://www.chictr.org.cn/showproj.aspx?proj=50453",NA,"China","Hubei","2020-Mar","2020-Apr","Recruiting","Randomised","Unspecified",3,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Radiographic Findings, Renal Outcome (Unspecified)","Corticosteroids, Standard of care",200
"CHICTR2000030433","http://www.chictr.org.cn/showproj.aspx?proj=50273",NA,"China","Fujian","2020-Mar","2020-Oct","Not Recruiting","Single-Arm","Unspecified",1,"Resolved","Resolved Discharged","Quality of Life","Respiratory support",80
"CHICTR2000030418","http://www.chictr.org.cn/showproj.aspx?proj=50341",NA,"China","Fujian","2020-Mar","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","IL-6, Quality of Life, Distress","Respiratory support, Standard of care",80
"CHICTR2000030467","http://www.chictr.org.cn/showproj.aspx?proj=50378",NA,"China","Liaoning","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Quality of Life","TCM, TCM + Psychological therapy",60
"CHICTR2000029898","http://www.chictr.org.cn/showproj.aspx?proj=49482",NA,"China","Beijing","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, IgG, IgM or IgA","HCQ",100
"CHICTR2000029755","http://www.chictr.org.cn/showproj.aspx?proj=49301",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","Standard of care, TCM",120
"CHICTR2000029975","http://www.chictr.org.cn/showproj.aspx?proj=49592",NA,"China","Jilin","2020-Feb","2020-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ",10
"CHICTR2000030432","http://www.chictr.org.cn/showproj.aspx?proj=50268",NA,"China","Fujian","2020-Mar","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers","Quality of Life","Respiratory support, Standard of care",80
"CHICTR2000030424","http://www.chictr.org.cn/showproj.aspx?proj=50174",NA,"China","Henan","2020-Mar","2022-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, CD4, CD8","DAA",30
"CHICTR2000030398","http://www.chictr.org.cn/showproj.aspx?proj=50173",NA,"China","Hubei","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Dyspnea, SpO2, Radiographic Findings","Other, Standard of care",340
"CHICTR2000030022","http://www.chictr.org.cn/showproj.aspx?proj=49797",NA,"China","Anhui","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Lung Inflamation","Standard of care, TCM",100
"CHICTR2000030013","http://www.chictr.org.cn/showproj.aspx?proj=49796",NA,"China","Beijing","2020-Feb","2020-Jun","Not Recruiting","Non-Randomised","Unspecified",2,"Healthy","Healthcare Workers","Pneumonia or ARDS, Cough, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","IFN, Standard of care",450
"CHICTR2000029899","http://www.chictr.org.cn/showproj.aspx?proj=49536",NA,"China","Beijing","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IgG, IgM or IgA","HCQ",100
"CHICTR2000030386","http://www.chictr.org.cn/showproj.aspx?proj=50323",NA,"China","Hunan","2020-Feb","2020-Dec","Not Recruiting","Single-Arm","Unspecified",1,"Healthy","Healthy Exposed","Quality of Life","TCM",1000
"CHICTR2000030333","http://www.chictr.org.cn/showproj.aspx?proj=48801",NA,"China","Hubei","2020-Feb","2020-Jul","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality, Viral Load or Clearance, Cough, Dyspnea, IL-8","Other, Standard of care",292
"CHICTR2000030219","http://www.chictr.org.cn/showproj.aspx?proj=50110",NA,"China","Tianjin","2020-Feb","2020-Dec","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Viral Load or Clearance, C-Reactive Protein, Radiographic Findings","TCM",120
"CHICTR2000030324","http://www.chictr.org.cn/showproj.aspx?proj=50231",NA,"China","Hubei","2020-Feb","2020-May","Not Recruiting","Single-Arm","Unspecified",2,"Confirmed","Outpatient","Cough, Fever, Dyspnea","Standard of care, TCM",40
"CHICTR2000030007","http://www.chictr.org.cn/showproj.aspx?proj=49619",NA,"China","Guangdong","2020-Feb","2020-Apr","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Viral Load or Clearance, Radiographic Findings","Standard of care, Stem cells",200
"CHICTR2000030314","http://www.chictr.org.cn/showproj.aspx?proj=50248",NA,"China","Hubei","2020-Feb","2020-Apr","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Cough, Fever, Dyspnea","TCM",40
"NCT04286503","https://ClinicalTrials.gov/show/NCT04286503",NA,"China","Beijing","2020-Feb","2021-Feb","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient, Hospital, ICU","Viral Load or Clearance, Fever, Radiographic Findings","Carrimycin, HCQ or LPV/r or Umifenovir",520
"CHICTR2000029759","http://www.chictr.org.cn/showproj.aspx?proj=49352",NA,"China","Chongqing","2020-Feb","2020-May","Suspended","Randomised","Open-Label",3,"Confirmed","Hospital","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","IFN + Other, LPV/r + IFN, Umifenovir + IFN",60
"CHICTR2000030288","http://www.chictr.org.cn/showproj.aspx?proj=50202",NA,"China","Beijing","2020-Feb","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance","Standard of care, TCM",204
"CHICTR2000030265","http://www.chictr.org.cn/showproj.aspx?proj=49691",NA,"China","Heilongjiang","2020-Feb","2021-Feb","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",30
"CHICTR2000030218","http://www.chictr.org.cn/showproj.aspx?proj=50115",NA,"China","Jiangxi","2020-Feb","2020-Jun","Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Viral Load or Clearance, Pneumonia or ARDS","LPV/r, LPV/r + TCM",80
"CHICTR2000030255","http://www.chictr.org.cn/showproj.aspx?proj=50089",NA,"China","Shanghai","2020-Feb","2020-Jul","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient, Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Respiratory Rate, Radiographic Findings","Standard of care, TCM",300
"CHICTR2000030261","http://www.chictr.org.cn/showproj.aspx?proj=49963",NA,"China","Jiangsu","2020-Feb","2020-May","Not Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Unclear","Viral Load or Clearance, White Blood Cell Count, Radiographic Findings","Other, Standard of care",26
"CHICTR2000030260","http://www.chictr.org.cn/showproj.aspx?proj=50130",NA,"China","Sichuan","2020-Feb","2021-Feb","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Albumin","Nutrition, Standard of care",20
"CHICTR2000030225","http://www.chictr.org.cn/showproj.aspx?proj=49945",NA,"China","Shanghai","2020-Feb","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any)","Standard of care, TCM",186
"CHICTR2000030258","http://www.chictr.org.cn/showproj.aspx?proj=49887",NA,"China","Heilongjiang","2020-Feb","2020-Aug","Not Recruiting","Single-Arm","Open-Label",2,"Confirmed","Hospital","Mortality, Viral Load or Clearance, Cough, Fever, SpO2, Respiratory Rate, 6-Minute Walking Distance, Radiographic Findings, Quality of Life, Depression, Anxiety","Respiratory support, Standard of care",60
"NCT04282902","https://ClinicalTrials.gov/show/NCT04282902",NA,"China","Hubei","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, PaO2-FiO2, Radiographic Findings","Other, Standard of care",294
"CHICTR2000030196","http://www.chictr.org.cn/showproj.aspx?proj=49883",NA,"China","Hubei","2020-Feb","2020-May","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Outpatient, Hospital","Adverse Events, Serious Adverse Events, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any)","TCZ",60
"CHICTR2000030138","http://www.chictr.org.cn/showproj.aspx?proj=50004",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Unclear","Clinical Improvement Score (Any)","Standard of care, Stem cells",60
"CHICTR2000030170","http://www.chictr.org.cn/showproj.aspx?proj=50017",NA,"China","Shanghai","2020-Feb","2020-Jul","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","JAKi",16
"CHICTR2000030002","http://www.chictr.org.cn/showproj.aspx?proj=49738",NA,"China","Anhui","2020-Feb","2020-Jul","Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient, Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",60
"CHICTR2000029851","http://www.chictr.org.cn/showproj.aspx?proj=49534",NA,"China","Shanghai","2020-Feb","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance","Other, Standard of care",68
"CHICTR2000030113","http://www.chictr.org.cn/showproj.aspx?proj=49988",NA,"China","Guangdong","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Radiographic Findings, Renal Outcome (Unspecified)","DAA, FPV",30
"CHICTR2000030020","http://www.chictr.org.cn/showproj.aspx?proj=49812",NA,"China","Hunan","2020-Feb","2022-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected","Unclear","Viral Load or Clearance, Radiographic Findings","Stem cells",20
"CHICTR2000030165","http://www.chictr.org.cn/showproj.aspx?proj=49947",NA,"China","Tianjin","2020-Feb","2020-Dec","Recruiting","Randomised","Unspecified",3,"Confirmed","Outpatient, Hospital","Viral Load or Clearance, Radiographic Findings","Respiratory support, Standard of care",60
"CHICTR2000029740","http://www.chictr.org.cn/showproj.aspx?proj=49317",NA,"China","Beijing","2020-Feb","2020-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance, Fever, Serious or Seconday Infections, Lymphocyte Count, IgG, IgM or IgA, Blood Pressure, Heart Rate, Respiratory Rate, Radiographic Findings","HCQ, Standard of care",78
"CHICTR2000030167","http://www.chictr.org.cn/showproj.aspx?proj=49567",NA,"China","Hubei","2020-Feb","2020-Sep","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, C-Reactive Protein, Natural Killer Cell Count, CD4, CD8","IFN, Standard of care",80
"CHICTR2000030173","http://www.chictr.org.cn/showproj.aspx?proj=49229",NA,"China","Hunan","2020-Feb","2020-Apr","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Viral Load or Clearance, Radiographic Findings","Standard of care, Stem cells",60
"CHICTR2000030179","http://www.chictr.org.cn/showproj.aspx?proj=50059",NA,"China","Jiangxi","2020-Feb","2020-Apr","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance","Plasma based therapy, Standard of care",100
"CHICTR2000030117","http://www.chictr.org.cn/showproj.aspx?proj=49762",NA,"China","Beijing","2020-Feb","2021-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance, Fever","LPV/r + IFN, TCM",348
"CHICTR2000030102","http://www.chictr.org.cn/showproj.aspx?proj=49747",NA,"China","Tianjin","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",6,"Confirmed","Outpatient, Hospital","Viral Load or Clearance, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein, Blood Gas, SpO2, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Non-invasive respiratory support, Standard of care",180
"CHICTR2000030088","http://www.chictr.org.cn/showproj.aspx?proj=49902",NA,"China","Beijing","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient, Hospital","Viral Load or Clearance, Radiographic Findings","Standard of care, Stem cells",40
"CHICTR2000030089","http://www.chictr.org.cn/showproj.aspx?proj=49889",NA,"China","Shanghai","2020-Feb","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events","mAb, Standard of care",60
"CHICTR2000030116","http://www.chictr.org.cn/showproj.aspx?proj=49901",NA,"China","Jiangxi","2020-Feb","2020-Aug","Recruiting","Single-Arm","Unspecified",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Stem cells",16
"CHICTR2000030093","http://www.chictr.org.cn/showproj.aspx?proj=49932",NA,"China","Shanxi","2020-Feb","2021-Mar","Not Recruiting","Non-Randomised","Unspecified",2,"Healthy","Healthcare Workers","Anxiety","Psychological therapy",60
"CHICTR2000030058","http://www.chictr.org.cn/showproj.aspx?proj=49831",NA,"China","Hubei","2020-Feb","2020-May","Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Viral Load or Clearance, Fever, C-Reactive Protein, Radiographic Findings","DMARD, Standard of care",200
"CHICTR2000030054","http://www.chictr.org.cn/showproj.aspx?proj=49869",NA,"China","Fujian","2020-Feb","2020-May","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Outpatient","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious Adverse Events, Heart Rate, Respiratory Rate","HCQ, Standard of care",100
"CHICTR2000030084","http://www.chictr.org.cn/showproj.aspx?proj=49952",NA,"China","Shanxi","2020-Feb","2022-Feb","Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient","Depression, Anxiety","Psychological therapy, Standard of care",180
"NCT04273529","https://ClinicalTrials.gov/show/NCT04273529",NA,"China","Zhejiang","2020-Feb","2020-May","Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, MCP-1, PaO2-FiO2, Respiratory Rate","Immunomodulators, Standard of care",100
"CHICTR2000030033","http://www.chictr.org.cn/showproj.aspx?proj=49703",NA,"China","Guangdong","2020-Feb","2020-Jun","Not Recruiting","Randomised","Open-Label",3,"Healthy","Healthy Exposed","Household Members with CoViD-19","Standard of care, TCM",828
"CHICTR2000030034","http://www.chictr.org.cn/showproj.aspx?proj=49647",NA,"China","Zhejiang","2020-Feb","2020-Jun","Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Viral Load or Clearance, Pneumonia or ARDS, Fever","Standard of care, TCM",132
"CHICTR2000030039","http://www.chictr.org.cn/showproj.aspx?proj=49544",NA,"China","Jiangsu","2020-Feb","2020-Feb","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Outpatient, Hospital","Viral Load or Clearance, C-Reactive Protein, IL-6, LDH, Respiratory Rate, Renal Outcome (Unspecified)","Plasma based therapy, Standard of care",90
"CHICTR2000030041","http://www.chictr.org.cn/showproj.aspx?proj=49891",NA,"China","Hubei","2020-Feb","2020-Jun","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Viral Load or Clearance",NA,40
"CHICTR2000030046","http://www.chictr.org.cn/showproj.aspx?proj=49861",NA,"China","Jiangxi","2020-Feb","2020-Apr","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Dyspnea, C-Reactive Protein, ALT, Bilirubin, Antibodies","Plasma based therapy",10
"CHICTR2000029996","http://www.chictr.org.cn/showproj.aspx?proj=49510",NA,"China","Beijing","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Other Mild Symptoms","FPV",60
"CHICTR2000030029","http://www.chictr.org.cn/showproj.aspx?proj=49824",NA,"China","Zhejiang","2020-Feb","2020-May","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Other",20
"CHICTR2000030043","http://www.chictr.org.cn/showproj.aspx?proj=49866",NA,"China","Beijing","2020-Feb","2020-Dec","Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Standard of care, TCM",300
"CHICTR2000030016","http://www.chictr.org.cn/showproj.aspx?proj=49799",NA,"China","Guangxi","2020-Feb","2022-Dec","Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events","Standard of care, Vaccine",60
"CHICTR2000030027","http://www.chictr.org.cn/showproj.aspx?proj=49852",NA,"China","Beijing","2020-Feb","2021-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Clinical Improvement Score (Any)","TCM",60
"CHICTR2000029992","http://www.chictr.org.cn/showproj.aspx?proj=49574",NA,"China","Fujian","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Hospital Discharge, Viral Load or Clearance, Fever, Serious Adverse Events, Respiratory Rate","HCQ, Standard of care",100
"CHICTR2000030000","http://www.chictr.org.cn/showproj.aspx?proj=49748",NA,"China","Jiangxi","2020-Feb",NA,"Recruiting","Non-Randomised","Unspecified",5,"Confirmed","Hospital","Viral Load or Clearance, Adverse Events, PaO2-FiO2, Respiratory Rate","DAA, IFN, TCM",50
"CHICTR2000029999","http://www.chictr.org.cn/showproj.aspx?proj=49717",NA,"China","Shanghai","2020-Feb",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Fever, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, IL-12, Tumor Necrosis Factor (Any), Erythrocyte Sedimentation Rate, D-Dimer, Weight, Height or BMI, ALT, AST, Albumin, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, Heart Rate, ECG, Respiratory Rate, Radiographic Findings","Nutrition",60
"CHICTR2000029994","http://www.chictr.org.cn/showproj.aspx?proj=49309",NA,"China","Shanghai","2020-Feb","2020-Aug","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospitalization, Natural Killer Cell Count, Radiographic Findings, Renal Outcome (Unspecified)","Standard of care, TCM",200
"CHICTR2000030010","http://www.chictr.org.cn/showproj.aspx?proj=49777",NA,"China","Hubei","2020-Feb","2020-May","Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Cough, Fever, Dyspnea, Other Mild Symptoms","Plasma based therapy, Standard of care",100
"CHICTR2000030006","http://www.chictr.org.cn/showproj.aspx?proj=49737",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Viral Load or Clearance, Fever, Radiographic Findings, Lung Inflamation","Other, Standard of care",60
"CHICTR2000030003","http://www.chictr.org.cn/showproj.aspx?proj=49770",NA,"China","Sichuan","2020-Feb","2020-Jul","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Fever","TCM",480
"CHICTR2000029781","http://www.chictr.org.cn/showproj.aspx?proj=49138",NA,"China","Hubei","2020-Feb","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Fever","Standard of care, TCM",160
"CHICTR2000029780","http://www.chictr.org.cn/showproj.aspx?proj=49220",NA,"China","Hubei","2020-Feb","2020-Jun","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Viral Load or Clearance, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events","Standard of care, TCM",160
"CHICTR2000029990","http://www.chictr.org.cn/showproj.aspx?proj=49674",NA,"China","Beijing","2020-Feb","2020-Mar","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital",NA,"Standard of care, Stem cells",120
"CHICTR2000029989","http://www.chictr.org.cn/showproj.aspx?proj=49720",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Viral Load or Clearance, Cough, Fever, Dyspnea, Respiratory Rate, Radiographic Findings","IFN, Standard of care",300
"CHICTR2000029988","http://www.chictr.org.cn/showproj.aspx?proj=49218",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","HCQ, Standard of care",80
"CHICTR2000029974","http://www.chictr.org.cn/showproj.aspx?proj=49321",NA,"China","Shandong","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious or Seconday Infections, Radiographic Findings","Standard of care, TCM",300
"CHICTR2000029855","http://www.chictr.org.cn/showproj.aspx?proj=49543",NA,"China","Zhejiang","2020-Feb",NA,"Recruiting","Randomised","Unspecified",3,"Confirmed","Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Fever","Standard of care, TCM",180
"CHICTR2000029941","http://www.chictr.org.cn/showproj.aspx?proj=49596",NA,"China","Shanghai","2020-Feb","2020-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, Radiographic Findings","Standard of care, TCM",200
"CHICTR2000029939","http://www.chictr.org.cn/showproj.aspx?proj=49612",NA,"China","Zhejiang","2020-Feb","2021-Feb","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Fever, Serious Adverse Events, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), ALT, Bilirubin, Radiographic Findings","HCQ, Standard of care",100
"CHICTR2000029935","http://www.chictr.org.cn/showproj.aspx?proj=49607",NA,"China","Zhejiang","2020-Feb","2021-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Serious Adverse Events, C-Reactive Protein","HCQ",100
"CHICTR2000029972","http://www.chictr.org.cn/showproj.aspx?proj=49664",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Viral Load or Clearance","Other, Standard of care",40
"CHICTR2000029960","http://www.chictr.org.cn/showproj.aspx?proj=49639",NA,"China","Hunan","2020-Feb","2020-May","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed Or Suspected","Unclear",NA,"Standard of care, TCM",100
"CHICTR2000029954","http://www.chictr.org.cn/showproj.aspx?proj=49402",NA,"China","Hubei","2020-Feb","2020-Feb","Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient, Hospital","ICU Admission, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Other Mild Symptoms, Radiographic Findings","Standard of care, TCM",300
"CHICTR2000029947","http://www.chictr.org.cn/showproj.aspx?proj=49599",NA,"China","Shanghai","2020-Feb","2020-Jun","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Quality of Life","Standard of care, TCM",200
"CHICTR2000029742","http://www.chictr.org.cn/showproj.aspx?proj=49297",NA,"China","Hubei","2020-Feb","2020-Dec","Recruiting","Randomised","Unspecified",5,"Confirmed Or Suspected","Outpatient, Hospital","Viral Load or Clearance, Radiographic Findings","Standard of care, TCM",90
"CHICTR2000029789","http://www.chictr.org.cn/showproj.aspx?proj=49348",NA,"China","Henan","2020-Feb","2021-Jun","Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Visits or Returns to Emergency Department, Pneumonia or ARDS, Radiographic Findings, Quality of Life","Standard of care, TCM",100
"CHICTR2000029853","http://www.chictr.org.cn/showproj.aspx?proj=49532",NA,"China","Henan","2020-Feb","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, CD4, Radiographic Findings","Antivirals, Standard of care",20
"CHICTR2000029867","http://www.chictr.org.cn/showproj.aspx?proj=49514",NA,"China","Beijing","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital, ICU","Viral Load or Clearance, Fever","Carrimycin, LPV/r",520
"CHICTR2000029850","http://www.chictr.org.cn/showproj.aspx?proj=49533",NA,"China","Zhejiang","2020-Feb","2022-Feb","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Anti SARS-COV-2 Titers, PaO2-FiO2","Plasma based therapy, Standard of care",20
"CHICTR2000029849","http://www.chictr.org.cn/showproj.aspx?proj=49530",NA,"China","Henan","2020-Feb","2021-Feb","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Fever","Standard of care, TCM",60
"CHICTR2000029763","http://www.chictr.org.cn/showproj.aspx?proj=49408",NA,"China","Beijing","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Fever, Radiographic Findings, Quality of Life","Standard of care, TCM",408
"CHICTR2000029790","http://www.chictr.org.cn/showproj.aspx?proj=49453",NA,"China","Shanghai","2020-Feb","2020-Oct","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Hospitalization, Viral Load or Clearance, Fever","Standard of care, TCM",120
"CHICTR2000029769","http://www.chictr.org.cn/showproj.aspx?proj=49415",NA,"China","Zhejiang","2020-Feb","2020-Apr","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality","Standard of care, TCM",40
"CHICTR2000029806","http://www.chictr.org.cn/showproj.aspx?proj=49161",NA,"China","Hubei","2020-Feb","2021-Jan","Recruiting","Randomised","Unspecified",3,"Confirmed","Hospital","Clinical Improvement Score (Any)","mAb, Other, Standard of care",120
"CHICTR2000029813","http://www.chictr.org.cn/showproj.aspx?proj=49425",NA,"China","Shanghai","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance, Cough, Fever, C-Reactive Protein","Standard of care, TCM",72
"CHICTR2000029819","http://www.chictr.org.cn/showproj.aspx?proj=49490",NA,"China","Zhejiang","2020-Feb","2020-Aug","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Viral Load or Clearance, Radiographic Findings","Standard of care, TCM",80
"CHICTR2000029814","http://www.chictr.org.cn/showproj.aspx?proj=49387",NA,"China","Shanghai","2020-Feb","2020-Dec","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Viral Load or Clearance, Cough, Fever, Dyspnea","Standard of care, TCM",30
"CHICTR2000029777","http://www.chictr.org.cn/showproj.aspx?proj=49380",NA,"China","Hubei","2020-Feb","2020-Jun","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Coagulation Test, Radiographic Findings","Standard of care, TCM",160
"CHICTR2000029776","http://www.chictr.org.cn/showproj.aspx?proj=49342",NA,"China","Zhejiang","2020-Feb","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","ICU Admission, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","Other, Standard of care",40
"CHICTR2000029768","http://www.chictr.org.cn/showproj.aspx?proj=49131",NA,"China","Hubei","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Viral Load or Clearance","Other, Standard of care",60
"CHICTR2000029765","http://www.chictr.org.cn/showproj.aspx?proj=49409",NA,"China","Anhui","2020-Feb","2020-May","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",188
"CHICTR2000029788","http://www.chictr.org.cn/showproj.aspx?proj=49452",NA,"China","Beijing","2020-Feb","2020-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Fever","Standard of care, TCM",60
"CHICTR2000029778","http://www.chictr.org.cn/showproj.aspx?proj=49422",NA,"China","Shanghai","2020-Feb","2020-May","Recruiting","Non-Randomised","Unspecified",5,"Confirmed","Unclear","Hospitalization, Viral Load or Clearance, Fever","Standard of care, TCM",600
"CHICTR2000029747","http://www.chictr.org.cn/showproj.aspx?proj=49287",NA,"China","Anhui","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Radiographic Findings","Standard of care, TCM",200
"CHICTR2000029741","http://www.chictr.org.cn/showproj.aspx?proj=49263",NA,"China","Guangdong","2020-Feb","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), Lymphocyte Count, Neutrophils, Platelet Count, D-Dimer, Myoglobin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, Renal Outcome (Unspecified)","HCQ, LPV/r",112
"CHICTR2000029517","http://www.chictr.org.cn/showproj.aspx?proj=48861",NA,"China","Zhejiang","2020-Feb","2020-Apr","Recruiting","Randomised","Double",2,"Suspected","Unclear","Mortality, Pneumonia or ARDS","Standard of care, TCM",100
"CHICTR2000029539","http://www.chictr.org.cn/showproj.aspx?proj=48991",NA,"China","Hubei","2020-Feb","2021-Feb","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Respiratory Rate","LPV/r, Standard of care",328
"CHICTR2000029518","http://www.chictr.org.cn/showproj.aspx?proj=48860",NA,"China","Zhejiang","2020-Feb","2020-Apr","Recruiting","Randomised","Double",4,"Confirmed","Outpatient, Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Adverse Events, Serious Adverse Events, Quality of Life","Standard of care, TCM",140
"CHICTR2000029495","http://www.chictr.org.cn/showproj.aspx?proj=48971",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Open-Label",3,"Resolved","Resolved Discharged","Quality of Life, Depression, Anxiety","Psychological therapy, TCM, TCM + Psychological therapy",90
"CHICTR2000029493","http://www.chictr.org.cn/showproj.aspx?proj=48931",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Adverse Events, 6-Minute Walking Distance, Quality of Life","Standard of care, TCM",100
"CHICTR2000029739","http://www.chictr.org.cn/showproj.aspx?proj=49283",NA,"China","Guangdong","2020-Feb","2021-Aug","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, ALT, Albumin, Bilirubin, Quality of Life","Non-invasive respiratory support",440
"CHICTR2000029578","http://www.chictr.org.cn/showproj.aspx?proj=49080",NA,"China","Zhejiang","2020-Feb","2020-Apr","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","TCM",1000
"CHICTR2000029559","http://www.chictr.org.cn/showproj.aspx?proj=48880","https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v1.full.pdf","China","Hubei","2020-Feb","2020-Feb","Completed w. Results","Randomised","Double",3,"Confirmed","Unclear","Viral Load or Clearance, CD4, CD8","HCQ, Standard of care",300
"CHICTR2000029558","http://www.chictr.org.cn/showproj.aspx?proj=48792",NA,"China","Sichuan","2020-Feb","2020-May","Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected","Unclear","Viral Load or Clearance, C-Reactive Protein, Erythrocyte Sedimentation Rate, D-Dimer, Myoglobin, Troponin, Radiographic Findings","TCM",200
"CHICTR2000029548","http://www.chictr.org.cn/showproj.aspx?proj=49015",NA,"China","Zhejiang","2020-Feb","2020-Jun","Not Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events","FPV, LPV/r, Other",30
"CHICTR2000029621","http://www.chictr.org.cn/showproj.aspx?proj=49165",NA,"China","Shanghai","2020-Feb","2020-Dec","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Viral Load or Clearance, Fever","Standard of care, Umifenovir",380
"CHICTR2000029609","http://www.chictr.org.cn/showproj.aspx?proj=49145",NA,"China","Guangdong","2020-Feb","2020-Dec","Not Recruiting","Non-Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance","HCQ, LPV/r, LPV/r + HCQ",205
"CHICTR2000029606","http://www.chictr.org.cn/showproj.aspx?proj=49146",NA,"China","Zhejiang","2020-Feb","2022-Dec","Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Standard of care, TCM",63
"CHICTR2000029603","http://www.chictr.org.cn/showproj.aspx?proj=49075",NA,"China","Zhejiang","2020-Feb","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, PaO2-FiO2, Respiratory Rate","LPV/r, Other",160
"CHICTR2000029602","http://www.chictr.org.cn/showproj.aspx?proj=48985",NA,"China","Hubei","2020-Feb","2020-Aug","Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Exposed","Clinical Improvement Score (Any), Viral Load or Clearance, Fever","Education + Monitoring + TCM, Psychological therapy",600
"CHICTR2000029601","http://www.chictr.org.cn/showproj.aspx?proj=48988",NA,"China","Hubei","2020-Feb","2020-Aug","Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Fever","Education, Education + TCM",400
"CHICTR2000029600","http://www.chictr.org.cn/showproj.aspx?proj=49042","https://reader.elsevier.com/reader/sd/pii/S2095809920300631?token=A28CA1B43E646EFBA54D61F15A05C13723D1BFA784EAC81E632C0FB769F1BD4BA964D4E304CB8D9EAA24DF528709668A","China","Guangdong","2020-Feb","2020-Apr","Completed w. Results","Non-Randomised","Unspecified",3,"Confirmed","Outpatient","Viral Load or Clearance, Radiographic Findings, Renal Outcome (Unspecified)","FPV + IFN, IFN, LPV/r + IFN",90
"CHICTR2000029656","http://www.chictr.org.cn/showproj.aspx?proj=49086",NA,"China","Hubei","2020-Feb","2020-Apr","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Radiographic Findings","Corticosteroids, Standard of care",100
"CHICTR2000029636","http://www.chictr.org.cn/showproj.aspx?proj=49215",NA,"China","Hubei","2020-Feb","2020-Jul","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","Other",40
"CHICTR2000029541","http://www.chictr.org.cn/showproj.aspx?proj=48992",NA,"China","Hubei","2020-Feb","2020-Dec","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Radiographic Findings","DRV/c + Other, LPV/r + Other, Other",100
"CHICTR2000029542","http://www.chictr.org.cn/showproj.aspx?proj=48968",NA,"China","Guangdong","2020-Feb","2020-Jul","Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein","HCQ, Standard of care",20
"CHICTR2000029436","http://www.chictr.org.cn/showproj.aspx?proj=48884",NA,"China","Henan","2020-Feb","2020-Dec","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Radiographic Findings, Quality of Life","Standard of care, TCM",100
"CHICTR2000029756","http://www.chictr.org.cn/showproj.aspx?proj=49222",NA,"China","Hubei","2020-Feb","2022-Feb","Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Blood Pressure, Heart Rate, Surfactant Factor Protein, PaO2-FiO2, Respiratory Rate, Radiographic Findings","IFN, TCM",238
"CHICTR2000029435","http://www.chictr.org.cn/showproj.aspx?proj=48827",NA,"China","Hubei","2020-Feb","2020-Mar","Not Recruiting","Randomised","Unspecified",8,"Suspected Or Healthy","Outpatient","Viral Load or Clearance, Fever, Weight, Height or BMI, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Blood Pressure, Heart Rate, Radiographic Findings","Standard of care, TCM",160
"CHICTR2000029432","http://www.chictr.org.cn/showproj.aspx?proj=48881",NA,"China","Guangdong","2020-Feb","2020-Apr","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected","Hospital","Fever, C-Reactive Protein, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Procalcitonin, ALT, Albumin, Bilirubin, Blood Gas, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","TCM",72
"CHICTR2000029431","http://www.chictr.org.cn/showproj.aspx?proj=48907",NA,"China","Liaoning","2020-Feb","2021-Dec","Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Pneumonia or ARDS, Radiographic Findings","Other, Standard of care",45
"CHICTR2000029544","http://www.chictr.org.cn/showproj.aspx?proj=49013",NA,"China","Zhejiang","2020-Feb","2020-May","Not Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Antivirals, FPV, Standard of care",30
"CHICTR2000029400","http://www.chictr.org.cn/showproj.aspx?proj=48824",NA,"China","Beijing","2020-Jan","2020-Dec","Recruiting","Non-Randomised","Unspecified",3,"Confirmed","Unclear","Viral Load or Clearance, Fever, White Blood Cell Count, Monocyte Count, Hemoglobin, Erythrocyte Sedimentation Rate, Radiographic Findings","LPV/r, LPV/r + TCM, TCM",60
"CHICTR2000029418","http://www.chictr.org.cn/showproj.aspx?proj=48886",NA,"China","Beijing","2020-Jan","2020-Aug","Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","ICU Admission, PaO2-FiO2, Respiratory Rate","Standard of care, TCM",42
"CHICTR2000029439","http://www.chictr.org.cn/showproj.aspx?proj=48904",NA,"China","Beijing","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient","Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","Standard of care, TCM",120
"CHICTR2000029461","http://www.chictr.org.cn/showproj.aspx?proj=48927",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient","Viral Load or Clearance, Cough, Fever, Adverse Events, 6-Minute Walking Distance, Quality of Life","Standard of care, TCM",100
"CHICTR2000029460","http://www.chictr.org.cn/showproj.aspx?proj=48930",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Open-Label",2,"Resolved","Resolved Discharged","Adverse Events, 6-Minute Walking Distance, Quality of Life","Exercise, Standard of care",100
"CHICTR2000029459","http://www.chictr.org.cn/showproj.aspx?proj=48929",NA,"China","Hubei","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Resolved","Resolved Discharged","Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate, 6-Minute Walking Distance, Quality of Life","Psychological therapy, Standard of care",100
"CHICTR2000029438","http://www.chictr.org.cn/showproj.aspx?proj=48911",NA,"China","Beijing","2020-Feb","2021-Dec","Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism","Standard of care, TCM",100
"CHICTR2000029468","http://www.chictr.org.cn/showproj.aspx?proj=48919",NA,"China","Sichuan","2020-Feb","2020-Jun","Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS","LPV/r",120
"NCT04261907","https://ClinicalTrials.gov/show/NCT04261907",NA,"China","Beijing","2020-Feb","2020-May","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, PaO2-FiO2, Respiratory Rate","LPV/r, Other",160
"NCT04260594","https://ClinicalTrials.gov/show/NCT04260594",NA,"China","Shanghai","2020-Feb","2020-Jul","Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2","Standard of care, Umifenovir",380
"2020-002482-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002482-34/3rd/",NA,"United States","Washington, Dc","2020-May",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious Adverse Events, SpO2, Respiratory Rate, Radiographic Findings, Quality of Life","Plasma based therapy, Standard of care",208
"2020-000890-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR/","https://www.sciencedirect.com/science/article/pii/S0924857920300996","France","Paris","2020-Mar",NA,"Completed w. Results","Unspecified","Unspecified",1,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Fever, Respiratory Rate","HCQ",NA
"2020-000919-69","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL/",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS","Standard of care, Vaccine",NA
"2020-001023-14","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB/",NA,"United Kingdom","London","2020-Mar",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Blood Pressure, Heart Rate, SpO2, Respiratory Rate","IFN, Standard of care",400
"2020-001072-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001072-15/GB/",NA,"United Kingdom","London","2020-Mar",NA,"Status Unclear","Randomised","Single",4,NA,"Healthy Unexposed","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Anti SARS-COV-2 Titers","Vaccine",1112
"2020-001010-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001010-38/NO/",NA,"Norway","Oslo","2020-Mar",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",NA
"2020-001254-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE/",NA,"Belgium","Brussels","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Ferritin, IL-2, IL-7, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, Interferon (Any), MCP-1, MIP-1, White Blood Cell Count, Lymphocyte Count, PaO2-FiO2, SpO2, Radiographic Findings","Other, Standard of care",NA
"2020-001243-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/BE/",NA,"Belgium","Brussels","2020-Mar",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO",NA,NA
"2020-001224-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001224-33/DE/",NA,"Germany","Berlin","2020-Mar",NA,"Suspended","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",NA
"2020-001236-10","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001236-10/NL/",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, Albumin, Bilirubin, PaO2-FiO2",NA,386
"2020-001156-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001156-18/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO",NA,NA
"2020-001273-73","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001273-73/FR/",NA,"France","Paris","2020-Mar",NA,"Status Unclear","Randomised","Double",3,"Healthy","Healthy Exposed, Healthcare Workers",NA,"AZT, HCQ, Standard of care",NA
"2020-001271-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001271-33/FR/",NA,"France","Paris","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-8, Tumor Necrosis Factor (Any), IgG, IgM or IgA, Antibodies",NA,NA
"2020-001306-35","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001306-35/FR/",NA,"France","Paris","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2","Corticosteroids + Other, Standard of care",NA
"2020-001194-69","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001194-69/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Mortality, Viral Load or Clearance",NA,NA
"2020-001409-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001409-21/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events",NA,NA
"2020-001329-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001329-30/AT/",NA,"China","Beijing","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,"ICU","PaO2-FiO2","Non-invasive respiratory support",200
"2020-001329-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001329-30/AT/",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,"ICU","PaO2-FiO2","Non-invasive respiratory support",200
"2020-001307-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001307-16/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO",NA,NA
"2020-001442-19","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001442-19/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, CK-MB, Troponin, Fibrinogen, ALT, AST, Bilirubin, Glucose, LDH","TCZ",NA
"2020-001391-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001391-15/IE/",NA,"Ireland","Dublin","2020-Mar",NA,"Recruiting","Randomised","Double",3,NA,"Hospital","Mortality, ICU Admission, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), PaO2-FiO2, Shock, Renal Outcome (Unspecified)","Other",36
"2020-001606-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001606-33/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events, Treatment-emergent Adverse Events, Ferritin, D-Dimer, LDH, PaO2-FiO2, Respiratory Rate",NA,NA
"2020-001500-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001500-41/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Recruiting","Randomised","Open-Label",6,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-6, PaO2-FiO2, Radiographic Findings, Hypoxia","Siltuximab, TCZ",NA
"2020-001275-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001275-32/DK/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Status Unclear","Randomised","Open-Label",4,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein","Sarilumab, TCZ",NA
"2020-001198-55","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001198-55/DK/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Visits or Returns to Emergency Department, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH, Quality of Life","AZT, HCQ, Standard of care",NA
"2020-001375-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001375-32/NL/",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Recruiting","Randomised","Open-Label",1,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-2, IL-6, IL-8, LDH, Radiographic Findings","TCZ",NA
"2020-001395-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001395-15/DK/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Shock, Quality of Life, Renal Outcome (Unspecified)","Corticosteroids, Standard of care",NA
"2020-001379-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001379-34/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Unclear","Mortality, Non-invasive Ventilation, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), PaO2-FiO2","Anesthetic, Standard of care",NA
"2020-001052-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)","Remdesivir, Standard of care",440
"2020-001052-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)","Remdesivir, Standard of care",440
"2020-001052-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)","Remdesivir, Standard of care",440
"2020-001413-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001413-20/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Suspended","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Ferritin, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, ALT, Bilirubin, LDH, SpO2, Radiographic Findings, Hypoxemia, Renal Outcome (Unspecified)","Corticosteroids, Siltuximab",NA
"2020-001587-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001587-29/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",6,"Confirmed","Unclear","Mortality, Viral Load or Clearance, Household Members with CoViD-19, Adverse Events, Hemoglobin, Weight, Height or BMI, Pregnancy or Birth Outcomes","HCQ, Standard of care",NA
"2020-001469-35","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001469-35/PL/",NA,"Poland","Warsaw","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Outpatient","Mortality, Hospitalization, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Heart Rate","HCQ, Standard of care",400
"2020-001490-68","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001490-68/SE/",NA,"Sweden","Stockholm","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,"ICU","Mortality, PaO2-FiO2","Non-invasive respiratory support, Standard of care",NA
"2020-001406-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001406-27/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate, Radiographic Findings","AZT, HCQ",NA
"2020-001435-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001435-27/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",5,NA,"Outpatient","Mortality, Hospitalization, Treatment-emergent Adverse Events","ARBs, FPV, HCQ, Imatinib",NA
"2020-001570-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001570-30/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,"ICU","Mortality, Secondary CoViD-19 Re-infection, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, Lymphocyte Count, D-Dimer, Fibrinogen, CD4, CD8, Renal Outcome (Unspecified)","Other, Standard of care",NA
"2020-001558-23","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001558-23/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality","HCQ, Standard of care",216
"2020-001530-35","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001530-35/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, IgG, IgM or IgA, Radiographic Findings, Distress","Melatonin, Standard of care",NA
"2020-001262-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001262-11/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",7,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Ferritin, IL-6, Lymphocyte Count, D-Dimer, Creatinine Phosphokinase, LDH, CD4, Blood Pressure, Renal Outcome (Unspecified)","Cyclosporine, Darunavir, HCQ, IFN, LPV/r, Other, TCZ",NA
"2020-001270-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001270-29/DK/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2",NA,350
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"Canada","Ottawa","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"France","Paris","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"Germany","Berlin","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"Ireland","Dublin","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"Italy","Rome","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"Spain","Madrid","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"Sweden","Stockholm","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"Switzerland","Bern","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"United Kingdom","London","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001154-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001154-22/DE/",NA,"United States","Washington, Dc","2020-Mar",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",450
"2020-001437-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001437-12/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",4,NA,"Hospital, ICU","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Ferritin, IL-1, IL-2, IL-6, IL-12, Tumor Necrosis Factor (Any), D-Dimer, Triglycerides, SpO2","Cyclosporine, TCZ",NA
"2020-001492-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001492-33/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","Inhaled solution, Standard of care",NA
"2020-001228-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Single",5,"Healthy","Healthy Unexposed","Stool Sample, CD4","Standard of care, Vaccine",12390
"2020-001453-49","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001453-49/ES/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Hospital","Treatment-emergent Adverse Events","Remdesivir",2500
"2020-001453-49","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001453-49/ES/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Hospital","Treatment-emergent Adverse Events","Remdesivir",2500
"2020-001453-49","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001453-49/ES/",NA,"Italy","Rome","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Hospital","Treatment-emergent Adverse Events","Remdesivir",2500
"2020-001453-49","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001453-49/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Hospital","Treatment-emergent Adverse Events","Remdesivir",2500
"2020-001453-49","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001453-49/ES/",NA,"Switzerland","Bern","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Hospital","Treatment-emergent Adverse Events","Remdesivir",2500
"2020-001453-49","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001453-49/ES/",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Hospital","Treatment-emergent Adverse Events","Remdesivir",2500
"2020-001333-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001333-13/FR/",NA,"France","Paris","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",2,NA,"Unclear","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections","Dexamethasone, HCQ",NA
"2020-001324-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001324-33/FR/",NA,"France","Paris","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality, ICU Admission, Hospitalization, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Quality of Life","Other, Standard of care",NA
"2020-001290-74","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001290-74/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,NA,"Unclear","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, IL-6, D-Dimer, Renal Outcome (Unspecified)","AZT, HCQ, Sarilumab",NA
"2020-001765-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001765-37/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Status Unclear","Single-Arm","Open-Label",1,NA,"Unclear","Clinical Improvement Score (Any), Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events","HCQ",NA
"2020-001321-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001321-31/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",4,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Anti SARS-COV-2 Titers, Peak RC-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, Troponin, Procalcitonin, Fibrinogen, Coagulation Test, ALT, AST, Albumin, Bilirubin, LDH, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings, Shock","HCQ, Imatinib, JAKi, LPV/r",NA
"2020-001301-23","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001301-23/FR/",NA,"France","Paris","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,NA,"Unclear","Mortality, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA)","NSAIDs, Standard of care",NA
"2020-001244-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001244-26/AT/",NA,"Austria","Vienna","2020-Mar",NA,"Recruiting","Randomised","Double",2,NA,"ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Urine Sample, Blood Gas, Blood Pressure, Heart Rate, ECG, PaO2-FiO2, Respiratory Rate, Radiographic Findings, Cardiac Outcome (Unspecified)","Other, Standard of care",40
"2020-001417-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001417-21/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Adverse Events, Serious Adverse Events","HCQ",NA
"2020-001511-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001511-25/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), D-Dimer, LDH","Colchicine, Standard of care",NA
"2020-001266-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001266-11/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,"ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Natural Killer Cell Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, Electrolytes, INR, ALT, AST, Bilirubin, Glucose, LDH, IgG, IgM or IgA, CD4, CD8, Blood Urea Nitrogen, PaO2-FiO2, SpO2, Radiographic Findings","Stem cells",NA
"2020-001420-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001420-34/DK/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Randomised","Open-Label",1,NA,"ICU","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Coagulation Test, Bilirubin, PaO2-FiO2, Renal Outcome (Unspecified)","Other",NA
"2020-001331-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001331-26/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Double",3,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Adverse Events","HCQ, Standard of care",NA
"2020-001536-98","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001536-98/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Status Unclear","Non-Randomised","Unspecified",3,NA,"Healthcare Workers","Viral Load or Clearance, Other Mild Symptoms","HCQ",NA
"2020-001448-24","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001448-24/GB/",NA,"Ghana","Accra","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","HCQ, LPV/r, Standard of care",6400
"2020-001448-24","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001448-24/GB/",NA,"India","New Delhi","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","HCQ, LPV/r, Standard of care",6400
"2020-001448-24","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001448-24/GB/",NA,"Nigeria","Niger","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","HCQ, LPV/r, Standard of care",6400
"2020-001448-24","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001448-24/GB/",NA,"South Africa","Pretoria","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","HCQ, LPV/r, Standard of care",6400
"2020-001257-51","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001257-51/DK/",NA,"Denmark","Copenhagen","2020-Mar",NA,"Status Unclear","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",NA
"2020-001302-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001302-30/AT/",NA,"Austria","Vienna","2020-Apr",NA,"Recruiting","Randomised","Open-Label",4,NA,"Outpatient, Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Serious or Seconday Infections, White Blood Cell Count, Hemoglobin, Creatinine Phosphokinase, Angiotensins, Bilirubin, Glucose, Quality of Life, Anxiety","Anticoagulants, ARBs, HCQ, LPV/r",NA
"2020-001038-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",4,"Confirmed","Healthy Unexposed","Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Antibodies","Vaccine",NA
"2020-001531-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001531-27/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,NA,"Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, IL-1, IL-6, IL-8, IL-10, IL-12, Tumor Necrosis Factor (Any), PAI-1, Interferon (Any), White Blood Cell Count, Neutrophils, Platelet Count, Hemoglobin, D-Dimer, ALT, AST, Bilirubin, Renal Outcome (Unspecified)","Sarilumab, Standard of care",NA
"2020-001640-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001640-26/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Single-Arm","Unspecified",2,NA,"ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Fibrinogen, PaO2-FiO2","Anticoagulants, Standard of care",36
"2020-001734-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001734-36/FR/",NA,"France","Paris","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, Platelet Count, D-Dimer, Fibrinogen, LDH, PaO2-FiO2, SpO2, Respiratory Rate, Shock","Anakinra, Standard of care",NA
"2020-001717-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001717-20/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Labor Absenteeism, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Adverse Events, IL-2, IL-4, IL-6, IL-8, IL-12, Tumor Necrosis Factor (Any), Interferon (Any), MIP-1, Respiratory Rate","Vitamins",NA
"2020-001823-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001823-15/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, D-Dimer, Fibrinogen, Renal Outcome (Unspecified)","Anticoagulants",NA
"2020-001659-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001659-42/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Ferritin, IL-6, D-Dimer, LDH, Blood Pressure, PaO2-FiO2, SpO2, Radiographic Findings","Other",NA
"2020-001440-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001440-26/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,"Healthcare Workers","Adverse Events, Anti SARS-COV-2 Titers","HCQ, Standard of care",NA
"2020-001573-78","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001573-78/FR/",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Immunomodulators, Standard of care",200
"2020-001723-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001723-13/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Serious Adverse Events","AZT",NA
"2020-001481-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001481-11/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Unspecified","Unspecified",1,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Hyper-Inflammation, Radiographic Findings","JAKi",NA
"2020-001622-64","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001622-64/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Outpatient","ICU Admission, Hospitalization, Blood Gas, ECG, SpO2, Radiographic Findings","Corticosteroids, Standard of care",NA
"2020-001364-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001364-29/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital, ICU","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Serious Adverse Events, ACE","LPV/r + HCQ, Stem cells",NA
"2020-001632-10","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Plasma based therapy, Standard of care",NA
"2020-001482-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001482-37/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance","HCQ, Standard of care",NA
"2020-001546-19","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001546-19/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Completed","Unspecified","Open-Label",1,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, D-Dimer, Procalcitonin, ECG","Immunomodulators",NA
"2020-001752-17","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001752-17/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Hospitalization, Viral Load or Clearance, Antibodies","AZT, Standard of care",NA
"2020-001501-24","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001501-24/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Healthy","Healthy Exposed, Healthcare Workers, Outpatient","Household Members with CoViD-19, Serious Adverse Events, Radiographic Findings, Quality of Life","HCQ, Standard of care",2300
"2020-001258-23","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001258-23/IT/",NA,"Italy","Rome","2020-Apr",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever","Colchicine, Standard of care",NA
"2020-001527-14","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001527-14/NL/",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Fever, Adverse Events, C-Reactive Protein, Respiratory Rate","HCQ, HCQ + AZT",60
"2020-001327-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001327-13/AT/",NA,"Austria","Vienna","2020-Mar",NA,"Recruiting","Randomised","Single",2,NA,"Healthy Unexposed","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance","AZT, Standard of care",NA
"2020-001697-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001697-30/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers","ICU Admission, Pneumonia or ARDS, Cough, Fever, Other Mild Symptoms, ECG","HCQ, Standard of care",NA
"2020-001408-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001408-41/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Status Unclear","Randomised","Double",2,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Ferritin, IL-6, D-Dimer, Procalcitonin, Shock, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Standard of care, TCZ",NA
"2020-001770-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001770-30/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Respiratory Rate, Radiographic Findings","Standard of care, TCZ",60
"2020-001512-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001512-26/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization","HCQ, Standard of care",NA
"2020-001614-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001614-38/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Creatinine Phosphokinase, eGFR, Troponin, ALT, AST, Bilirubin, Glucose, ECG, 6-Minute Walking Distance, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","AZT, Standard of care",NA
"2020-001459-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001459-42/DK/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Unspecified","Open-Label",1,NA,"Hospital","Mortality","JAKi",NA
"2020-001618-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001618-39/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Ferritin, IL-1, IL-6, Lymphocyte Count, Neutrophils, Platelet Count, D-Dimer, LDH, SpO2","Other, Standard of care",NA
"2020-001541-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001541-39/ES/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Unspecified","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Anti SARS-COV-2 Titers, White Blood Cell Count, Neutrophils, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, PaO2-FiO2, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","mAb",NA
"2020-001686-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001686-36/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Double",6,"Confirmed","ICU","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","mAb, Standard of care",NA
"2020-001745-40","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001745-40/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital",NA,"Sarilumab",40
"2020-001265-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001265-36/IE/",NA,"Ireland","Dublin","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, PaO2-FiO2","HCQ, HCQ + AZT, Standard of care",267
"2020-000705-86","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000705-86/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",3,"Confirmed","ICU","ICU Admission","Other",NA
"2020-001363-85","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001363-85/DK/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance","HCQ, Standard of care",NA
"2020-001784-88","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001784-88/FI/",NA,"Finland","Helsinki","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events","HCQ, Remdesivir, Standard of care",NA
"2020-001736-95","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001736-95/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",4,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, Respiratory Rate, Quality of Life","Other, Standard of care",1800
"2020-001667-85","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001667-85/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Serious Adverse Events","Corticosteroids, Standard of care",NA
"2020-001825-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001825-29/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, SpO2","Anakinra, AZT, HCQ, LPV/r",NA
"2020-001390-76","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001390-76/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), Monocyte Count, Lymphocyte Count, Platelet Count, D-Dimer, Fibrinogen, LDH, CD4, CD8, PaO2-FiO2, SpO2, Radiographic Findings, Hypoxemia","Sarilumab, Standard of care",171
"2020-001854-23","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001854-23/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Open-Label",7,"Confirmed","Unclear","Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Troponin, Prothrombin, Triglycerides, INR, ALT, AST, Albumin, Bilirubin, LDH, PaO2-FiO2, Radiographic Findings","HCQ, HCQ + Corticosteroids, HCQ + JAKi, HCQ + mAb, HCQ + Sarilumab, HCQ + Siltuximab, HCQ + TCZ",1400
"2020-001827-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001827-15/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Ferritin, IL-6, D-Dimer, SpO2","Corticosteroids, HCQ + TCZ + LPV/r",NA
"2020-001700-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001700-42/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cough, SpO2, Renal Outcome (Unspecified)","ACEi, Standard of care",NA
"2020-001768-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001768-27/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Unspecified","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, C-Reactive Protein, Ferritin, Lymphocyte Count, Platelet Count, LDH","Igs",NA
"2020-001951-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001951-42/PL/",NA,"Canada","Ottawa","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, SpO2","CCB, Other, Standard of care",804
"2020-001951-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001951-42/PL/",NA,"Italy","Rome","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, SpO2","CCB, Other, Standard of care",804
"2020-001951-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001951-42/PL/",NA,"Poland","Warsaw","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, SpO2","CCB, Other, Standard of care",804
"2020-001951-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001951-42/PL/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, SpO2","CCB, Other, Standard of care",804
"2020-001598-66","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001598-66/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Confirmed","ICU","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Radiographic Findings","Other, Standard of care",20
"2020-001678-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001678-31/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Healthy","Healthy Unexposed, Healthy Exposed, Healthcare Workers","ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers","Standard of care, Vaccine",NA
"2020-002032-69","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002032-69/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, IL-10, IL-12, IL-17, D-Dimer, Procalcitonin, PaO2-FiO2, SpO2, Radiographic Findings, Quality of Life","Standard of care, TCZ",NA
"2020-001709-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001709-21/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",7,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Dyspnea, Deep Vein Thrombosis or Pulmonary Embolism, Hemoglobin, Radiographic Findings, Renal Outcome (Unspecified)","Anticoagulants",NA
"2020-001349-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001349-37/SE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-2, IL-6, Tumor Necrosis Factor (Any), Monocyte Count, Lymphocyte Count, D-Dimer, Procalcitonin, LDH, CD4, CD8, PaO2-FiO2, Radiographic Findings","Non-invasive respiratory support",200
"2020-001349-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001349-37/SE/",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-2, IL-6, Tumor Necrosis Factor (Any), Monocyte Count, Lymphocyte Count, D-Dimer, Procalcitonin, LDH, CD4, CD8, PaO2-FiO2, Radiographic Findings","Non-invasive respiratory support",200
"2020-001349-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001349-37/SE/",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-2, IL-6, Tumor Necrosis Factor (Any), Monocyte Count, Lymphocyte Count, D-Dimer, Procalcitonin, LDH, CD4, CD8, PaO2-FiO2, Radiographic Findings","Non-invasive respiratory support",200
"2020-001349-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001349-37/SE/",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-2, IL-6, Tumor Necrosis Factor (Any), Monocyte Count, Lymphocyte Count, D-Dimer, Procalcitonin, LDH, CD4, CD8, PaO2-FiO2, Radiographic Findings","Non-invasive respiratory support",200
"2020-001891-14","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001891-14/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2, Respiratory Rate","Anticoagulants",NA
"2020-001994-66","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001994-66/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed Or Healthy","Healthy Exposed, Outpatient","Mortality, Viral Load or Clearance, Household Members with CoViD-19, Anti SARS-COV-2 Titers","Ivermectin, Standard of care",NA
"2020-001937-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001937-11/GB/",NA,"United Kingdom","London","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Pneumonia or ARDS, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, D-Dimer, Procalcitonin","Inhaled solution, Standard of care",40
"2020-001888-90","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001888-90/DK/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Labor Absenteeism, Fever","Standard of care, Vaccine",NA
"2020-001402-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001402-38/GB/",NA,"Ireland","Dublin","2020-May",NA,"Status Unclear","Randomised","Unspecified",2,"Healthy","Healthcare Workers","Mortality, Cough, Fever, Dyspnea, Other Mild Symptoms","Standard of care, Vaccine",30000
"2020-001402-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001402-38/GB/",NA,"United Kingdom","London","2020-May",NA,"Status Unclear","Randomised","Unspecified",2,"Healthy","Healthcare Workers","Mortality, Cough, Fever, Dyspnea, Other Mild Symptoms","Standard of care, Vaccine",30000
"2020-001777-71","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001777-71/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Unspecified","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, Radiographic Findings","JAKi",NA
"2020-001960-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001960-28/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge","Standard of care, Vitamins",NA
"2020-002274-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002274-28/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance","Standard of care, Vitamins",NA
"2020-001474-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001474-29/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Viral Load or Clearance, Cough, Fever, Adverse Events, IgG, IgM or IgA","Ivermectin, Standard of care",NA
"2020-001603-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001603-16/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Colchicine, Standard of care",NA
"2020-001684-89","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001684-89/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, Neutrophils, D-Dimer, Triglycerides, LDH, PaO2-FiO2, SpO2, Respiratory Rate","mAb, Other",NA
"2020-001783-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001783-28/HU/",NA,"Hungary","Budapest","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Labor Absenteeism, Fever","Standard of care, Vaccine",NA
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"Belgium","Brussels","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, Standard of care",200
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"France","Paris","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, Standard of care",200
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"Italy","Rome","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, Standard of care",200
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"Spain","Madrid","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, Standard of care",200
"2020-001786-36","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001786-36/GB/",NA,"United States","Washington, Dc","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings","Other, Standard of care",200
"2020-002111-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002111-22/PL/",NA,"Poland","Warsaw","2020-Apr",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Dyspnea, IgG, IgM or IgA, Shock, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Standard of care, Vaccine",NA
"2020-001354-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001354-22/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified)","JAKi, mAb, Standard of care",NA
"2020-001513-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001513-20/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected","Unclear","Hospitalization, Adverse Events","Antithrombotics",50
"2020-001203-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001203-16/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","NSAIDs, Standard of care",NA
"2020-002123-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002123-11/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Adverse Events","HCQ, HCQ + Cyclosporine",NA
"2020-001934-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001934-37/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Shock","Corticosteroids, Standard of care",NA
"2020-001987-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001987-28/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Single",2,"Healthy","Healthcare Workers","ICU Admission, Hospitalization, Pneumonia or ARDS, Cough, Fever, Adverse Events, Antibodies","HCQ, Standard of care",1000
"2020-001357-52","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001357-52/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Distress","HCQ, Standard of care",NA
"2020-001754-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001754-21/FR/",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Fever, Organ Failure or Dysfunction (SOFA)","JAKi + TCZ or Anakinra, Standard of care, TCZ or Anakinra",150
"2020-001795-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001795-15/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Platelet Count, D-Dimer, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings","mAb, Standard of care",50
"2020-001473-79","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001473-79/GB/",NA,"Italy","Rome","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SGLT2, Standard of care",900
"2020-001473-79","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001473-79/GB/",NA,"Spain","Madrid","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SGLT2, Standard of care",900
"2020-001473-79","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001473-79/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SGLT2, Standard of care",900
"2020-001473-79","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001473-79/GB/",NA,"United States","Washington, Dc","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","SGLT2, Standard of care",900
"2020-001441-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001441-39/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",40000
"2020-001860-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Platelet Count, Hemoglobin, ALT, SpO2, Radiographic Findings","Other, Standard of care",250
"2020-001928-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001928-34/SE/",NA,"Sweden","Stockholm","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Dyspnea","Corticosteroids",NA
"2020-001319-26","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001319-26/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Resolved Discharged","Mortality","Standard of care, Statins",NA
"2020-002027-10","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002027-10/SE/",NA,"Sweden","Stockholm","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Hormone therapy, Standard of care",NA
"2020-001376-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001376-15/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality, ICU Admission, Fever","Standard of care, Vaccine",NA
"2020-001704-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001704-42/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",NA
"2020-002287-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002287-31/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","Mortality, Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ, Standard of care",1930
"2020-001995-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001995-13/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Unspecified","Open-Label",1,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Procalcitonin, PaO2-FiO2, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","TCZ",NA
"2020-001886-35","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001886-35/GB/",NA,"United Kingdom","London","2020-May",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, Surfactant Factor Protein, PaO2-FiO2","Other, Standard of care",20
"2020-001921-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001921-30/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","ICU","Mortality","Anticoagulants, Corticosteroids + Anticoagulants",200
"2020-002035-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002035-30/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","HCQ, HCQ + JAKi",116
"2020-001805-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001805-21/GB/",NA,"United Kingdom","London","2020-May",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified)","Oseltamivir, Oseltamivir + Other",120
"2020-002091-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002091-12/BG/",NA,"Bulgaria","Sofia","2020-May",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any)","Ivermectin, Standard of care",NA
"2020-001605-23","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001605-23/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge","HCQ + AZT, HCQ + LPV/r",NA
"2020-001643-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001643-13/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin","DPP1 inhibitor, Standard of care",400
"2020-001849-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001849-39/SE/",NA,"Sweden","Stockholm","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, SpO2","Inhaled solution, Standard of care",NA
"2020-001841-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001841-38/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Ferritin, IL-6, Erythrocyte Sedimentation Rate, Troponin, Fibrinogen","Colchicine, Standard of care",NA
"2020-001623-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001623-13/GR/",NA,"Greece","Athens","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","ICU","Clinical Improvement Score (Any)","Hormone therapy, Standard of care",60
"2020-001739-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001739-28/BE/",NA,"Belgium","Brussels","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Hyper-Inflammation, Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, eGFR, Troponin, Fibrinogen, ALT, AST, Albumin, Bilirubin, Glucose, LDH, Radiographic Findings, Cardiac Outcome (Unspecified)","Anticoagulants + Anakinra + Other, Standard of care",NA
"2020-000982-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000982-18/SE/",NA,"Sweden","Stockholm","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",3,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, eGFR, Radiographic Findings, Quality of Life, Cardiac Outcome (Unspecified)","HCQ, Remdesivir",NA
"2020-002448-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002448-21/GR/",NA,"Greece","Athens","2020-May",NA,"Recruiting","Randomised","Double",2,"Healthy","Unclear","Visits or Returns to Emergency Department, IgG, IgM or IgA, Antibodies, Radiographic Findings, Cardiac Outcome (Unspecified)","Standard of care, Vaccine",NA
"2020-001904-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001904-41/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"FPV, Standard of care",302
"2020-001972-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001972-13/IT/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, IL-6, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, Fibrinogen","Anticoagulants",300
"2020-002312-43","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002312-43/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-1, IL-2, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), MIP-1, D-Dimer, Creatinine Phosphokinase, Troponin, Procalcitonin, Fibrinogen, Coagulation Test, Triglycerides, Electrolytes, ALT, AST, Albumin, Bilirubin, Glucose, LDH, Renal Outcome (Unspecified)","Standard of care, Vitamins",NA
"2020-002037-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002037-15/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified)","Sarilumab, Standard of care",NA
"2020-002130-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002130-33/BE/",NA,"Belgium","Brussels","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, D-Dimer, Procalcitonin, Blood Gas, PaO2-FiO2, SpO2, Radiographic Findings, Hypoxia, Cardiac Outcome (Unspecified)","Immunomodulators, Standard of care",NA
"2020-001671-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001671-32/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6","Immunomodulators, Standard of care",60
"2020-002233-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002233-15/DE/",NA,"Germany","Berlin","2020-May",NA,"Recruiting","Randomised","Single",2,"Confirmed","Unclear","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-6, Weight, Height or BMI, Coagulation Test, LDH, Blood Pressure, SpO2, Respiratory Rate","Other, Standard of care",NA
"2020-002186-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002186-34/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, SpO2","Corticosteroids, Standard of care",NA
"2020-002120-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002120-37/GB/",NA,"France","Paris","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, SpO2","Other, Standard of care",300
"2020-002120-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002120-37/GB/",NA,"Germany","Berlin","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, SpO2","Other, Standard of care",300
"2020-002120-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002120-37/GB/",NA,"Italy","Rome","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, SpO2","Other, Standard of care",300
"2020-002120-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002120-37/GB/",NA,"Netherlands","Amsterdam","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, SpO2","Other, Standard of care",300
"2020-002120-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002120-37/GB/",NA,"Spain","Madrid","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, SpO2","Other, Standard of care",300
"2020-002120-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002120-37/GB/",NA,"United Kingdom","London","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, SpO2","Other, Standard of care",300
"2020-002120-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002120-37/GB/",NA,"United States","Washington, Dc","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, SpO2","Other, Standard of care",300
"2020-002456-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002456-21/NL/",NA,"Netherlands","Amsterdam","2020-May",NA,"Completed","Randomised","Open-Label",5,"Healthy","Unclear","Monocyte Count","Vaccine + Bisphosphonate, Vaccine + Vaccine",NA
"2020-001732-10","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001732-10/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","ICU Admission, C-Reactive Protein, Ferritin, IL-6, IgG, IgM or IgA","JAKi",NA
"2020-001264-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001264-28/DE/",NA,"Bulgaria","Sofia","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), D-Dimer, Troponin, Procalcitonin, LDH, IgG, IgM or IgA, Antibodies, ECG, SpO2, Renal Outcome (Unspecified)","Immunomodulators, Standard of care",200
"2020-001675-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001675-33/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Healthy","Unclear","Mortality, ICU Admission, Fever","Standard of care, Vaccine",NA
"2020-001597-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001597-30/GB/",NA,"Ireland","Dublin","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Serious Adverse Events, SpO2","Other, Standard of care",90
"2020-001597-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001597-30/GB/",NA,"Italy","Rome","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Serious Adverse Events, SpO2","Other, Standard of care",90
"2020-001597-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001597-30/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Serious Adverse Events, SpO2","Other, Standard of care",90
"2020-001597-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001597-30/GB/",NA,"United States","Washington, Dc","2020-Apr",NA,"Status Unclear","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Serious Adverse Events, SpO2","Other, Standard of care",90
"2020-001971-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001971-33/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Blood Gas","HCQ + AZT, Ivermectin",NA
"2020-001707-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001707-16/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Dyspnea, Ferritin, IL-6, Lymphocyte Count, D-Dimer, LDH, PaO2-FiO2, Respiratory Rate, Distress","Corticosteroids, TCZ",NA
"2020-001889-10","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001889-10/GB/",NA,"United Kingdom","London","2020-May",NA,"Status Unclear","Randomised","Open-Label",2,"Suspected","Outpatient","Visits or Returns to Emergency Department, Viral Load or Clearance, Fever, SpO2","Corticosteroids, Standard of care",478
"2020-002193-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002193-27/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Coagulation Test, LDH, PaO2-FiO2, SpO2, Radiographic Findings","Standard of care, Stem cells",NA
"2020-001431-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001431-27/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","ARBs, Standard of care",NA
"2020-001483-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001483-28/BE/",NA,"Belgium","Brussels","2020-Jun",NA,"Recruiting","Randomised","Double",7,"Healthy","Healthy Unexposed","Serious Adverse Events, IL-4, Antibodies","Standard of care, Vaccine",1045
"2020-001483-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001483-28/BE/",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Double",7,"Healthy","Healthy Unexposed","Serious Adverse Events, IL-4, Antibodies","Standard of care, Vaccine",1045
"2020-001890-56","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001890-56/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Ferritin, IL-6, D-Dimer, Procalcitonin, Antibodies","Igs, Standard of care",NA
"2020-001903-17","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001903-17/ES/",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, C-Reactive Protein, Ferritin, IL-6, LDH","TCZ, TCZ + Vitamins",NA
"2020-001794-77","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001794-77/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO","Alternative therapy, Standard of care",NA
"2020-002310-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002310-41/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","ICU","Mortality, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",NA
"2020-001504-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001504-42/BE/",NA,"Belgium","Brussels","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Serious Adverse Events, Coagulation Test","Other, Standard of care",60
"2020-001504-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001504-42/BE/",NA,"France","Paris","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Serious Adverse Events, Coagulation Test","Other, Standard of care",60
"2020-001504-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001504-42/BE/",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Serious Adverse Events, Coagulation Test","Other, Standard of care",60
"2020-002229-27","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002229-27/GB/",NA,"United Kingdom","London","2020-May",NA,"Status Unclear","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, LDH, SpO2, Renal Outcome (Unspecified)","Other, Other + SGLT2, Standard of care",1407
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Argentina","Buenos Aires","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Brazil","Brasilia","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Chile","Santiago","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"France","Paris","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Germany","Berlin","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Italy","Rome","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Japan","Tokyo","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Mexico","Mexico","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Peru","Lima","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Russia","Moscow","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"South Africa","Pretoria","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Spain","Madrid","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Sweden","Stockholm","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-001644-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001644-25/DE/",NA,"Turkey","Ankara","2020-May",NA,"Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, SpO2","Acalabrutinib, Standard of care",177
"2020-002449-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002449-41/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Organ Failure or Dysfunction (SOFA), Adverse Events, Distress","HCQ, Standard of care",NA
"2020-001808-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001808-42/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Melatonin, Standard of care",NA
"2020-002472-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002472-12/NL/",NA,"Netherlands","Amsterdam","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Adverse Events","mAb",80
"2020-001929-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001929-31/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Ferritin, IL-6, IL-10, IL-12, Lymphocyte Count, D-Dimer, Troponin","Other, Standard of care",NA
"2020-002110-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002110-41/GB/",NA,"United Kingdom","London","2020-May",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Non-invasive Ventilation","Other, Standard of care",NA
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Argentina","Buenos Aires","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Brazil","Brasilia","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Canada","Ottawa","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Chile","Santiago","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"India","New Delhi","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Japan","Tokyo","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Mexico","Mexico","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Peru","Lima","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Russia","Moscow","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"South Africa","Pretoria","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Belgium","Brussels","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"France","Paris","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Netherlands","Amsterdam","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Poland","Warsaw","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"Spain","Madrid","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-001759-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001759-42/BE/",NA,"United Kingdom","London","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","mAb, Standard of care",1150
"2020-002060-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002060-31/CZ/",NA,"Czechia","Prague","2020-May",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital","Mortality, ICU Admission","HCQ, IFN, LPV/r, Remdesivir, Standard of care",100000
"2020-002230-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002230-32/GB/",NA,"United Kingdom","London","2020-Jun",NA,"Status Unclear","Unspecified","Unspecified",3,"Confirmed","Unclear","Hospital Discharge, Viral Load or Clearance, Adverse Events, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","Anticoagulants, Other, Standard of care",NA
"2020-002668-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002668-29/GB/",NA,"United Kingdom","London","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, von Wildebrandt Factor, Troponin, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Plasma based therapy, Standard of care",NA
"2020-001767-86","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001767-86/IE/",NA,"Ireland","Dublin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Viral Load or Clearance, Non-invasive Ventilation, C-Reactive Protein, Ferritin, IL-6, D-Dimer, LDH, Radiographic Findings, Shock","Standard of care, TCZ",90
"2020-001549-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001549-38/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified)","IFN, LPV/r, Remdesivir, Standard of care",NA
"2020-002166-13","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002166-13/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Radiographic Findings","Other, Standard of care",NA
"2020-001747-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001747-21/PT/",NA,"Portugal","Lisbon","2020-May",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Blood Pressure, Heart Rate, SpO2, Pregnancy or Birth Outcomes","Other, Standard of care",NA
"2020-002632-75","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002632-75/GB/",NA,"United Kingdom","London","2020-Jun",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Blood Gas, PaO2-FiO2, Respiratory Rate, Blood pH","Other, Standard of care",85
"2020-002713-17","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002713-17/ES/",NA,"Mexico","Mexico","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Antibodies, ECG, Hypoxemia","mAb, Standard of care",300
"2020-002713-17","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002713-17/ES/",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Antibodies, ECG, Hypoxemia","mAb, Standard of care",300
"2020-002713-17","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002713-17/ES/",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Antibodies, ECG, Hypoxemia","mAb, Standard of care",300
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Argentina","Buenos Aires","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Brazil","Brasilia","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Denmark","Copenhagen","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Germany","Berlin","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Hungary","Budapest","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"India","New Delhi","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Mexico","Mexico","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Peru","Lima","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Russia","Moscow","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"South Africa","Pretoria","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-001870-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001870-32/DE/",NA,"Spain","Madrid","2020-Apr",NA,"Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","Other, Standard of care",120
"2020-002106-68","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002106-68/GB/",NA,"United Kingdom","London","2020-Jul",NA,"Status Unclear","Randomised","Double",4,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Fever, Adverse Events, Bilirubin, Stool Sample","FPV, LPV/r, LPV/r + FPV, Standard of care",240
"2020-001782-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001782-37/SK/",NA,"Brazil","Brasilia","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",464
"2020-001782-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001782-37/SK/",NA,"Russia","Moscow","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",464
"2020-001782-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001782-37/SK/",NA,"France","Paris","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",464
"2020-001782-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001782-37/SK/",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",464
"2020-001782-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001782-37/SK/",NA,"Poland","Warsaw","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",464
"2020-001782-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001782-37/SK/",NA,"Romania","Bucharest","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",464
"2020-001782-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001782-37/SK/",NA,"Slovakia","Bratislava","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",464
"2020-002677-95","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002677-95/IT/",NA,"Brazil","Brasilia","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",270
"2020-002677-95","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002677-95/IT/",NA,"Italy","Rome","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",270
"2020-002677-95","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002677-95/IT/",NA,"Mexico","Mexico","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",270
"2020-002677-95","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002677-95/IT/",NA,"Russia","Moscow","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",270
"2020-002677-95","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002677-95/IT/",NA,"United Kingdom","London","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",270
"2020-002677-95","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002677-95/IT/",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Other, Standard of care",270
"2020-002869-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002869-34/BE/",NA,"Brazil","Brasilia","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, SpO2","Other, Standard of care",190
"2020-002869-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002869-34/BE/",NA,"Egypt","Cairo","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, SpO2","Other, Standard of care",190
"2020-002869-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002869-34/BE/",NA,"Moldova","Chisinau","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, SpO2","Other, Standard of care",190
"2020-002869-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002869-34/BE/",NA,"Romania","Bucharest","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, SpO2","Other, Standard of care",190
"2020-002869-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002869-34/BE/",NA,"South Africa","Pretoria","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, SpO2","Other, Standard of care",190
"2020-002869-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002869-34/BE/",NA,"Ukraine","Kyiv (Kiev)","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, SpO2","Other, Standard of care",190
"2020-002869-34","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002869-34/BE/",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, SpO2","Other, Standard of care",190
"2020-000936-23","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/PT/",NA,"Portugal","Lisbon","2020-Jul",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)","HCQ, LPV/r, Remdesivir",3100
"2020-003363-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003363-25/DK/",NA,"India","New Delhi","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Shock, Renal Outcome (Unspecified)","Dexamethasone, Standard of care",1000
"2020-003363-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003363-25/DK/",NA,"Sweden","Stockholm","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Shock, Renal Outcome (Unspecified)","Dexamethasone, Standard of care",1000
"2020-002641-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002641-42/DE/",NA,"Argentina","Buenos Aires","2020-Aug",NA,"Recruiting","Randomised","Open-Label",4,"Healthy","Healthy Unexposed","Fever, Other Mild Symptoms, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",43998
"2020-002641-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002641-42/DE/",NA,"Brazil","Brasilia","2020-Aug",NA,"Recruiting","Randomised","Open-Label",4,"Healthy","Healthy Unexposed","Fever, Other Mild Symptoms, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",43998
"2020-002641-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002641-42/DE/",NA,"South Africa","Pretoria","2020-Aug",NA,"Recruiting","Randomised","Open-Label",4,"Healthy","Healthy Unexposed","Fever, Other Mild Symptoms, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",43998
"2020-002641-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002641-42/DE/",NA,"Turkey","Ankara","2020-Aug",NA,"Recruiting","Randomised","Open-Label",4,"Healthy","Healthy Unexposed","Fever, Other Mild Symptoms, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",43998
"2020-002641-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002641-42/DE/",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Open-Label",4,"Healthy","Healthy Unexposed","Fever, Other Mild Symptoms, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",43998
"2020-002641-42","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002641-42/DE/",NA,"Germany","Berlin","2020-Aug",NA,"Recruiting","Randomised","Open-Label",4,"Healthy","Healthy Unexposed","Fever, Other Mild Symptoms, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",43998
"2020-002503-19","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002503-19/GB/",NA,"Australia","Canberra","2020-Jul",NA,"Status Unclear","Randomised","Single",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Radiographic Findings, Distress","Standard of care, Vaccine",7244
"2020-002503-19","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002503-19/GB/",NA,"Netherlands","Amsterdam","2020-Jul",NA,"Status Unclear","Randomised","Single",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Radiographic Findings, Distress","Standard of care, Vaccine",7244
"2020-002503-19","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002503-19/GB/",NA,"Spain","Madrid","2020-Jul",NA,"Status Unclear","Randomised","Single",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Radiographic Findings, Distress","Standard of care, Vaccine",7244
"2020-002503-19","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002503-19/GB/",NA,"United Kingdom","London","2020-Jul",NA,"Status Unclear","Randomised","Single",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Radiographic Findings, Distress","Standard of care, Vaccine",7244
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Argentina","Buenos Aires","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Brazil","Brasilia","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"France","Paris","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Germany","Berlin","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Hungary","Budapest","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Italy","Rome","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Peru","Lima","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Philippines","Manila","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Russia","Moscow","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Spain","Madrid","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"Ukraine","Kyiv (Kiev)","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"United Kingdom","London","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-002259-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002259-39/HU/",NA,"United States","Washington, Dc","2020-Aug",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Adverse Events, ECG","Other, Standard of care",146
"2020-001498-63","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001498-63/GB/",NA,"Belgium","Brussels","2020-Jun",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Angiotensins, ACE, ECG, SpO2","Other, Standard of care",465
"2020-001498-63","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001498-63/GB/",NA,"Brazil","Brasilia","2020-Jun",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Angiotensins, ACE, ECG, SpO2","Other, Standard of care",465
"2020-001498-63","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001498-63/GB/",NA,"France","Paris","2020-Jun",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Angiotensins, ACE, ECG, SpO2","Other, Standard of care",465
"2020-001498-63","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001498-63/GB/",NA,"United Kingdom","London","2020-Jun",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Angiotensins, ACE, ECG, SpO2","Other, Standard of care",465
"2020-001498-63","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001498-63/GB/",NA,"United States","Washington, Dc","2020-Jun",NA,"Status Unclear","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Angiotensins, ACE, ECG, SpO2","Other, Standard of care",465
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"Argentina","Buenos Aires","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"Brazil","Brasilia","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"Finland","Helsinki","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"Moldova","Chisinau","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"Poland","Warsaw","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"Romania","Bucharest","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"South Africa","Pretoria","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"Ukraine","Kyiv (Kiev)","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"United Kingdom","London","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-001807-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001807-18/FI/",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"Other, Standard of care",222
"2020-003125-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003125-39/GB/",NA,"Australia","Canberra","2020-Oct",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Distress","Anticoagulants, Standard of care",1370
"2020-003125-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003125-39/GB/",NA,"Belgium","Brussels","2020-Oct",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Distress","Anticoagulants, Standard of care",1370
"2020-003125-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003125-39/GB/",NA,"Brazil","Brasilia","2020-Oct",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Distress","Anticoagulants, Standard of care",1370
"2020-003125-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003125-39/GB/",NA,"India","New Delhi","2020-Oct",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Distress","Anticoagulants, Standard of care",1370
"2020-003125-39","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003125-39/GB/",NA,"South Africa","Pretoria","2020-Oct",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Distress","Anticoagulants, Standard of care",1370
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Argentina","Buenos Aires","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Australia","Canberra","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Brazil","Brasilia","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Ethiopia","Addis Ababa","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Georgia","Tbilisi","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Mexico","Mexico","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Mozambique","Maputo","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Peru","Lima","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Singapore","Singapore","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Uganda","Kampala","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"United States","Washington, Dc","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Belgium","Brussels","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Denmark","Copenhagen","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"France","Paris","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Germany","Berlin","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Greece","Athens","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Ireland","Dublin","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Italy","Rome","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Poland","Warsaw","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Portugal","Lisbon","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Spain","Madrid","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Sweden","Stockholm","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"Switzerland","Bern","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-003278-37","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003278-37/GR/",NA,"United Kingdom","London","2021-Jan",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Antibodies, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Monoclonal antibody",2000
"2020-001396-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001396-33/GB/",NA,"France","Paris","2020-Apr",NA,"Status Unclear","Randomised","Double",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, PaO2-FiO2","Other",284
"2020-001396-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001396-33/GB/",NA,"Ireland","Dublin","2020-Apr",NA,"Status Unclear","Randomised","Double",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, PaO2-FiO2","Other",284
"2020-001396-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001396-33/GB/",NA,"Israel","Jerusalem","2020-Apr",NA,"Status Unclear","Randomised","Double",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, PaO2-FiO2","Other",284
"2020-001396-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001396-33/GB/",NA,"South Africa","Pretoria","2020-Apr",NA,"Status Unclear","Randomised","Double",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, PaO2-FiO2","Other",284
"2020-001396-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001396-33/GB/",NA,"Spain","Madrid","2020-Apr",NA,"Status Unclear","Randomised","Double",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, PaO2-FiO2","Other",284
"2020-001396-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001396-33/GB/",NA,"United Kingdom","London","2020-Apr",NA,"Status Unclear","Randomised","Double",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, PaO2-FiO2","Other",284
"2020-001396-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001396-33/GB/",NA,"United States","Washington, Dc","2020-Apr",NA,"Status Unclear","Randomised","Double",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, PaO2-FiO2","Other",284
"2020-004356-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004356-16/GB/",NA,"Belgium","Brussels","2020-Oct",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Unexposed","Visits or Returns to Emergency Department, Antibodies","Monoclonal antibody",5000
"2020-004356-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004356-16/GB/",NA,"France","Paris","2020-Oct",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Unexposed","Visits or Returns to Emergency Department, Antibodies","Monoclonal antibody",5000
"2020-004356-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004356-16/GB/",NA,"Spain","Madrid","2020-Oct",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Unexposed","Visits or Returns to Emergency Department, Antibodies","Monoclonal antibody",5000
"2020-004356-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004356-16/GB/",NA,"United Kingdom","London","2020-Oct",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Unexposed","Visits or Returns to Emergency Department, Antibodies","Monoclonal antibody",5000
"2020-004356-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004356-16/GB/",NA,"United States","Washington, Dc","2020-Oct",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Unexposed","Visits or Returns to Emergency Department, Antibodies","Monoclonal antibody",5000
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"Czechia","Prague","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"France","Paris","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"Hungary","Budapest","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"India","New Delhi","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"Ireland","Dublin","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"Italy","Rome","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"South Korea","Seoul","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"Romania","Bucharest","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"South Africa","Pretoria","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"Spain","Madrid","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"United Kingdom","London","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-003369-20","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003369-20/IT/",NA,"United States","Washington, Dc","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Weight, Height or BMI, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Pregnancy or Birth Outcomes","Monoclonal antibody, Standard of care",1020
"2020-004719-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004719-28/GB/",NA,"United States","Washington, Dc","2020-Oct",NA,"Status Unclear","Randomised","Double",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody + Monoclonal antibody, Standard of care",1125
"2020-004719-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004719-28/GB/",NA,"United Kingdom","London","2020-Oct",NA,"Status Unclear","Randomised","Double",2,"Suspected","Outpatient","Mortality, Antibodies","Monoclonal antibody + Monoclonal antibody, Standard of care",1125
"2020-001662-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001662-11/FR/",NA,"France","Paris","2020-May",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2, Renal Outcome (Unspecified)","JAKi, Standard of care",402
"2020-001662-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001662-11/FR/",NA,"Germany","Berlin","2020-May",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2, Renal Outcome (Unspecified)","JAKi, Standard of care",402
"2020-001662-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001662-11/FR/",NA,"Italy","Rome","2020-May",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2, Renal Outcome (Unspecified)","JAKi, Standard of care",402
"2020-001662-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001662-11/FR/",NA,"Spain","Madrid","2020-May",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2, Renal Outcome (Unspecified)","JAKi, Standard of care",402
"2020-001662-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001662-11/FR/",NA,"United Kingdom","London","2020-May",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2, Renal Outcome (Unspecified)","JAKi, Standard of care",402
"2020-001662-11","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001662-11/FR/",NA,"United States","Washington, Dc","2020-May",NA,"Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2, Renal Outcome (Unspecified)","JAKi, Standard of care",402
"2020-001857-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001857-31/BG/",NA,"Israel","Jerusalem","2020-Nov",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",40
"2020-001857-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001857-31/BG/",NA,"Bulgaria","Sofia","2020-Nov",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",40
"2020-001857-31","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001857-31/BG/",NA,"Germany","Berlin","2020-Nov",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",40
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/IT/",NA,"Japan","Tokyo","2021-Jan",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2","mAb, Standard of care",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/IT/",NA,"United States","Washington, Dc","2021-Jan",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2","mAb, Standard of care",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/IT/",NA,"France","Paris","2021-Jan",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2","mAb, Standard of care",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/IT/",NA,"Germany","Berlin","2021-Jan",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2","mAb, Standard of care",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/IT/",NA,"Italy","Rome","2021-Jan",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2","mAb, Standard of care",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/IT/",NA,"Spain","Madrid","2021-Jan",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2","mAb, Standard of care",270
"2020-001497-30","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001497-30/IT/",NA,"United Kingdom","London","2021-Jan",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2","mAb, Standard of care",270
"IRCT20200310046736N1","http://en.irct.ir/trial/46424",NA,"Iran","Golestan","2020-Apr","2020-Jul","Not Recruiting","Randomised","Single",3,"Confirmed","Hospital, ICU","Clinical Improvement Score (Any), Viral Load or Clearance",NA,45
"IRCT20200128046294N2","http://en.irct.ir/trial/46463",NA,"Iran","Tehran","2020-Mar","2020-Jun","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate","DAA, Standard of care",70
"IRCT20200314046774N1","http://en.irct.ir/trial/46519",NA,"Iran","Qom","2020-Jun","2020-Jun","Completed","Randomised","Triple",2,"Confirmed","Hospital","Radiographic Findings","Standard of care, Vitamins",94
"IRCT20200314046764N1","http://en.irct.ir/trial/46533",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Single",2,NA,"Unclear","Cough, Dyspnea, Other Mild Symptoms","LPV/r + HCQ + Oseltamivir + Antivirals, LPV/r + HCQ + Oseltamivir + Pirfenidone",40
"IRCT20100228003449N30","http://en.irct.ir/trial/46536",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Single-Arm","Open-Label",1,"Confirmed Or Suspected","Hospital","Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events","HCQ + LPV/r",50
"IRCT20100228003449N28","http://en.irct.ir/trial/46538",NA,"Iran","Tehran","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Hospitalization, Clinical Improvement Score (Any), Adverse Events","IFN, Standard of care",30
"IRCT20100228003449N27","http://en.irct.ir/trial/46545",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Hospitalization, Clinical Improvement Score (Any), Adverse Events","IFN, Standard of care",30
"IRCT20150303021315N17","http://en.irct.ir/trial/46550",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Single-Arm","Open-Label",1,NA,"Unclear","Mortality, Non-invasive Ventilation, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Radiographic Findings","TCZ",85
"IRCT20200312046749N1","http://en.irct.ir/trial/46551",NA,"Iran","Tehran","2020-Mar","2020-Sep","Completed","Non-Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Radiographic Findings","Standard of care, TNF inhibitor",80
"IRCT20200316046792N1","http://en.irct.ir/trial/46554",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Double",3,"Confirmed","Hospital","Mortality, Hospitalization, Cough, Fever, Treatment-emergent Adverse Events, Respiratory Rate","Alternative therapy, Standard of care",150
"IRCT20151227025726N12","http://en.irct.ir/trial/46561",NA,"Iran","Tehran","2020-Mar","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, Radiographic Findings","HCQ + Oseltamivir + LPV/r + IFN",20
"IRCT20170117032004N3","http://en.irct.ir/trial/46564",NA,"Iran","East Azarbaijan","2020-Mar","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Standard of care, Vitamins",30
"IRCT20100228003449N29","http://en.irct.ir/trial/46567",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Radiographic Findings, Renal Outcome (Unspecified)","DAA, Standard of care",50
"IRCT20200317046797N1","http://en.irct.ir/trial/46573",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Radiographic Findings",NA,40
"IRCT20160625028622N1","http://en.irct.ir/trial/46576",NA,"Iran","Tehran","2020-Mar","2020-Apr","Completed","Non-Randomised","Double",2,"Confirmed","Outpatient, Hospital","Cough, Radiographic Findings","Other, Standard of care",125
"IRCT20140528017891N8","http://en.irct.ir/trial/46623",NA,"Iran","Tehran","2020-Mar","2020-Apr","Completed","Randomised","Double",2,"Confirmed","ICU","Mortality, Pneumonia or ARDS, C-Reactive Protein, Procalcitonin, CD4, CD8, Radiographic Findings","Standard of care, Stem cells",10
"IRCT20200321046828N1","http://en.irct.ir/trial/46624",NA,"Iran","Tehran","2020-Mar","2020-Mar","Completed","Non-Randomised","Open-Label",6,NA,"Hospital","Fever, Radiographic Findings",NA,30
"IRCT20140617018126N2","http://en.irct.ir/trial/46637",NA,"Iran","East Azarbaijan","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","C-Reactive Protein, White Blood Cell Count, Respiratory Rate",NA,60
"IRCT20190727044343N2","http://en.irct.ir/trial/46639",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Double",2,NA,"Hospital","Mortality, Hospital Discharge, C-Reactive Protein","Standard of care, Statins",100
"IRCT20171122037571N2","http://en.irct.ir/trial/46660",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Cough, Fever, Adverse Events, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Remdesivir + Chloroqines + LPV/r or Atazanavir",120
"IRCT20150914024017N1","http://en.irct.ir/trial/46665",NA,"Iran","Tehran","2020-Apr","2021-Feb","Completed","Randomised","Triple",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, Treatment-emergent Adverse Events","IFN, Standard of care",40
"IRCT20140911019125N6","http://en.irct.ir/trial/46668",NA,"Iran","Kerman","2020-Apr","2020-Oct","Completed","Single-Arm","Open-Label",1,"Confirmed","Unclear","Viral Load or Clearance","Stem cells",10
"IRCT20160316027081N1","http://en.irct.ir/trial/46678",NA,"Iran","Fars","2020-Mar","2020-Apr","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Respiratory Rate",NA,374
"IRCT20151227025726N13","http://en.irct.ir/trial/46681",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Radiographic Findings","TCZ + LPV/r + HCQ",40
"IRCT20160310026998N11","http://en.irct.ir/trial/46690",NA,"Iran","East Azarbaijan","2020-Mar","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO",NA,200
"IRCT20180610040049N3","http://en.irct.ir/trial/46697",NA,"Iran","Markazi","2020-Mar","2020-May","Completed","Randomised","Triple",2,"Confirmed","Hospital","C-Reactive Protein, Lung Inflamation","Alternative therapy, Standard of care",60
"IRCT20200324046852N1","http://en.irct.ir/trial/46706",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Double",2,NA,"Hospital","Viral Load or Clearance, C-Reactive Protein, Radiographic Findings","Corticosteroids + Other + HCQ + LPV/r, HCQ + LPV/r",30
"IRCT20200324046851N1","http://en.irct.ir/trial/46712",NA,"Iran","East Azarbaijan","2020-Apr","2020-Apr","Completed","Non-Randomised","Double",2,NA,"ICU","Viral Load or Clearance","Alternative therapy, Standard of care",86
"IRCT20200323046841N1","http://en.irct.ir/trial/46715",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Triple",2,"Confirmed","Hospital","Clinical Improvement Score (Any)",NA,60
"IRCT20180923041093N3","http://en.irct.ir/trial/46721",NA,"Iran","Tehran","2020-Mar","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, Cough, Fever, Other Mild Symptoms, Respiratory Rate",NA,70
"IRCT20200322046833N1","http://en.irct.ir/trial/46731",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Double",2,NA,"Hospital","Cough, Fever, Dyspnea, Adverse Events, Serious Adverse Events","HCQ + Antiretrovirals, HCQ + Antiretrovirals + Umifenovir",100
"IRCT20200324046850N1","http://en.irct.ir/trial/46732",NA,"Iran","Khuzestan","2020-Mar","2020-Jul","Completed","Randomised","Double",4,NA,"Hospital","Cough, Fever, Dyspnea","Other, Standard of care, Vitamins, Vitamins + Other",100
"IRCT20160131026298N2","http://en.irct.ir/trial/46733",NA,"Iran","Tehran","2020-Apr","2020-Mar","Completed","Randomised","Open-Label",2,NA,"Hospital","Cough, Dyspnea, Radiographic Findings","Alternative therapy, Standard of care",64
"IRCT20140907019073N4","http://en.irct.ir/trial/46736",NA,"Iran","Fars","2020-Mar","2020-Jul","Completed","Randomised","Double",2,"Suspected","Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein","Alternative therapy, Standard of care",60
"IRCT20190804044429N1","http://en.irct.ir/trial/46741",NA,"Iran","Mazandaran","2020-Apr","2020-Jun","Completed","Unspecified","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Cough, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, LDH","HCQ + LPV/r, IFN + HCQ + LPV/r",70
"IRCT20200324046850N5","http://en.irct.ir/trial/46751",NA,"Iran","Tehran","2020-Apr","2020-Dec","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Cough, Fever, Respiratory Rate",NA,400
"IRCT20200325046860N1","http://en.irct.ir/trial/46759",NA,"Iran","Tehran","2020-Mar","2020-Aug","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Respiratory Rate",NA,200
"IRCT20160313027033N2","http://en.irct.ir/trial/46762",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"Outpatient","Mortality, Hospitalization, Cough, Fever, Other Mild Symptoms, Respiratory Rate","Nutrition, Standard of care",120
"IRCT20101219005416N2","http://en.irct.ir/trial/46775",NA,"Iran","Kerman","2020-Apr","2020-May","Completed","Randomised","Double",2,NA,"Hospital","Mortality, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, SpO2, Respiratory Rate","Alternative therapy, Standard of care",80
"IRCT20200204046369N1","http://en.irct.ir/trial/46776",NA,"Iran","Tehran","2020-Apr","2020-Nov","Completed","Randomised","Triple",2,NA,"Hospital","Fever, Blood Urea Nitrogen, PaO2-FiO2, Respiratory Rate, Radiographic Findings","Corticosteroids, Standard of care",82
"IRCT20180712040449N2","http://en.irct.ir/trial/46782",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,NA,"Hospital","Lung Inflamation","Alternative therapy, Standard of care",68
"IRCT20200318046812N1","http://en.irct.ir/trial/46783",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Radiographic Findings","HCQ + FPV, HCQ + LPV/r",324
"IRCT20200328046882N1","http://en.irct.ir/trial/46784",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Double",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","DAA",60
"IRCT20200317046797N2","http://en.irct.ir/trial/46786",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea",NA,40
"IRCT20200325046860N2","http://en.irct.ir/trial/46789",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Non-Randomised","Open-Label",1,NA,"Hospital","Respiratory Rate","Stem cells",5
"IRCT20130812014333N145","http://en.irct.ir/trial/46790",NA,"Iran","Tehran","2020-Mar","2020-Jul","Completed","Randomised","Single",2,NA,"Hospital","Clinical Improvement Score (Any)","HCQ + LPV/r, HCQ + LPV/r + DAA",80
"IRCT20190917044805N2","http://en.irct.ir/trial/46804",NA,"Iran","Tehran","2020-Mar","2020-Oct","Completed","Randomised","Double",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, Erythrocyte Sedimentation Rate","Standard of care, Vitamins",60
"IRCT20120225009124N4","http://en.irct.ir/trial/46810",NA,"Iran","Fars","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",3,NA,"Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","Corticosteroids + Igs + IFN, HCQ + Antivirals",105
"IRCT20200325046859N1","http://en.irct.ir/trial/46811",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Single-Arm","Open-Label",1,NA,"Hospital","Fever, White Blood Cell Count, Respiratory Rate, Radiographic Findings","Igs",50
"IRCT20161204031229N3","http://en.irct.ir/trial/46814",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,NA,"Hospital","Fever, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, Blood Pressure, Respiratory Rate, Radiographic Findings","HCQ + DAA, HCQ + LPV/r (or + DAA + Antibiotics)",40
"IRCT20180802040678N4","http://en.irct.ir/trial/46824",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any)",NA,100
"IRCT20151228025732N51","http://en.irct.ir/trial/46828",NA,"Iran","Semnan","2020-Apr","2020-Jun","Completed","Non-Randomised","Open-Label",2,NA,"Hospital","Cough, Fever, Dyspnea, Other Mild Symptoms","Alternative therapy, Standard of care",60
"IRCT20150704023055N2","http://en.irct.ir/trial/46837",NA,"Iran","Mazandaran","2020-Apr","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Clinical Improvement Score (Any), IL-6",NA,10
"IRCT20200319046819N1","http://en.irct.ir/trial/46838",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Single",2,NA,"ICU","Mortality, Hospitalization, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), White Blood Cell Count, Erythrocyte Sedimentation Rate","Standard of care, Vitamins",60
"IRCT20180610040049N4","http://en.irct.ir/trial/46850",NA,"Iran","Qom","2020-Apr","2020-May","Completed","Randomised","Triple",2,NA,"Unclear","C-Reactive Protein, Lung Inflamation","Alternative therapy, Standard of care",60
"IRCT20130812014333N147","http://en.irct.ir/trial/46853",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Single",4,NA,"Hospital","Hospitalization","DAA, HCQ, Lithium, Other",80
"IRCT20190810044500N5","http://en.irct.ir/trial/46867",NA,"Iran","Tehran","2020-May","2021-Feb","Completed","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Mortality, Hospitalization, Hospital Discharge, Cough, Fever, Dyspnea, C-Reactive Protein, Ferritin, Platelet Count, Erythrocyte Sedimentation Rate, D-Dimer, LDH, SpO2","Colchicine, HCQ + Colchicine",200
"IRCT20081019001369N2","http://en.irct.ir/trial/46868",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Double",2,NA,"Outpatient","Clinical Improvement Score (Any), Fever, C-Reactive Protein","Alternative therapy, Standard of care",40
"IRCT20200402046923N1","http://en.irct.ir/trial/46879",NA,"Iran","East Azarbaijan","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"Hospital","ICU Admission, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events, ALT","Alternative therapy, Standard of care",110
"IRCT20200328046886N1","http://en.irct.ir/trial/46885",NA,"Iran","Mazandaran","2020-Apr","2020-Mar","Completed","Randomised","Double",2,NA,"Hospital","Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","DAA + Antiviral, Standard of care",48
"IRCT20131215015805N2","http://en.irct.ir/trial/46887",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Pneumonia or ARDS, Radiographic Findings","Other, Standard of care",50
"IRCT20200404046933N1","http://en.irct.ir/trial/46893",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Double",2,NA,"Outpatient","Clinical Improvement Score (Any), C-Reactive Protein","Alternative therapy, Standard of care",40
"IRCT20180725040596N2","http://en.irct.ir/trial/46897",NA,"Iran","Tehran","2020-Apr","2020-Sep","Completed","Randomised","Open-Label",2,NA,"Hospital","Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, Radiographic Findings","HCQ + LPV/r, HCQ + Umifenovir",100
"IRCT20200404046937N1","http://en.irct.ir/trial/46903",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Double",2,NA,"Hospital","Viral Load or Clearance, Cough, Fever, Dyspnea, C-Reactive Protein, Radiographic Findings","Alternative therapy, Standard of care",60
"IRCT20200404046947N1","http://en.irct.ir/trial/46904",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Single",2,NA,"Hospital","Mortality, Non-invasive Ventilation, Radiographic Findings","Corticosteroids, Standard of care",68
"IRCT20080901001157N16","http://en.irct.ir/trial/46907",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Triple",2,NA,"Unclear","Cough, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, ALT, Blood Urea Nitrogen, Respiratory Rate, Lung Inflamation","Alternative therapy, Standard of care",60
"IRCT20200404046934N1","http://en.irct.ir/trial/46913",NA,"Iran","Qom","2020-Apr","2020-Apr","Completed","Randomised","Triple",2,NA,"Unclear","Fever, Blood Pressure, Respiratory Rate","Alternative therapy, Standard of care",130
"IRCT20200403046926N1","http://en.irct.ir/trial/46926",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"Outpatient","Hospitalization, C-Reactive Protein","HCQ, HCQ + LPV/r",60
"IRCT20151228025732N53","http://en.irct.ir/trial/46931",NA,"Iran","Semnan","2020-Apr","2020-Jun","Completed","Non-Randomised","Open-Label",2,NA,"Hospital","Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, White Blood Cell Count, CD4, CD8","Plasma based therapy, Standard of care",12
"IRCT20200404046935N1","http://en.irct.ir/trial/46940",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,NA,"Unclear","Pneumonia or ARDS, Fever, Erythrocyte Sedimentation Rate","HCQ + LPV/r, HCQ + LPV/r + Alternative therapy",40
"IRCT20151227025726N14","http://en.irct.ir/trial/46942",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","FPV, LPV/r",84
"IRCT20200405046958N1","http://en.irct.ir/trial/46946",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Triple",2,NA,"Healthy Unexposed","Viral Load or Clearance","HCQ, Standard of care",60
"IRCT20200406046965N1","http://en.irct.ir/trial/46958",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Double",2,NA,"Outpatient","Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein","Alternative therapy, Standard of care",40
"IRCT20200405046960N1","http://en.irct.ir/trial/46961",NA,"Iran","Tehran","2020-Apr","2020-Apr","Completed","Single-Arm","Open-Label",1,NA,"Hospital","C-Reactive Protein, White Blood Cell Count, Respiratory Rate","Alternative therapy",15
"IRCT20151228025732N52","http://en.irct.ir/trial/46963",NA,"Iran","Semnan","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,NA,"ICU","Organ Failure or Dysfunction (SOFA), Respiratory Rate, Radiographic Findings","Melatonin + Vitamins + Sulfate, Standard of care",30
"IRCT20200318046812N2","http://en.irct.ir/trial/46968",NA,"Iran","Tehran","2020-Apr","2021-Apr","Recruiting","Randomised","Open-Label",3,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, Serious Adverse Events, C-Reactive Protein, Radiographic Findings","HCQ + AZT + Corticosteroids, HCQ + AZT + NSAIDs, HCQ + LPV/r",906
"IRCT20200317046797N4","http://en.irct.ir/trial/46969",NA,"Iran","East Azarbaijan","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",60
"IRCT20200404046948N1","http://en.irct.ir/trial/46973",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, PaO2-FiO2, Respiratory Rate","Plasma based therapy, Standard of care",60
"IRCT20180520039738N2","http://en.irct.ir/trial/46974",NA,"Iran","Markazi","2020-Apr","2020-Apr","Completed","Randomised","Double",2,NA,"Unclear","Cough, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, LDH, Respiratory Rate, Blood pH","Standard of care, Vitamins",140
"IRCT20081027001411N3","http://en.irct.ir/trial/46975",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Randomised","Single",2,"Confirmed","Hospital","Troponin","Corticosteroids, Standard of care",60
"IRCT20081019001369N4","http://en.irct.ir/trial/46977",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Double",2,NA,"Outpatient","Clinical Improvement Score (Any), Fever, C-Reactive Protein","Antibiotics, Standard of care",40
"IRCT20081019001369N3","http://en.irct.ir/trial/46978",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Double",2,NA,"Outpatient","Clinical Improvement Score (Any), Fever, C-Reactive Protein","Alternative therapy, Standard of care",40
"IRCT20091201002804N12","http://en.irct.ir/trial/46983",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Randomised","Triple",2,"Confirmed","ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",60
"IRCT20200408046992N1","http://en.irct.ir/trial/47006",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Open-Label",2,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Fever, C-Reactive Protein, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Renal Outcome (Unspecified)","HCQ, HCQ + Other",70
"IRCT20200401046909N2","http://en.irct.ir/trial/47010",NA,"Iran","Tehran","2020-Apr","2020-Oct","Completed","Randomised","Double",2,NA,"Healthy Exposed, Healthcare Workers","Cough, Fever, Dyspnea, Radiographic Findings","Standard of care, Vitamins",540
"IRCT20200408046987N1","http://en.irct.ir/trial/47012",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Double",5,"Confirmed","Unclear","Hospitalization, C-Reactive Protein, Radiographic Findings","Ivermectin, Standard of care",125
"IRCT20200317046797N3","http://en.irct.ir/trial/47014",NA,"Iran","East Azarbaijan","2020-Apr","2020-Jul","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Radiographic Findings","HCQ + LPV/r + Antivirals, Igs + HCQ + LPV/r + Antivirals",100
"IRCT20200317046797N5","http://en.irct.ir/trial/47015",NA,"Iran","East Azarbaijan","2020-Apr","2020-Jul","Completed","Single-Arm","Open-Label",1,NA,"ICU","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Radiographic Findings","Dialysis",10
"IRCT20200404046937N2","http://en.irct.ir/trial/47016",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Double",2,NA,"Hospital","Viral Load or Clearance, Cough, Fever, C-Reactive Protein, Radiographic Findings","Alternative therapy, Standard of care",60
"IRCT20180923041093N5","http://en.irct.ir/trial/47018",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Cough, Fever, Other Mild Symptoms, C-Reactive Protein, Respiratory Rate, Radiographic Findings, Anxiety","Alternative therapy, Standard of care",60
"IRCT20160131026298N3","http://en.irct.ir/trial/47019",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Double",2,"Confirmed","Unclear","Cough, Dyspnea, Radiographic Findings, Quality of Life","Alternative therapy, Standard of care",80
"IRCT20200406046968N1","http://en.irct.ir/trial/47021",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Single-Arm","Open-Label",2,NA,"ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Standard of care, TCZ",10
"IRCT20150808023559N20","http://en.irct.ir/trial/47022",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization","FPV + HCQ, HCQ + LPV/r",100
"IRCT20200217046526N1","http://en.irct.ir/trial/47030",NA,"Iran","Tehran","2020-Apr","2020-Mar","Completed","Single-Arm","Open-Label",1,NA,"Hospital, ICU","Adverse Events, SpO2","Stem cells",6
"IRCT20200411047016N1","http://en.irct.ir/trial/47044",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, SpO2","Alternative therapy, Standard of care",150
"IRCT20200410047009N1","http://en.irct.ir/trial/47052",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, Clinical Improvement Score (Any)","NSAIDs, Standard of care",101
"IRCT20200409047007N1","http://en.irct.ir/trial/47058",NA,"Iran","Razavi Khorasan","2020-Apr","2020-Aug","Completed","Non-Randomised","Open-Label",2,NA,"ICU","Mortality, ICU Admission","Plasma based therapy, Standard of care",64
"IRCT20200408046990N1","http://en.irct.ir/trial/47061",NA,"Iran","Tehran","2020-Apr","2020-Sep","Completed","Non-Randomised","Open-Label",2,NA,"Outpatient","Hospitalization, Cough, Fever, Other Mild Symptoms, Adverse Events, Radiographic Findings","Alternative therapy",60
"IRCT20190727044343N3","http://en.irct.ir/trial/47062",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Randomised","Double",2,"Confirmed","Unclear","C-Reactive Protein, IL-6, Radiographic Findings","Antivirals, Vitamins",60
"IRCT20200411047025N1","http://en.irct.ir/trial/47078",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"Hospital","Fever, C-Reactive Protein, Respiratory Rate","HCQ + Antiretroviral, HCQ + Antiretroviral + Vitamins",110
"IRCT20080901001165N46","http://en.irct.ir/trial/47087",NA,"Iran","Tehran","2020-Apr","2020-Aug","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Cough, Fever, Adverse Events, IL-1, IL-6, Tumor Necrosis Factor (Any)","Standard of care, Umifenovir",200
"IRCT20200406046963N1","http://en.irct.ir/trial/47088",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"ICU","Mortality, ICU Admission, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Radiographic Findings","Corticosteroids, Standard of care",40
"IRCT20190122042450N4","http://en.irct.ir/trial/47090",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,NA,"Healthy Exposed","Viral Load or Clearance, Radiographic Findings","HCQ, Standard of care",1000
"IRCT20200411047030N1","http://en.irct.ir/trial/47099",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Unspecified","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Fever, Other Mild Symptoms, C-Reactive Protein","HCQ + AZT + Melatonin",82
"IRCT20190717044241N2","http://en.irct.ir/trial/47110",NA,"Iran","Tehran","2020-Apr","2020-Oct","Completed","Single-Arm","Open-Label",1,NA,"ICU","PaO2-FiO2","Stem cells",5
"IRCT20200406046968N2","http://en.irct.ir/trial/47115",NA,"Iran","East Azarbaijan","2020-Apr","2020-Jul","Completed","Single-Arm","Open-Label",1,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Plasma based therapy",30
"IRCT20170207032444N3","http://en.irct.ir/trial/47119",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Blood Pressure","HCQ, HCQ + Immunomodulators",60
"IRCT20200413047053N1","http://en.irct.ir/trial/47139",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Double",3,NA,"Outpatient","C-Reactive Protein","Alternative therapy, Standard of care",60
"IRCT20081019001369N5","http://en.irct.ir/trial/47141",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Double",2,"Confirmed","Outpatient","Clinical Improvement Score (Any), Cough, Fever, Other Mild Symptoms, C-Reactive Protein","Lithium, Standard of care",40
"IRCT20200413047062N1","http://en.irct.ir/trial/47146",NA,"Iran","Tehran","2020-May","2020-May","Completed","Non-Randomised","Single",2,"Confirmed","Hospital","Mortality","Standard of care, Statins",76
"IRCT20191125045492N2","http://en.irct.ir/trial/47149",NA,"Iran","Mazandaran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"Unclear","Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein","Non-invasive respiratory support",80
"IRCT20200406046968N3","http://en.irct.ir/trial/47152",NA,"Iran","East Azarbaijan","2020-May","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","HCQ + LPV/r, HCQ + LPV/r + Other",60
"IRCT20200413047063N1","http://en.irct.ir/trial/47156",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Adverse Events, Serious Adverse Events, PaO2-FiO2","Standard of care, Stem cells",20
"IRCT20200414047072N1","http://en.irct.ir/trial/47163",NA,"Iran","Tehran","2020-Apr","2021-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Viral Load or Clearance, Fever, Dyspnea, Organ Failure or Dysfunction (SOFA), Respiratory Rate, Radiographic Findings","Plasma based therapy",357
"IRCT20200414047070N1","http://en.irct.ir/trial/47169",NA,"Iran","Tehran","2020-Apr","2020-Sep","Completed","Randomised","Open-Label",2,NA,"Unclear","Viral Load or Clearance","Other, Standard of care",50
"IRCT20170210032478N3","http://en.irct.ir/trial/47173",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Pneumonia or ARDS, C-Reactive Protein","Other, Standard of care",200
"IRCT20081019001369N6","http://en.irct.ir/trial/47188",NA,"Iran","Tehran","2020-May","2020-Oct","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","Alternative therapy, Standard of care",30
"IRCT20200415047082N1","http://en.irct.ir/trial/47193",NA,"Iran","East Azarbaijan","2020-Apr","2020-Jun","Completed","Randomised","Double",2,NA,"Hospital","Fever, Other Mild Symptoms, C-Reactive Protein, Blood Pressure, Heart Rate, Respiratory Rate, Radiographic Findings","Alternative therapy, Standard of care",70
"IRCT20091012002582N21","http://en.irct.ir/trial/47197",NA,"Iran","Tehran","2020-May","2019-Aug","Completed","Randomised","Double",2,"Confirmed","ICU","Blood Gas","Plasma based therapy, Standard of care",30
"IRCT20200325046859N2","http://en.irct.ir/trial/47200",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Single",2,"Confirmed","Hospital","Fever, C-Reactive Protein, White Blood Cell Count, LDH, Respiratory Rate, Radiographic Findings","HCQ, HCQ + Umifenovir",100
"IRCT20190418043307N1","http://en.irct.ir/trial/47209",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count","HCQ, HCQ + Other",100
"IRCT20200413047056N1","http://en.irct.ir/trial/47212",NA,"Iran","South Khorasan","2020-Apr","2020-Jun","Completed","Randomised","Open-Label",3,NA,"Hospital","Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, White Blood Cell Count, Erythrocyte Sedimentation Rate, LDH, Blood Gas, SpO2, Radiographic Findings","Igs, Plasma based therapy, Standard of care",15
"IRCT20200418047116N1","http://en.irct.ir/trial/47219",NA,"Iran","Tehran","2020-May","2020-May","Completed","Non-Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Radiographic Findings","Igs, LPV/r",20
"IRCT20200415047089N1","http://en.irct.ir/trial/47234",NA,"Iran","Markazi","2020-Apr","2020-May","Completed","Randomised","Single",2,NA,"Outpatient","Hospitalization, Other Mild Symptoms","Alternative therapy, Standard of care",100
"IRCT20200415047092N1","http://en.irct.ir/trial/47244",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Randomised","Open-Label",2,NA,"Hospital","ICU Admission, Hospitalization, Fever","AZT + Oseltamivir + LPV/r + Antiretroviral + HCQ, Oseltamivir + LPV/r + Antiretroviral + HCQ",110
"IRCT20200416047104N1","http://en.irct.ir/trial/47251",NA,"Iran","Tehran","2020-Apr","2020-Jun","Completed","Randomised","Double",2,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Ferritin, Creatinine Phosphokinase, LDH, Blood Pressure, Respiratory Rate","Alternative therapy, Standard of care",66
"IRCT20200417047113N1","http://en.irct.ir/trial/47264",NA,"Iran","Tehran","2020-Apr","2020-Dec","Completed","Randomised","Double",7,NA,"Hospital","Cough, Respiratory Rate, Lung Inflamation","Natural Killer Cells, Standard of care",70
"IRCT20200416047099N1","http://en.irct.ir/trial/47266",NA,"Iran","Tehran","2020-Apr","2020-May","Completed","Single-Arm","Open-Label",1,NA,"ICU","Fever, PaO2-FiO2, Respiratory Rate, Radiographic Findings","Plasma based therapy",10
"IRCT20200418047121N2","http://en.irct.ir/trial/47275",NA,"Iran","Tehran","2020-May","2020-Sep","Completed","Non-Randomised","Double",2,"Confirmed","Hospital, Unclear","Radiographic Findings","Standard of care, Stem cells",6
"IRCT20200411047019N1","http://en.irct.ir/trial/47279",NA,"Iran","Alborz","2020-May","2021-Jun","Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Anti SARS-COV-2 Titers","Standard of care, Vaccine",500
"IRCT20080901001165N48","http://en.irct.ir/trial/47318",NA,"Iran","Tehran","2020-Apr","2020-Jul","Completed","Randomised","Open-Label",2,NA,"Hospital","Cough, Fever","Alternative therapy, Standard of care",100
"IRCT20200420047147N1","http://en.irct.ir/trial/47334",NA,"Iran","Tehran","2020-Apr","2020-Aug","Completed","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Radiographic Findings","DPP-4i, HCQ + LPV/r",84
"IRCT20150303021315N19","http://en.irct.ir/trial/47335",NA,"Iran","Tehran","2020-May","2020-Nov","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Dyspnea","mAb",62
"IRCT20200416047099N2","http://en.irct.ir/trial/47357",NA,"Iran","Tehran","2020-Jul","2020-Sep","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","Tumor Necrosis Factor (Any), Bilirubin","Plasma based therapy",10
"IRCT20170922036314N4","http://en.irct.ir/trial/47383",NA,"Iran","Tehran","2020-Jun","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Serious or Seconday Infections, Depression, Anxiety","Psychological therapy, Standard of care",112
"IRCT20080901001165N59","http://en.irct.ir/trial/47477",NA,"Iran","Tehran","2020-May","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Fever","Hygiene, Standard of care",80
"IRCT20200209046427N1","http://en.irct.ir/trial/47504",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, C-Reactive Protein","Alternative therapy, Standard of care",60
"IRCT20180425039414N2","http://en.irct.ir/trial/47516",NA,"Iran","Tehran","2020-May","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Cough, Fever, Dyspnea, SpO2","HCQ, HCQ + Zinc",80
"IRCT20200427047215N1","http://en.irct.ir/trial/47520",NA,"Iran","Tehran","2020-May","2020-Jul","Completed","Randomised","Single",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, SpO2","Other, Standard of care",60
"IRCT20200428047229N1","http://en.irct.ir/trial/47530",NA,"Iran","Tehran","2020-Jun","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Fever, Radiographic Findings","Alternative therapy, Standard of care",60
"IRCT20200428047228N1","http://en.irct.ir/trial/47559",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Double",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2","HCQ, HCQ + FPV",50
"IRCT20150808023559N21","http://en.irct.ir/trial/47594",NA,"Iran","Tehran","2020-May","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge","Plasma based therapy, Standard of care",60
"IRCT20200501047259N1","http://en.irct.ir/trial/47609",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Single-Arm","Triple",1,"Confirmed","Hospital, ICU","SpO2, Radiographic Findings","Igs",40
"IRCT20200501047258N1","http://en.irct.ir/trial/47629",NA,"Iran","Tehran","2020-May","2021-May","Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"Plasma based therapy, Standard of care",120
"IRCT20200503047281N1","http://en.irct.ir/trial/47632",NA,"Iran","Yazd","2020-Jul","2021-Jan","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge","Plasma based therapy, Standard of care",40
"IRCT20200428047232N1","http://en.irct.ir/trial/47637",NA,"Iran","Tehran","2020-Jul","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge","HCQ, HCQ + Immunomodulators",60
"IRCT20131129015584N2","http://en.irct.ir/trial/47639",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Hospitalization, SpO2","LPV/r + AZT, LPV/r + AZT + Alternative therapy",152
"IRCT20080901001165N52","http://en.irct.ir/trial/47641",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Hospital Discharge, Shock, Hypoxemia","Corticosteroids, Standard of care",50
"IRCT20200115046144N2","http://en.irct.ir/trial/47645",NA,"Iran","Semnan","2020-May","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Other Mild Symptoms","Alternative therapy, Standard of care",40
"IRCT20131129015584N3","http://en.irct.ir/trial/47665",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Open-Label",2,"Suspected","Hospital","Hospitalization, SpO2","Alternative therapy + AZT + LPV/r, AZT + LPV/r",68
"IRCT20150107020592N25","http://en.irct.ir/trial/47666",NA,"Iran","Tehran","2020-Jun","2020-May","Completed","Single-Arm","Open-Label",1,"Confirmed","ICU",NA,"Positioning",30
"IRCT20200504047298N2","http://en.irct.ir/trial/47675",NA,"Iran","Alborz","2020-Jun","2020-Jul","Completed","Randomised","Double",2,"Confirmed","Hospital","Cough, Fever, Dyspnea, Other Mild Symptoms","Alternative therapy",48
"IRCT20160706028815N5","http://en.irct.ir/trial/47682",NA,"Iran","Tehran","2020-May","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","Antivirals, Other + Antivirals",40
"IRCT20171213037866N2","http://en.irct.ir/trial/47684",NA,"Iran","Semnan","2020-May","2020-Aug","Completed","Randomised","Single",2,"Confirmed","Unclear","Hospital Discharge, Radiographic Findings","Alternative therapy, Standard of care",68
"IRCT20200502047268N1","http://en.irct.ir/trial/47692",NA,"Iran","Tehran","2020-May","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Lymphocyte Count","Other, Standard of care",10
"IRCT20171105037262N4","http://en.irct.ir/trial/47696",NA,"Iran","Tehran","2020-Jun","2020-Jul","Completed","Randomised","Single",2,"Confirmed","Unclear",NA,"HCQ, HCQ + mAb",100
"IRCT20200503047280N1","http://en.irct.ir/trial/47704",NA,"Iran","East Azarbaijan","2020-Jun","2020-Jul","Completed","Randomised","Triple",3,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",300
"IRCT20200418047126N1","http://en.irct.ir/trial/47707",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Single",2,"Confirmed","Hospital","Hospitalization, Fever","HCQ, HCQ + Colchicine",100
"IRCT20200405046951N1","http://en.irct.ir/trial/47722",NA,"Iran","Tehran","2020-Jun","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","SpO2","Standard of care, Vitamins",120
"IRCT20170211032494N3","http://en.irct.ir/trial/47735",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Single-Arm","Open-Label",1,"Confirmed","Hospital","IL-1, SpO2","Radiation therapy",10
"IRCT20200326046868N1","http://en.irct.ir/trial/47934",NA,"Iran","Khuzestan","2020-May","2020-Jun","Completed","Randomised","Triple",2,"Confirmed","Unclear","Platelet Count","Alternative therapy, Standard of care",88
"IRCT20081011001323N25","http://en.irct.ir/trial/47935",NA,"Iran","Tehran","2020-May","2020-Dec","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Radiographic Findings","Alternative therapy, Standard of care",80
"IRCT20200508047346N1","http://en.irct.ir/trial/47953",NA,"Iran","Tehran","2020-May","2021-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Fever, PaO2-FiO2","Other, Standard of care",124
"IRCT20200421047150N1","http://en.irct.ir/trial/47964",NA,"Iran","Tehran","2020-May","2020-Oct","Completed","Randomised","Triple",2,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, Radiographic Findings","Standard of care, Stem cells",90
"IRCT20180923041093N6","http://en.irct.ir/trial/47974",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Radiographic Findings","Alternative therapy, Standard of care",60
"IRCT20200508047345N1","http://en.irct.ir/trial/47987",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Unspecified","Open-Label",2,"Confirmed","Outpatient","SpO2","Alternative therapy",100
"IRCT20140428017469N1","http://en.irct.ir/trial/47989",NA,"Iran","Fars","2020-May","2020-Jul","Completed","Single-Arm","Open-Label",1,"Healthy","Healthy Exposed",NA,"Vaccine",130000
"IRCT20200506047323N2","http://en.irct.ir/trial/47990",NA,"Iran","Tehran","2020-May","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Serious Adverse Events, SpO2","HCQ, HCQ + Alternative therapy",60
"IRCT20200509047373N1","http://en.irct.ir/trial/48001",NA,"Iran","Fars","2020-May","2020-Aug","Completed","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Fever, SpO2","Alternative therapy, Standard of care",60
"IRCT20110907007511N4","http://en.irct.ir/trial/48013",NA,"Iran","Tehran","2020-Jul","2020-Sep","Completed","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Dyspnea, Anxiety","Alternative therapy, Standard of care",30
"IRCT20151227025726N15","http://en.irct.ir/trial/48018",NA,"Iran","Tehran","2020-May","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Dyspnea","LPV/r, Umifenovir",100
"IRCT20150716023235N15","http://en.irct.ir/trial/48019",NA,"Iran","Razavi Khorasan","2020-May","2020-Jul","Completed","Randomised","Single",2,"Confirmed","Hospital","IL-6","HCQ + AZT + NSAIDs, HCQ + AZT + NSAIDs + Hormone therapy",80
"IRCT20200510047383N1","http://en.irct.ir/trial/48024",NA,"Iran","Tehran","2020-May","2020-Aug","Completed","Randomised","Double",2,"Confirmed","ICU","Mortality, SpO2","Standard of care, TCZ",100
"IRCT20120215009014N355","http://en.irct.ir/trial/48039",NA,"Iran","Hamadan","2020-May","2020-Aug","Completed","Randomised","Double",2,"Confirmed","Hospital","Mortality","Other, Standard of care",92
"IRCT20120215009014N354","http://en.irct.ir/trial/48043",NA,"Iran","Hamadan","2020-May","2020-Aug","Completed","Randomised","Double",3,"Confirmed","ICU","Mortality","Corticosteroids, Dexamethasone",81
"IRCT20200511047399N1","http://en.irct.ir/trial/48045",NA,"Iran","Tehran","2020-Jul","2020-Jun","Completed","Randomised","Single",2,"Confirmed","Hospital",NA,"HCQ, HCQ + Nutrition",30
"IRCT20200511047396N1","http://en.irct.ir/trial/48048",NA,"Iran","Tehran","2020-May","2020-Nov","Completed","Randomised","Double",2,"Confirmed","Hospital","Viral Load or Clearance, Cough","HCQ, HCQ + IFN",50
"IRCT20170731035423N2","http://en.irct.ir/trial/48049",NA,"Iran","Tehran","2020-Jun","2021-Mar","Recruiting","Randomised","Double",4,"Confirmed","Hospital","Radiographic Findings","Other",120
"IRCT20090609002017N35","http://en.irct.ir/trial/48058",NA,"Iran","East Azarbaijan","2020-May","2020-Jun","Completed","Randomised","Double",4,"Confirmed","Unclear","C-Reactive Protein","Other, Standard of care",40
"IRCT20080901001165N55","http://en.irct.ir/trial/48061",NA,"Iran","Tehran","2020-May","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Fever","Other, Standard of care",72
"IRCT20080901001165N53","http://en.irct.ir/trial/48066",NA,"Iran","Tehran","2020-May","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Fever","IFN, Standard of care",100
"IRCT20180425039414N3","http://en.irct.ir/trial/48083",NA,"Iran","Tehran","2020-Jun","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization","HCQ + LPV/r, HCQ + LPV/r + Vitamins",80
"IRCT20200506047319N1","http://en.irct.ir/trial/48095",NA,"Iran","Zanjan","2020-May","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Cough, Fever, Dyspnea, Other Mild Symptoms","Alternative therapy, Standard of care",100
"IRCT20200428047228N2","http://en.irct.ir/trial/48096",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Randomised","Double",2,"Confirmed","ICU","Mortality","HCQ, HCQ + AZT",40
"IRCT20200510047385N1","http://en.irct.ir/trial/48099",NA,"Iran","Tehran","2020-Jul","2021-Mar","Recruiting","Unspecified","Double",4,"Confirmed","ICU","IL-1","Other, Standard of care",60
"IRCT20080901001165N60","http://en.irct.ir/trial/48102",NA,"Iran","Tehran","2020-May","2020-Jul","Completed","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Fever, C-Reactive Protein","Alternative therapy, Standard of care",30
"IRCT20200506047323N1","http://en.irct.ir/trial/48114",NA,"Iran","Tehran","2020-May","2020-Aug","Completed","Randomised","Double",2,"Confirmed","Hospital","Fever, Serious Adverse Events, C-Reactive Protein, SpO2, Respiratory Rate","Alternative therapy + HCQ, HCQ",84
"IRCT20080901001165N56","http://en.irct.ir/trial/48116",NA,"Iran","Tehran","2020-May","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Cough, Fever, Dyspnea, Adverse Events","Alternative therapy + Polyphenols, Standard of care",60
"IRCT20200405046960N2","http://en.irct.ir/trial/48126",NA,"Iran","Tehran","2020-May","2020-Jul","Completed","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Cough, Fever, C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, SpO2, Respiratory Rate","Alternative therapy, Standard of care",60
"IRCT20200516047462N1","http://en.irct.ir/trial/48141",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Double",2,"Suspected","Outpatient","Cough, Dyspnea","Alternative therapy + Other, Standard of care",50
"IRCT20151227025726N17","http://en.irct.ir/trial/48153",NA,"Iran","Tehran","2020-May","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Dexamethasone + LPV/r, LPV/r",48
"IRCT20200516047468N1","http://en.irct.ir/trial/48176",NA,"Iran","Tehran","2020-May","2020-May","Completed","Randomised","Double",2,"Confirmed","Hospital","Radiographic Findings","Antibiotics + AZT + LPV/r, Vitamins + Antibiotics + AZT + LPV/r",50
"IRCT20150107020592N23","http://en.irct.ir/trial/48185",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Single-Arm","Open-Label",1,"Confirmed","ICU","IL-6","Plasma based therapy",15
"IRCT20160809029275N1","http://en.irct.ir/trial/48187",NA,"Iran","Tehran","2020-May","2020-Oct","Completed","Randomised","Double",2,"Confirmed","Hospital",NA,"Standard of care, Stem cells",20
"IRCT20151226025699N3","http://en.irct.ir/trial/48213",NA,"Iran","Razavi Khorasan","2020-May","2020-Jun","Completed","Randomised","Triple",2,"Confirmed Or Suspected","ICU","C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, Neutrophils, Creatinine Phosphokinase, LDH","Nutrition, Standard of care",50
"IRCT20180608040007N2","http://en.irct.ir/trial/48218",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Randomised","Open-Label",2,"Suspected","Hospital","Anxiety","Alternative therapy, Standard of care",70
"IRCT20200517047485N1","http://en.irct.ir/trial/48226",NA,"Iran","Tehran","2020-May","2021-Apr","Recruiting","Non-Randomised","Double",2,"Confirmed","Hospital","Hospitalization, SpO2","HCQ + Atazanavir/ritonavir, HCQ + LPV/r",108
"IRCT20200513047426N1","http://en.irct.ir/trial/48236",NA,"Iran","Tehran","2020-Jun","2020-Jul","Completed","Randomised","Double",2,"Healthy","Healthy Exposed",NA,"HCQ, Standard of care",500
"IRCT20150107020592N22","http://en.irct.ir/trial/48262",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Single-Arm","Open-Label",1,"Confirmed Or Suspected","ICU","SpO2, Radiographic Findings","Cyclosporine",60
"IRCT20110726007117N11","http://en.irct.ir/trial/48287",NA,"Iran","Razavi Khorasan","2020-Jul","2021-Jan","Completed","Randomised","Double",2,"Confirmed","Unclear","C-Reactive Protein, Glucose","Standard of care, Vitamins",210
"IRCT20200518047497N1","http://en.irct.ir/trial/48289",NA,"Iran","East Azarbaijan","2020-May","2020-Jul","Completed","Randomised","Triple",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, SpO2, Respiratory Rate, Radiographic Findings","Alternative therapy, Standard of care",80
"IRCT20200519047510N1","http://en.irct.ir/trial/48292",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Non-Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",60
"IRCT20151227025726N18","http://en.irct.ir/trial/48312",NA,"Iran","Tehran","2020-Jun","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Igs, LPV/r",30
"IRCT20161206031256N3","http://en.irct.ir/trial/48329",NA,"Iran","Razavi Khorasan","2020-Jun","2020-Jul","Completed","Randomised","Triple",4,"Confirmed","Hospital","Hospital Discharge, Blood Gas","IFN, Standard of care",76
"IRCT20200112046089N1","http://en.irct.ir/trial/48330",NA,"Iran","Golestan","2020-Jun","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Platelet Count, Radiographic Findings","Alternative therapy, Standard of care",50
"IRCT20200330046899N1","http://en.irct.ir/trial/48365",NA,"Iran","Tehran","2020-Jun","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","White Blood Cell Count","Alternative therapy, Standard of care",50
"IRCT20080901001165N58","http://en.irct.ir/trial/48394",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, SpO2, Shock, Hypoxemia","Plasma based therapy, Standard of care",100
"IRCT20081027001411N4","http://en.irct.ir/trial/48396",NA,"Iran","Tehran","2020-Jul","2020-Jul","Completed","Randomised","Double",2,"Confirmed","Hospital","Hospital Discharge, C-Reactive Protein, Ferritin, IL-6, Platelet Count, Hemoglobin, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, Troponin, ALT, AST","Standard of care, TCZ",40
"IRCT20160126026217N4","http://en.irct.ir/trial/48403",NA,"Iran","Tehran","2020-Jun","2020-Sep","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Positioning, Standard of care",74
"IRCT20200422047168N2","http://en.irct.ir/trial/48444",NA,"Iran","Khuzestan","2020-May","2020-Jul","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality, Hospital Discharge","HCQ + LPV/r, HCQ + LPV/r + Ivermectin",60
"IRCT20200525047562N1","http://en.irct.ir/trial/48493",NA,"Iran","Tehran","2020-Jun","2020-Jul","Completed","Non-Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","ICU Admission, Hospitalization, Hospital Discharge","Plasma based therapy, Standard of care",100
"IRCT20200523047550N1","http://en.irct.ir/trial/48495",NA,"Iran","Tehran","2020-Jun","2020-May","Completed","Non-Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient",NA,"HCQ, HCQ + Umifenovir",50
"IRCT20200317046797N6","http://en.irct.ir/trial/48500",NA,"Iran","East Azarbaijan","2020-Jun","2020-Jul","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",30
"IRCT20160118026097N3","http://en.irct.ir/trial/48517",NA,"Iran","Tehran","2020-May","2020-Jun","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Organ Failure or Dysfunction (SOFA)","IFN, Standard of care",60
"IRCT20150107020592N24","http://en.irct.ir/trial/48534",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Single-Arm","Open-Label",1,"Confirmed","ICU","Hospitalization","Opiate analgesics",60
"IRCT20200504047298N1","http://en.irct.ir/trial/48640",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, C-Reactive Protein, Platelet Count, Erythrocyte Sedimentation Rate, Blood Pressure","Antiretrovirals, LPV/r",100
"IRCT20200518047497N2","http://en.irct.ir/trial/48644",NA,"Iran","East Azarbaijan","2020-Jun","2020-Aug","Completed","Randomised","Triple",2,"Confirmed","Hospital","Mortality","Alternative therapy, Standard of care",80
"IRCT20150107020592N29","http://en.irct.ir/trial/48695",NA,"Iran","Tehran","2020-Jun","2020-May","Completed","Single-Arm","Open-Label",2,"Confirmed","ICU","IL-6","Other",12
"IRCT20200607047675N1","http://en.irct.ir/trial/48700",NA,"Iran","Tehran","2020-Jun","2020-Sep","Completed","Randomised","Single",2,"Confirmed","Hospital","Lymphocyte Count, Platelet Count","Alternative therapy, Standard of care",100
"IRCT20120703010178N20","http://en.irct.ir/trial/48702",NA,"Iran","Tehran","2020-Jun","2020-Sep","Completed","Randomised","Open-Label",2,"Confirmed","Outpatient","Mortality, Hospitalization, IL-1","Anakinra, Standard of care",30
"IRCT20200608047686N1","http://en.irct.ir/trial/48717",NA,"Iran","Tehran","2020-Jun","2020-Jul","Completed","Randomised","Single",2,"Confirmed","Hospital","Mortality","Antibiotics, Standard of care",30
"IRCT20200412047042N1","http://en.irct.ir/trial/48749",NA,"Iran","East Azarbaijan","2020-Jun","2020-Aug","Completed","Randomised","Single",3,"Confirmed","Hospital","Organ Failure or Dysfunction (SOFA), Platelet Count, Coagulation Test, Bilirubin, PaO2-FiO2, Renal Outcome (Unspecified)","HCQ, HCQ + Raltagravir, HCQ + Raltagravir + IFN",60
"IRCT20200609047707N1","http://en.irct.ir/trial/48764",NA,"Iran","North Khorasan","2020-Jun","2020-Sep","Completed","Randomised","Open-Label",3,"Confirmed","Hospital","Hospitalization","HCQ + LPV/r, Other",90
"IRCT20200611047735N1","http://en.irct.ir/trial/48843",NA,"Iran","Tehran","2020-Jun","2020-Sep","Completed","Randomised","Double",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",40
"IRCT20200610047722N1","http://en.irct.ir/trial/48869",NA,"Iran","Tehran","2020-Jul","2020-Jul","Completed","Randomised","Double",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",100
"IRCT20150107020592N27","http://en.irct.ir/trial/48907",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Single-Arm","Open-Label",1,"Confirmed","ICU","Radiographic Findings","Igs",60
"IRCT20200515047456N1","http://en.irct.ir/trial/48929",NA,"Iran","Tehran","2020-Jun","2020-Jul","Completed","Randomised","Single",3,"Confirmed","Hospital",NA,"Anticoagulants, Standard of care, Thrombolytics",15
"IRCT20200611047727N1","http://en.irct.ir/trial/48941",NA,"Iran","Tehran","2020-Jun","2020-Oct","Completed","Randomised","Open-Label",2,"Resolved","Resolved Discharged",NA,"Device, Respiratory support",40
"IRCT20150107020592N28","http://en.irct.ir/trial/48972",NA,"Iran","Tehran","2020-Jun","2020-Jun","Completed","Single-Arm","Open-Label",1,"Confirmed","ICU",NA,"Alternative therapy",50
"IRCT20150107020592N30","http://en.irct.ir/trial/48992",NA,"Iran","Tehran","2020-Jul","2020-Jul","Completed","Single-Arm","Open-Label",1,"Healthy","Healthcare Workers",NA,"FPV",30
"IRCT20200404046937N3","http://en.irct.ir/trial/49029",NA,"Iran","Tehran","2020-Jun","2020-Jul","Completed","Randomised","Double",2,"Confirmed","Hospital","Radiographic Findings","Alternative therapy, Standard of care",60
"IRCT20150725023332N3","http://en.irct.ir/trial/49112",NA,"Iran","Tehran","2020-Jun","2020-Sep","Completed","Randomised","Open-Label",3,"Confirmed","Outpatient","C-Reactive Protein","Other, Standard of care",60
"IRCT20180712040446N2","http://en.irct.ir/trial/49120",NA,"Iran","Tehran","2020-Jul","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Cough","Alternative therapy, HCQ",60
"IRCT20190121042444N3","http://en.irct.ir/trial/49132",NA,"Iran","Tehran","2020-Jul","2021-Feb","Completed","Randomised","Single",2,"Confirmed","Hospital","C-Reactive Protein","Standard of care, Vitamins + Other",78
"IRCT20111224008507N3","http://en.irct.ir/trial/49174",NA,"Iran","Mazandaran","2020-Jun","2020-Aug","Completed","Randomised","Double",2,"Confirmed","Hospital","Respiratory Rate","Ivermectin, Standard of care",60
"IRCT20190602043787N3","http://en.irct.ir/trial/49180",NA,"Iran","Tehran","2020-Jul","2020-Nov","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","C-Reactive Protein, Platelet Count, Erythrocyte Sedimentation Rate, D-Dimer","Ivermectin, Standard of care",40
"IRCT20200624047908N1","http://en.irct.ir/trial/49198",NA,"Iran","Khuzestan","2020-Jul","2020-Sep","Completed","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Cough, Fever, Dyspnea, Other Mild Symptoms","DAA, Standard of care",1000
"IRCT20150623022884N3","http://en.irct.ir/trial/49249",NA,"Iran","Tehran","2020-Nov","2020-May","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","ICU Admission, Hospitalization, Hospital Discharge, Pneumonia or ARDS","Colchicine + Alternative therapy, Standard of care",120
"IRCT20190624043993N3","http://en.irct.ir/trial/49257",NA,"Iran","Kermanshah","2020-Jul","2020-Nov","Completed","Non-Randomised","Open-Label",2,"Confirmed","Unclear","Mortality","Other, Standard of care",50
"IRCT20190624043993N2","http://en.irct.ir/trial/49280",NA,"Iran","Kermanshah","2020-Jul","2021-Feb","Completed","Randomised","Open-Label",2,"Confirmed","Unclear","Radiographic Findings","Ivermectin, Standard of care",50
"IRCT20200105046009N4","http://en.irct.ir/trial/49365",NA,"Iran","Tehran","2020-Jul","2020-Dec","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Cough","Nutrition, Standard of care",80
"IRCT20200426047206N2","http://en.irct.ir/trial/49385",NA,"Iran","Tehran","2020-Jul","2020-Dec","Completed","Randomised","Double",2,"Confirmed",NA,NA,"Standard of care, Stem cells",30
"IRCT20200506047323N3","http://en.irct.ir/trial/49463",NA,"Iran","Tehran","2020-Jul","2020-Sep","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Serious Adverse Events, SpO2","IFN + FPV, LPV/r + IFN",60
"IRCT20200705048013N1","http://en.irct.ir/trial/49525",NA,"Iran","Tehran","2020-Jul","2020-Jul","Completed","Randomised","Single",2,"Confirmed","Hospital","ICU Admission, SpO2","HCQ + Vitamins + Non-invasive respiratory support + Plasma based therapy, Other",150
"IRCT20190406043175N3","http://en.irct.ir/trial/49530",NA,"Iran","Tehran","2020-Jul","2021-Aug","Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient",NA,"Nutrition, Standard of care",80
"IRCT20170117032025N7","http://en.irct.ir/trial/49534",NA,"Iran","Tehran","2020-Jul","2020-Oct","Completed","Randomised","Double",4,"Confirmed","Outpatient","Viral Load or Clearance","Hygiene, Standard of care",60
"IRCT20190415043279N6","http://en.irct.ir/trial/49544",NA,"Iran","Tehran","2020-Jul","2020-Oct","Completed","Randomised","Double",2,"Confirmed","Hospital","Heart Rate","Alternative therapy, Standard of care",80
"IRCT20200426047206N3","http://en.irct.ir/trial/49579",NA,"Iran","Tehran","2020-Jul","2020-Nov","Completed","Randomised","Single",2,"Confirmed","Hospital","C-Reactive Protein","Cyclosporine, Standard of care",48
"IRCT20200516047462N2","http://en.irct.ir/trial/49628",NA,"Iran","Tehran","2020-Jul","2020-Dec","Completed","Randomised","Double",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",140
"IRCT20200408046990N3","http://en.irct.ir/trial/49629",NA,"Iran","Tehran","2020-Jul","2020-Nov","Completed","Randomised","Triple",2,"Confirmed","Hospital",NA,"Standard of care, Statins",40
"IRCT20151227025726N20","http://en.irct.ir/trial/49638",NA,"Iran","Tehran","2020-Jul","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","HCQ + LPV/r, HCQ + LPV/r + Igs",80
"IRCT20101020004976N6","http://en.irct.ir/trial/49670",NA,"Iran","Tehran","2020-Jul","2020-Sep","Completed","Randomised","Double",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Nutrition, Standard of care",80
"IRCT20191228045924N1","http://en.irct.ir/trial/49767",NA,"Iran","Tehran","2020-Sep","2020-Aug","Completed","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, White Blood Cell Count, PaO2-FiO2","Other",80
"IRCT20200731048257N1","http://en.irct.ir/trial/50012",NA,"Iran","Tehran","2020-Nov","2021-Mar","Completed","Randomised","Triple",2,"Confirmed","Hospital","Dyspnea","Other + HCQ + NSAIDs + AZT",224
"DRKS00021238","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021238",NA,"Germany","Baden-Wurttemberg","2020-Apr",NA,"Suspended","Randomised","Triple",2,NA,"ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, PaO2-FiO2","Standard of care, TCZ",200
"DRKS00021248","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021248",NA,"Germany","Baden-Wurttemberg","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, D-Dimer, Urine Sample","ECMO, ECMO + Cytokine removal",80
"DRKS00021300","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021300",NA,"Germany","Baden-Wurttemberg","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, IL-6","ECMO, ECMO + Cytokine removal",30
"DRKS00021447","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021447",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Renal Outcome (Unspecified)","Cytokine removal, Standard of care",100
"DRKS00021626","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021626",NA,"Germany","Berlin","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Non-invasive respiratory support, Standard of care",200
"DRKS00021732","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021732",NA,"Germany","Saxony","2020-Jun",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient, Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any)","ACEi, ARBs, Standard of care",300
"DRKS00022203","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022203",NA,"Germany","Berlin","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, SpO2, Respiratory Rate","DAA, HCQ, Standard of care",90
"DRKS00022484","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022484",NA,"Germany","Berlin","2020-Jul",NA,"Completed","Single-Arm","Double",1,"Confirmed","Hospital","Viral Load or Clearance","Hygiene",50
"CHICTR2000029381","http://www.chictr.org.cn/showproj.aspx?proj=48768",NA,"China","Guangdong","2020-Jan",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, ALT, Albumin, Bilirubin, IgG, IgM or IgA, PaO2-FiO2, Respiratory Rate, Radiographic Findings","Standard of care, TCM",400
"CHICTR2000030215","http://www.chictr.org.cn/showproj.aspx?proj=50107",NA,"China","Jiangxi","2020-Feb",NA,"Not Recruiting","Randomised","Unspecified",6,"Confirmed","Outpatient, Hospital","Viral Load or Clearance, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, CD4, Respiratory Rate, Radiographic Findings","Standard of care, TCM",120
"CHICTR2000029387","http://www.chictr.org.cn/showproj.aspx?proj=48782",NA,"China","Chongqing","2020-Jan",NA,"Recruiting","Randomised","Unspecified",3,"Confirmed","Outpatient","Mortality, Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Antivirals + IFN, Antivirals + LPV/r + IFN, LPV/r + IFN",108
"CHICTR2000029386","http://www.chictr.org.cn/showproj.aspx?proj=48777",NA,"China","Chongqing","2020-Jan",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO","Corticosteroids, Standard of care",48
"CHICTR2000030503","http://www.chictr.org.cn/showproj.aspx?proj=49632",NA,"China","Zhejiang","2020-Mar",NA,"Recruiting","Non-Randomised","Unspecified",2,NA,"ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, IL-6, PaO2-FiO2","Other",60
"CHICTR2000030254","http://www.chictr.org.cn/showproj.aspx?proj=50137","https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1.full.pdf","China","Hubei","2020-Feb",NA,"Completed w. Results","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events","FPV, Umifenovir",240
"CHICTR2000029573","http://www.chictr.org.cn/showproj.aspx?proj=49065",NA,"China","Zhejiang","2020-Feb",NA,"Recruiting","Randomised","Unspecified",4,NA,"Outpatient, Hospital","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Radiographic Findings","Other",480
"CHICTR2000031781","http://www.chictr.org.cn/showproj.aspx?proj=52006",NA,"China","Jiangsu","2020-Apr",NA,"Not Recruiting","Randomised","Double",3,NA,"Unclear","Serious or Seconday Infections, Adverse Events, Anti SARS-COV-2 Titers","Standard of care, Vaccine",500
"EUCTR2020-001039-29-GR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001039-29",NA,"Greece","Athens","2020-Mar",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), PaO2-FiO2, Radiographic Findings","Anakinra, TCZ",40
"ACTRN12620000472976","https://anzctr.org.au/ACTRN12620000472976.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",1,NA,"Hospital","Other Mild Symptoms","Other",100
"ACTRN12620000470998","https://anzctr.org.au/ACTRN12620000470998.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Non-Randomised","Unspecified",1,NA,"Unclear","Viral Load or Clearance","Hygiene",20
"ACTRN12620000478910","https://anzctr.org.au/ACTRN12620000478910.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",1,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Anti SARS-COV-2 Titers","Stem cells",24
"EUCTR2020-001320-34-NL","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001320-34",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,NA,"Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","ARBs, Standard of care",641
"EUCTR2020-001303-16-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001303-16",NA,"France","Paris","2020-Mar",NA,"Not Recruiting","Randomised","Double",4,NA,"Hospital","Mortality, ICU Admission, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Serious Adverse Events, C-Reactive Protein, Blood Pressure, 6-Minute Walking Distance","Alternative therapy, ARBs, AZT, HCQ",1600
"EUCTR2020-001682-36-ES","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001682-36",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,"ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Radiographic Findings","Standard of care, Stem cells",24
"CHICTR2000032205","http://www.chictr.org.cn/showproj.aspx?proj=52662",NA,"China","Hubei","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"Standard of care, TCM",200
"ISRCTN13311119","http://isrctn.com/ISRCTN13311119",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient",NA,"Alternative therapy, Standard of care",116
"EUCTR2020-001449-38-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001449-38",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","FPV, HCQ + AZT + Zinc, Standard of care",450
"EUCTR2020-001721-31-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001721-31",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Double",3,"Confirmed Or Suspected","Unclear","Viral Load or Clearance","Hygiene, Standard of care",40
"EUCTR2020-001882-36-GR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001882-36",NA,"Greece","Athens","2020-Apr",NA,"Not Recruiting","Unspecified","Open-Label",1,"Confirmed Or Suspected","Unclear","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Cough, Dyspnea","Antibiotics",90
"EUCTR2020-001206-35-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001206-35",NA,"Austria","Vienna","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Angiotensins, ACE, ACE-II, PaO2-FiO2","ACEi + ARBs, Other",798
"EUCTR2020-001696-32-ES","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001696-32",NA,"Spain","Madrid","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Igs, Standard of care",100
"CHICTR2000030262","http://www.chictr.org.cn/showproj.aspx?proj=50136",NA,"China","Shanghai","2020-Feb",NA,"Recruiting","Non-Randomised","Unspecified",4,"Confirmed","Unclear","Hospitalization, Viral Load or Clearance, Radiographic Findings","IFN, Standard of care",140
"CHICTR2000029638","http://www.chictr.org.cn/showproj.aspx?proj=49224",NA,"China","Sichuan","2020-Feb",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, White Blood Cell Count, Hemoglobin, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, Myoglobin, Troponin, Procalcitonin, Coagulation Test, Urine Sample, Blood Pressure, Heart Rate, Respiratory Rate, Radiographic Findings","IFN",100
"IRCT20130306012728N8","http://en.irct.ir/trial/46932",NA,"Iran","East Azarbaijan","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,"Healthy Exposed, Healthcare Workers","Mortality, Hospitalization, Viral Load or Clearance","HCQ, Standard of care",500
"IRCT20200419047128N1","http://en.irct.ir/trial/47265",NA,"Iran","Tehran","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Pneumonia or ARDS, Radiographic Findings","Other",60
"IRCT20190618043923N4","http://en.irct.ir/trial/47363",NA,"Iran","Tehran","2020-May",NA,"Recruiting","Randomised","Single",2,"Confirmed","ICU","Renal Outcome (Unspecified)","Non-invasive respiratory support, Standard of care",20
"IRCT20200419047128N2","http://en.irct.ir/trial/47396",NA,"Iran","Golestan","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",60
"KCT0005003","http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16635",NA,"South Korea","Seoul","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any)","Anticoagulants, Standard of care",84
"JPRN-JRCT2031190264","https://jrct.niph.go.jp/latest-detail/jRCT2031190264",NA,"Japan","Toyama","2020-Mar",NA,"Not Recruiting","Randomised","Double",NA,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)",NA,100
"JPRN-JRCT2031190264","https://jrct.niph.go.jp/latest-detail/jRCT2031190264",NA,"South Korea","Seoul","2020-Mar",NA,"Not Recruiting","Randomised","Double",NA,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified)",NA,100
"ISRCTN85216856","http://isrctn.com/ISRCTN85216856",NA,"Ecuador","Quito","2020-Nov",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Plasma based therapy, Standard of care",200
"ISRCTN50212645","http://isrctn.com/ISRCTN50212645",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Unspecified","Unspecified",2,"Confirmed","Healthcare Workers, Hospital",NA,"Other",2000
"EUCTR2020-001673-75-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Unclear","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, D-Dimer, Troponin","Other, Standard of care",1034
"CHICTR2000033491","http://www.chictr.org.cn/showproj.aspx?proj=54278",NA,"China","Jiangsu","2020-Jun",NA,"Not Recruiting","Unspecified","Unspecified",1,"Confirmed","Unclear",NA,"FPV",9
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"United States","Washington, Dc","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Spain","Madrid","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Austria","Vienna","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Israel","Jerusalem","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"United Kingdom","London","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Italy","Rome","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"France","Paris","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Canada","Ottawa","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Belgium","Brussels","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Malaysia","Kuala Lumpur","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Australia","Canberra","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Germany","Berlin","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"KCT0005105","http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16795",NA,"South Korea","Seoul","2020-Jun",NA,"Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear",NA,"Corticosteroids, HCQ + Corticosteroids, Standard of care",141
"JPRN-JRCTS031190227","https://jrct.niph.go.jp/latest-detail/jRCTs031190227",NA,"Japan","Gunma","2020-Feb",NA,"Not Recruiting","Single-Arm","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance, C-Reactive Protein","HCQ + LPV/r, Oseltamivir + HCQ + LPV/r",50
"JPRN-UMIN000040341","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046023",NA,"Japan","Tokyo","2020-Sep",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear",NA,"TCM",15
"JPRN-UMIN000040407","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046108",NA,"Japan","Tokyo","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear",NA,"TCM",15
"JPRN-UMIN000040479","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046202",NA,"Japan","Tokyo","2020-May",NA,"Recruiting","Single-Arm","Open-Label",3,"Healthy","Unclear",NA,"Other",30
"ACTRN12620000500954","https://anzctr.org.au/ACTRN12620000500954.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",1,"Confirmed","Outpatient, Hospital, ICU","Mortality, Hospitalization, Adverse Events","Device",20
"ACTRN12620000676910","https://anzctr.org.au/ACTRN12620000676910.aspx",NA,"Australia","Canberra","2020-Jun",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","ICU","Mortality, PaO2-FiO2","Standard of care, Stem cells",40
"ISRCTN33578935","http://isrctn.com/ISRCTN33578935",NA,"Germany","Berlin","2020-Feb",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Adverse Events, PaO2-FiO2","Standard of care, Stem cells",64
"ISRCTN21363594","http://isrctn.com/ISRCTN21363594",NA,"Oman","Muscat","2020-May",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","ICU","Mortality, Serious Adverse Events","Plasma based therapy, Standard of care",80
"ISRCTN21363594","http://isrctn.com/ISRCTN21363594",NA,"Saudi Arabia","Riyadh","2020-May",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","ICU","Mortality, Serious Adverse Events","Plasma based therapy, Standard of care",80
"ISRCTN21363594","http://isrctn.com/ISRCTN21363594",NA,"United Arab Emirates","Abu Dhabi","2020-May",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","ICU","Mortality, Serious Adverse Events","Plasma based therapy, Standard of care",80
"EUCTR2020-001636-95-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001636-95",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","ICU","IL-1, IL-6","Anakinra, Standard of care",40
"ISRCTN54917435","http://isrctn.com/ISRCTN54917435",NA,"Sweden","Stockholm","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Positioning, Standard of care",240
"IRCT20150107020592N26","http://en.irct.ir/trial/48746",NA,"Iran","Tehran","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU",NA,"FPV",20
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"United States","Washington, Dc","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Spain","Madrid","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Austria","Vienna","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Israel","Jerusalem","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Italy","Rome","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"United Kingdom","London","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"India","New Delhi","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"France","Paris","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Canada","Ottawa","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Belgium","Brussels","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Malaysia","Kuala Lumpur","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Australia","Canberra","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"EUCTR2020-001411-25-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Germany","Berlin","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate","Other, Standard of care",230
"JPRN-JRCTS031190226","https://jrct.niph.go.jp/latest-detail/jRCTs031190226",NA,"Japan","Gunma","2020-Feb",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Viral Load or Clearance, C-Reactive Protein","FPV",100
"JPRN-JRCTS041200025","https://jrct.niph.go.jp/latest-detail/jRCTs041200025",NA,"Japan","Aichi","2020-Jan",NA,"Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","FPV + Corticosteroids",69
"ACTRN12620000740998","https://anzctr.org.au/ACTRN12620000740998.aspx",NA,"Australia","Canberra","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","SpO2","Positioning, Standard of care",20
"ACTRN12620000731998","https://anzctr.org.au/ACTRN12620000731998.aspx",NA,"Australia","Canberra","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Adverse Events, Blood Pressure, Radiographic Findings","ARBs, Standard of care",36
"ACTRN12620000737932","https://anzctr.org.au/ACTRN12620000737932.aspx",NA,"United Kingdom","London","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers",NA,"Hygien, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Germany","Berlin","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Australia","Canberra","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Malaysia","Kuala Lumpur","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Belgium","Brussels","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Canada","Ottawa","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"United States","Washington, Dc","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"France","Paris","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"India","New Delhi","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"United Kingdom","London","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Israel","Jerusalem","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"EUCTR2020-001411-25-AT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25",NA,"Austria","Vienna","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",300
"ACTRN12620000588998","https://anzctr.org.au/ACTRN12620000588998.aspx",NA,"Australia","Canberra","2020-May",NA,"Status Unclear","Randomised","Unspecified",2,"Confirmed Or Suspected","ICU","Blood Gas, PaO2-FiO2","Other, Standard of care",160
"ACTRN12620000566932","https://anzctr.org.au/ACTRN12620000566932.aspx",NA,"Australia","Canberra","2020-May",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Hospital","Mortality","HCQ, Standard of care",400
"ISRCTN14212905","http://isrctn.com/ISRCTN14212905",NA,"United Kingdom","London","2020-Jul",NA,"Recruiting","Randomised","Unspecified",4,"Confirmed","Outpatient, Hospital","Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, Troponin, Prothrombin, Fibrinogen, Coagulation Test, Triglycerides, Electrolytes, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, Blood Pressure, Heart Rate, ECG, Respiratory Rate, Bicarbonates","Anticoagulants, Other, Standard of care",100
"ISRCTN13035264","http://isrctn.com/ISRCTN13035264",NA,"Denmark","Copenhagen","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Non-invasive Ventilation","Remdesivir, Standard of care",400
"ISRCTN13035264","http://isrctn.com/ISRCTN13035264",NA,"Greece","Athens","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Non-invasive Ventilation","Remdesivir, Standard of care",400
"ISRCTN13035264","http://isrctn.com/ISRCTN13035264",NA,"United Kingdom","London","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Non-invasive Ventilation","Remdesivir, Standard of care",400
"ISRCTN17072692","http://isrctn.com/ISRCTN17072692",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Unspecified",3,"Confirmed","Healthy Unexposed","Fever, Other Mild Symptoms, Serious Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",320
"ISRCTN88057279","http://isrctn.com/ISRCTN88057279",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Hospital",NA,"HCQ, Standard of care",500
"JPRN-UMIN000041160","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047000",NA,"Japan","Tokyo","2020-Jan",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Healthy","Outpatient",NA,"Monitoring",42
"CHICTR2000032459","http://www.chictr.org.cn/showproj.aspx?proj=53003",NA,"China","Henan","2020-Apr",NA,"Recruiting","Randomised","Double",68,"Healthy","Healthy Exposed",NA,"Standard of care, Vaccine",288
"ISRCTN60069084","http://isrctn.com/ISRCTN60069084",NA,"Oman","Muscat","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation","Other, Standard of care",1180
"ISRCTN60069084","http://isrctn.com/ISRCTN60069084",NA,"Saudi Arabia","Riyadh","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation","Other, Standard of care",1180
"ISRCTN40302986","http://isrctn.com/ISRCTN40302986",NA,"Nigeria","Niger","2020-May",NA,"Recruiting","Randomised","Double",3,"Confirmed","Unclear",NA,"Ivermectin, Standard of care",45
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"United Kingdom","London","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"Italy","Rome","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"Germany","Berlin","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"Chile","Santiago","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"Peru","Lima","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"Belgium","Brussels","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"Brazil","Brasilia","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"Mexico","Mexico","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"EUCTR2020-001673-75-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2","Other, Standard of care",1034
"JPRN-JAPICCTI-205238","https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205238",NA,"Japan","Tokyo","2020-Mar",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, Radiographic Findings","FPV, Standard of care",96
"JPRN-JRCTS041190120","https://jrct.niph.go.jp/latest-detail/jRCTs041190120",NA,"Japan","Aichi","2020-Feb",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Viral Load or Clearance","FPV, Standard of care",86
"ACTRN12620000454976","https://anzctr.org.au/ACTRN12620000454976.aspx",NA,"Australia","Canberra","2020-Aug",NA,"Recruiting","Randomised","Unspecified",2,NA,"Hospital","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Standard of care, Zinc",160
"ACTRN12620000473965","https://anzctr.org.au/ACTRN12620000473965.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Healthcare Workers","Viral Load or Clearance, Other Mild Symptoms, Serious or Seconday Infections, Anti SARS-COV-2 Titers","Immunomodulators, Standard of care",1000
"ACTRN12620000517976","https://anzctr.org.au/ACTRN12620000517976.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital",NA,"Anticoagulants, Standard of care",206
"ACTRN12620000580976","https://anzctr.org.au/ACTRN12620000580976.aspx",NA,"Australia","Canberra","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU",NA,"Standard of care, TCZ",150
"ACTRN12620000698976","https://anzctr.org.au/ACTRN12620000698976.aspx",NA,"Australia","Canberra","2020-Jun",NA,"Recruiting","Non-Randomised","Open-Label",1,"Confirmed Or Healthy","Outpatient","Depression, Anxiety","Psychological therapy + Nutrition + Exercise",40
"ACTRN12620000707965","https://anzctr.org.au/ACTRN12620000707965.aspx",NA,"Australia","Canberra","2020-Jun",NA,"Status Unclear","Randomised","Double",2,"Healthy","Healthy Unexposed, Healthy Exposed, Healthcare Workers",NA,"Standard of care, Vaccine",3468
"EUCTR2020-001466-11-GR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001466-11",NA,"Greece","Athens","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",1,NA,"Unclear","Other Mild Symptoms, Organ Failure or Dysfunction (SOFA)","Anakinra + Cotrimoxazole",400
"EUCTR2020-001722-66-ES","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001722-66",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified)","Igs, Plasma based therapy",116
"JPRN-JRCTS031190269","https://jrct.niph.go.jp/latest-detail/jRCTs031190269",NA,"Japan","Toyama","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",NA,"Confirmed","Outpatient","Viral Load or Clearance, Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events",NA,90
"EUCTR2020-001367-88-DK","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001367-88",NA,"Denmark","Copenhagen","2020-Jan",NA,"Not Recruiting","Randomised","Double",6,NA,"Unclear","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events","HCQ, JAKi, Sarilumab, Standard of care",1500
"ISRCTN10207947","http://isrctn.com/ISRCTN10207947",NA,"Indonesia","Jakarta","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",40000
"ISRCTN10207947","http://isrctn.com/ISRCTN10207947",NA,"Laos","Vientiane","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",40000
"ISRCTN10207947","http://isrctn.com/ISRCTN10207947",NA,"Pakistan","Islamabad","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",40000
"ISRCTN10207947","http://isrctn.com/ISRCTN10207947",NA,"Thailand","Nan","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",40000
"ISRCTN10207947","http://isrctn.com/ISRCTN10207947",NA,"United Kingdom","London","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",40000
"EUCTR2020-001803-17-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001803-17",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Remdesivir",52
"EUCTR2020-001803-17-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001803-17",NA,"Spain","Madrid","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Remdesivir",52
"EUCTR2020-001803-17-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001803-17",NA,"Italy","Rome","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Remdesivir",52
"EUCTR2020-001803-17-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001803-17",NA,"United Kingdom","London","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Remdesivir",52
"ACTRN12620000457943","https://anzctr.org.au/ACTRN12620000457943.aspx",NA,"New Zealand","Wellington","2020-Aug",NA,"Status Unclear","Randomised","Double",2,NA,"Outpatient","Mortality, Clinical Improvement Score (Any), Fever, Adverse Events","HCQ, Standard of care",70
"ACTRN12620000557932","https://anzctr.org.au/ACTRN12620000557932.aspx",NA,"Australia","Canberra","2020-Nov",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","HCQ + Zinc + Vitamins + AZT",200
"ACTRN12620000557932","https://anzctr.org.au/ACTRN12620000557932.aspx",NA,"Turkey","Ankara","2020-Nov",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","HCQ + Zinc + Vitamins + AZT",200
"ISRCTN13447477","http://isrctn.com/ISRCTN13447477",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Single-Arm","Open-Label",2,"Confirmed","Hospital",NA,"Hygiene",22
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Argentina","Buenos Aires","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Brazil","Brasilia","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Canada","Ottawa","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Germany","Berlin","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Honduras","Tegucigalpa","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"India","New Delhi","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Indonesia","Jakarta","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Iran","Tehran","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Ireland","Dublin","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Israel","Jerusalem","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Italy","Rome","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Kenya","Nairobi","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Lebanon","Beirut","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Malaysia","Kuala Lumpur","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Norway","Oslo","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Peru","Lima","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Philippines","Manila","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Qatar","Doha","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Saudi Arabia","Riyadh","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"South Africa","Pretoria","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Spain","Madrid","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Switzerland","Bern","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Thailand","Nan","2020-Mar",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + IFN, Remdesivir, Standard of care",10000
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"France","Paris","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, Standard of care",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Canada","Ottawa","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, Standard of care",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, Standard of care",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Russia","Moscow","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, Standard of care",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Israel","Jerusalem","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, Standard of care",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Germany","Berlin","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, Standard of care",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Japan","Tokyo","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, Standard of care",460
"EUCTR2020-001162-12-FR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT","Sarilumab, Standard of care",460
"JPRN-JAPICCTI-205326","https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205326",NA,"Japan","Tokyo","2020-Jun",NA,"Recruiting","Single-Arm","Unspecified",1,"Healthy","Unclear",NA,"Other",7
"JPRN-JRCTS061200002","https://jrct.niph.go.jp/latest-detail/jRCTs061200002",NA,"Japan","Okayama","2020-May",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Unclear","Mortality, Fever, Adverse Events","Other, Standard of care",100
"ISRCTN11188345","http://isrctn.com/ISRCTN11188345",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","JAKi, mAb, Standard of care",375
"EUCTR2020-001953-36-ES","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001953-36",NA,"Spain","Madrid","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",100
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Italy","Rome","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"India","New Delhi","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"France","Paris","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Peru","Lima","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"South Africa","Pretoria","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Netherlands","Amsterdam","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Moldova","Chisinau","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Turkey","Ankara","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"United Kingdom","Southampton","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Mexico","Mexico","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Canada","Ottawa","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Argentina","Buenos Aires","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Brazil","Brasilia","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Belgium","Brussels","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"United States","Washington, Dc","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Portugal","Lisbon","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Serbia","Belgrade","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Spain","Madrid","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Ukraine","Kyiv (Kiev)","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Israel","Jerusalem","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Chile","Santiago","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Russia","Moscow","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Colombia","Bogota","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Poland","Warsaw","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Romania","Bucharest","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"EUCTR2020-004743-83-GB","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83",NA,"Germany","Berlin","2020-Oct",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"IFN, Standard of care",900
"JPRN-JAPICCTI-205270","https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205270",NA,"Japan","Tokyo","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6","TCZ",10
"ACTRN12620000788976","https://anzctr.org.au/ACTRN12620000788976.aspx",NA,"Australia","Canberra","2020-May",NA,"Recruiting","Non-Randomised","Open-Label",1,"Confirmed","Outpatient","Serious Adverse Events","Other + Alternative therapy",40
"ISRCTN14241621","http://isrctn.com/ISRCTN14241621",NA,"United Kingdom","London","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any)","IFN, Standard of care",220
"NCT04244591","https://clinicaltrials.gov/show/NCT04244591",NA,"China","Beijing","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Radiographic Findings","Corticosteroids, Standard of care",80
"NCT04252664","https://clinicaltrials.gov/show/NCT04252664",NA,"China","Beijing","2020-Jan",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","Remdesivir, Standard of care",308
"NCT04254874","https://clinicaltrials.gov/show/NCT04254874",NA,"China","Beijing","2020-Feb",NA,"Recruiting","Randomised","Single",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, Radiographic Findings","Umifenovir, Umifenovir + IFN",100
"NCT04255017","https://clinicaltrials.gov/show/NCT04255017",NA,"China","Beijing","2020-Feb",NA,"Recruiting","Randomised","Single",4,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, Radiographic Findings","LPV/r, Oseltamivir, Standard of care, Umifenovir",400
"NCT04257656","https://clinicaltrials.gov/show/NCT04257656",NA,"China","Beijing","2020-Jan",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","Remdesivir, Standard of care",237
"NCT04261270","https://clinicaltrials.gov/show/NCT04261270",NA,"China","Beijing","2020-Apr",NA,"Recruiting","Randomised","Single",3,"Confirmed","Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, C-Reactive Protein, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, ALT, PaO2-FiO2, Respiratory Rate","Oseltamivir, Oseltamivir + Antivirals, Other + Oseltamivir",60
"NCT04261426","https://clinicaltrials.gov/show/NCT04261426",NA,"China","Beijing","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Igs, Standard of care",80
"NCT04263402","https://clinicaltrials.gov/show/NCT04263402",NA,"China","Beijing","2020-Feb",NA,"Recruiting","Randomised","Single",2,"Confirmed","Unclear","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Radiographic Findings","Corticosteroids",100
"NCT04264533","https://clinicaltrials.gov/show/NCT04264533",NA,"China","Beijing","2020-Apr",NA,"Not Recruiting","Randomised","Triple",2,"Confirmed","ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), PaO2-FiO2, Respiratory Rate, Hypoxia, Hypoxemia","Standard of care, Vitamins",56
"NCT04264858","https://clinicaltrials.gov/show/NCT04264858",NA,"China","Beijing","2020-Aug",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Antibodies, PaO2-FiO2, Radiographic Findings","Igs",10
"NCT04268537","https://clinicaltrials.gov/show/NCT04268537",NA,"China","Beijing","2020-Aug",NA,"Not Recruiting","Randomised","Single",3,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Procalcitonin, Radiographic Findings","mAb, Other",120
"NCT04273581","https://clinicaltrials.gov/show/NCT04273581",NA,"China","Beijing","2020-Feb",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, MCP-1, MIP-1","Immunomodulators, Standard of care",40
"NCT04275245","https://clinicaltrials.gov/show/NCT04275245","https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf","China","Beijing","2020-Jun",NA,"Completed w. Results","Single-Arm","Open-Label",1,"Confirmed","Unclear","Viral Load or Clearance, Pneumonia or ARDS, Fever, C-Reactive Protein, D-Dimer, PaO2-FiO2, Respiratory Rate, Radiographic Findings","mAb",20
"NCT04278963","https://clinicaltrials.gov/show/NCT04278963",NA,"China","Beijing","2020-Feb",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"TCM",300
"NCT04279197","https://clinicaltrials.gov/show/NCT04279197",NA,"China","Beijing","2020-Feb",NA,"Recruiting","Randomised","Triple",3,"Resolved","Resolved Discharged","Pneumonia or ARDS, Dyspnea, 6-Minute Walking Distance, Radiographic Findings","Standard of care, TCM",160
"NCT04291729","https://clinicaltrials.gov/show/NCT04291729",NA,"China","Beijing","2020-Feb",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events","DAA + IFN",11
"NCT04303299","https://clinicaltrials.gov/show/NCT04303299",NA,"Thailand","Nan","2020-Feb",NA,"Recruiting","Randomised","Open-Label",7,"Confirmed","Outpatient","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","DRV/r + FPV + HCQ, DRV/r + Oseltamivir, DRV/r + Oseltamivir + HCQ, HCQ + Oseltamivir, LPV/r + FPV, LPV/r + Oseltamivir, Standard of care",320
"NCT04305106","https://clinicaltrials.gov/show/NCT04305106",NA,"China","Beijing","2020-Sep",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","mAb, Standard of care",140
"NCT04310865","https://clinicaltrials.gov/show/NCT04310865",NA,"China","Beijing","2020-Mar",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, PaO2-FiO2","TCM",116
"NCT04315480","https://clinicaltrials.gov/show/NCT04315480",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2","TCZ",38
"NCT04315896","https://clinicaltrials.gov/show/NCT04315896",NA,"Mexico","Mexico","2020-Mar",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","HCQ, Standard of care",500
"NCT04315987","https://clinicaltrials.gov/show/NCT04315987",NA,"Brazil","Brasilia","2020-Mar",NA,"Not Recruiting","Randomised","Quadruple",1,"Confirmed","Hospital",NA,"Stem cells",90
"NCT04318015","https://clinicaltrials.gov/show/NCT04318015",NA,"Mexico","Mexico","2020-Mar",NA,"Recruiting","Randomised","Quadruple",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ, Standard of care",400
"NCT04319731","https://clinicaltrials.gov/show/NCT04319731",NA,"United States","Washington, Dc","2020-Mar",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, IL-6","Other",10
"NCT04320277","https://clinicaltrials.gov/show/NCT04320277",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Unclear","ICU Admission, Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any)","JAKi, Standard of care",200
"NCT04320615","https://clinicaltrials.gov/show/NCT04320615",NA,"United States","Washington, Dc","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","Standard of care, TCZ",450
"NCT04320615","https://clinicaltrials.gov/show/NCT04320615",NA,"Canada","Ottawa","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","Standard of care, TCZ",450
"NCT04320615","https://clinicaltrials.gov/show/NCT04320615",NA,"Denmark","Copenhagen","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","Standard of care, TCZ",450
"NCT04320615","https://clinicaltrials.gov/show/NCT04320615",NA,"France","Paris","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","Standard of care, TCZ",450
"NCT04320615","https://clinicaltrials.gov/show/NCT04320615",NA,"Germany","Berlin","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","Standard of care, TCZ",450
"NCT04320615","https://clinicaltrials.gov/show/NCT04320615",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","Standard of care, TCZ",450
"NCT04320615","https://clinicaltrials.gov/show/NCT04320615",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","Standard of care, TCZ",450
"NCT04320615","https://clinicaltrials.gov/show/NCT04320615",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","Standard of care, TCZ",450
"NCT04320615","https://clinicaltrials.gov/show/NCT04320615",NA,"United Kingdom","London","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","Standard of care, TCZ",450
"NCT04321616","https://clinicaltrials.gov/show/NCT04321616",NA,"Norway","Oslo","2020-Mar",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital, ICU","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA)","HCQ, Remdesivir, Standard of care",700
"NCT04323514","https://clinicaltrials.gov/show/NCT04323514",NA,"Italy","Rome","2020-Mar",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Peak RRadiographic Findings","Vitamins",500
"NCT04326075","https://clinicaltrials.gov/show/NCT04326075",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, Standard of care",900
"NCT04326114","https://clinicaltrials.gov/show/NCT04326114",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Single",3,"Healthy","Healthy Unexposed","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events","Non-invasive respiratory support, Standard of care",240
"NCT04328441","https://clinicaltrials.gov/show/NCT04328441",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Fever, Other Mild Symptoms, Anti SARS-COV-2 Titers, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",1500
"NCT04329572","https://clinicaltrials.gov/show/NCT04329572",NA,"Brazil","Brasilia","2020-Mar",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","HCQ + AZT",400
"NCT04329650","https://clinicaltrials.gov/show/NCT04329650",NA,"Spain","Madrid","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission","Corticosteroids, Siltuximab",200
"NCT04330144","https://clinicaltrials.gov/show/NCT04330144",NA,"South Korea","Seoul","2020-Mar",NA,"Not Recruiting","Randomised","Single",1,"Healthy","Healthy Exposed","Viral Load or Clearance","HCQ",2486
"NCT04330495","https://clinicaltrials.gov/show/NCT04330495",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, ICU Admission","HCQ, Standard of care",800
"NCT04331054","https://clinicaltrials.gov/show/NCT04331054",NA,"France","Paris","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2","Corticosteroids, Standard of care",436
"NCT04331470","https://clinicaltrials.gov/show/NCT04331470",NA,"Iran","Tehran","2020-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2","HCQ + LPV/r, LPV/r + HCQ + Other",30
"NCT04331613","https://clinicaltrials.gov/show/NCT04331613",NA,"China","Beijing","2020-Jun",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","Mortality, Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-6, IL-8, CK-MB, Procalcitonin",NA,9
"NCT04331665","https://clinicaltrials.gov/show/NCT04331665",NA,"Canada","Ottawa","2020-Jan",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events","JAKi",64
"NCT04331795","https://clinicaltrials.gov/show/NCT04331795",NA,"United States","Washington, Dc","2020-Jan",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","TCZ",32
"NCT04331899","https://clinicaltrials.gov/show/NCT04331899",NA,"United States","Washington, Dc","2020-Mar",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Outpatient","Viral Load or Clearance","IFN, Standard of care",120
"NCT04332094","https://clinicaltrials.gov/show/NCT04332094",NA,"Spain","Madrid","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, TCZ + AZT + HCQ",276
"NCT04333251","https://clinicaltrials.gov/show/NCT04333251",NA,"United States","Texas","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, Plasma based therapy",115
"NCT04334005","https://clinicaltrials.gov/show/NCT04334005",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms","Standard of care, Vitamins",200
"NCT04334980","https://clinicaltrials.gov/show/NCT04334980",NA,"Australia","Canberra","2020-Mar",NA,"Recruiting","Single-Arm","Open-Label",6,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",12
"NCT04334980","https://clinicaltrials.gov/show/NCT04334980",NA,"Canada","Ottawa","2020-Mar",NA,"Recruiting","Single-Arm","Open-Label",6,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",12
"NCT04334980","https://clinicaltrials.gov/show/NCT04334980",NA,"United States","Washington, Dc","2020-Mar",NA,"Recruiting","Single-Arm","Open-Label",6,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine",12
"NCT04335032","https://clinicaltrials.gov/show/NCT04335032",NA,"Switzerland","Bern","2020-Jan",NA,"Not Recruiting","Randomised","Triple",1,"Confirmed","Hospital",NA,"Nutrition",284
"NCT04335305","https://clinicaltrials.gov/show/NCT04335305",NA,"Spain","Madrid","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, Coagulation Test, ALT, AST, Albumin, Bilirubin, Glucose, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","Standard of care, TCZ + mAb",24
"NCT04335786","https://clinicaltrials.gov/show/NCT04335786",NA,"Netherlands","Amsterdam","2020-Feb",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation","ARBs, Standard of care",651
"NCT04336254","https://clinicaltrials.gov/show/NCT04336254",NA,"China","Beijing","2020-Mar",NA,"Recruiting","Randomised","Triple",1,"Confirmed","Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Treatment-emergent Adverse Events, C-Reactive Protein, Respiratory Rate, Radiographic Findings",NA,20
"NCT04336748","https://clinicaltrials.gov/show/NCT04336748",NA,"Austria","Vienna","2020-Apr",NA,"Not Recruiting","Randomised","Triple",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Labor Absenteeism",NA,440
"NCT04338802","https://clinicaltrials.gov/show/NCT04338802",NA,"China","Hubei","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO",NA,96
"NCT04338906","https://clinicaltrials.gov/show/NCT04338906",NA,"Germany","Berlin","2020-Mar",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Clinical Improvement Score (Any), C-Reactive Protein, Troponin",NA,334
"NCT04339816","https://clinicaltrials.gov/show/NCT04339816",NA,"Czechia","Prague","2020-Jun",NA,"Not Recruiting","Randomised","Triple",2,NA,"ICU","Mortality, Viral Load or Clearance, Treatment-emergent Adverse Events",NA,3
"NCT04340414","https://clinicaltrials.gov/show/NCT04340414",NA,"China","Beijing","2020-Mar",NA,"Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,10
"NCT04341038","https://clinicaltrials.gov/show/NCT04341038",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Single",1,"Confirmed","ICU",NA,NA,84
"NCT04341285","https://clinicaltrials.gov/show/NCT04341285",NA,"Germany","Berlin","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality","ECMO",200
"NCT04341389","https://clinicaltrials.gov/show/NCT04341389",NA,"China","Beijing","2020-Jul",NA,"Not Recruiting","Randomised","Double",3,NA,"Healthy Unexposed","Viral Load or Clearance, Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Interferon (Any), IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",508
"NCT04341870","https://clinicaltrials.gov/show/NCT04341870",NA,"France","Paris","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ + AZT + Sarilumab, Sarilumab",27
"NCT04342182","https://clinicaltrials.gov/show/NCT04342182",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","Plasma based therapy, Standard of care",426
"NCT04342897","https://clinicaltrials.gov/show/NCT04342897",NA,"United States","Washington, Dc","2020-Oct",NA,"Not Recruiting","Randomised","Double",1,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events","mAb",95
"NCT04343144","https://clinicaltrials.gov/show/NCT04343144",NA,"France","Paris","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Serious Adverse Events",NA,92
"NCT04343963","https://clinicaltrials.gov/show/NCT04343963",NA,"Mexico","Mexico","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, IL-6","Other, Standard of care",436
"NCT04343989","https://clinicaltrials.gov/show/NCT04343989",NA,"United States","Washington, Dc","2020-Sep",NA,"Recruiting","Randomised","Double",3,NA,"ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","mAb, Standard of care",90
"NCT04344080","https://clinicaltrials.gov/show/NCT04344080",NA,"Germany","Berlin","2020-Sep",NA,"Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), Procalcitonin, Bicarbonates, Renal Outcome (Unspecified)","Cytokine removal, Standard of care",24
"NCT04344236","https://clinicaltrials.gov/show/NCT04344236",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Open-Label",4,NA,"Unclear","Viral Load or Clearance, Pneumonia or ARDS, Heart Rate","Hygiene, Standard of care",48
"NCT04344444","https://clinicaltrials.gov/show/NCT04344444",NA,"United States","Washington, Dc","2020-Oct",NA,"Not Recruiting","Randomised","Open-Label",3,NA,"Hospital",NA,"HCQ, HCQ + AZT, Standard of care",600
"NCT04344457","https://clinicaltrials.gov/show/NCT04344457",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Single-Arm","Open-Label",3,"Confirmed","Outpatient","Clinical Improvement Score (Any), Cough, Fever, Treatment-emergent Adverse Events","AZT, HCQ, NSAIDs",80
"NCT04344535","https://clinicaltrials.gov/show/NCT04344535",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Distress","Plasma based therapy, Standard of care",500
"NCT04344548","https://clinicaltrials.gov/show/NCT04344548",NA,"Colombia","Bogota","2020-Oct",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,"Outpatient","ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Household Members with CoViD-19, Labor Absenteeism, Adverse Events, Treatment-emergent Adverse Events",NA,10
"NCT04344561","https://clinicaltrials.gov/show/NCT04344561",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance",NA,70
"NCT04344600","https://clinicaltrials.gov/show/NCT04344600",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Single",2,NA,"Healthy Exposed","Viral Load or Clearance","IFN, Standard of care",164
"NCT04344756","https://clinicaltrials.gov/show/NCT04344756",NA,"France","Paris","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Bicarbonates, Renal Outcome (Unspecified)","Anticoagulants, Standard of care",808
"NCT04344782","https://clinicaltrials.gov/show/NCT04344782",NA,"France","Paris","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,"Unclear","Hospital",NA,"mAb, Standard of care",130
"NCT04345276","https://clinicaltrials.gov/show/NCT04345276",NA,"China","Beijing","2020-Oct",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious Adverse Events",NA,10
"NCT04345406","https://clinicaltrials.gov/show/NCT04345406",NA,"Egypt","Cairo","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Unclear","Viral Load or Clearance, Radiographic Findings","Antihypertensive, Standard of care",60
"NCT04345653","https://clinicaltrials.gov/show/NCT04345653",NA,"United States","Washington, Dc","2020-Aug",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Serious Adverse Events","HCQ",44
"NCT04345692","https://clinicaltrials.gov/show/NCT04345692",NA,"United States","Washington, Dc","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Heart Rate","HCQ, Standard of care",17
"NCT04345848","https://clinicaltrials.gov/show/NCT04345848",NA,"Switzerland","Bern","2020-Jul",NA,"Recruiting","Randomised","Single",2,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test","Anticoagulants",200
"NCT04345887","https://clinicaltrials.gov/show/NCT04345887",NA,"Turkey","Ankara","2020-Oct",NA,"Not Recruiting","Randomised","Triple",2,"Unclear","ICU","Organ Failure or Dysfunction (SOFA), PaO2-FiO2","Other, Standard of care",60
"NCT04346329","https://clinicaltrials.gov/show/NCT04346329",NA,"Colombia","Bogota","2020-Oct",NA,"Not Recruiting","Randomised","Double",2,NA,"Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, Standard of care",86
"NCT04346355","https://clinicaltrials.gov/show/NCT04346355",NA,"Italy","Rome","2020-Dec",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",126
"NCT04346446","https://clinicaltrials.gov/show/NCT04346446",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2","Plasma based therapy, Standard of care",29
"NCT04346628","https://clinicaltrials.gov/show/NCT04346628",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Double",2,NA,"Outpatient","Clinical Improvement Score (Any), Viral Load or Clearance, Other Mild Symptoms, Anti SARS-COV-2 Titers","FPV, Standard of care",120
"NCT04346797","https://clinicaltrials.gov/show/NCT04346797",NA,"France","Paris","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital, ICU","Organ Failure or Dysfunction (SOFA)","mAb, Standard of care",120
"NCT04347226","https://clinicaltrials.gov/show/NCT04347226",NA,"United States","Washington, Dc","2020-Feb",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any)","mAb, Standard of care",138
"NCT04347681","https://clinicaltrials.gov/show/NCT04347681",NA,"Saudi Arabia","Riyadh","2020-Aug",NA,"Recruiting","Non-Randomised","Open-Label",2,NA,"Hospital, ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events","Plasma based therapy",575
"NCT04347941","https://clinicaltrials.gov/show/NCT04347941",NA,"Ireland","Dublin","2020-Aug",NA,"Recruiting","Randomised","Double",2,NA,"ICU","Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Respiratory Rate, Patient Positioning","Positioning, Standard of care",200
"NCT04347980","https://clinicaltrials.gov/show/NCT04347980",NA,"France","Paris","2020-Sep",NA,"Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Patient Positioning","Dexamethasone + HCQ, HCQ",122
"NCT04348305","https://clinicaltrials.gov/show/NCT04348305",NA,"Denmark","Copenhagen","2020-Nov",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital, ICU","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Quality of Life","Corticosteroids, Standard of care",1000
"NCT04348409","https://clinicaltrials.gov/show/NCT04348409",NA,"Brazil","Brasilia","2020-Mar",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Antivirals, Standard of care",50
"NCT04348461","https://clinicaltrials.gov/show/NCT04348461",NA,"Spain","Madrid","2020-Oct",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","ICU","Adverse Events","Standard of care, Stem cells",100
"NCT04348474","https://clinicaltrials.gov/show/NCT04348474",NA,"Brazil","Brasilia","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Unclear","Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any)","HCQ + AZT",200
"NCT04348500","https://clinicaltrials.gov/show/NCT04348500",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation","mAb, Standard of care",17
"NCT04348513","https://clinicaltrials.gov/show/NCT04348513",NA,"Greece","Athens","2020-Sep",NA,"Recruiting","Randomised","Triple",2,"Confirmed","ICU","Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, Fibrinogen, ALT, Bilirubin, Urine Sample, Blood Pressure, PaO2-FiO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Hormone therapy, Standard of care",60
"NCT04350281","https://clinicaltrials.gov/show/NCT04350281",NA,"China","Hong Kong","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","HCQ, IFN",60
"NCT04350580","https://clinicaltrials.gov/show/NCT04350580",NA,"France","Paris","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","ICU","Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, C-Reactive Protein, Procalcitonin, PaO2-FiO2, Radiographic Findings, Renal Outcome (Unspecified)","Igs, Standard of care",138
"NCT04351191","https://clinicaltrials.gov/show/NCT04351191",NA,"Pakistan","Islamabad","2020-Apr",NA,"Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance","HCQ, Standard of care",400
"NCT04351295","https://clinicaltrials.gov/show/NCT04351295",NA,"Egypt","Cairo","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance","FPV, Standard of care",90
"NCT04351347","https://clinicaltrials.gov/show/NCT04351347",NA,"Egypt","Cairo","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Viral Load or Clearance","Antivirals, HCQ, Ivermectin",300
"NCT04351490","https://clinicaltrials.gov/show/NCT04351490",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Unclear","Hospital","Mortality, Viral Load or Clearance","Standard of care, Zinc + Vitamins",3140
"NCT04351906","https://clinicaltrials.gov/show/NCT04351906",NA,"Germany","Berlin","2020-Sep",NA,"Recruiting","Single-Arm","Open-Label",1,"Unclear","ICU","Adverse Events","Device",20
"NCT04352400","https://clinicaltrials.gov/show/NCT04352400",NA,"Italy","Padova","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Cardiac Outcome (Unspecified)","Anticoagulants, Standard of care",256
"NCT04352465","https://clinicaltrials.gov/show/NCT04352465",NA,"Brazil","Brasilia","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",2,NA,"Hospital",NA,"Other",42
"NCT04352608","https://clinicaltrials.gov/show/NCT04352608",NA,"China","Beijing","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",5,NA,"Healthy Unexposed","Visits or Returns to Emergency Department, Antibodies","Standard of care, Vaccine",744
"NCT04352751","https://clinicaltrials.gov/show/NCT04352751",NA,"Pakistan","Islamabad","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,NA,"Hospital, ICU","Clinical Improvement Score (Any), Dyspnea, Other Mild Symptoms","Plasma based therapy",2000
"NCT04352803","https://clinicaltrials.gov/show/NCT04352803",NA,"United States","Massachusetts","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events","Stem cells",20
"NCT04352946","https://clinicaltrials.gov/show/NCT04352946",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",2,NA,"Healthcare Workers","Mortality, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Adverse Events, Anti SARS-COV-2 Titers","HCQ, Standard of care",374
"NCT04352985","https://clinicaltrials.gov/show/NCT04352985",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Unspecified","Unspecified",2,NA,"ICU",NA,"Antibiotics",NA
"NCT04353518","https://clinicaltrials.gov/show/NCT04353518",NA,"India","Madhya Pradesh","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",1,NA,"Healthy Unexposed","Serious or Seconday Infections, Adverse Events, Serious Adverse Events","Other",4000
"NCT04353674","https://clinicaltrials.gov/show/NCT04353674",NA,"Canada","Ottawa","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,NA,"ICU","ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), White Blood Cell Count, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Dialysis, Standard of care",40
"NCT04354259","https://clinicaltrials.gov/show/NCT04354259",NA,"Canada","Ottawa","2020-Apr",NA,"Recruiting","Randomised","Quadruple",4,NA,"Outpatient, Hospital","Hospitalization, Serious Adverse Events","IFN, Standard of care",140
"NCT04354428","https://clinicaltrials.gov/show/NCT04354428",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Double",4,NA,"Outpatient","Mortality, Hospitalization, Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Serious Adverse Events","HCQ, HCQ + AZT, Standard of care",300
"NCT04354597","https://clinicaltrials.gov/show/NCT04354597",NA,"Jordan","Amman","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Healthcare Workers","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Adverse Events","HCQ + AZT, Standard of care",200
"NCT04354870","https://clinicaltrials.gov/show/NCT04354870",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",2,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Other Mild Symptoms, Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers","HCQ, Standard of care",130
"NCT04355052","https://clinicaltrials.gov/show/NCT04355052",NA,"Israel","Jerusalem","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",3,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ + AZT, HCQ + Other, Standard of care",250
"NCT04356482","https://clinicaltrials.gov/show/NCT04356482",NA,"Mexico","Mexico","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Adverse Events","Plasma based therapy",90
"NCT04356508","https://clinicaltrials.gov/show/NCT04356508",NA,"China","Hong Kong","2020-Oct",NA,"Not Recruiting","Non-Randomised","Open-Label",2,NA,"Outpatient, Hospital","Hospitalization, Viral Load or Clearance, Treatment-emergent Adverse Events, IL-1, IL-2, IL-6, Tumor Necrosis Factor (Any)","mAb, Standard of care",15
"NCT04356534","https://clinicaltrials.gov/show/NCT04356534",NA,"Bahrain","Manama","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, Troponin, Procalcitonin, LDH, Radiographic Findings","Plasma based therapy, Standard of care",40
"NCT04356677","https://clinicaltrials.gov/show/NCT04356677",NA,"United States","New Jersey","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Antivirals",50
"NCT04356833","https://clinicaltrials.gov/show/NCT04356833",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, Fibrinogen, PaO2-FiO2","Other, Standard of care",24
"NCT04356937","https://clinicaltrials.gov/show/NCT04356937",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,"Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","Standard of care, TCZ",243
"NCT04357028","https://clinicaltrials.gov/show/NCT04357028",NA,"Egypt","Cairo","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,"Healthy Unexposed",NA,"Standard of care, Vaccine",200
"NCT04357457","https://clinicaltrials.gov/show/NCT04357457",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Respiratory stimulant, Standard of care",212
"NCT04357613","https://clinicaltrials.gov/show/NCT04357613",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events","Imatinib, Standard of care",99
"NCT04357730","https://clinicaltrials.gov/show/NCT04357730",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Anticoagulants, Standard of care",60
"NCT04357860","https://clinicaltrials.gov/show/NCT04357860",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",3,NA,"Hospital",NA,"Sarilumab, Standard of care",120
"NCT04358068","https://clinicaltrials.gov/show/NCT04358068",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Double",3,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, Standard of care",20
"NCT04358068","https://clinicaltrials.gov/show/NCT04358068",NA,"Puerto Rico","Puerto Rico","2020-Apr",NA,"Not Recruiting","Randomised","Double",3,NA,"Outpatient","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Treatment-emergent Adverse Events, Cardiac Outcome (Unspecified)","HCQ + AZT, Standard of care",20
"NCT04358211","https://clinicaltrials.gov/show/NCT04358211",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Unspecified","Unspecified",2,NA,"ICU",NA,"Plasma based therapy",NA
"NCT04358614","https://clinicaltrials.gov/show/NCT04358614",NA,"Italy","Rome","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",2,NA,"Hospital","ICU Admission, Hospital Discharge, Adverse Events, Serious Adverse Events","JAKi",12
"NCT04358809","https://clinicaltrials.gov/show/NCT04358809",NA,"India","Chhattisgarh","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",2,NA,"Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Other Mild Symptoms, Adverse Events, Serious Adverse Events","Other, Standard of care",480
"NCT04359251","https://clinicaltrials.gov/show/NCT04359251",NA,"China","Beijing","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",3,NA,"Hospital","PaO2-FiO2","Non-invasive respiratory support",20
"NCT04359290","https://clinicaltrials.gov/show/NCT04359290",NA,"Germany","Berlin","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-6, Radiographic Findings","JAKi",15
"NCT04359329","https://clinicaltrials.gov/show/NCT04359329",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Outpatient","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Estrogen steroid hormone, Standard of care",110
"NCT04359511","https://clinicaltrials.gov/show/NCT04359511",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Single",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Quality of Life","Corticosteroids, Standard of care",210
"NCT04359537","https://clinicaltrials.gov/show/NCT04359537",NA,"Pakistan","Islamabad","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Other Mild Symptoms, Treatment-emergent Adverse Events","HCQ, Standard of care",200
"NCT04359654","https://clinicaltrials.gov/show/NCT04359654",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, PaO2-FiO2","Inhaled solution, Standard of care",50
"NCT04359810","https://clinicaltrials.gov/show/NCT04359810",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation","Plasma based therapy, Standard of care",219
"NCT04359810","https://clinicaltrials.gov/show/NCT04359810",NA,"Brazil","Brasilia","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,"Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation","Plasma based therapy, Standard of care",219
"NCT04359862","https://clinicaltrials.gov/show/NCT04359862",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital, Unclear","Mortality, IL-1, IL-6, IL-8, Tumor Necrosis Factor (Any), PaO2-FiO2","Anesthetic",50
"NCT04359901","https://clinicaltrials.gov/show/NCT04359901",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Non-invasive Ventilation","Sarilumab, Standard of care",120
"NCT04360824","https://clinicaltrials.gov/show/NCT04360824",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Cardiac Outcome (Unspecified)","Anticoagulants",170
"NCT04360980","https://clinicaltrials.gov/show/NCT04360980",NA,"Iran","Tehran","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, C-Reactive Protein, LDH","Colchicine, Standard of care",80
"NCT04361032","https://clinicaltrials.gov/show/NCT04361032",NA,"Tunisia","Tunis","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality","Standard of care, TCZ + mAb",260
"NCT04361253","https://clinicaltrials.gov/show/NCT04361253",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Double",2,NA,"Hospital, ICU","Mortality, Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",220
"NCT04361435","https://clinicaltrials.gov/show/NCT04361435",NA,"Canada","Quebec","2020-Dec",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"ICU","SpO2","Respiratory support",50
"NCT04361474","https://clinicaltrials.gov/show/NCT04361474",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Single",2,NA,"Unclear","Clinical Improvement Score (Any), Blood Pressure, Heart Rate, Respiratory Rate","Corticosteroids, Standard of care",120
"NCT04362059","https://clinicaltrials.gov/show/NCT04362059",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Adverse Events, Serious Adverse Events, PaO2-FiO2","Other, Standard of care",24
"NCT04362111","https://clinicaltrials.gov/show/NCT04362111",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Triple",2,NA,"Hospital","Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, D-Dimer, LDH","Anakinra, Standard of care",30
"NCT04362189","https://clinicaltrials.gov/show/NCT04362189",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",4,NA,"Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, Myoglobin, Troponin, Prothrombin, Electrolytes, INR, ALT, Albumin, Bilirubin, Glucose, CD4, CD8, Blood Urea Nitrogen, Blood Gas, ECG, SpO2, Bicarbonates, Renal Outcome (Unspecified)","HCQ + AZT, HCQ + AZT + Stem cells, Standard of care, Stem cells",100
"NCT04362332","https://clinicaltrials.gov/show/NCT04362332",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",3,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Treatment-emergent Adverse Events","HCQ, Standard of care",25
"NCT04363060","https://clinicaltrials.gov/show/NCT04363060",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital",NA,"Amoxicillin/clavulanate, AZT + Amoxicillin/clavulanate",104
"NCT04363203","https://clinicaltrials.gov/show/NCT04363203",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Single-Arm","Quadruple",3,"Confirmed","Outpatient","Mortality, Hospitalization, Cough, Fever, Dyspnea","AZT, HCQ, Standard of care",300
"NCT04363463","https://clinicaltrials.gov/show/NCT04363463",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Positioning, Standard of care",400
"NCT04363541","https://clinicaltrials.gov/show/NCT04363541",NA,"Mexico","Mexico","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital",NA,"Alternative therapy, Standard of care",274
"NCT04363736","https://clinicaltrials.gov/show/NCT04363736",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, IL-6","TCZ",100
"NCT04363814","https://clinicaltrials.gov/show/NCT04363814",NA,"Dominican Republic","Santo Domingo","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Blood Pressure, Heart Rate, SpO2, Cardiac Outcome (Unspecified)","Other, Standard of care",100
"NCT04363840","https://clinicaltrials.gov/show/NCT04363840",NA,"United States","Louisiana","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Hospitalization","Antihypertensive, Antihypertensive + Nutrition, Standard of care",1080
"NCT04363853","https://clinicaltrials.gov/show/NCT04363853",NA,"Mexico","Mexico","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital, ICU","Pneumonia or ARDS, White Blood Cell Count, Hemoglobin, Glucose, Blood Urea Nitrogen, Radiographic Findings","TCZ",200
"NCT04364802","https://clinicaltrials.gov/show/NCT04364802",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",4,NA,"Healthcare Workers, Hospital",NA,"Hygiene, Standard of care",300
"NCT04365101","https://clinicaltrials.gov/show/NCT04365101",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Clinical Improvement Score (Any), Adverse Events","Natural Killer Cells, Standard of care",86
"NCT04365439","https://clinicaltrials.gov/show/NCT04365439",NA,"Switzerland","Ticino","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","Viral Load or Clearance, IL-6, Antibodies","Plasma based therapy",10
"NCT04365517","https://clinicaltrials.gov/show/NCT04365517",NA,"Italy","Rome","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Clinical Improvement Score (Any)","DPP-4i, Standard of care",170
"NCT04365582","https://clinicaltrials.gov/show/NCT04365582",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",4,NA,"Outpatient",NA,"AZT, HCQ, LPV/r, Standard of care",640
"NCT04366245","https://clinicaltrials.gov/show/NCT04366245",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Radiographic Findings","HCQ + AZT or LPV/r + IFN, Plasma based therapy",72
"NCT04366271","https://clinicaltrials.gov/show/NCT04366271",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality","Standard of care, Stem cells",106
"NCT04366323","https://clinicaltrials.gov/show/NCT04366323",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"ICU","Adverse Events","Standard of care, Stem cells",26
"NCT04366856","https://clinicaltrials.gov/show/NCT04366856",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","Positioning, Standard of care",500
"NCT04367831","https://clinicaltrials.gov/show/NCT04367831",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Single",3,NA,"ICU","ICU Admission","Anticoagulants",100
"NCT04368923","https://clinicaltrials.gov/show/NCT04368923",NA,"Egypt","Cairo","2020-Apr",NA,"Not Recruiting","Randomised","Single",2,NA,"Outpatient","Blood Gas, Blood pH","Non-invasive respiratory support, Standard of care",60
"NCT04368988","https://clinicaltrials.gov/show/NCT04368988",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",10,NA,"Healthy Exposed","Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",1419
"NCT04368988","https://clinicaltrials.gov/show/NCT04368988",NA,"Australia","Canberra","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",10,NA,"Healthy Exposed","Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",1419
"NCT04369794","https://clinicaltrials.gov/show/NCT04369794",NA,"Brazil","Brasilia","2020-Apr",NA,"Recruiting","Randomised","Quadruple",2,NA,"Healthy Exposed",NA,"Standard of care, Vaccine",1000
"NCT04370015","https://clinicaltrials.gov/show/NCT04370015",NA,"Pakistan","Punjab","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",2,NA,"Healthcare Workers","Labor Absenteeism, Adverse Events","HCQ, Standard of care",374
"NCT04371107","https://clinicaltrials.gov/show/NCT04371107",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Outpatient",NA,"AZT, Standard of care",64
"NCT04371393","https://clinicaltrials.gov/show/NCT04371393",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Triple",2,NA,"ICU","Mortality","Standard of care, Stem cells",300
"NCT04372082","https://clinicaltrials.gov/show/NCT04372082",NA,"France","Nord","2020-Apr",NA,"Not Recruiting","Randomised","Single",3,NA,"Hospital","Mortality, Hospitalization","CCB + Other, HCQ, Standard of care",480
"NCT04373044","https://clinicaltrials.gov/show/NCT04373044",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Hemoglobin, Blood Pressure, Respiratory Rate, Radiographic Findings, Cardiac Outcome (Unspecified)","JAKi + Antivirals",144
"NCT04373707","https://clinicaltrials.gov/show/NCT04373707",NA,"France","Paris","2020-Jan",NA,"Recruiting","Randomised","Single",2,"Confirmed Or Suspected","Hospital, ICU",NA,"Anticoagulants",602
"NCT04373824","https://clinicaltrials.gov/show/NCT04373824",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Ivermectin, Standard of care",50
"NCT04374019","https://clinicaltrials.gov/show/NCT04374019",NA,"United States","Washington, Dc","2020-Jan",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Unclear",NA,"HCQ, HCQ + AZT, HCQ + Ivermectin, Other",240
"NCT04374032","https://clinicaltrials.gov/show/NCT04374032",NA,"Bosnia & Herzegovina","Sarajevo","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Adverse Events, Radiographic Findings","Other, Standard of care",120
"NCT04374149","https://clinicaltrials.gov/show/NCT04374149",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Plasma based therapy, Plasma based therapy + JAKi",20
"NCT04374487","https://clinicaltrials.gov/show/NCT04374487",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality, Pneumonia or ARDS, PaO2-FiO2","Plasma based therapy, Standard of care",100
"NCT04374591","https://clinicaltrials.gov/show/NCT04374591",NA,"Egypt","Cairo","2020-Feb",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Other",180
"NCT04375735","https://clinicaltrials.gov/show/NCT04375735",NA,"Canada","Ontario","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Adverse Events","Other, Standard of care",20
"NCT04376814","https://clinicaltrials.gov/show/NCT04376814",NA,"Iran","Tehran","2020-Mar",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Dyspnea, C-Reactive Protein, SpO2","HCQ + FPV, HCQ + LPV/r",40
"NCT04377308","https://clinicaltrials.gov/show/NCT04377308",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient, Hospital","Mortality, Hospitalization","SSRIs, Standard of care",2000
"NCT04377503","https://clinicaltrials.gov/show/NCT04377503",NA,"Brazil","Maranhao","2020-Feb",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Corticosteroids, TCZ",40
"NCT04377646","https://clinicaltrials.gov/show/NCT04377646",NA,"Tunisia","Tunis","2020-Jan",NA,"Not Recruiting","Randomised","Triple",3,"Healthy","Healthy Unexposed",NA,"HCQ, HCQ + Zinc, Standard of care",660
"NCT04377659","https://clinicaltrials.gov/show/NCT04377659",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality","TCZ",9
"NCT04377711","https://clinicaltrials.gov/show/NCT04377711",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, SpO2","Corticosteroids, Standard of care",400
"NCT04377997","https://clinicaltrials.gov/show/NCT04377997",NA,"United States","Massachusetts","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Mortality, Deep Vein Thrombosis or Pulmonary Embolism, Shock, Cardiac Outcome (Unspecified)","Anticoagulants",300
"NCT04378244","https://clinicaltrials.gov/show/NCT04378244",NA,"United States","California","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital",NA,"Other",18
"NCT04379336","https://clinicaltrials.gov/show/NCT04379336",NA,"South Africa","Pretoria","2020-Apr",NA,"Recruiting","Randomised","Quadruple",2,"Healthy","Healthcare Workers","Hospitalization","Standard of care, Vaccine",500
"NCT04380818","https://clinicaltrials.gov/show/NCT04380818",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",7,"Confirmed","Hospital",NA,"HCQ + LPV/r + TCZ + AZT + Corticosteroids + Anticoagulants + Non-invasive respiratory support, Radiation therapy + HCQ + LPV/r + TCZ + AZT + Corticosteroids + Anticoagulants + Non-invasive respiratory support",106
"NCT04380935","https://clinicaltrials.gov/show/NCT04380935",NA,"Indonesia","Jakarta","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, D-Dimer, PaO2-FiO2","Plasma based therapy, Standard of care",60
"NCT04381364","https://clinicaltrials.gov/show/NCT04381364",NA,"Sweden","Stockholm","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Non-invasive Ventilation","Corticosteroids, Standard of care",446
"NCT04381858","https://clinicaltrials.gov/show/NCT04381858",NA,"Mexico","Mexico","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","ICU","Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Igs, Plasma based therapy",196
"NCT04381871","https://clinicaltrials.gov/show/NCT04381871",NA,"Sudan","Khartoum","2020-Aug",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality","Other",110
"NCT04381962","https://clinicaltrials.gov/show/NCT04381962",NA,"United Kingdom","London","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Mortality","AZT, Standard of care",800
"NCT04381988","https://clinicaltrials.gov/show/NCT04381988",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Triple",2,"Healthy","Healthy Unexposed",NA,"HCQ + Radiation therapy, Radiation therapy",132
"NCT04382131","https://clinicaltrials.gov/show/NCT04382131",NA,"United Kingdom","London","2020-Aug",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient","Hospitalization, Clinical Improvement Score (Any), Other Mild Symptoms, Adverse Events","Hygiene, Standard of care",405
"NCT04382391","https://clinicaltrials.gov/show/NCT04382391",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Invasive Mechanical Ventilation or ECMO","Device, Standard of care",20
"NCT04382547","https://clinicaltrials.gov/show/NCT04382547",NA,"Belarus","Minsk","2020-Aug",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Standard of care, Stem cells",40
"NCT04382729","https://clinicaltrials.gov/show/NCT04382729",NA,"Italy","Rome","2020-Aug",NA,"Recruiting","Randomised","Single",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Other Mild Symptoms, 6-Minute Walking Distance, Quality of Life","Exercise, Other",80
"NCT04382950","https://clinicaltrials.gov/show/NCT04382950",NA,"Egypt","Cairo","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Fever","Other, Standard of care",24
"NCT04383535","https://clinicaltrials.gov/show/NCT04383535",NA,"Argentina","Buenos Aires","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Ferritin, D-Dimer, Antibodies","Plasma based therapy, Standard of care",333
"NCT04383548","https://clinicaltrials.gov/show/NCT04383548",NA,"Egypt","Asyut","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Healthy","Healthy Exposed, Unclear","Adverse Events, IgG, IgM or IgA","Igs",100
"NCT04383574","https://clinicaltrials.gov/show/NCT04383574",NA,"China","Beijing","2020-Sep",NA,"Not Recruiting","Randomised","Double",4,"Healthy","Healthy Unexposed","Antibodies","Standard of care, Vaccine",422
"NCT04383717","https://clinicaltrials.gov/show/NCT04383717",NA,"Egypt","Cairo","2020-Apr",NA,"Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Viral Load or Clearance, Fever, Dyspnea","HCQ + AZT, Other",60
"NCT04384549","https://clinicaltrials.gov/show/NCT04384549",NA,"France","Paris","2020-Jun",NA,"Recruiting","Randomised","Single",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Standard of care, Vaccine",1120
"NCT04384588","https://clinicaltrials.gov/show/NCT04384588",NA,"Chile","Santiago","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",4,"Confirmed","Unclear","Mortality","Plasma based therapy",100
"NCT04385095","https://clinicaltrials.gov/show/NCT04385095",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Outpatient, Hospital","Clinical Improvement Score (Any)","IFN, Standard of care",820
"NCT04385264","https://clinicaltrials.gov/show/NCT04385264",NA,"Switzerland","Bern","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient",NA,"HCQ, Standard of care",800
"NCT04385771","https://clinicaltrials.gov/show/NCT04385771",NA,"Germany","Berlin","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Invasive Mechanical Ventilation or ECMO, IL-6","ECMO, ECMO + Cytokine removal",80
"NCT04385849","https://clinicaltrials.gov/show/NCT04385849",NA,"United States","California","2020-Jul",NA,"Not Recruiting","Randomised","Triple",2,"Confirmed","Unclear","Adverse Events, Lymphocyte Count","Other, Standard of care",30
"NCT04386694","https://clinicaltrials.gov/show/NCT04386694",NA,"Brazil","Brasilia","2020-Aug",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","ICU","Hospital Discharge","Device, Standard of care",30
"NCT04387409","https://clinicaltrials.gov/show/NCT04387409",NA,"Germany","Berlin","2020-Nov",NA,"Not Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Standard of care, Vaccine",59
"NCT04387760","https://clinicaltrials.gov/show/NCT04387760",NA,"Bahrain","Manama","2020-Sep",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Viral Load or Clearance","FPV, HCQ, Standard of care",150
"NCT04389411","https://clinicaltrials.gov/show/NCT04389411",NA,"Canada","Quebec","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Hospitalization, Visits or Returns to Emergency Department","Other, Standard of care",600
"NCT04389450","https://clinicaltrials.gov/show/NCT04389450",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Quadruple",5,"Confirmed","Hospital",NA,"Standard of care, Stem cells",140
"NCT04389450","https://clinicaltrials.gov/show/NCT04389450",NA,"Israel","Jerusalem","2020-May",NA,"Recruiting","Randomised","Quadruple",5,"Confirmed","Hospital",NA,"Standard of care, Stem cells",140
"NCT04389671","https://clinicaltrials.gov/show/NCT04389671",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU",NA,"Other",30
"NCT04389801","https://clinicaltrials.gov/show/NCT04389801",NA,"Egypt","Cairo","2020-May",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality","Other, Standard of care",200
"NCT04390061","https://clinicaltrials.gov/show/NCT04390061",NA,"Italy","Ancona","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + JAKi",116
"NCT04390139","https://clinicaltrials.gov/show/NCT04390139",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","ICU","Mortality","Standard of care, Stem cells",30
"NCT04390412","https://clinicaltrials.gov/show/NCT04390412",NA,"Iran","Tehran","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","ICU Admission, Hospitalization","Radiation therapy",5
"NCT04390464","https://clinicaltrials.gov/show/NCT04390464",NA,"United Kingdom","London","2020-Aug",NA,"Recruiting","Randomised","Open-Label",3,"Suspected","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","JAKi, mAb, Standard of care",1167
"NCT04391101","https://clinicaltrials.gov/show/NCT04391101",NA,"Colombia","Bogota","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU","Mortality","Plasma based therapy, Standard of care",231
"NCT04391127","https://clinicaltrials.gov/show/NCT04391127",NA,"Mexico","Mexico","2020-Dec",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Invasive Mechanical Ventilation or ECMO","HCQ + Ivermectin, Ivermectin",108
"NCT04391140","https://clinicaltrials.gov/show/NCT04391140",NA,"Spain","Madrid","2020-Oct",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Positioning + Respiratory support, Respiratory support",248
"NCT04392427","https://clinicaltrials.gov/show/NCT04392427",NA,"Egypt","Cairo","2020-Dec",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Unclear",NA,"Ivermectin + Antivirals, Standard of care",100
"NCT04392713","https://clinicaltrials.gov/show/NCT04392713",NA,"Pakistan","Islamabad","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed",NA,NA,"Ivermectin, Standard of care",100
"NCT04392973","https://clinicaltrials.gov/show/NCT04392973",NA,"Saudi Arabia","Riyadh","2020-Oct",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","HCQ + FPV, Standard of care",520
"NCT04393051","https://clinicaltrials.gov/show/NCT04393051",NA,"Italy","Rome","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","JAKi, Standard of care",126
"NCT04393246","https://clinicaltrials.gov/show/NCT04393246",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed Or Suspected","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","Other, SGLT2 + Other, Standard of care",1407
"NCT04393415","https://clinicaltrials.gov/show/NCT04393415",NA,"Egypt","Cairo","2020-May",NA,"Recruiting","Randomised","Double",3,"Confirmed","Hospital",NA,"Standard of care, Stem cells",100
"NCT04393948","https://clinicaltrials.gov/show/NCT04393948",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital","Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS","Radiation therapy, Standard of care",48
"NCT04394169","https://clinicaltrials.gov/show/NCT04394169",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Single",2,"Resolved","Resolved Discharged","Quality of Life","Rehabilitation, Standard of care",102
"NCT04394182","https://clinicaltrials.gov/show/NCT04394182",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","SpO2","Radiation therapy + Non-invasive respiratory support + LPV/r + HCQ + AZT + Other + Anticoagulants + Corticosteroids + TCZ",15
"NCT04394793","https://clinicaltrials.gov/show/NCT04394793",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization","Radiation therapy",10
"NCT04395105","https://clinicaltrials.gov/show/NCT04395105",NA,"Argentina","Buenos Aires","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Dexamethasone, Standard of care",284
"NCT04395716","https://clinicaltrials.gov/show/NCT04395716",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","ECG, SpO2","Respiratory support",50
"NCT04395807","https://clinicaltrials.gov/show/NCT04395807",NA,"Sweden","Stockholm","2020-May",NA,"Recruiting","Randomised","Single",2,"Confirmed","Hospital",NA,"Non-invasive respiratory support",120
"NCT04395976","https://clinicaltrials.gov/show/NCT04395976",NA,"United Kingdom","London","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Suspected","Healthy Exposed","Viral Load or Clearance","Alternative therapy, Standard of care",120
"NCT04396067","https://clinicaltrials.gov/show/NCT04396067",NA,"Egypt","Cairo","2020-May",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"Other, Standard of care",360
"NCT04397497","https://clinicaltrials.gov/show/NCT04397497",NA,"Italy","Rome","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Anti SARS-COV-2 Titers, IL-1, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Hemoglobin, PaO2-FiO2, SpO2, Radiographic Findings","mAb, Standard of care",50
"NCT04397562","https://clinicaltrials.gov/show/NCT04397562",NA,"Russia","Moscow","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality","mAb, Standard of care",206
"NCT04397692","https://clinicaltrials.gov/show/NCT04397692",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, SpO2","Non-invasive respiratory support, Standard of care",20
"NCT04397796","https://clinicaltrials.gov/show/NCT04397796",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Unclear","Mortality","Standard of care, Stem cells",45
"NCT04399252","https://clinicaltrials.gov/show/NCT04399252",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed",NA,"Nutrition, Standard of care",1000
"NCT04399746","https://clinicaltrials.gov/show/NCT04399746",NA,"Mexico","Mexico","2020-May",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Outpatient","Viral Load or Clearance","AZT + Ivermectin + Vitamins, Standard of care",30
"NCT04399980","https://clinicaltrials.gov/show/NCT04399980",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"mAb, Standard of care",30
"NCT04400032","https://clinicaltrials.gov/show/NCT04400032",NA,"Canada","Ottawa","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",3,"Confirmed","Hospital","Adverse Events, Radiographic Findings","Stem cells",9
"NCT04400929","https://clinicaltrials.gov/show/NCT04400929",NA,"Singapore","Singapore","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Immunomodulators",30
"NCT04401150","https://clinicaltrials.gov/show/NCT04401150",NA,"Canada","Ottawa","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital, ICU","Mortality, Organ Failure or Dysfunction (SOFA)","Standard of care, Vitamins",800
"NCT04401202","https://clinicaltrials.gov/show/NCT04401202",NA,"Saudi Arabia","Riyadh","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Other, Standard of care",200
"NCT04402060","https://clinicaltrials.gov/show/NCT04402060",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Treatment-emergent Adverse Events, Serious Adverse Events","Other, Standard of care",66
"NCT04402060","https://clinicaltrials.gov/show/NCT04402060",NA,"Brazil","Brasilia","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Treatment-emergent Adverse Events, Serious Adverse Events","Other, Standard of care",66
"NCT04402203","https://clinicaltrials.gov/show/NCT04402203",NA,"Bangladesh","Dhaka","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Radiographic Findings","FPV, Standard of care",50
"NCT04402840","https://clinicaltrials.gov/show/NCT04402840",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","Mortality, Adverse Events","Other",5
"NCT04402944","https://clinicaltrials.gov/show/NCT04402944",NA,"United States","Washington, Dc","2020-Dec",NA,"Recruiting","Randomised","Double",2,"Confirmed","ICU",NA,"Other, Standard of care",60
"NCT04403243","https://clinicaltrials.gov/show/NCT04403243",NA,"Russia","Moscow","2020-May",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","Unclear",NA,"Colchicine, JAKi, mAb, Standard of care",70
"NCT04403269","https://clinicaltrials.gov/show/NCT04403269",NA,"France","Paris","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality","Igs",35
"NCT04403477","https://clinicaltrials.gov/show/NCT04403477",NA,"Bangladesh","Dhaka","2020-May",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality","Plasma based therapy, Standard of care",20
"NCT04403685","https://clinicaltrials.gov/show/NCT04403685",NA,"Brazil","Brasilia","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Standard of care, TCZ",129
"NCT04404218","https://clinicaltrials.gov/show/NCT04404218",NA,"Canada","Ottawa","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient",NA,"Other, Standard of care",480
"NCT04405271","https://clinicaltrials.gov/show/NCT04405271",NA,"Argentina","Buenos Aires","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthcare Workers",NA,"NRTIs, Standard of care",1378
"NCT04405310","https://clinicaltrials.gov/show/NCT04405310",NA,"Mexico","Mexico","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality","HCQ + AZT, Plasma based therapy + HCQ + AZT",80
"NCT04405921","https://clinicaltrials.gov/show/NCT04405921",NA,"Tunisia","Tunis","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"HCQ, HCQ + AZT",200
"NCT04407390","https://clinicaltrials.gov/show/NCT04407390",NA,"Denmark","Copenhagen","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear",NA,"Standard of care, Vitamins",100
"NCT04407507","https://clinicaltrials.gov/show/NCT04407507",NA,"Mexico","Jalisco","2020-May",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Outpatient",NA,"Ivermectin, Standard of care",66
"NCT04408209","https://clinicaltrials.gov/show/NCT04408209",NA,"Greece","Athens","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear",NA,"Plasma based therapy",60
"NCT04408235","https://clinicaltrials.gov/show/NCT04408235",NA,"Italy","Rome","2020-May",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Hospital",NA,"Anticoagulants",300
"NCT04409522","https://clinicaltrials.gov/show/NCT04409522",NA,"Iran","Tehran","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"Melatonin, Standard of care",55
"NCT04409834","https://clinicaltrials.gov/show/NCT04409834",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed","ICU",NA,"Anticoagulants, Anticoagulants + Antiplatelets",750
"NCT04409873","https://clinicaltrials.gov/show/NCT04409873",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Double",4,"Confirmed","Unclear","Viral Load or Clearance","Hygiene",150
"NCT04410328","https://clinicaltrials.gov/show/NCT04410328",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital",NA,"Other, Standard of care",132
"NCT04411446","https://clinicaltrials.gov/show/NCT04411446",NA,"Argentina","Buenos Aires","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Standard of care, Vitamins",1264
"NCT04411628","https://clinicaltrials.gov/show/NCT04411628",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Adverse Events","Other, Standard of care",24
"NCT04411667","https://clinicaltrials.gov/show/NCT04411667",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Igs + Corticosteroids, Standard of care",34
"NCT04412018","https://clinicaltrials.gov/show/NCT04412018",NA,"Canada","Ottawa","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","C-Reactive Protein","Other, Standard of care",100
"NCT04412057","https://clinicaltrials.gov/show/NCT04412057",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Other, Standard of care",82
"NCT04412330","https://clinicaltrials.gov/show/NCT04412330",NA,"United States","Washington, Dc","2020-Dec",NA,"Recruiting","Single-Arm","Open-Label",1,"Resolved","Resolved Discharged","Adverse Events","Exercise",20
"NCT04412356","https://clinicaltrials.gov/show/NCT04412356",NA,"Sweden","Stockholm","2020-May",NA,"Recruiting","Randomised","Single",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Procedure",180
"NCT04412395","https://clinicaltrials.gov/show/NCT04412395",NA,"Egypt","Cairo","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear",NA,"Nutrition, Standard of care",516
"NCT04412538","https://clinicaltrials.gov/show/NCT04412538",NA,"China","Beijing","2020-May",NA,"Recruiting","Randomised","Quadruple",7,"Healthy","Healthy Unexposed","IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",942
"NCT04413864","https://clinicaltrials.gov/show/NCT04413864",NA,"France","Paris","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU",NA,"Other",50
"NCT04414098","https://clinicaltrials.gov/show/NCT04414098",NA,"United States","Massachusetts","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",2,"Confirmed","Unclear",NA,"JAKi, Standard of care",100
"NCT04415060","https://clinicaltrials.gov/show/NCT04415060",NA,"Canada","Ottawa","2020-Feb",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge, Quality of Life","Anesthetic, Standard of care",752
"NCT04416113","https://clinicaltrials.gov/show/NCT04416113",NA,"Egypt","Cairo","2020-May",NA,"Not Recruiting","Randomised","Single",3,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",60
"NCT04416139","https://clinicaltrials.gov/show/NCT04416139",NA,"Mexico","Mexico","2020-May",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Fever, Heart Rate, PaO2-FiO2, Respiratory Rate, Cardiac Outcome (Unspecified)","Standard of care, Stem cells",10
"NCT04417335","https://clinicaltrials.gov/show/NCT04417335",NA,"Netherlands","Amsterdam","2020-May",NA,"Not Recruiting","Randomised","Single",2,NA,"Healthy Unexposed","Mortality, ICU Admission, Hospitalization, Secondary CoViD-19 Re-infection, Fever, Other Mild Symptoms","Standard of care, Vaccine",2014
"NCT04419623","https://clinicaltrials.gov/show/NCT04419623",NA,"United States","Washington, Dc","2020-Mar",NA,"Recruiting","Single-Arm","Quadruple",2,"Confirmed","Hospital","Mortality","Other, Standard of care",146
"NCT04420260","https://clinicaltrials.gov/show/NCT04420260",NA,"Venezuela","Miranda","2020-May",NA,"Not Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Exposed, Healthcare Workers","IgG, IgM or IgA","Other, Standard of care",300
"NCT04420741","https://clinicaltrials.gov/show/NCT04420741",NA,"Denmark","Copenhagen","2020-Apr",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","ICU","Invasive Mechanical Ventilation or ECMO","Other, Standard of care",80
"NCT04420988","https://clinicaltrials.gov/show/NCT04420988",NA,"United States","Washington, Dc","2020-Jun",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","ICU",NA,"Plasma based therapy",NA
"NCT04422561","https://clinicaltrials.gov/show/NCT04422561",NA,"Egypt","Cairo","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Exposed","Cough, Fever, Dyspnea, Other Mild Symptoms","Ivermectin, Standard of care",340
"NCT04422678","https://clinicaltrials.gov/show/NCT04422678",NA,"Egypt","Al Iskandariyah","2020-May",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"Imatinib, Standard of care",30
"NCT04423289","https://clinicaltrials.gov/show/NCT04423289",NA,"Spain","Madrid","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Resolved","Resolved Discharged",NA,"Psychological therapy, Standard of care",150
"NCT04423861","https://clinicaltrials.gov/show/NCT04423861",NA,"Brazil","Brasilia","2020-Aug",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Antivirals, Standard of care",380
"NCT04424056","https://clinicaltrials.gov/show/NCT04424056",NA,"France","Paris","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed","ICU",NA,"Anakinra + Ruxolitinib, Standard of care, TCZ + Ruxolitinib",216
"NCT04424901","https://clinicaltrials.gov/show/NCT04424901",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Single-Arm","Open-Label",2,"Confirmed","Hospital","Coagulation Test","Other, Standard of care",100
"NCT04425460","https://clinicaltrials.gov/show/NCT04425460",NA,"China","Beijing","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"FPV, Standard of care",256
"NCT04425460","https://clinicaltrials.gov/show/NCT04425460",NA,"Germany","Berlin","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"FPV, Standard of care",256
"NCT04425460","https://clinicaltrials.gov/show/NCT04425460",NA,"Romania","Bucharest","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"FPV, Standard of care",256
"NCT04425707","https://clinicaltrials.gov/show/NCT04425707",NA,"Egypt","Cairo","2020-Aug",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear",NA,"Ivermectin, Standard of care",100
"NCT04425720","https://clinicaltrials.gov/show/NCT04425720",NA,"United States","Washington, Dc","2020-Feb",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Visits or Returns to Emergency Department, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","Monitoring, Standard of care",300
"NCT04425915","https://clinicaltrials.gov/show/NCT04425915",NA,"India","New Delhi","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",400
"NCT04427566","https://clinicaltrials.gov/show/NCT04427566",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","Mortality","Radiation therapy",24
"NCT04428021","https://clinicaltrials.gov/show/NCT04428021",NA,"Italy","Rome","2020-Jul",NA,"Recruiting","Randomised","Triple",3,"Confirmed","Hospital",NA,"Plasma based therapy, Standard of care",180
"NCT04429334","https://clinicaltrials.gov/show/NCT04429334",NA,"France","Paris","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Adverse Events","Other, Standard of care",60
"NCT04429711","https://clinicaltrials.gov/show/NCT04429711",NA,"Israel","Jerusalem","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Viral Load or Clearance","Ivermectin, Standard of care",100
"NCT04429867","https://clinicaltrials.gov/show/NCT04429867",NA,"United States","Washington, Dc","2020-Oct",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization","HCQ, Standard of care",700
"NCT04432051","https://clinicaltrials.gov/show/NCT04432051",NA,"Turkey","Ankara","2020-Nov",NA,"Recruiting","Randomised","Triple",2,"Confirmed","ICU",NA,"Monitoring, Standard of care",100
"NCT04432766","https://clinicaltrials.gov/show/NCT04432766",NA,"United States","Washington, Dc","2020-Dec",NA,"Not Recruiting","Randomised","Double",6,"Confirmed","Hospital","Adverse Events","Other, Standard of care",174
"NCT04433078","https://clinicaltrials.gov/show/NCT04433078",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Hypoxemia","Antibiotics, Standard of care",20
"NCT04433949","https://clinicaltrials.gov/show/NCT04433949",NA,"United States","Washington, Dc","2020-Dec",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Radiation therapy, Standard of care",52
"NCT04433988","https://clinicaltrials.gov/show/NCT04433988",NA,"Egypt","Cairo","2020-Jun",NA,"Not Recruiting","Randomised","Triple",2,"Confirmed","Unclear",NA,"Other, Standard of care",200
"NCT04434131","https://clinicaltrials.gov/show/NCT04434131",NA,"United States","Washington, Dc","2020-Sep",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital",NA,"Plasma based therapy",30
"NCT04435015","https://clinicaltrials.gov/show/NCT04435015",NA,"United States","Connecticut","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","D-Dimer","Other, Standard of care",200
"NCT04435314","https://clinicaltrials.gov/show/NCT04435314",NA,"Brazil","Brasilia","2020-Aug",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Exposed",NA,"Antivirals, Standard of care",200
"NCT04435353","https://clinicaltrials.gov/show/NCT04435353",NA,"Kazakhstan","Astana","2020-Jun",NA,"Recruiting","Randomised","Single",2,"Confirmed","Hospital",NA,"Alternative therapy",200
"NCT04435717","https://clinicaltrials.gov/show/NCT04435717",NA,"Spain","Madrid","2020-Nov",NA,"Recruiting","Single-Arm","Open-Label",3,"Confirmed","Hospital","IL-12","Standard of care, TCZ",78
"NCT04435795","https://clinicaltrials.gov/show/NCT04435795",NA,"Canada","Ottawa","2020-Jun",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Cough, Fever, Dyspnea","Corticosteroids, Standard of care",454
"NCT04436471","https://clinicaltrials.gov/show/NCT04436471",NA,"Russia","Moscow","2020-Jun",NA,"Not Recruiting","Non-Randomised","Open-Label",3,"Healthy","Healthy Unexposed","Adverse Events","Vaccine",38
"NCT04437875","https://clinicaltrials.gov/show/NCT04437875",NA,"Russia","Moscow","2020-Jun",NA,"Not Recruiting","Non-Randomised","Open-Label",3,"Healthy","Healthy Unexposed","Adverse Events, Antibodies","Vaccine",38
"NCT04438694","https://clinicaltrials.gov/show/NCT04438694",NA,"Egypt","Cairo","2020-Jun",NA,"Recruiting","Single-Arm","Open-Label",3,"Confirmed","Hospital","Hospitalization","Plasma based therapy, Standard of care",67
"NCT04439006","https://clinicaltrials.gov/show/NCT04439006",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Other, Standard of care",72
"NCT04439045","https://clinicaltrials.gov/show/NCT04439045",NA,"Canada","Ottawa","2020-Mar",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",3626
"NCT04441398","https://clinicaltrials.gov/show/NCT04441398",NA,"Brazil","Brasilia","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient",NA,"Antivirals, Standard of care",300
"NCT04441918","https://clinicaltrials.gov/show/NCT04441918",NA,"China","Beijing","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Adverse Events","mAb, Standard of care",40
"NCT04442958","https://clinicaltrials.gov/show/NCT04442958",NA,"Turkey","Ankara","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","ICU","C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Procalcitonin, Fibrinogen","Plasma based therapy, Standard of care",60
"NCT04443673","https://clinicaltrials.gov/show/NCT04443673",NA,"Mexico","Mexico","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear","Mortality","Nutrition, Standard of care",82
"NCT04443868","https://clinicaltrials.gov/show/NCT04443868",NA,"Canada","British Columbia","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient",NA,"Non-invasive respiratory support, Standard of care",50
"NCT04443881","https://clinicaltrials.gov/show/NCT04443881",NA,"Spain","Madrid","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, SpO2","Anakinra, Standard of care",180
"NCT04444700","https://clinicaltrials.gov/show/NCT04444700",NA,"Brazil","Brasilia","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Anticoagulants, Standard of care",462
"NCT04445220","https://clinicaltrials.gov/show/NCT04445220",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Unclear","Serious Adverse Events","Standard of care, Stem cells",22
"NCT04445246","https://clinicaltrials.gov/show/NCT04445246",NA,"Qatar","Doha","2020-Sep",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected","ICU",NA,"Vasodilators",40
"NCT04445311","https://clinicaltrials.gov/show/NCT04445311",NA,"Egypt","Cairo","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient",NA,"Ivermectin, Standard of care",100
"NCT04445337","https://clinicaltrials.gov/show/NCT04445337",NA,"United States","Nebraska","2020-Sep",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","Pneumonia or ARDS","Other",10
"NCT04445376","https://clinicaltrials.gov/show/NCT04445376",NA,"Pakistan","Islamabad","2020-Jun",NA,"Not Recruiting","Non-Randomised","Single",2,"Healthy","Resolved Discharged","Dyspnea, 6-Minute Walking Distance","Exercise",20
"NCT04445389","https://clinicaltrials.gov/show/NCT04445389",NA,"South Korea","Seoul","2020-Jun",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",210
"NCT04445428","https://clinicaltrials.gov/show/NCT04445428",NA,"Guinea-Bissau","Bissau","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Mortality","Standard of care, Vaccine",3400
"NCT04445467","https://clinicaltrials.gov/show/NCT04445467",NA,"Australia","Canberra","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient, Hospital",NA,"FPV, Standard of care",190
"NCT04445623","https://clinicaltrials.gov/show/NCT04445623",NA,"Italy","Rome","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","PaO2-FiO2","Antiplatelet, Standard of care",128
"NCT04446065","https://clinicaltrials.gov/show/NCT04446065",NA,"Chile","Bio-Bio","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Alternative therapy, Standard of care",524
"NCT04449380","https://clinicaltrials.gov/show/NCT04449380",NA,"Italy","Rome","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance","IFN, Standard of care",126
"NCT04451239","https://clinicaltrials.gov/show/NCT04451239",NA,"Kuwait","Kuwait City","2020-Jun",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Outpatient",NA,"Cyclosporin + Steroids",12
"NCT04451291","https://clinicaltrials.gov/show/NCT04451291",NA,"Canada","Ottawa","2020-Jun",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital",NA,"Other",20
"NCT04452773","https://clinicaltrials.gov/show/NCT04452773",NA,"Spain","Madrid","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Healthy","Healthcare Workers",NA,"Other, Standard of care",315
"NCT04452812","https://clinicaltrials.gov/show/NCT04452812",NA,"Mexico","Mexico","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","ICU","Mortality","Plasma based therapy, Standard of care",15
"NCT04453371","https://clinicaltrials.gov/show/NCT04453371",NA,"Russia","Moscow","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Pneumonia or ARDS, PaO2-FiO2","Other, Standard of care",50
"NCT04453488","https://clinicaltrials.gov/show/NCT04453488",NA,"Spain","Madrid","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthcare Workers",NA,"Standard of care, Vaccine",315
"NCT04455360","https://clinicaltrials.gov/show/NCT04455360",NA,"United Kingdom","London","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Resolved","Resolved Discharged","Adverse Events","Psychological therapy, Standard of care",26
"NCT04455958","https://clinicaltrials.gov/show/NCT04455958",NA,"United States","Washington, Dc","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"LPV/r, Standard of care",75
"NCT04456049","https://clinicaltrials.gov/show/NCT04456049",NA,"Switzerland","Bern","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient",NA,"Other, Standard of care",90
"NCT04456361","https://clinicaltrials.gov/show/NCT04456361",NA,"Mexico","Mexico","2020-Jun",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","SpO2","Stem cells",9
"NCT04457349","https://clinicaltrials.gov/show/NCT04457349",NA,"Egypt","Cairo","2020-Jun",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality","Plasma based therapy",10
"NCT04457609","https://clinicaltrials.gov/show/NCT04457609",NA,"Indonesia","Jakarta","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","ICU","Clinical Improvement Score (Any), Fever, Dyspnea, Blood Pressure, Heart Rate, SpO2, Respiratory Rate","AZT + Oseltamivir, Stem cells + AZT + Oseltamivir",40
"NCT04457726","https://clinicaltrials.gov/show/NCT04457726",NA,"Singapore","Singapore","2020-Feb",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Other",18
"NCT04458948","https://clinicaltrials.gov/show/NCT04458948",NA,"United States","Washington, Dc","2020-Sep",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Hospitalization","HCQ + AZT",10000
"NCT04459247","https://clinicaltrials.gov/show/NCT04459247",NA,"India","New Delhi","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Standard of care, Vitamins",30
"NCT04459676","https://clinicaltrials.gov/show/NCT04459676",NA,"Brazil","Brasilia","2020-Mar",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Other, Standard of care",100
"NCT04459702","https://clinicaltrials.gov/show/NCT04459702",NA,"United States","Washington, Dc","2020-Jun",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Unclear",NA,"HCQ + AZT, HCQ + AZT + LPV/r",200
"NCT04460651","https://clinicaltrials.gov/show/NCT04460651",NA,"Argentina","Buenos Aires","2020-Feb",NA,"Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Other, Standard of care",2000
"NCT04460690","https://clinicaltrials.gov/show/NCT04460690",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Single-Arm","Open-Label",1,"Suspected","Healthy Unexposed, Healthy Exposed",NA,"Other",10000
"NCT04463264","https://clinicaltrials.gov/show/NCT04463264",NA,"Argentina","Buenos Aires","2020-Jun",NA,"Recruiting","Randomised","Single",2,"Confirmed","Unclear",NA,"Antivirals, Standard of care",135
"NCT04465513","https://clinicaltrials.gov/show/NCT04465513",NA,"Canada","Ottawa","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Hospitalization, Non-invasive Ventilation, SpO2","Nutrition, Standard of care",100
"NCT04466098","https://clinicaltrials.gov/show/NCT04466098",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Adverse Events","Standard of care, Stem cells",30
"NCT04466280","https://clinicaltrials.gov/show/NCT04466280",NA,"Iran","Tehran","2020-Sep",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Unexposed",NA,"HCQ + Other, Other",180
"NCT04466683","https://clinicaltrials.gov/show/NCT04466683",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"Radiation therapy, Standard of care",100
"NCT04467918","https://clinicaltrials.gov/show/NCT04467918",NA,"Brazil","Brasilia","2020-Mar",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient, Unclear","Radiographic Findings","Alternative therapy, Standard of care",100
"NCT04468139","https://clinicaltrials.gov/show/NCT04468139",NA,"Saudi Arabia","Riyadh","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Hospital Discharge","Alternative therapy + Zinc + Vitamins",60
"NCT04468958","https://clinicaltrials.gov/show/NCT04468958",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Quadruple",5,"Healthy","Unclear","Adverse Events","Igs, Standard of care",28
"NCT04468971","https://clinicaltrials.gov/show/NCT04468971",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Unclear",NA,"Standard of care, Stem cells",45
"NCT04469179","https://clinicaltrials.gov/show/NCT04469179",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Quadruple",4,"Confirmed","Outpatient","Adverse Events","Igs, Standard of care",21
"NCT04470297","https://clinicaltrials.gov/show/NCT04470297",NA,"Brazil","Sao Paulo","2020-Dec",NA,"Not Recruiting","Randomised","Triple",2,"Confirmed Or Suspected","Hospital",NA,"Other, Standard of care",100
"NCT04470531","https://clinicaltrials.gov/show/NCT04470531",NA,"Bangladesh","Dhaka","2020-Nov",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality","Antibiotics, Standard of care",94
"NCT04470609","https://clinicaltrials.gov/show/NCT04470609",NA,"China","Beijing","2020-Jul",NA,"Recruiting","Randomised","Quadruple",4,"Confirmed","Healthy Unexposed","IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",471
"NCT04471519","https://clinicaltrials.gov/show/NCT04471519",NA,"India","New Delhi","2020-Nov",NA,"Not Recruiting","Randomised","Quadruple",5,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","Standard of care, Vaccine",755
"NCT04471636","https://clinicaltrials.gov/show/NCT04471636",NA,"Germany","Berlin","2020-Sep",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Hospitalization, Visits or Returns to Emergency Department","Device + Other, Standard of care",600
"NCT04471766","https://clinicaltrials.gov/show/NCT04471766",NA,"Guinea-Bissau","Bissau","2020-Jul",NA,"Recruiting","Randomised","Single",2,"Unclear","Unclear","Mortality","Device, Standard of care",66000
"NCT04472611","https://clinicaltrials.gov/show/NCT04472611",NA,"United States","Washington, Dc","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU",NA,"Standard of care, Statins + Colchicine",466
"NCT04474340","https://clinicaltrials.gov/show/NCT04474340",NA,"Kuwait","Kuwait City","2020-Jul",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital, ICU","Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",300
"NCT04475081","https://clinicaltrials.gov/show/NCT04475081",NA,"United States","Louisiana","2020-Jul",NA,"Not Recruiting","Randomised","Single",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Standard of care, Vaccine",60
"NCT04475120","https://clinicaltrials.gov/show/NCT04475120",NA,"Italy","Rome","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed","Hospital","Viral Load or Clearance","Nutrition, Standard of care",60
"NCT04475302","https://clinicaltrials.gov/show/NCT04475302",NA,"India","New Delhi","2020-Jul",NA,"Recruiting","Single-Arm","Open-Label",2,"Healthy","Healthy Exposed","Mortality","Standard of care, Vaccine",2175
"NCT04475588","https://clinicaltrials.gov/show/NCT04475588",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","mAb, Standard of care",30
"NCT04476940","https://clinicaltrials.gov/show/NCT04476940",NA,"United States","Washington, Dc","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Unclear","Unclear","Pregnancy or Birth Outcomes","Education",200
"NCT04476979","https://clinicaltrials.gov/show/NCT04476979",NA,"France","Paris","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Corticosteroids, TCZ + Corticosteroids",120
"NCT04477083","https://clinicaltrials.gov/show/NCT04477083",NA,"Egypt","Cairo","2020-Jul",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Unclear","Viral Load or Clearance, Cough","HCQ, Standard of care",40
"NCT04479163","https://clinicaltrials.gov/show/NCT04479163",NA,"Argentina","Buenos Aires","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Respiratory Rate","Plasma based therapy, Standard of care",165
"NCT04479202","https://clinicaltrials.gov/show/NCT04479202",NA,"China","Beijing","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Stool Sample","Alternative therapy",76
"NCT04481633","https://clinicaltrials.gov/show/NCT04481633",NA,"France","Paris","2020-Jul",NA,"Recruiting","Non-Randomised","Open-Label",2,"Resolved Or Healthy","Unclear",NA,"HCQ, Standard of care",800
"NCT04482634","https://clinicaltrials.gov/show/NCT04482634",NA,"Turkey","Ankara","2020-Jul",NA,"Recruiting","Randomised","Single",2,"Resolved","Resolved Discharged","6-Minute Walking Distance","Exercise, Rehabilitation",122
"NCT04482673","https://clinicaltrials.gov/show/NCT04482673",NA,"United States","Washington, Dc","2020-Jan",NA,"Recruiting","Randomised","Quadruple",4,"Suspected","Outpatient","Anti SARS-COV-2 Titers","Standard of care, Vitamins",140
"NCT04484493","https://clinicaltrials.gov/show/NCT04484493",NA,"Egypt","Cairo","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Resolved","Resolved Discharged",NA,"Corticosteroids, Standard of care",100
"NCT04486144","https://clinicaltrials.gov/show/NCT04486144",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed Or Suspected","Healthy Exposed, Outpatient","Mortality","Alternative therapy, Standard of care",100
"NCT04487990","https://clinicaltrials.gov/show/NCT04487990",NA,"Brazil","Brasilia","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear",NA,"Anticoagulants, Standard of care",90
"NCT04490239","https://clinicaltrials.gov/show/NCT04490239",NA,"United States","Washington, Dc","2020-Jul",NA,"Not Recruiting","Unspecified","Open-Label",2,"Healthy","Unclear","Platelet Count","Inhaled solution",6
"NCT04491240","https://clinicaltrials.gov/show/NCT04491240",NA,"Russia","Moscow","2020-Jul",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Serious Adverse Events","Other, Standard of care",30
"NCT04492228","https://clinicaltrials.gov/show/NCT04492228",NA,"Italy","Rome","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission","Nutrition, Standard of care",100
"NCT04492501","https://clinicaltrials.gov/show/NCT04492501",NA,"Pakistan","Islamabad","2020-Jul",NA,"Not Recruiting","Non-Randomised","Open-Label",4,"Confirmed","Hospital",NA,"Plasma based therapy, Plasma based therapy + TCZ + Remdesivir + Stem cells, Standard of care",600
"NCT04492514","https://clinicaltrials.gov/show/NCT04492514",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"mAb, Standard of care",60
"NCT04493242","https://clinicaltrials.gov/show/NCT04493242",NA,"United States","Texas","2020-Jul",NA,"Not Recruiting","Randomised","Single",3,"Confirmed","Unclear","Mortality","Standard of care, Stem cells",60
"NCT04493359","https://clinicaltrials.gov/show/NCT04493359",NA,"Brazil","Brasilia","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission","Antihypertensive",240
"NCT04495842","https://clinicaltrials.gov/show/NCT04495842",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Single",2,"Suspected Or Healthy","Healthy Exposed, Outpatient","Anxiety","Alternative therapy, Standard of care",65
"NCT04495933","https://clinicaltrials.gov/show/NCT04495933",NA,"Australia","Canberra","2020-Jul",NA,"Recruiting","Randomised","Triple",5,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","Standard of care, Vaccine",216
"NCT04496245","https://clinicaltrials.gov/show/NCT04496245",NA,"Australia","Canberra","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers",NA,"Immunomodulators, Standard of care",1000
"NCT04497389","https://clinicaltrials.gov/show/NCT04497389",NA,"United States","Washington, Dc","2020-Sep",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital","C-Reactive Protein","Other, Standard of care",60
"NCT04497519","https://clinicaltrials.gov/show/NCT04497519",NA,"Netherlands","Amsterdam","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Unclear",NA,"HCQ",12
"NCT04498936","https://clinicaltrials.gov/show/NCT04498936",NA,"Egypt","Cairo","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital, ICU","Clinical Improvement Score (Any)","Antivirals, DAA, Standard of care",240
"NCT04499677","https://clinicaltrials.gov/show/NCT04499677",NA,"United Kingdom","London","2020-Jun",NA,"Recruiting","Randomised","Triple",4,"Confirmed Or Suspected","Outpatient","Viral Load or Clearance","FPV, LPV/r, LPV/r + FPV, Standard of care",240
"NCT04500067","https://clinicaltrials.gov/show/NCT04500067",NA,"Ukraine","Kyiv (Kiev)","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Fever, Lymphocyte Count","Igs, Standard of care",76
"NCT04502667","https://clinicaltrials.gov/show/NCT04502667",NA,"Mexico","Mexico","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Ferritin, IL-2","Standard of care, Vitamins",40
"NCT04505592","https://clinicaltrials.gov/show/NCT04505592",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Triple",3,"Confirmed","Hospital",NA,"Other, Standard of care",60
"NCT04507867","https://clinicaltrials.gov/show/NCT04507867",NA,"Mexico","Mexico","2020-Jun",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Cough, Fever, Dyspnea, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, D-Dimer, Weight, Height or BMI, Prothrombin, Fibrinogen, Triglycerides, INR, AST, Albumin, Bilirubin, Glucose, Blood Urea Nitrogen, Blood Pressure, Heart Rate, SpO2","Nutrition, Standard of care",240
"NCT04508439","https://clinicaltrials.gov/show/NCT04508439",NA,"Mexico","Mexico","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Weight, Height or BMI","Anticoagulants",130
"NCT04510207","https://clinicaltrials.gov/show/NCT04510207",NA,"Bahrain","Manama","2020-Mar",NA,"Recruiting","Randomised","Quadruple",3,"Healthy","Unclear",NA,"Standard of care, Vaccine",45000
"NCT04510207","https://clinicaltrials.gov/show/NCT04510207",NA,"Egypt","Cairo","2020-Mar",NA,"Recruiting","Randomised","Quadruple",3,"Healthy","Unclear",NA,"Standard of care, Vaccine",45000
"NCT04510207","https://clinicaltrials.gov/show/NCT04510207",NA,"Jordan","Amman","2020-Mar",NA,"Recruiting","Randomised","Quadruple",3,"Healthy","Unclear",NA,"Standard of care, Vaccine",45000
"NCT04510207","https://clinicaltrials.gov/show/NCT04510207",NA,"United Arab Emirates","Abu Dhabi","2020-Mar",NA,"Recruiting","Randomised","Quadruple",3,"Healthy","Unclear",NA,"Standard of care, Vaccine",45000
"NCT04518969","https://clinicaltrials.gov/show/NCT04518969",NA,"Belgium","Brussels","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","ICU",NA,"Cytokine removal, Standard of care",24
"NCT04521322","https://clinicaltrials.gov/show/NCT04521322",NA,"Argentina","Buenos Aires","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers",NA,"Other, Standard of care",400
"NCT04521400","https://clinicaltrials.gov/show/NCT04521400",NA,"Iran","Tehran","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","LPV/r + IFN",100
"NCT04522817","https://clinicaltrials.gov/show/NCT04522817",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Adverse Events","Other",12
"NCT04527224","https://clinicaltrials.gov/show/NCT04527224",NA,"South Korea","Seoul","2020-Aug",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Adverse Events","Stem cells",10
"NCT04527354","https://clinicaltrials.gov/show/NCT04527354",NA,"Russia","Moscow","2020-Aug",NA,"Not Recruiting","Randomised","Double",2,"Resolved","Outpatient, Hospital",NA,"Other, Standard of care",60
"NCT04528771","https://clinicaltrials.gov/show/NCT04528771",NA,"United States","Washington, Dc","2020-Aug",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization","Inhaled solution",21
"NCT04530370","https://clinicaltrials.gov/show/NCT04530370",NA,"Egypt","Cairo","2020-Aug",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed",NA,NA,"Plasma based therapy, Standard of care",30
"NCT04530578","https://clinicaltrials.gov/show/NCT04530578",NA,"Argentina","Buenos Aires","2020-Aug",NA,"Recruiting","Randomised","Open-Label",2,"Suspected","Hospital","Invasive Mechanical Ventilation or ECMO","Anticoagulants",200
"NCT04533399","https://clinicaltrials.gov/show/NCT04533399",NA,"South Africa","Pretoria","2020-Aug",NA,"Recruiting","Randomised","Quadruple",4,"Healthy","Healthy Unexposed","Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",4400
"NCT04534478","https://clinicaltrials.gov/show/NCT04534478",NA,"Spain","Barcelona","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Resolved","Hospital",NA,"Corticosteroids",120
"NCT04535063","https://clinicaltrials.gov/show/NCT04535063",NA,"Argentina","Buenos Aires","2020-Aug",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear",NA,"Plasma based therapy",200
"NCT04536090","https://clinicaltrials.gov/show/NCT04536090",NA,"Canada","Quebec","2020-Aug",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",150
"NCT04536363","https://clinicaltrials.gov/show/NCT04536363",NA,"Colombia","Bogota","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Other, Standard of care",284
"NCT04542993","https://clinicaltrials.gov/show/NCT04542993",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Single-Arm","Single",2,"Confirmed","Outpatient","Viral Load or Clearance","Resveratrol + Zinc, Standard of care",60
"NCT04549337","https://clinicaltrials.gov/show/NCT04549337",NA,"Denmark","Copenhagen","2020-Sep",NA,"Recruiting","Randomised","Double",3,"Resolved","Resolved Discharged",NA,"Exercise",10
"NCT04560881","https://clinicaltrials.gov/show/NCT04560881",NA,"Argentina","Buenos Aires","2020-Sep",NA,"Not Recruiting","Randomised","Triple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",3000
"NCT04563208","https://clinicaltrials.gov/show/NCT04563208",NA,"South Africa","Pretoria","2020-Sep",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear","Viral Load or Clearance","Antivirals, Standard of care",40
"NCT04568876","https://clinicaltrials.gov/show/NCT04568876",NA,"Italy","Rome","2020-Sep",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Nutrition + Standard of care, Standard of care",40
"NCT04588480","https://clinicaltrials.gov/show/NCT04588480",NA,"Japan","Tokyo","2020-Oct",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Serious Adverse Events, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",160
"NCT04597242","https://clinicaltrials.gov/show/NCT04597242",NA,"United States","Washington, Dc","2020-Oct",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Hospital",NA,"Antistaphylococcal lysin",NA
"NCT04603729","https://clinicaltrials.gov/show/NCT04603729",NA,"Pakistan","Islamabad","2020-Oct",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, C-Reactive Protein, SpO2","Corticosteroids, Dexamethasone",100
"NCT04642014","https://clinicaltrials.gov/show/NCT04642014",NA,"Poland","Warsaw","2020-Nov",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality","Plasma based therapy",500
"NCT04643691","https://clinicaltrials.gov/show/NCT04643691",NA,"France","Paris","2020-Nov",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Organ Failure or Dysfunction (SOFA)","ARBs + Other, Standard of care",90
"NCT04647734","https://clinicaltrials.gov/show/NCT04647734",NA,"Denmark","Copenhagen","2020-Nov",NA,"Not Recruiting","Randomised","Single",2,"Resolved","Resolved Discharged",NA,"Exercise, Standard of care",40
"ACTRN12620000417987","https://anzctr.org.au/ACTRN12620000417987.aspx",NA,"Australia","Canberra","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",1,"Healthy","Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ",680
"ACTRN12620000501943","https://anzctr.org.au/ACTRN12620000501943.aspx",NA,"Australia","Canberra","2020-Apr",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",650
"ACTRN12620000612910","https://anzctr.org.au/ACTRN12620000612910.aspx",NA,"Australia","Canberra","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","ICU","ICU Admission, Fever, Treatment-emergent Adverse Events, Blood Gas, PaO2-FiO2","Standard of care, Stem cells",24
"ISRCTN59048638","http://isrctn.com/ISRCTN59048638",NA,"Mexico","Mexico","2020-Apr",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Suspected","Outpatient","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",200
"NCT04324021","https://clinicaltrials.gov/show/NCT04324021",NA,"United States","Washington, Dc","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Healthcare Workers, Unclear",NA,"Anakinra, mAb",16
"NCT04324021","https://clinicaltrials.gov/show/NCT04324021",NA,"Italy","Rome","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Healthcare Workers, Unclear",NA,"Anakinra, mAb",16
"NCT04332107","https://clinicaltrials.gov/show/NCT04332107",NA,"United States","Washington, Dc","2020-Mar",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Viral Load or Clearance, Household Members with CoViD-19, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events","AZT, Standard of care",2271
"NCT04333914","https://clinicaltrials.gov/show/NCT04333914",NA,"France","Paris","2020-Jan",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Neutrophils, Hemoglobin","HCQ, mAb, Standard of care, TCZ",219
"NCT04341441","https://clinicaltrials.gov/show/NCT04341441",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Triple",6,NA,"Healthcare Workers","Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Adverse Events, Serious Adverse Events, IgG, IgM or IgA","HCQ, Standard of care",3000
"NCT04368000","https://clinicaltrials.gov/show/NCT04368000",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","PaO2-FiO2, SpO2","Positioning, Standard of care",30
"NCT04369599","https://clinicaltrials.gov/show/NCT04369599",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Unclear","ICU",NA,"Device",24
"NCT04370782","https://clinicaltrials.gov/show/NCT04370782",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",3,NA,"Outpatient","ICU Admission, Hospitalization","HCQ + AZT + Zinc, HCQ + Zinc + Antibiotics",18
"NCT04382924","https://clinicaltrials.gov/show/NCT04382924",NA,"United States","Washington, Dc","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Quality of Life","Other, Standard of care",682
"NCT04382924","https://clinicaltrials.gov/show/NCT04382924",NA,"Australia","Canberra","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Quality of Life","Other, Standard of care",682
"NCT04382924","https://clinicaltrials.gov/show/NCT04382924",NA,"Philippines","Manila","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Quality of Life","Other, Standard of care",682
"NCT04382924","https://clinicaltrials.gov/show/NCT04382924",NA,"Romania","Bucharest","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Quality of Life","Other, Standard of care",682
"NCT04386252","https://clinicaltrials.gov/show/NCT04386252",NA,"United States","Washington, Dc","2020-Nov",NA,"Not Recruiting","Non-Randomised","Open-Label",6,"Healthy","Healthcare Workers",NA,"Vaccine",175
"NCT04395911","https://clinicaltrials.gov/show/NCT04395911",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Mortality, Renal Outcome (Unspecified)","Device",30
"NCT04397718","https://clinicaltrials.gov/show/NCT04397718",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever","Hormone therapy, Standard of care",198
"NCT04401293","https://clinicaltrials.gov/show/NCT04401293",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital","Mortality","Anticoagulants",308
"NCT04402983","https://clinicaltrials.gov/show/NCT04402983",NA,"Turkey","Ankara","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Resolved Discharged","Dyspnea, Other Mild Symptoms","Other, Standard of care",34
"NCT04405843","https://clinicaltrials.gov/show/NCT04405843",NA,"Colombia","Bogota","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear",NA,"Ivermectin, Standard of care",476
"NCT04407286","https://clinicaltrials.gov/show/NCT04407286",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear",NA,"Vitamins",41
"NCT04408183","https://clinicaltrials.gov/show/NCT04408183",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Triple",2,"Healthy","Healthcare Workers","Adverse Events, Radiographic Findings","Other, Standard of care",225
"NCT04433546","https://clinicaltrials.gov/show/NCT04433546",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Other",54
"NCT04447534","https://clinicaltrials.gov/show/NCT04447534",NA,"Egypt","Cairo","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality","HCQ, HCQ + Zinc",200
"NCT04453384","https://clinicaltrials.gov/show/NCT04453384",NA,"France","Paris","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Non-invasive Ventilation, Adverse Events, Antibodies","other, Standard of care",414
"NCT04453839","https://clinicaltrials.gov/show/NCT04453839",NA,"United States","Washington, Dc","2020-Jun",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Hospital",NA,"Other",NA
"NCT04460443","https://clinicaltrials.gov/show/NCT04460443",NA,"Egypt","Cairo","2020-Apr",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear",NA,"DAA, DAA + Antiviral, Standard of care",60
"NCT04469491","https://clinicaltrials.gov/show/NCT04469491",NA,"France","Paris","2020-Jul",NA,"Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"IFN, Standard of care",60
"NCT04476745","https://clinicaltrials.gov/show/NCT04476745",NA,"Jordan","Amman","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed","IL-1, IL-6, Tumor Necrosis Factor (Any)","Vitamins",100
"NCT04479631","https://clinicaltrials.gov/show/NCT04479631",NA,"China","Beijing","2020-Jul",NA,"Not Recruiting","Randomised","Single",6,"Healthy","Healthy Unexposed","Adverse Events, Radiographic Findings","mAb, Standard of care",16
"NCT04479644","https://clinicaltrials.gov/show/NCT04479644",NA,"China","Beijing","2020-Jul",NA,"Not Recruiting","Randomised","Single",6,"Healthy","Healthy Unexposed","Adverse Events, Radiographic Findings","mAb, Standard of care",17
"NCT04482686","https://clinicaltrials.gov/show/NCT04482686",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Triple",4,"Confirmed","Unclear",NA,"Ivermectin + Doxycycline + Zinc + Vitamins, Vitamins + Zinc",300
"NCT04483271","https://clinicaltrials.gov/show/NCT04483271",NA,"Jordan","Amman","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed","IL-1, IL-6, Tumor Necrosis Factor (Any)","Nutrition, Standard of care",100
"NCT04519437","https://clinicaltrials.gov/show/NCT04519437",NA,"United States","Washington, Dc","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear","Adverse Events","mAb, Standard of care",974
"NCT04601077","https://clinicaltrials.gov/show/NCT04601077",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Blood Pressure","Other, Standard of care",100
"NCT04606784","https://clinicaltrials.gov/show/NCT04606784",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Single",2,"Confirmed","Hospital","Adverse Events","Plasma based therapy, Standard of care",40
"NCT04608266","https://clinicaltrials.gov/show/NCT04608266",NA,"France","Paris","2020-Oct",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization","Other, Standard of care",596
"NCT04661527","https://clinicaltrials.gov/show/NCT04661527",NA,"Spain","Madrid","2020-Oct",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital",NA,"Sarilumab",60
"NCT04666012","https://clinicaltrials.gov/show/NCT04666012",NA,"South Korea","Seoul","2020-Oct",NA,"Not Recruiting","Randomised","Open-Label",5,"Healthy","Healthy Unexposed","Adverse Events","Vaccine",150
"EUCTR2020-001528-32-IT","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001528-32",NA,"Italy","Rome","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",5,"Confirmed","Outpatient","Hospitalization","Darunavir, FPV, HCQ, LPV/r, Standard of care",435
"NCT04358939","https://clinicaltrials.gov/show/NCT04358939",NA,"France","Paris","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Patient Positioning","Positioning",404
"NCT04366115","https://clinicaltrials.gov/show/NCT04366115",NA,"United States","Washington","2020-Apr",NA,"Not Recruiting","Randomised","Triple",2,NA,"ICU","Mortality","Corticosteroids, Dexamethasone + Other",16
"NCT04401475","https://clinicaltrials.gov/show/NCT04401475",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",396
"NCT04401475","https://clinicaltrials.gov/show/NCT04401475",NA,"Canada","Ottawa","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",396
"NCT04407182","https://clinicaltrials.gov/show/NCT04407182",NA,"Ecuador","Quito","2020-May",NA,"Not Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",60
"NCT04435587","https://clinicaltrials.gov/show/NCT04435587",NA,"Thailand","Nan","2020-Jun",NA,"Recruiting","Randomised","Single",2,"Confirmed","Unclear","Adverse Events","HCQ + Antivirals, Ivermectin",80
"NCT04470544","https://clinicaltrials.gov/show/NCT04470544",NA,"United States","Washington, Dc","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"Other, Standard of care",264
"NCT04524663","https://clinicaltrials.gov/show/NCT04524663",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Other, Standard of care",120
"NCT04639466","https://clinicaltrials.gov/show/NCT04639466",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Double",3,"Healthy","Healthy Unexposed","Adverse Events","Standard of care, Vaccine, Vaccine + Standard of care",129
"NCT04679415","https://clinicaltrials.gov/show/NCT04679415",NA,"Indonesia","Jakarta","2020-Dec",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal IgG4 + Standard of care, Standard of care",63
"NCT04705844","https://clinicaltrials.gov/show/NCT04705844",NA,"United States","Florida","2021-Oct",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality","Anti-TNF, Standard of care",1444
"NCT04340349","https://clinicaltrials.gov/show/NCT04340349",NA,"Mexico","Mexico","2020-Feb",NA,"Recruiting","Randomised","Triple",3,NA,"Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6",NA,280
"NCT04364009","https://clinicaltrials.gov/show/NCT04364009",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, Fibrinogen, LDH, PaO2-FiO2, Respiratory Rate, Quality of Life","Anakinra, Standard of care",71
"NCT04364763","https://clinicaltrials.gov/show/NCT04364763",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital",NA,"Other, Standard of care",252
"NCT04371367","https://clinicaltrials.gov/show/NCT04371367",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,"ICU","Clinical Improvement Score (Any)","mAb, Standard of care",208
"NCT04373460","https://clinicaltrials.gov/show/NCT04373460",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Outpatient","Mortality, Hospitalization, Serious Adverse Events","Plasma based therapy, Standard of care",1344
"NCT04390152","https://clinicaltrials.gov/show/NCT04390152",NA,"Colombia","Bogota","2020-Dec",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality","HCQ + LPV/r or AZT, Stem cells",40
"NCT04395144","https://clinicaltrials.gov/show/NCT04395144",NA,"Canada","Ottawa","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Positioning, Standard of care",346
"NCT04403555","https://clinicaltrials.gov/show/NCT04403555",NA,"Egypt","Cairo","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality","HCQ, Ivermectin + Docycline",160
"NCT04404361","https://clinicaltrials.gov/show/NCT04404361",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","JAKi, Standard of care",364
"NCT04406532","https://clinicaltrials.gov/show/NCT04406532",NA,"United States","New York","2020-May",NA,"Not Recruiting","Randomised","Single",2,"Confirmed Or Suspected","Healthcare Workers",NA,"Other",100
"NCT04407689","https://clinicaltrials.gov/show/NCT04407689",NA,"France","Paris","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Lymphocyte Count","Other, Standard of care",48
"NCT04411680","https://clinicaltrials.gov/show/NCT04411680",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Other, Standard of care",120
"NCT04420676","https://clinicaltrials.gov/show/NCT04420676",NA,"Austria","Vienna","2020-Apr",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Stool Sample","Nutrition, Standard of care",120
"NCT04433910","https://clinicaltrials.gov/show/NCT04433910",NA,"Germany","Berlin","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital, ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any)","Plasma based therapy, Standard of care",106
"NCT04438850","https://clinicaltrials.gov/show/NCT04438850",NA,"Italy","Rome","2020-Oct",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Healthcare Workers, Outpatient, Unclear","Viral Load or Clearance","Ivermectin, Standard of care",102
"NCT04438850","https://clinicaltrials.gov/show/NCT04438850",NA,"Spain","Madrid","2020-Oct",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Healthcare Workers, Outpatient, Unclear","Viral Load or Clearance","Ivermectin, Standard of care",102
"NCT04456452","https://clinicaltrials.gov/show/NCT04456452",NA,"United States","Washington, Dc","2020-Jun",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Adverse Events","Other, Standard of care",10
"NCT04457817","https://clinicaltrials.gov/show/NCT04457817",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, Blood Pressure, Renal Outcome (Unspecified)","Other, Standard of care",100
"NCT04458363","https://clinicaltrials.gov/show/NCT04458363",NA,"United States","Washington, Dc","2020-Jun",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Adverse Events","Plasma based therapy",3
"NCT04458519","https://clinicaltrials.gov/show/NCT04458519",NA,"Canada","Ottawa","2020-Jan",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Other, Standard of care",40
"NCT04460183","https://clinicaltrials.gov/show/NCT04460183",NA,"United Kingdom","London","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Non-invasive respiratory support, Standard of care",300
"NCT04477954","https://clinicaltrials.gov/show/NCT04477954",NA,"Argentina","Buenos Aires","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","ICU",NA,"Non-invasive respiratory support, Standard of care",40
"NCT04482699","https://clinicaltrials.gov/show/NCT04482699",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Double",4,"Confirmed","Unclear","Mortality","Standard of care, Stem cells",88
"NCT04487210","https://clinicaltrials.gov/show/NCT04487210",NA,"Taiwan","Taipei","2020-Jul",NA,"Not Recruiting","Non-Randomised","Open-Label",3,"Healthy","Healthy Unexposed",NA,"Vaccine",45
"NCT04507256","https://clinicaltrials.gov/show/NCT04507256",NA,"United Kingdom","London","2020-Jul",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Adverse Events","mAb, Standard of care",60
"NCT04522089","https://clinicaltrials.gov/show/NCT04522089",NA,"Taiwan","Taipei","2020-Dec",NA,"Recruiting","Randomised","Open-Label",4,"Healthy","Unclear","Adverse Events","Vaccine",70
"NCT04576312","https://clinicaltrials.gov/show/NCT04576312",NA,"Denmark","Copenhagen","2020-Sep",NA,"Not Recruiting","Randomised","Quadruple",7,"Healthy","Unclear",NA,"Inhaled solution",64
"NCT04703205","https://clinicaltrials.gov/show/NCT04703205",NA,"Japan","Tokyo","2020-Jan",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Ivermectin, Standard of care",240
"NCT04709835","https://clinicaltrials.gov/show/NCT04709835",NA,"Bulgaria","Sofia","2021-Dec",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Other, Standard of care",220
"NCT04709835","https://clinicaltrials.gov/show/NCT04709835",NA,"Ireland","Dublin","2021-Dec",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Other, Standard of care",220
"NCT04709835","https://clinicaltrials.gov/show/NCT04709835",NA,"United Kingdom","London","2021-Dec",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Other, Standard of care",220
"ISRCTN15913068","http://isrctn.com/ISRCTN15913068",NA,"United Kingdom","London","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospital Discharge, Lymphocyte Count","Other, Standard of care",48
"JPRN-JRCT2031200035","https://jrct.niph.go.jp/latest-detail/jRCT2031200035",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization","Remdesivir, Remdesivir + JAKi",35
"JPRN-JRCT2031200035","https://jrct.niph.go.jp/latest-detail/jRCT2031200035",NA,"Denmark","Copenhagen","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization","Remdesivir, Remdesivir + JAKi",35
"JPRN-JRCT2031200035","https://jrct.niph.go.jp/latest-detail/jRCT2031200035",NA,"South Korea","Seoul","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization","Remdesivir, Remdesivir + JAKi",35
"JPRN-JRCT2031200035","https://jrct.niph.go.jp/latest-detail/jRCT2031200035",NA,"Mexico","Mexico","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization","Remdesivir, Remdesivir + JAKi",35
"JPRN-JRCT2031200035","https://jrct.niph.go.jp/latest-detail/jRCT2031200035",NA,"Singapore","Singapore","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization","Remdesivir, Remdesivir + JAKi",35
"JPRN-JRCT2031200035","https://jrct.niph.go.jp/latest-detail/jRCT2031200035",NA,"Japan","Toyama","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization","Remdesivir, Remdesivir + JAKi",35
"JPRN-JRCT2031200035","https://jrct.niph.go.jp/latest-detail/jRCT2031200035",NA,"United Kingdom","London","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization","Remdesivir, Remdesivir + JAKi",35
"JPRN-JRCT2071200023","https://jrct.niph.go.jp/latest-detail/jRCT2071200023",NA,"Japan","Nagasaki","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance","Antivirals, Standard of care",120
"JPRN-JRCTS031200026","https://jrct.niph.go.jp/latest-detail/jRCTs031200026",NA,"Japan","Tokyo","2020-Jan",NA,"Recruiting","Randomised","Single",2,"Confirmed","Unclear","Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, Coagulation Test, ALT, Bilirubin, Glucose, SpO2, Radiographic Findings, Renal Outcome (Unspecified)","Anticoagulants, FPV",160
"CTRI/2020/03/024402","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42638",NA,"India","New Delhi","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Healthcare Workers","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms","HCQ",500
"CTRI/2020/04/024479","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42713",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Heart Rate","HCQ, Standard of care",32
"CTRI/2020/04/024659","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42967",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,"Healthy Exposed","Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Alternative therapy",30
"CTRI/2020/04/024706","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43039",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Invasive Mechanical Ventilation or ECMO","Plasma based therapy, Standard of care",40
"CTRI/2020/04/024731","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42912",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Exposed","Cough, Other Mild Symptoms","Alternative therapy",50
"CTRI/2020/04/024729","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42933",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"HCQ, Standard of care",60
"CTRI/2020/04/024775","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43149",NA,"India","Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, PaO2-FiO2","Plasma based therapy, Standard of care",452
"CTRI/2020/04/024749","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42972",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed, Healthy Exposed, Healthcare Workers",NA,"Standard of care, Vaccine",5946
"CTRI/2020/04/024806","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42843",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Imatinib, Standard of care",100
"CTRI/2020/04/024804","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42849",NA,"India","Karnataka","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","ICU","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Organ Failure or Dysfunction (SOFA), Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Distress, Renal Outcome (Unspecified)","Plasma based therapy, Standard of care",24
"CTRI/2020/04/024833","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43105",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Cough, Fever, Dyspnea, Antibodies, Distress","Standard of care, Vaccine",1826
"CTRI/2020/04/024846","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43004",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge","Standard of care, Vaccine",300
"CTRI/2020/04/024857","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43212",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed","Outpatient","ICU Admission","Alternative therapy",100
"CTRI/2020/04/024858","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43236",NA,"India","Delhi","2020-Apr",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance","Ivermectin, Standard of care",50
"CTRI/2020/04/024882","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42899",NA,"India","Haryana","2020-Apr",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Hospital Discharge","Alternative therapy, Standard of care",60
"CTRI/2020/04/024904","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43130",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, HCQ + AZT",300
"CTRI/2020/04/024883","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43168",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",112
"CTRI/2020/04/024915","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43332",NA,"India","Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, PaO2-FiO2","Plasma based therapy, Standard of care",100
"CTRI/2020/04/024948","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43364",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed","Unclear",NA,"Corticosteroids, HCQ, Ivermectin, Standard of care",120
"CTRI/2020/04/024949","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43400",NA,"India","New Delhi","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient",NA,"Other, Standard of care",48
"CTRI/2020/04/024947","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43259",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",1,"Confirmed","Hospital",NA,"Alternative therapy",100
"CTRI/2020/05/024967","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43338",NA,"India","New Delhi","2020-Jan",NA,"Not Recruiting","Single-Arm","Open-Label",2,"Suspected","Healthy Exposed","C-Reactive Protein, D-Dimer, LDH","Other, Standard of care",42
"CTRI/2020/05/024959","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42878",NA,"India","New Delhi","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, D-Dimer, SpO2","mAb, Standard of care",30
"CTRI/2020/05/024969","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43393",NA,"India","Delhi","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Mortality","Alternative therapy, Standard of care",100
"CTRI/2020/05/024962","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43237",NA,"India","New Delhi","2020-Jan",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Viral Load or Clearance","Hygiene, Standard of care",96
"CTRI/2020/05/024981","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43374",NA,"India","New Delhi","2020-Feb",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed",NA,"Alternative therapy, Standard of care",600
"CTRI/2020/05/024986","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43455",NA,"India","Delhi","2020-Apr",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Suspected","Healthy Exposed",NA,"Alternative therapy",10000
"CTRI/2020/05/025013","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42858",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Distress","Standard of care, Vaccine",60
"CTRI/2020/05/025022","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43183",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"HCQ, Standard of care",166
"CTRI/2020/05/025067","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43019",NA,"India","New Delhi","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers",NA,"HCQ, Standard of care",6950
"CTRI/2020/05/025049","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43313",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed Or Suspected","Unclear","Mortality","Alternative therapy",100
"CTRI/2020/05/025069","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43522",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Exposed",NA,"Alternative therapy",9200
"CTRI/2020/05/025068","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43449",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance","Ivermectin, Standard of care",50
"CTRI/2020/05/025071","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43447",NA,"India","New Delhi","2020-Aug",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","ICU Admission, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support, Standard of care",40
"CTRI/2020/05/025088","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43555",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed, Healthy Exposed",NA,"Alternative therapy, Standard of care",1200
"CTRI/2020/05/025093","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43539",NA,"India","New Delhi","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed, Healthy Exposed",NA,"Alternative therapy, Standard of care",1200
"CTRI/2020/05/025114","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43504",NA,"India","New Delhi","2020-Dec",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"FPV, Standard of care",150
"CTRI/2020/05/025156","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43590",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance","Alternative therapy, Standard of care",60
"CTRI/2020/05/025161","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43442",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Cough, Fever, Dyspnea","Alternative therapy, Standard of care",120
"CTRI/2020/05/025166","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43553",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed",NA,"Alternative therapy, Standard of care",1200
"CTRI/2020/05/025178","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43557",NA,"India","Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",140
"CTRI/2020/05/025167","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43378",NA,"India","New Delhi","2020-May",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Outpatient",NA,"Other, Standard of care",100
"CTRI/2020/05/025171","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43487",NA,"India","Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed, Healthy Exposed",NA,"Alternative therapy, Standard of care",50000
"CTRI/2020/05/025213","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43698",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Healthy","Healthy Exposed",NA,"Alternative therapy",1500
"CTRI/2020/05/025205","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43721",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",33000
"CTRI/2020/05/025214","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43727",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear",NA,"Alternative therapy, Standard of care",80
"CTRI/2020/05/025209","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43251",NA,"India","New Delhi","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge","Plasma based therapy, Standard of care",80
"CTRI/2020/05/025215","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43769",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance","Alternative therapy, Vitamins + Zinc",50
"CTRI/2020/05/025222","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43803",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Exposed",NA,"Alternative therapy",275
"CTRI/2020/05/025224","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43728",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Ivermectin, Standard of care",50
"CTRI/2020/05/025242","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43057",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Unspecified",1,"Healthy","Healthcare Workers",NA,"HCQ",400
"CTRI/2020/05/025272","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43790",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",800
"CTRI/2020/05/025254","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43630",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Healthy","Healthy Exposed",NA,"Alternative therapy",40000
"CTRI/2020/05/025276","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43892",NA,"India","Delhi","2020-May",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear",NA,"Alternative therapy",50
"CTRI/2020/05/025273","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43900",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",120
"CTRI/2020/05/025275","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43917",NA,"India","Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers",NA,"Alternative therapy, Standard of care",200
"CTRI/2020/05/025271","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43206",NA,"India","New Delhi","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Other, Standard of care",480
"CTRI/2020/05/025248","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43479",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Non-Randomised","Unspecified",1,"Suspected","Unclear","Anxiety","Psychological therapy",128
"CTRI/2020/05/025277","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43176",NA,"India","New Delhi","2020-May",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed",NA,"Other, Standard of care",4000
"CTRI/2020/05/025299","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43752",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Pneumonia or ARDS","Plasma based therapy, Standard of care",20
"CTRI/2020/05/025298","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43761",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Alternative therapy, Standard of care",21500
"CTRI/2020/05/025320","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43576",NA,"India","New Delhi","2020-May",NA,"Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Pneumonia or ARDS","Exercise + Nutrition + Hygiene + Alternative therapy + Other, Standard of care",658
"CTRI/2020/05/025319","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42751",NA,"India","New Delhi","2020-May",NA,"Recruiting","Randomised","Unspecified",2,"Unclear","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","ARBs, Standard of care",186
"CTRI/2020/05/025328","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43703",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Mortality, Organ Failure or Dysfunction (SOFA)","Plasma based therapy, Standard of care",100
"CTRI/2020/05/025338","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44033",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear",NA,"Alternative therapy",40
"CTRI/2020/05/025336","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43934",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",300
"CTRI/2020/05/025337","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43940",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Clinical Improvement Score (Any)","Alternative therapy, Standard of care",200
"CTRI/2020/05/025335","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43949",NA,"India","Delhi","2020-May",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Outpatient",NA,"Alternative therapy",40
"CTRI/2020/05/025341","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44013",NA,"India","New Delhi","2020-May",NA,"Recruiting","Randomised","Unspecified",1,"Confirmed","Unclear",NA,"Exercise + Alternative therapy",30
"CTRI/2020/05/025346","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43005",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, PaO2-FiO2","Plasma based therapy, Standard of care",90
"CTRI/2020/05/025350","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43559",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","Hospital Discharge, Clinical Improvement Score (Any)","Other",50
"CTRI/2020/05/025370","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44064",NA,"India","Rajasthan","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Suspected","Hospital","Viral Load or Clearance","Alternative therapy",40
"CTRI/2020/05/025385","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43953",NA,"India","Delhi","2020-May",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",30000
"CTRI/2020/05/025369","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43485",NA,"India","Haryana","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Standard of care, TCZ",180
"CTRI/2020/05/025425","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44043",NA,"India","Punjab","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed, Healthy Exposed, Healthcare Workers",NA,"Alternative therapy",50
"CTRI/2020/05/025429","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44058",NA,"India","New Delhi","2020-May",NA,"Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",5000
"CTRI/2020/05/025434","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43957",NA,"India","New Delhi","2020-May",NA,"Recruiting","Randomised","Double",1,"Confirmed","Hospital",NA,"Alternative therapy",135
"CTRI/2020/05/025483","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44041",NA,"India","Tamil Nadu","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance, Cough, Fever, Respiratory Rate","Alternative therapy, Standard of care",100
"CTRI/2020/05/025485","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44052",NA,"India","New Delhi","2020-May",NA,"Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Alternative therapy, Standard of care",5000
"CTRI/2020/05/025484","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44055",NA,"India","New Delhi","2020-May",NA,"Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Alternative therapy, Standard of care",5000
"CTRI/2020/05/025490","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44042",NA,"India","New Delhi","2020-May",NA,"Recruiting","Randomised","Unspecified",2,"Suspected Or Healthy","Healthy Exposed, Healthcare Workers, Outpatient",NA,"Other + Vitamins + Alternative therapy + Nutrition, Standard of care",110
"CTRI/2020/05/025488","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44062",NA,"India","Rajasthan","2020-May",NA,"Not Recruiting","Randomised","Open-Label",1,"Healthy","Healthy Unexposed",NA,"Alternative therapy",12000
"CTRI/2020/05/025491","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44065",NA,"India","New Delhi","2020-May",NA,"Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed, Healthcare Workers","Mortality","Alternative therapy, Standard of care",1000
"CTRI/2020/05/025496","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44192",NA,"India","New Delhi","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed",NA,"Alternative therapy",10
"CTRI/2020/06/025527","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43968",NA,"India","New Delhi","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",42
"CTRI/2020/06/025557","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43812",NA,"India","New Delhi","2020-Feb",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospitalization","Alternative therapy, Standard of care",420
"CTRI/2020/06/025530","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43305",NA,"India","New Delhi","2020-Feb",NA,"Not Recruiting","Non-Randomised","Unspecified",1,"Healthy","Healthy Unexposed","Fever","Alternative therapy",10000
"CTRI/2020/06/025556","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44144",NA,"India","New Delhi","2020-Feb",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Cough, Fever, Dyspnea","Alternative therapy, Standard of care",30
"CTRI/2020/06/025558","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43411",NA,"India","New Delhi","2020-Feb",NA,"Not Recruiting","Randomised","Double",2,"Suspected","Outpatient",NA,"Alternative therapy, Standard of care",300
"CTRI/2020/06/025575","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43076",NA,"India","New Delhi","2020-Mar",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Cough, Fever, SpO2, Respiratory Rate","HCQ + Antivirals, LPV/r + antivirals",175
"CTRI/2020/06/025590","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44121",NA,"India","New Delhi","2020-Mar",NA,"Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","Hospital","Cough","Alternative therapy, Standard of care",120
"CTRI/2020/06/025613","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44346",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed","C-Reactive Protein","Melatonin, Standard of care",200
"CTRI/2020/06/025637","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43550",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Unspecified",1,"Healthy","Healthy Unexposed","C-Reactive Protein, Ferritin, Troponin, LDH","Alternative therapy",10
"CTRI/2020/06/025625","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43345",NA,"India","New Delhi","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Unclear",NA,"Alternative therapy, Standard of care",86
"CTRI/2020/06/025650","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44412",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",1,"Healthy","Healthy Exposed",NA,"Alternative therapy",4000
"CTRI/2020/06/025672","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44415",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Cough, Fever, Dyspnea, Other Mild Symptoms","Alternative therapy",60
"CTRI/2020/06/025671","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44425",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","IL-6","Alternative therapy, Standard of care",10
"CTRI/2020/06/025704","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44170",NA,"India","New Delhi","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","HCQ + AZT, HCQ + Other + AZT",120
"CTRI/2020/06/025763","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44340",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Randomised","Unspecified",1,"Confirmed","Outpatient, Hospital",NA,"Alternative therapy",150
"CTRI/2020/06/025766","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44171",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Other, Standard of care",300
"CTRI/2020/06/025760","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44441",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","Mortality","DAA",50
"CTRI/2020/06/025768","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44445",NA,"India","New Delhi","2020-Sep",NA,"Recruiting","Randomised","Open-Label",1,"Confirmed","Unclear",NA,"Alternative therapy",200
"CTRI/2020/06/025762","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44259",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed","Unclear",NA,"Alternative therapy",200
"CTRI/2020/06/025769","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44260",NA,"India","New Delhi","2020-Sep",NA,"Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Alternative therapy, Standard of care",40000
"CTRI/2020/06/025801","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44293",NA,"India","New Delhi","2020-Oct",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Alternative therapy",40
"CTRI/2020/06/025796","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44181",NA,"India","New Delhi","2020-Oct",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",90
"CTRI/2020/06/025779","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44463",NA,"India","Rajasthan","2020-Oct",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Exposed",NA,"Alternative therapy",50
"CTRI/2020/06/025799","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44480",NA,"India","Maharashtra","2020-Oct",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"FPV, Standard of care",156
"CTRI/2020/06/025800","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44485",NA,"India","New Delhi","2020-Oct",NA,"Not Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Quality of Life","Alternative therapy, Standard of care",120
"CTRI/2020/06/025804","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44572",NA,"India","New Delhi","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2","Positioning",120
"CTRI/2020/06/025803","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44478",NA,"India","Delhi","2020-Nov",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",400
"CTRI/2020/06/025849","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44408",NA,"India","New Delhi","2020-Dec",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospital Discharge, Viral Load or Clearance","HCQ, HCQ + Antivirals",158
"CTRI/2020/06/025852","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44204",NA,"India","New Delhi","2020-Dec",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","Clinical Improvement Score (Any)","Alternative therapy",20
"CTRI/2020/06/025854","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44078",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Non-Randomised","Unspecified",1,"Healthy","Unclear","Mortality","Vaccine",1450
"CTRI/2020/06/025856","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44606",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear",NA,"Alternative therapy, HCQ + Vitamins + AZT + Zinc + Other",200
"CTRI/2020/06/025855","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44386",NA,"India","Gujarat","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Mortality, Clinical Improvement Score (Any)","Alternative therapy, Standard of care",200
"CTRI/2020/06/025861","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44072",NA,"India","New Delhi","2020-Jun",NA,"Recruiting","Randomised","Open-Label",7,"Confirmed, Suspected Or Healthy","Healthy Unexposed, Healthy Exposed, Outpatient, Hospital","Clinical Improvement Score (Any), Quality of Life","Alternative therapy, Standard of care",500
"CTRI/2020/06/025862","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43858",NA,"India","Delhi","2020-Jun",NA,"Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear",NA,"Radiation therapy",10
"CTRI/2020/06/025874","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44684",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance, Cough, Fever, IL-2, IL-6, IL-10, Tumor Necrosis Factor (Any), IgG, IgM or IgA","Alternative therapy, Vitamins + Zinc",60
"CTRI/2020/06/025928","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44664",NA,"India","New Delhi","2020-Jun",NA,"Recruiting","Randomised","Open-Label",1,"Healthy","Healthy Exposed","Viral Load or Clearance","Hygiene",204
"CTRI/2020/06/025957","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44709",NA,"India","New Delhi","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","FPV, FPV + Umifenovir",158
"CTRI/2020/06/025977","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44449",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",120
"CTRI/2020/06/025996","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44622",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",200
"CTRI/2020/06/025998","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707",NA,"India","Uttar Pradesh","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",60
"CTRI/2020/06/026001","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44196",NA,"India","Delhi","2020-Jun",NA,"Recruiting","Randomised","Unspecified",3,"Confirmed","Hospital","Viral Load or Clearance","Ivermectin, Standard of care",120
"CTRI/2020/06/025999","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44764",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Cough, C-Reactive Protein, IgG, IgM or IgA, CD4, CD8","Alternative therapy, Standard of care",60
"CTRI/2020/06/026002","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44799",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance","Alternative therapy, Standard of care",60
"CTRI/2020/06/026045","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44677",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Alternative therapy, Standard of care",800
"CTRI/2020/06/026055","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44306",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",5000
"CTRI/2020/06/026056","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44130",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",5000
"CTRI/2020/06/026087","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43775",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"IFN, Standard of care",40
"CTRI/2020/06/026123","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44667",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any)","Plasma based therapy, Standard of care",472
"CTRI/2020/06/026119","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44218",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",90
"CTRI/2020/06/026147","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43778",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Exposed",NA,"Exercise + Alternative therapy, Standard of care",604
"CTRI/2020/06/026151","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43770",NA,"India","Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Exposed",NA,"Exercise + Alternative therapy, Standard of care",452
"CTRI/2020/06/026161","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44832",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",140
"CTRI/2020/06/026190","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45005",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any)","Alternative therapy, Standard of care",160
"CTRI/2020/06/026187","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45027",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Cough, C-Reactive Protein, IgG, IgM or IgA","Alternative therapy, Standard of care",60
"CTRI/2020/06/026189","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45029",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","ICU Admission, Hospitalization, C-Reactive Protein","Other + Vitamins",210
"CTRI/2020/06/026191","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45075",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Double",1,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Other + Vitamins",500
"CTRI/2020/06/026192","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44815",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","C-Reactive Protein","Other, Standard of care",100
"CTRI/2020/06/026192","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44815",NA,"Russia","Moscow","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","C-Reactive Protein","Other, Standard of care",100
"CTRI/2020/06/026192","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44815",NA,"Ukraine","Kyiv (Kiev)","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","C-Reactive Protein","Other, Standard of care",100
"CTRI/2020/06/026192","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44815",NA,"United Kingdom","London","2020-Jun",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","C-Reactive Protein","Other, Standard of care",100
"CTRI/2020/06/026195","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45129",NA,"India","Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Mortality","Alternative therapy, Standard of care",300
"CTRI/2020/06/026196","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482",NA,"Benin","Porto-Novo","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, Hospital Discharge, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"CTRI/2020/06/026196","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482",NA,"Ghana","Accra","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, Hospital Discharge, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"CTRI/2020/06/026196","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, Hospital Discharge, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"CTRI/2020/06/026196","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482",NA,"Italy","Rome","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, Hospital Discharge, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"CTRI/2020/06/026196","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482",NA,"Mexico","Mexico","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, Hospital Discharge, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"CTRI/2020/06/026196","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482",NA,"Nigeria","Niger","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, Hospital Discharge, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"CTRI/2020/06/026196","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482",NA,"Rwanda","Kigali","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, Hospital Discharge, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"CTRI/2020/06/026196","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482",NA,"South Africa","Pretoria","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, Hospital Discharge, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"CTRI/2020/06/026196","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43482",NA,"United Kingdom","London","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Hospital","Mortality, Hospital Discharge, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"CTRI/2020/06/026193","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44766",NA,"India","New Delhi","2020-Jun",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital, ICU","Mortality","HCQ  +/- AZT, HCQ + Lithium +/- AZT",100
"CTRI/2020/06/026197","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45052",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Unclear",NA,"Alternative therapy, Standard of care",60
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"Brazil","Brasilia","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"France","Paris","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"Germany","Berlin","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"Italy","Rome","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"Japan","Tokyo","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"Russia","Moscow","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"Spain","Madrid","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"Sweden","Stockholm","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026228","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554",NA,"Turkey","Ankara","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Acalabrutinib, Standard of care",140
"CTRI/2020/06/026222","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44299",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Clinical Improvement Score (Any)","Igs, Standard of care",100
"CTRI/2020/06/026227","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44584",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Non-Randomised","Unspecified",4,"Healthy","Healthy Exposed",NA,"Alternative therapy, Standard of care",60
"CTRI/2020/06/026229","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45105",NA,"India","New Delhi","2020-Jun",NA,"Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, Hospital Discharge, Clinical Improvement Score (Any)","Alternative therapy, Standard of care",100
"CTRI/2020/06/026220","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44350",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","Anticoagulants, Standard of care",40
"CTRI/2020/06/026232","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45156",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed, Healthy Exposed","Cough, Other Mild Symptoms","Ivermectin",50
"CTRI/2020/06/026231","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44497",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",4,"Confirmed Or Healthy","Healthcare Workers, Unclear",NA,"Alternative therapy, Standard of care",160
"CTRI/2020/06/026221","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44542",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear",NA,"Alternative therapy, HCQ",100
"CTRI/2020/06/026262","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43889",NA,"India","New Delhi","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Healthy","Healthy Exposed, Healthcare Workers, Outpatient, Hospital","Hospital Discharge","Alternative therapy, Standard of care",120
"CTRI/2020/07/026337","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44863",NA,"India","New Delhi","2020-Feb",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission","Alternative therapy, Standard of care",36
"CTRI/2020/07/026340","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44929",NA,"India","New Delhi","2020-Feb",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge","Standard of care, Zinc",100
"CTRI/2020/07/026343","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45204",NA,"India","New Delhi","2020-Mar",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2, Shock, Distress","Alternative therapy, Standard of care",200
"CTRI/2020/07/026349","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42918",NA,"India","Delhi","2020-Mar",NA,"Recruiting","Non-Randomised","Unspecified",2,"Confirmed Or Suspected","ICU","Hospital Discharge, Invasive Mechanical Ventilation or ECMO","Positioning",20
"CTRI/2020/07/026355","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45327",NA,"India","Rajasthan","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Exposed",NA,"Alternative therapy",500
"CTRI/2020/07/026354","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45173",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","C-Reactive Protein, Ferritin, LDH, SpO2, Radiographic Findings","Non-invasive respiratory support, Standard of care",60
"CTRI/2020/07/026353","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45266",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Outpatient",NA,"Alternative therapy",30
"CTRI/2020/07/026352","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",1048
"CTRI/2020/07/026371","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45272",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Fever","Alternative therapy, Standard of care",30
"CTRI/2020/07/026433","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45252",NA,"India","New Delhi","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Clinical Improvement Score (Any)","Alternative therapy, AZT + Vitamins + Other",25
"CTRI/2020/07/026463","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43844",NA,"India","Maharashtra","2020-Sep",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Hospitalization, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Platelet Count","Alternative therapy, Standard of care",15
"CTRI/2020/07/026462","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44637",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital",NA,"Alternative therapy",124
"CTRI/2020/07/026471","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45318",NA,"India","New Delhi","2020-Oct",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","Viral Load or Clearance","Alternative therapy",60
"CTRI/2020/07/026468","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44844",NA,"India","New Delhi","2020-Oct",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",140
"CTRI/2020/07/026470","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45363",NA,"India","New Delhi","2020-Oct",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Outpatient",NA,"Alternative therapy",200
"CTRI/2020/07/026514","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45580",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Clinical Improvement Score (Any)","Alternative therapy, Standard of care",200
"CTRI/2020/07/026515","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45584",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",300
"CTRI/2020/07/026532","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44354",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Dyspnea, Patient Positioning","Positioning",90
"CTRI/2020/07/026534","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45137",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance, Cough, Fever, SpO2, Respiratory Rate","Alternative therapy, Standard of care",70
"CTRI/2020/07/026529","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45475",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"Other, Standard of care",18
"CTRI/2020/07/026528","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45269",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed, Healthcare Workers",NA,"Alternative therapy",500
"CTRI/2020/07/026530","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45532",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient, Hospital","Cough, Other Mild Symptoms","Alternative therapy, Standard of care",200
"CTRI/2020/07/026535","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45535",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed","Unclear","C-Reactive Protein, Ferritin, IL-6, Erythrocyte Sedimentation Rate, D-Dimer, Procalcitonin, LDH","Inhaled solution",60
"CTRI/2020/07/026560","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45385",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Alternative therapy, Standard of care",200
"CTRI/2020/07/026575","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45500",NA,"India","Gujarat","2020-Jul",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",48
"CTRI/2020/07/026570","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45007",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",60
"CTRI/2020/07/026579","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45034",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",1,"Healthy","Healthcare Workers",NA,"Alternative therapy",100
"CTRI/2020/07/026608","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45638",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Mortality, Hospitalization, Fever, C-Reactive Protein, Ferritin, IL-6, D-Dimer","Corticosteroids, Dexamethasone",40
"CTRI/2020/07/026601","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45564",NA,"India","Maharashtra","2020-Jul",NA,"Not Recruiting","Single-Arm","Unspecified",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",70
"CTRI/2020/07/026630","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45581",NA,"India","New Delhi","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Cough, C-Reactive Protein, IgG, IgM or IgA","Alternative therapy, Standard of care",60
"CTRI/2020/07/026632","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45680",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear",NA,"Alternative therapy",40
"CTRI/2020/07/026631","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45494",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Outpatient, Hospital",NA,"Alternative therapy",30
"CTRI/2020/07/026667","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44342",NA,"India","Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Exposed","Antibodies","Psychological therapy, Standard of care",250
"CTRI/2020/07/026669","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45623",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear","SpO2","Alternative therapy",60
"CTRI/2020/07/026673","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45673",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Cough, Fever, Other Mild Symptoms, SpO2, Respiratory Rate","Alternative therapy, Standard of care",60
"CTRI/2020/07/026668","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45677",NA,"India","Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",800
"CTRI/2020/07/026670","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45713",NA,"India","Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed",NA,"Alternative therapy",500
"CTRI/2020/07/026671","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45728",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Cough, Fever, Ferritin, IL-6, D-Dimer, LDH, PaO2-FiO2, Respiratory Rate, Radiographic Findings","Non-invasive respiratory support",10
"CTRI/2020/07/026674","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45712",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"HCQ, Nutrition",130
"CTRI/2020/07/026675","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45731",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient, Hospital","Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms","Alternative therapy, HCQ + AZT + Oseltamivir + Vitamins",76
"CTRI/2020/07/026705","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45088",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",80
"CTRI/2020/07/026700","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45207",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Alternative therapy, Standard of care",200
"CTRI/2020/07/026757","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45824",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",200
"CTRI/2020/07/026756","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45755",NA,"India","Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Healthy","Healthy Exposed",NA,"Alternative therapy + Hygiene+  Exercise + Psychological therapy",425
"CTRI/2020/07/026791","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44814",NA,"India","New Delhi","2020-Jul",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO","Antihypertensive, Standard of care, Statins",800
"CTRI/2020/07/026796","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45868",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",1,"Healthy","Healthy Unexposed, Healthy Exposed",NA,"Device",10000
"CTRI/2020/07/026789","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45111",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Clinical Improvement Score (Any), Adverse Events","Antimalarial + Alternative therapy + Vitamins, Standard of care",50
"CTRI/2020/07/026793","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45721",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",1,"Confirmed Or Healthy","Healthy Exposed, Healthcare Workers, Unclear","Hospital Discharge, Cough, Other Mild Symptoms","Alternative therapy + Hygiene + Nutrition",120
"CTRI/2020/07/026831","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44605",NA,"India","Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"ARBs, Standard of care",605
"CTRI/2020/07/026820","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45936",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"Alternative therapy, Standard of care",200
"CTRI/2020/07/026840","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45981",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Viral Load or Clearance","Alternative therapy, HCQ",30
"CTRI/2020/07/026839","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45994",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient, Hospital","Clinical Improvement Score (Any), Cough, C-Reactive Protein, Ferritin, IL-6, D-Dimer","Alternative therapy, Standard of care",200
"CTRI/2020/07/026835","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44539",NA,"India","Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","ICU","ICU Admission, Invasive Mechanical Ventilation or ECMO","Non-invasive respiratory support",100
"CTRI/2020/07/026841","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45659",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital",NA,"Nutrition",260
"CTRI/2020/07/026925","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45587",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Unexposed",NA,"Standard of care, TCM",60
"CTRI/2020/07/026922","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45909",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital",NA,"Alternative therapy",30
"CTRI/2020/08/026957","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45825",NA,"India","New Delhi","2020-Feb",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","Alternative therapy, Standard of care",100
"CTRI/2020/08/026980","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46082",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",180
"CTRI/2020/08/026985","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46168",NA,"India","New Delhi","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Hospital","Viral Load or Clearance","Alternative therapy, Standard of care",126
"CTRI/2020/08/026978","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44435",NA,"Nepal","Kathmandu","2020-Apr",NA,"Status Unclear","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance","Alternative therapy, Standard of care",100
"CTRI/2020/08/027007","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45827",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",200
"CTRI/2020/08/026999","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46134",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Viral Load or Clearance, Cough, Fever, C-Reactive Protein, Ferritin, D-Dimer, LDH","Alternative therapy, Ivermectin + Antibiotics + Vitamins + Zinc + Other",100
"CTRI/2020/08/027005","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46189",NA,"India","Delhi","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",96
"CTRI/2020/08/027009","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46269",NA,"India","New Delhi","2020-May",NA,"Not Recruiting","Randomised","Open-Label",1,"Healthy","Healthcare Workers",NA,"Alternative therapy",100
"CTRI/2020/08/027033","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46096",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy + Hygiene, HCQ + AZT + Other + Vitamins + Zinc + Anticoagulants + Corticosteroids + Alternative therapy",100
"CTRI/2020/08/027032","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45920",NA,"India","Karnataka","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hospital Discharge","Psychological therapy, Standard of care",40
"CTRI/2020/08/027038","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46197",NA,"India","New Delhi","2020-Jul",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"Non-invasive respiratory support, Standard of care",100
"CTRI/2020/08/027037","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46324",NA,"India","New Delhi","2020-Jul",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Quality of Life, Depression, Anxiety","Exercise, Standard of care",60
"CTRI/2020/08/027040","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45846",NA,"India","New Delhi","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",200
"CTRI/2020/08/027043","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43175",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Hospital","Mortality, Pneumonia or ARDS, Fever, Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Platelet Count, Myoglobin, Troponin, Electrolytes, PaO2-FiO2, SpO2, Respiratory Rate","Stem cells",20
"CTRI/2020/08/027041","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46258",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Non-Randomised","Open-Label",1,"Confirmed","Unclear","C-Reactive Protein, D-Dimer, LDH","Alternative therapy",40
"CTRI/2020/08/027044","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44249",NA,"India","New Delhi","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Alternative therapy, Standard of care",100
"CTRI/2020/08/027084","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44420",NA,"India","Delhi","2020-Oct",NA,"Not Recruiting","Randomised","Unspecified",3,"Confirmed Or Healthy","Healthy Exposed, Outpatient","Viral Load or Clearance","Alternative therapy, Standard of care",61000
"CTRI/2020/08/027061","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45729",NA,"India","New Delhi","2020-Oct",NA,"Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Unclear","Mortality, ICU Admission, Hospitalization, Hospital Discharge","Other",15
"CTRI/2020/08/027080","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46272",NA,"India","New Delhi","2020-Oct",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed Or Suspected","ICU",NA,"Positioning",100
"CTRI/2020/08/027085","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46278",NA,"India","New Delhi","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Cough, Fever, Dyspnea, Other Mild Symptoms","Alternative therapy, Standard of care",20
"CTRI/2020/08/027106","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44639",NA,"India","Maharashtra","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Alternative therapy, Standard of care",120
"CTRI/2020/08/027109","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44387",NA,"Russia","Moscow","2020-Aug",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge","Immunomodulators, Standard of care",256
"CTRI/2020/08/027109","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44387",NA,"Indonesia","Jakarta","2020-Aug",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge","Immunomodulators, Standard of care",256
"CTRI/2020/08/027109","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44387",NA,"Italy","Rome","2020-Aug",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge","Immunomodulators, Standard of care",256
"CTRI/2020/08/027109","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44387",NA,"Spain","Madrid","2020-Aug",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge","Immunomodulators, Standard of care",256
"CTRI/2020/08/027109","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44387",NA,"India","New Delhi","2020-Aug",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Hospital Discharge","Immunomodulators, Standard of care",256
"CTRI/2020/08/027120","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46319",NA,"India","New Delhi","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Cough, Fever, Dyspnea, Other Mild Symptoms","Alternative therapy, Standard of care",60
"CTRI/2020/08/027163","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46406",NA,"India","New Delhi","2020-Aug",NA,"Recruiting","Randomised","Unspecified",2,"Healthy","Healthcare Workers",NA,"Alternative therapy, HCQ",400
"CTRI/2020/08/027162","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46240",NA,"India","New Delhi","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","Antivirals, Standard of care",60
"CTRI/2020/08/027168","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45750",NA,"India","Maharashtra","2020-Aug",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Clinical Improvement Score (Any)","Nutrition, Standard of care",60
"CTRI/2020/08/027170","http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46186",NA,"India","New Delhi","2020-Aug",NA,"Not Recruiting","Randomised","Unspecified",3,"Healthy","Healthy Unexposed","IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",1600
"NCT04335136","https://clinicaltrials.gov/show/NCT04335136",NA,"Austria","Vienna","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Antihypertensive, Standard of care",200
"NCT04335136","https://clinicaltrials.gov/show/NCT04335136",NA,"Denmark","Copenhagen","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Antihypertensive, Standard of care",200
"NCT04335136","https://clinicaltrials.gov/show/NCT04335136",NA,"Germany","Berlin","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Antihypertensive, Standard of care",200
"NCT04335136","https://clinicaltrials.gov/show/NCT04335136",NA,"Russia","Moscow","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Antihypertensive, Standard of care",200
"NCT04335136","https://clinicaltrials.gov/show/NCT04335136",NA,"United Kingdom","London","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Antihypertensive, Standard of care",200
"NCT04335136","https://clinicaltrials.gov/show/NCT04335136",NA,"United States","Washington, Dc","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Antihypertensive, Standard of care",200
"NCT04367077","https://clinicaltrials.gov/show/NCT04367077",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Quadruple",2,NA,"Hospital","Treatment-emergent Adverse Events, Radiographic Findings","Standard of care, Stem cells",400
"NCT04382651","https://clinicaltrials.gov/show/NCT04382651",NA,"United States","Washington, Dc","2020-Aug",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, Quality of Life","Other, Standard of care",140
"NCT04410562","https://clinicaltrials.gov/show/NCT04410562",NA,"Spain","Madrid","2020-May",NA,"Recruiting","Randomised","Quadruple",2,NA,"Unclear","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Hemoglobin, Pregnancy or Birth Outcomes","HCQ, Standard of care",714
"NCT04414124","https://clinicaltrials.gov/show/NCT04414124",NA,"United States","Washington, Dc","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Treatment-emergent Adverse Events","Other, Standard of care",350
"NCT04442048","https://clinicaltrials.gov/show/NCT04442048",NA,"Canada","Ottawa","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",1500
"NCT04482595","https://clinicaltrials.gov/show/NCT04482595",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Quadruple",2,"Resolved","Resolved Discharged","6-Minute Walking Distance","Alternative therapy, Standard of care",66
"NCT04483960","https://clinicaltrials.gov/show/NCT04483960",NA,"Australia","Canberra","2020-Jul",NA,"Recruiting","Randomised","Open-Label",6,"Confirmed","Hospital","Mortality, Non-invasive Ventilation","HCQ + LPV/r, HCQ + LPV/r + Plasma based therapy, LPV/r, LPV/r + Plasma based therapy, Plasma based therapy, Standard of care",2400
"NCT04502433","https://clinicaltrials.gov/show/NCT04502433",NA,"United Kingdom","London","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital, ICU",NA,"Other, Standard of care",85
"NCT04530396","https://clinicaltrials.gov/show/NCT04530396",NA,"Russia","Moscow","2020-Aug",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",33758
"NCT04565665","https://clinicaltrials.gov/show/NCT04565665",NA,"United States","Washington, Dc","2020-Sep",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Unclear","Serious Adverse Events","Standard of care, Stem cells",70
"NCT04709328","https://clinicaltrials.gov/show/NCT04709328",NA,"China","Beijing","2021-Jan",NA,"Not Recruiting","Randomised","Triple",4,"Confirmed Or Suspected","Outpatient","Mortality, Hospitalization","Monoclonal antibody + Standard of care, Standard of care",690
"NCT04712344","https://clinicaltrials.gov/show/NCT04712344",NA,"Germany","Berlin","2020-Dec",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Organ Failure or Dysfunction (SOFA)","Plasma based therapy, Standard of care",58
"NCT04713176","https://clinicaltrials.gov/show/NCT04713176",NA,"South Korea","Seoul","2021-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Remdesivir + Other, Remdesivir + Standard of care",1120
"NCT04718285","https://clinicaltrials.gov/show/NCT04718285",NA,"Turkey","Ankara","2021-Jan",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Hospitalization","FPV, Other, Other + FPV",380
"NCT04718506","https://clinicaltrials.gov/show/NCT04718506",NA,"Spain","Madrid","2021-Jan",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Rehabilitation, Rehabilitation + Standard of care",56
"ISRCTN86534580","http://isrctn.com/ISRCTN86534580",NA,"United Kingdom","London","2020-Mar",NA,"Recruiting","Randomised","Unspecified",2,"Suspected","Outpatient","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, Standard of care",3000
"NCT04333225","https://clinicaltrials.gov/show/NCT04333225",NA,"United States","Washington, Dc","2020-Jan",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), Radiographic Findings","HCQ, Standard of care",228
"NCT04338958","https://clinicaltrials.gov/show/NCT04338958",NA,"Germany","Berlin","2020-Jul",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Viral Load or Clearance, Antibodies","JAKi",200
"NCT04345601","https://clinicaltrials.gov/show/NCT04345601",NA,"United States","Washington, Dc","2020-Oct",NA,"Recruiting","Randomised","Open-Label",1,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2","Stem cells",30
"NCT04345614","https://clinicaltrials.gov/show/NCT04345614",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, IL-17, Tumor Necrosis Factor (Any), Procalcitonin, PaO2-FiO2, SpO2, Blood pH","Other, Standard of care",400
"NCT04345614","https://clinicaltrials.gov/show/NCT04345614",NA,"Puerto Rico","Puerto Rico","2020-Jul",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, IL-17, Tumor Necrosis Factor (Any), Procalcitonin, PaO2-FiO2, SpO2, Blood pH","Other, Standard of care",400
"NCT04346693","https://clinicaltrials.gov/show/NCT04346693",NA,"Russia","Moscow","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",3,NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",320
"NCT04347031","https://clinicaltrials.gov/show/NCT04347031",NA,"Russia","Moscow","2020-Jul",NA,"Not Recruiting","Randomised","Open-Label",4,NA,"Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Adverse Events, Serious Adverse Events, C-Reactive Protein","HCQ, Other, TCZ + AZT + HCQ",320
"NCT04347174","https://clinicaltrials.gov/show/NCT04347174",NA,"India","New Delhi","2020-Mar",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA)","Other, Standard of care",40
"NCT04354155","https://clinicaltrials.gov/show/NCT04354155",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,NA,"Hospital","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, D-Dimer","Anticoagulants",38
"NCT04358406","https://clinicaltrials.gov/show/NCT04358406",NA,"Romania","Bucharest","2020-Apr",NA,"Recruiting","Single-Arm","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Antibodies","Plasma based therapy, Standard of care",60
"NCT04358406","https://clinicaltrials.gov/show/NCT04358406",NA,"Spain","Madrid","2020-Apr",NA,"Recruiting","Single-Arm","Quadruple",2,NA,"Hospital","Mortality, Hospitalization, Hospital Discharge, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Antibodies","Plasma based therapy, Standard of care",60
"NCT04365127","https://clinicaltrials.gov/show/NCT04365127",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital",NA,"Hormone therapy, Standard of care",40
"NCT04365153","https://clinicaltrials.gov/show/NCT04365153",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",3,NA,"Hospital","Hospital Discharge, Clinical Improvement Score (Any)","mAb, Standard of care",45
"NCT04368845","https://clinicaltrials.gov/show/NCT04368845",NA,"Greece","Athens","2020-Apr",NA,"Recruiting","Randomised","Single",2,NA,"Resolved Discharged","Quality of Life, Depression, Anxiety","Non-invasive respiratory support, Standard of care",100
"NCT04372186","https://clinicaltrials.gov/show/NCT04372186",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,"Hospital","Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",379
"NCT04372186","https://clinicaltrials.gov/show/NCT04372186",NA,"Brazil","Brasilia","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,"Hospital","Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",379
"NCT04372186","https://clinicaltrials.gov/show/NCT04372186",NA,"Kenya","Nairobi","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,"Hospital","Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",379
"NCT04372186","https://clinicaltrials.gov/show/NCT04372186",NA,"Mexico","Mexico","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,"Hospital","Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",379
"NCT04372186","https://clinicaltrials.gov/show/NCT04372186",NA,"Peru","Lima","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,"Hospital","Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",379
"NCT04372186","https://clinicaltrials.gov/show/NCT04372186",NA,"South Africa","Pretoria","2020-Apr",NA,"Not Recruiting","Randomised","Double",2,NA,"Hospital","Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",379
"NCT04372589","https://clinicaltrials.gov/show/NCT04372589",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified)","Anticoagulants, Standard of care",1203
"NCT04372589","https://clinicaltrials.gov/show/NCT04372589",NA,"Brazil","Brasilia","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified)","Anticoagulants, Standard of care",1203
"NCT04372589","https://clinicaltrials.gov/show/NCT04372589",NA,"Canada","Ottawa","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified)","Anticoagulants, Standard of care",1203
"NCT04372589","https://clinicaltrials.gov/show/NCT04372589",NA,"Mexico","Mexico","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified)","Anticoagulants, Standard of care",1203
"NCT04373291","https://clinicaltrials.gov/show/NCT04373291",NA,"Denmark","Copenhagen","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Labor Absenteeism, Fever, Other Mild Symptoms","Standard of care, Vaccine",1293
"NCT04401410","https://clinicaltrials.gov/show/NCT04401410",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Single-Arm","Open-Label",2,"Confirmed","Hospital","Hospital Discharge, Radiographic Findings","Other",58
"NCT04403100","https://clinicaltrials.gov/show/NCT04403100",NA,"Brazil","Brasilia","2020-May",NA,"Recruiting","Randomised","Quadruple",4,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization","HCQ, HCQ + LPV/r, LPV/r, Standard of care",1968
"NCT04411433","https://clinicaltrials.gov/show/NCT04411433",NA,"Turkey","Ankara","2020-May",NA,"Not Recruiting","Randomised","Open-Label",6,"Confirmed Or Suspected","Hospital","Hospital Discharge, Viral Load or Clearance","FPV, FPV + AZT, HCQ, HCQ + AZT, HCQ + FPV",1008
"NCT04412668","https://clinicaltrials.gov/show/NCT04412668",NA,"United States","Washington, Dc","2020-Jan",NA,"Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Treatment-emergent Adverse Events","Other, Standard of care",32
"NCT04412668","https://clinicaltrials.gov/show/NCT04412668",NA,"Puerto Rico","Puerto Rico","2020-Jan",NA,"Not Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital","Treatment-emergent Adverse Events","Other, Standard of care",32
"NCT04420364","https://clinicaltrials.gov/show/NCT04420364",NA,"United States","Massachusetts","2020-Apr",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","IL-6","Immunomodulators",50
"NCT04440007","https://clinicaltrials.gov/show/NCT04440007",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Other, Standard of care",80
"NCT04446429","https://clinicaltrials.gov/show/NCT04446429",NA,"Brazil","Brasilia","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Hospitalization","Hormone therapy + Ivermectin + AZT, Ivermectin + AZT",262
"NCT04452097","https://clinicaltrials.gov/show/NCT04452097",NA,"United States","California","2020-Jun",NA,"Not Recruiting","Non-Randomised","Open-Label",3,"Confirmed","ICU","Treatment-emergent Adverse Events, Serious Adverse Events","Stem cells",39
"NCT04498377","https://clinicaltrials.gov/show/NCT04498377",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"Immunomodulators, Standard of care",38
"NCT04498442","https://clinicaltrials.gov/show/NCT04498442",NA,"United States","Washington, Dc","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",3,"Healthy","Unclear",NA,"Exercise, Other, Respiratory support",8519
"NCT04575038","https://clinicaltrials.gov/show/NCT04575038",NA,"United States","Washington, Dc","2020-Jan",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Viral Load or Clearance","DHODH inhibitor, Standard of care",100
"NCT04590365","https://clinicaltrials.gov/show/NCT04590365",NA,"United Kingdom","Swansea","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Healthcare Workers",NA,"Alternative therapy, Standard of care",480
"NCT04623021","https://clinicaltrials.gov/show/NCT04623021",NA,"Russia","Moscow","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","Anticoagulants + Standard of care, Standard of care",104
"NCT04646603","https://clinicaltrials.gov/show/NCT04646603",NA,"United States","Washington, Dc","2020-Nov",NA,"Recruiting","Randomised","Double",2,"Confirmed Or Healthy","Healthy Exposed",NA,"Other, Standard of care",18
"ACTRN12620000445976","https://anzctr.org.au/ACTRN12620000445976.aspx",NA,"India","New Delhi","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + HCQ",2500
"ACTRN12620000445976","https://anzctr.org.au/ACTRN12620000445976.aspx",NA,"New Zealand","Wellington","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + HCQ",2500
"ACTRN12620000445976","https://anzctr.org.au/ACTRN12620000445976.aspx",NA,"Australia","Canberra","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"HCQ, LPV/r, LPV/r + HCQ",2500
"NCT04325061","https://clinicaltrials.gov/show/NCT04325061",NA,"Spain","Madrid","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Dexamethasone, Standard of care",19
"NCT04335084","https://clinicaltrials.gov/show/NCT04335084",NA,"United States","Washington, Dc","2020-Feb",NA,"Recruiting","Single-Arm","Double",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events","HCQ + Vitamins + Zinc, Standard of care",600
"NCT04343248","https://clinicaltrials.gov/show/NCT04343248",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Triple",2,"Healthy","Healthy Exposed","Mortality, Clinical Improvement Score (Any), PaO2-FiO2","Antivirals, Standard of care",800
"NCT04344730","https://clinicaltrials.gov/show/NCT04344730",NA,"France","Paris","2020-Sep",NA,"Not Recruiting","Randomised","Quadruple",7,NA,"ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Hypoxemia, Cardiac Outcome (Unspecified)","Dexamethasone, Dexamethasone + Non-invasive respiratory support, Mechanical ventilation + Dexamethasone, Non-invasive respiratory support, Non-invasive respiratory support + Dexamethasone, Standard of care",550
"NCT04348383","https://clinicaltrials.gov/show/NCT04348383",NA,"Spain","Madrid","2020-Aug",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Non-invasive Ventilation, C-Reactive Protein, IL-6, D-Dimer, Creatinine Phosphokinase, LDH, Radiographic Findings","Antithrombotics, Standard of care",150
"NCT04358549","https://clinicaltrials.gov/show/NCT04358549",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance","FPV, Standard of care",50
"NCT04358926","https://clinicaltrials.gov/show/NCT04358926",NA,"Israel","Jerusalem","2020-Apr",NA,"Not Recruiting","Randomised","Single",2,NA,"Unclear","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Other Mild Symptoms, Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-1, IL-2, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Erythrocyte Sedimentation Rate, Procalcitonin, IgG, IgM or IgA, Antibodies, PaO2-FiO2","Non-invasive respiratory support",30
"NCT04359680","https://clinicaltrials.gov/show/NCT04359680",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Triple",2,NA,"Healthcare Workers","Viral Load or Clearance","Antivirals, Standard of care",1407
"NCT04370236","https://clinicaltrials.gov/show/NCT04370236",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Quadruple",1,NA,"Hospital",NA,"Other",366
"NCT04383613","https://clinicaltrials.gov/show/NCT04383613",NA,"Canada","Ottawa","2020-May",NA,"Recruiting","Randomised","Single",2,"Confirmed Or Suspected","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Positioning, Standard of care",350
"NCT04384731","https://clinicaltrials.gov/show/NCT04384731",NA,"France","Paris","2020-Jul",NA,"Recruiting","Randomised","Single",2,"Confirmed","ICU","PaO2-FiO2","Other, Standard of care",20
"NCT04385901","https://clinicaltrials.gov/show/NCT04385901",NA,"United States","Washington, Dc","2020-Jun",NA,"Not Recruiting","Non-Randomised","Double",2,"Confirmed","Outpatient","6-Minute Walking Distance","Rehabilitation, Standard of care",26
"NCT04404426","https://clinicaltrials.gov/show/NCT04404426",NA,"France","Paris","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","ICU","Organ Failure or Dysfunction (SOFA)","Other, Standard of care",32
"NCT04407130","https://clinicaltrials.gov/show/NCT04407130",NA,"Bangladesh","Dhaka","2020-May",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Cough, Fever","Ivermectin, Ivermectin + Antibiotics, Standard of care",72
"NCT04409262","https://clinicaltrials.gov/show/NCT04409262",NA,"France","Paris","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospital Discharge","Remdesivir, Remdesivir + TCZ",650
"NCT04409262","https://clinicaltrials.gov/show/NCT04409262",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospital Discharge","Remdesivir, Remdesivir + TCZ",650
"NCT04409262","https://clinicaltrials.gov/show/NCT04409262",NA,"Spain","Madrid","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospital Discharge","Remdesivir, Remdesivir + TCZ",650
"NCT04409262","https://clinicaltrials.gov/show/NCT04409262",NA,"Russia","Moscow","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospital Discharge","Remdesivir, Remdesivir + TCZ",650
"NCT04409262","https://clinicaltrials.gov/show/NCT04409262",NA,"Brazil","Brasilia","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Hospital Discharge","Remdesivir, Remdesivir + TCZ",650
"NCT04409327","https://clinicaltrials.gov/show/NCT04409327",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Exposed","Hospitalization","Other, Standard of care",36
"NCT04417257","https://clinicaltrials.gov/show/NCT04417257",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital",NA,"Other, Standard of care",240
"NCT04417257","https://clinicaltrials.gov/show/NCT04417257",NA,"Canada","Ottawa","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed Or Suspected","Hospital",NA,"Other, Standard of care",240
"NCT04435522","https://clinicaltrials.gov/show/NCT04435522",NA,"United States","Washington, Dc","2020-Jun",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Clinical Improvement Score (Any)","Antivirals",9
"NCT04476706","https://clinicaltrials.gov/show/NCT04476706",NA,"Switzerland","Basel-Stadt","2020-Jul",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Hospital",NA,"mAb",NA
"NCT04486313","https://clinicaltrials.gov/show/NCT04486313",NA,"United States","Washington, Dc","2020-Jul",NA,"Not Recruiting","Randomised","Triple",2,"Suspected","Outpatient",NA,"Antivirals + Vitamins, Vitamins",1092
"NCT04486508","https://clinicaltrials.gov/show/NCT04486508",NA,"Iran","Tehran","2020-Jul",NA,"Recruiting","Randomised","Single",4,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care, Statins",600
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"Ukraine","Kyiv (Kiev)","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"Philippines","Manila","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"United States","Washington, Dc","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"South Africa","Pretoria","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"Peru","Lima","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"Mexico","Mexico","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"Colombia","Bogota","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"Chile","Santiago","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"Brazil","Brasilia","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04505722","https://clinicaltrials.gov/show/NCT04505722",NA,"Argentina","Buenos Aires","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",44325
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"South Africa","Pretoria","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"Poland","Warsaw","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"Philippines","Manila","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"Panama","Panama","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"Nepal","Kathmandu","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"Germany","Berlin","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"Dominican Republic","Santo Domingo","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"Colombia","Bogota","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"Brazil","Brasilia","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04672395","https://clinicaltrials.gov/show/NCT04672395",NA,"Belgium","Brussels","2020-Dec",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",22000
"NCT04713488","https://clinicaltrials.gov/show/NCT04713488",NA,"Russia","Moscow","2021-Jan",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Healthy Unexposed","Adverse Events, Antibodies","Vaccine",110
"NCT04738136","https://clinicaltrials.gov/show/NCT04738136",NA,"Canada","Alberta","2021-Jan",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Standard of care, Standard of care + Other",30
"NCT04283461","https://clinicaltrials.gov/show/NCT04283461",NA,"United States","Washington, Dc","2020-Feb",NA,"Not Recruiting","Non-Randomised","Open-Label",3,"Healthy","Healthy Unexposed","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Ferritin, IL-6, D-Dimer, Glucose, Antibodies, PaO2-FiO2","Vaccine",120
"NCT04328012","https://clinicaltrials.gov/show/NCT04328012",NA,"United States","Washington, Dc","2020-Mar",NA,"Recruiting","Randomised","Quadruple",4,"Confirmed","Hospital","Clinical Improvement Score (Any), C-Reactive Protein, D-Dimer","ARBs, HCQ, LPV/r, Standard of care",100
"NCT04335201","https://clinicaltrials.gov/show/NCT04335201",NA,"Italy","Rome","2020-Mar",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","Mortality, Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), LDH",NA,50
"NCT04336332","https://clinicaltrials.gov/show/NCT04336332",NA,"United States","Washington, Dc","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient, Hospital","Viral Load or Clearance","HCQ, HCQ + AZT, Standard of care",160
"NCT04346147","https://clinicaltrials.gov/show/NCT04346147",NA,"Spain","Madrid","2020-Jul",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Clinical Improvement Score (Any), Treatment-emergent Adverse Events, Serious Adverse Events","HCQ + Imatinib, HCQ + JAKi, HCQ + LPV/r",165
"NCT04352959","https://clinicaltrials.gov/show/NCT04352959",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Triple",2,NA,"Unclear","Viral Load or Clearance","Hygiene, Standard of care",176
"NCT04368156","https://clinicaltrials.gov/show/NCT04368156",NA,"Spain","Madrid","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital",NA,"Device",110
"NCT04368728","https://clinicaltrials.gov/show/NCT04368728",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Triple",7,NA,"Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",43998
"NCT04368728","https://clinicaltrials.gov/show/NCT04368728",NA,"Argentina","Buenos Aires","2020-Apr",NA,"Not Recruiting","Randomised","Triple",7,NA,"Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",43998
"NCT04368728","https://clinicaltrials.gov/show/NCT04368728",NA,"Brazil","Brasilia","2020-Apr",NA,"Not Recruiting","Randomised","Triple",7,NA,"Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",43998
"NCT04368728","https://clinicaltrials.gov/show/NCT04368728",NA,"Germany","Berlin","2020-Apr",NA,"Not Recruiting","Randomised","Triple",7,NA,"Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",43998
"NCT04368728","https://clinicaltrials.gov/show/NCT04368728",NA,"South Africa","Pretoria","2020-Apr",NA,"Not Recruiting","Randomised","Triple",7,NA,"Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",43998
"NCT04368728","https://clinicaltrials.gov/show/NCT04368728",NA,"Turkey","Ankara","2020-Apr",NA,"Not Recruiting","Randomised","Triple",7,NA,"Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",43998
"NCT04374279","https://clinicaltrials.gov/show/NCT04374279",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital","Clinical Improvement Score (Any)","Ivermectin, Other, Standard of care",60
"NCT04378920","https://clinicaltrials.gov/show/NCT04378920",NA,"France","Paris","2020-May",NA,"Recruiting","Single-Arm","Open-Label",2,"Confirmed","Hospital","PaO2-FiO2","Other",90
"NCT04392453","https://clinicaltrials.gov/show/NCT04392453",NA,"Italy","Rome","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Healthy","Hospital",NA,"Device",40
"NCT04392531","https://clinicaltrials.gov/show/NCT04392531",NA,"Spain","Madrid","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Cyclosporine, Standard of care",120
"NCT04405076","https://clinicaltrials.gov/show/NCT04405076",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies, Blood Pressure, Respiratory Rate","Vaccine",600
"NCT04414293","https://clinicaltrials.gov/show/NCT04414293",NA,"Spain","Madrid","2020-Jan",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital","SpO2, Radiographic Findings","Radiation therapy",41
"NCT04419610","https://clinicaltrials.gov/show/NCT04419610",NA,"United Kingdom","London","2020-Apr",NA,"Recruiting","Single-Arm","Double",2,"Confirmed","Hospital",NA,"Antihypertensive, Standard of care",60
"NCT04436458","https://clinicaltrials.gov/show/NCT04436458",NA,"United States","Massachusetts","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Stool Sample","Other, Standard of care",100
"NCT04456595","https://clinicaltrials.gov/show/NCT04456595",NA,"Brazil","Brasilia","2020-Jun",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthcare Workers","Adverse Events","Standard of care, Vaccine",12688
"NCT04482712","https://clinicaltrials.gov/show/NCT04482712",NA,"United States","Washington, Dc","2020-Jul",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital",NA,"Other, Standard of care",20
"NCT04494984","https://clinicaltrials.gov/show/NCT04494984",NA,"Argentina","Buenos Aires","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"Igs, Standard of care",242
"NCT04517422","https://clinicaltrials.gov/show/NCT04517422",NA,"Mexico","Mexico","2020-Aug",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, ICU Admission","Nutrition, Standard of care",300
"NCT04530409","https://clinicaltrials.gov/show/NCT04530409",NA,"Egypt","Cairo","2020-Aug",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Hospitalization, Pneumonia or ARDS","Dexamethasone",450
"NCT04530539","https://clinicaltrials.gov/show/NCT04530539",NA,"United States","Washington, Dc","2020-Aug",NA,"Recruiting","Randomised","Triple",3,"Confirmed","Outpatient",NA,"Melatonin, Standard of care, Vitamins",150
"NCT04534790","https://clinicaltrials.gov/show/NCT04534790",NA,"Mexico","Mexico","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Hospital","Clinical Improvement Score (Any)","Radiation therapy, Standard of care",30
"NCT04540406","https://clinicaltrials.gov/show/NCT04540406",NA,"United States","Washington, Dc","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Outpatient",NA,"Other + Standard of care, Standard of care",100
"NCT04591210","https://clinicaltrials.gov/show/NCT04591210",NA,"Canada","Ottawa","2020-Jun",NA,"Recruiting","Randomised","Single",3,"Confirmed","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified)","Antihypertensive, Standard of care",1155
"NCT04659239","https://clinicaltrials.gov/show/NCT04659239",NA,"Malaysia","Kuala Lumpur","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",34020
"NCT04659239","https://clinicaltrials.gov/show/NCT04659239",NA,"Brazil","Brasilia","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Healthy","Unclear",NA,"Standard of care, Vaccine",34020
"NCT04746365","https://clinicaltrials.gov/show/NCT04746365",NA,"Egypt","Cairo","2021-Jun",NA,"Not Recruiting","Randomised","Double",3,"Confirmed","Hospital","Hospital Discharge","HCQ, Ivermectin, Standard of care",300
"SLCTR/2020/011","https://slctr.lk/trials/slctr-2020-011",NA,"Sri Lanka","Western Province","2020-May",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthy Exposed","Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ, Standard of care",400
"JPRN-JRCT2031200126","https://jrct.niph.go.jp/latest-detail/jRCT2031200126",NA,"United States","Washington, Dc","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality","mAb, Standard of care",270
"JPRN-JRCT2031200126","https://jrct.niph.go.jp/latest-detail/jRCT2031200126",NA,"United Kingdom","London","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality","mAb, Standard of care",270
"JPRN-JRCT2031200126","https://jrct.niph.go.jp/latest-detail/jRCT2031200126",NA,"France","Paris","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality","mAb, Standard of care",270
"JPRN-JRCT2031200126","https://jrct.niph.go.jp/latest-detail/jRCT2031200126",NA,"Spain","Madrid","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality","mAb, Standard of care",270
"JPRN-JRCT2031200126","https://jrct.niph.go.jp/latest-detail/jRCT2031200126",NA,"Japan","Tokyo","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"ICU","Mortality","mAb, Standard of care",270
"JPRN-UMIN000040602","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046338",NA,"Brazil","Brasilia","2020-Jan",NA,"Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Alternative therapy, Standard of care",100
"PACTR202004801273802","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10928",NA,"Nigeria","Niger","2020-Feb",NA,"Recruiting","Randomised","Double",2,NA,"Hospital","Clinical Improvement Score (Any), Viral Load or Clearance","HCQ, Standard of care",800
"PACTR202004693933092","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10953",NA,"Egypt","Cairo","2020-Dec",NA,"Not Recruiting","Randomised","Unspecified",2,NA,"Healthcare Workers","Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms","Standard of care, Vaccine",200
"PACTR202004761408382","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10957",NA,"Nigeria","Niger","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",2,NA,"Hospital","Hospital Discharge, Viral Load or Clearance, Cough, Other Mild Symptoms, Adverse Events, Anti SARS-COV-2 Titers, Creatinine Phosphokinase, Electrolytes, ALT, CD4, CD8, Blood Urea Nitrogen","Alternative therapy, Standard of care",72
"PACTR202005599385499","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10971",NA,"Egypt","Cairo","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed, Suspected Or Healthy","Healthy Exposed, Healthcare Workers",NA,"Nutrition, Standard of care",60
"PACTR202004893013257","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10981",NA,"Ghana","Accra","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",4,"Healthy","Hospital","Mortality, Pneumonia or ARDS, Distress","HCQ, HCQ + LPV/r, LPV/r, Standard of care",6400
"PACTR202005681895696","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10988",NA,"Kenya","Nairobi","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Healthy","Healthy Unexposed","Serious Adverse Events, IgG, IgM or IgA, Antibodies","Vaccine",400
"PACTR202007653923168","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11047",NA,"Kenya","Nairobi","2020-May",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","ICU","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Plasma based therapy, Standard of care",206
"PACTR202005622389003","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11053",NA,"Senegal","Dakar","2020-May",NA,"Not Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","Viral Load or Clearance","HCQ + AZT, Zinc",384
"PACTR202006717277937","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11088",NA,"Nigeria","Niger","2020-May",NA,"Not Recruiting","Randomised","Unspecified",7,"Healthy","Healthy Exposed",NA,"Other + Alternative therapy, Other + Alternative therapy + Corticosteroids",48
"PACTR202006899597082","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11103",NA,"Madagascar","Antananarivo","2020-May",NA,"Not Recruiting","Randomised","Unspecified",3,"Confirmed","Outpatient",NA,"Other, Other + Vitamins, Standard of care",60
"PACTR202007589336711","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11115",NA,"Nigeria","Niger","2020-Apr",NA,"Not Recruiting","Non-Randomised","Unspecified",2,"Confirmed","Unclear",NA,"Exercise, Standard of care",30
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Burkina Faso","Ouagadougou","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Cameroon","Yaounde","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Switzerland","Geneve","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Equatorial Guinea","Malabo","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Ethiopia","Addis Ababa","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Ghana","Accra","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Guinea","Conakry","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Kenya","Nairobi","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Mozambique","Maputo","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Sudan","Khartoum","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Tanzania","Dodoma","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202006537901307","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150",NA,"Uganda","Kampala","2020-Jun",NA,"Recruiting","Randomised","Open-Label",3,"Confirmed","Outpatient","Mortality, SpO2","HCQ, LPV/r, Standard of care",3000
"PACTR202007606032743","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12158",NA,"Egypt","Cairo","2020-Jun",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","PaO2-FiO2","Anticoagulants, Standard of care",100
"PACTR202006760881890","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12168",NA,"Nigeria","Niger","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Plasma based therapy, Standard of care",100
"PACTR202006883882711","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12175",NA,"Egypt","Cairo","2020-Jun",NA,"Not Recruiting","Randomised","Unspecified",2,"Healthy","Healthcare Workers","Cough, Fever","Standard of care, Vaccine",200
"PACTR202007720062393","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12183",NA,"Cte dIvoire","Lacs","2020-Feb",NA,"Not Recruiting","Randomised","Unspecified",3,"Confirmed","Unclear","C-Reactive Protein","LPV/r, LPV/r + Immunomodulators, LPV/r + Statins",294
"PACTR202007611764617","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12192",NA,"Nigeria","Niger","2020-Jun",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Viral Load or Clearance","Alternative therapy, LPV/r",80
"PACTR202007700757139","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12194",NA,"South Africa","Pretoria","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Outpatient","SpO2","LPV/r, Vitamins",420
"PACTR202008485004797","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12214",NA,"South Africa","Pretoria","2020-Jul",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed Or Healthy","Healthy Exposed, Outpatient","IgG, IgM or IgA","Education, Standard of care",720
"PACTR202008855701534","https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12266",NA,"Nigeria","Niger","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance","Antivirals + Antiretrovirals, Standard of care",98
"RPCEC00000306","https://rpcec.sld.cu/en/trials/RPCEC00000306-En",NA,"Cuba","Havana","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,NA,"Healthy Exposed","Viral Load or Clearance, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Prothrombin, Triglycerides, ALT, Albumin, Bilirubin, Glucose","Standard of care, Vaccine",80
"RPCEC00000307","https://rpcec.sld.cu/en/trials/RPCEC00000307-En",NA,"Cuba","Havana","2020-Apr",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear","Labor Absenteeism","IFN",120
"RPCEC00000308","https://rpcec.sld.cu/en/trials/RPCEC00000308-En",NA,"Cuba","Havana","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",6,"Healthy","Healthy Unexposed",NA,"IFN",30
"RPCEC00000309","https://rpcec.sld.cu/en/trials/RPCEC00000309-En",NA,"Mexico","Mexico","2020-May",NA,"Recruiting","Randomised","Open-Label",5,"Confirmed","Outpatient, Hospital, ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Other, Standard of care",100
"RPCEC00000311","https://rpcec.sld.cu/en/trials/RPCEC00000311-En",NA,"Cuba","Havana","2020-Dec",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","Hospital",NA,"mAb",80
"RPCEC00000313","https://rpcec.sld.cu/en/trials/RPCEC00000313-En",NA,"Cuba","Havana","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","Mortality, ICU Admission, Hospital Discharge","Other",16
"RPCEC00000314","https://rpcec.sld.cu/en/trials/RPCEC00000314-En",NA,"Cuba","Havana","2020-May",NA,"Recruiting","Unspecified","Open-Label",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",115000
"RPCEC00000315","https://rpcec.sld.cu/en/trials/RPCEC00000315-En",NA,"Cuba","Havana","2020-May",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Healthy Unexposed","Monocyte Count, Lymphocyte Count, Dendritic Cell Count, CD4, CD8","Other",60
"RPCEC00000317","https://rpcec.sld.cu/en/trials/RPCEC00000317-En",NA,"Cuba","Havana","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Unclear",NA,"Other, Standard of care",20
"RPCEC00000320","https://rpcec.sld.cu/en/trials/RPCEC00000320-En",NA,"Cuba","Havana","2020-May",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ + Antivirals + Inferon, Other + HCQ + Antivirals + Inferon",32
"RPCEC00000321","https://rpcec.sld.cu/en/trials/RPCEC00000321-En",NA,"Cuba","Havana","2020-Jun",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU",NA,"Immunomodulators",NA
"RPCEC00000322","https://rpcec.sld.cu/en/trials/RPCEC00000322-En",NA,"Cuba","Havana","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Resolved","Unclear","Pneumonia or ARDS","Corticosteroids, Stem cells",20
"PER-013-20","https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=013-20",NA,"Peru","Lima","2020-Jun",NA,"Recruiting","Unspecified","Unspecified",2,"Confirmed","Hospital, ICU","Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","Plasma based therapy, Standard of care",192
"PER-027-20","https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=027-20",NA,"Panama","Panama","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",60
"PER-027-20","https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=027-20",NA,"South Africa","Pretoria","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",60
"PER-027-20","https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=027-20",NA,"Brazil","Brasilia","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",60
"PER-027-20","https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=027-20",NA,"Mexico","Mexico","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",60
"PER-027-20","https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=027-20",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Standard of care, TCZ",60
"NCT04312997","https://clinicaltrials.gov/show/NCT04312997",NA,"United States","Washington, Dc","2020-Mar",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Unclear","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation","Other, Standard of care",100
"NCT04313023","https://clinicaltrials.gov/show/NCT04313023",NA,"United States","Washington, Dc","2020-Mar",NA,"Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Exposed","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation","Other, Standard of care",200
"NCT04328480","https://clinicaltrials.gov/show/NCT04328480",NA,"Argentina","Buenos Aires","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Colchicine, Standard of care",1200
"NCT04331366","https://clinicaltrials.gov/show/NCT04331366",NA,"United States","Washington, Dc","2020-Mar",NA,"Not Recruiting","Single-Arm","Open-Label",2,"Confirmed","Hospital","SpO2","Non-invasive respiratory support, Standard of care",2
"NCT04331834","https://clinicaltrials.gov/show/NCT04331834",NA,"Spain","Madrid","2020-Jan",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, Standard of care",275
"NCT04334148","https://clinicaltrials.gov/show/NCT04334148",NA,"United States","Washington, Dc","2020-Feb",NA,"Not Recruiting","Randomised","Triple",2,"Healthy","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ, Standard of care",1363
"NCT04334460","https://clinicaltrials.gov/show/NCT04334460",NA,"United States","Washington, Dc","2020-Feb",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04334460","https://clinicaltrials.gov/show/NCT04334460",NA,"Brazil","Brasilia","2020-Feb",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2",NA,120
"NCT04346615","https://clinicaltrials.gov/show/NCT04346615",NA,"United States","Washington, Dc","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified)","Other, Standard of care",120
"NCT04348435","https://clinicaltrials.gov/show/NCT04348435",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Quadruple",4,"Healthy","Healthcare Workers","Hospitalization","Standard of care, Stem cells",100
"NCT04355728","https://clinicaltrials.gov/show/NCT04355728",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Randomised","Triple",2,NA,"Hospital, ICU","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, D-Dimer, Troponin, Antibodies","Standard of care, Stem cells",24
"NCT04358003","https://clinicaltrials.gov/show/NCT04358003",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Single-Arm","Open-Label",1,NA,"ICU","Mortality, Organ Failure or Dysfunction (SOFA)","Plasma based therapy",2000
"NCT04360096","https://clinicaltrials.gov/show/NCT04360096",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Quadruple",2,NA,"Hospital","Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Dyspnea, PaO2-FiO2, 6-Minute Walking Distance","Inhaled solution, Standard of care",288
"NCT04363502","https://clinicaltrials.gov/show/NCT04363502",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Triple",2,"Confirmed","ICU","C-Reactive Protein","mAb, Standard of care",30
"NCT04379076","https://clinicaltrials.gov/show/NCT04379076",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Lymphocyte Count","Other, Standard of care",48
"NCT04386616","https://clinicaltrials.gov/show/NCT04386616",NA,"United States","Washington, Dc","2020-Nov",NA,"Not Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"mAb, Other, Standard of care",410
"NCT04386616","https://clinicaltrials.gov/show/NCT04386616",NA,"Brazil","Brasilia","2020-Nov",NA,"Not Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"mAb, Other, Standard of care",410
"NCT04386616","https://clinicaltrials.gov/show/NCT04386616",NA,"Mexico","Mexico","2020-Nov",NA,"Not Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"mAb, Other, Standard of care",410
"NCT04386616","https://clinicaltrials.gov/show/NCT04386616",NA,"Spain","Madrid","2020-Nov",NA,"Not Recruiting","Randomised","Double",4,"Confirmed","Hospital",NA,"mAb, Other, Standard of care",410
"NCT04389840","https://clinicaltrials.gov/show/NCT04389840",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Invasive Mechanical Ventilation or ECMO","Anticoagulants, Standard of care",525
"NCT04390217","https://clinicaltrials.gov/show/NCT04390217",NA,"United States","California","2020-May",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"Other, Standard of care",120
"NCT04395456","https://clinicaltrials.gov/show/NCT04395456",NA,"United States","Pennsylvania","2020-May",NA,"Not Recruiting","Randomised","Single",2,"Confirmed","Hospital","Pneumonia or ARDS, PaO2-FiO2","Other, Standard of care",144
"NCT04397510","https://clinicaltrials.gov/show/NCT04397510",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, PaO2-FiO2","Anticoagulants, Standard of care",50
"NCT04397523","https://clinicaltrials.gov/show/NCT04397523",NA,"Macedonia","Skopje","2020-May",NA,"Recruiting","Single-Arm","Open-Label",1,"Confirmed","ICU","ICU Admission, Serious Adverse Events","Plasma based therapy",200
"NCT04402866","https://clinicaltrials.gov/show/NCT04402866",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",222
"NCT04402866","https://clinicaltrials.gov/show/NCT04402866",NA,"Brazil","Brasilia","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",222
"NCT04402866","https://clinicaltrials.gov/show/NCT04402866",NA,"Finland","Helsinki","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",222
"NCT04402866","https://clinicaltrials.gov/show/NCT04402866",NA,"Moldova","Chisinau","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",222
"NCT04402866","https://clinicaltrials.gov/show/NCT04402866",NA,"Romania","Bucharest","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",222
"NCT04402866","https://clinicaltrials.gov/show/NCT04402866",NA,"Ukraine","Kyiv (Kiev)","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",222
"NCT04402866","https://clinicaltrials.gov/show/NCT04402866",NA,"United Kingdom","London","2020-May",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",222
"NCT04402957","https://clinicaltrials.gov/show/NCT04402957",NA,"United States","Washington, Dc","2020-Dec",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Pneumonia or ARDS","Other, Standard of care",60
"NCT04402957","https://clinicaltrials.gov/show/NCT04402957",NA,"Canada","Ottawa","2020-Dec",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Pneumonia or ARDS","Other, Standard of care",60
"NCT04402957","https://clinicaltrials.gov/show/NCT04402957",NA,"Turkey","Ankara","2020-Dec",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Pneumonia or ARDS","Other, Standard of care",60
"NCT04405570","https://clinicaltrials.gov/show/NCT04405570",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient","Adverse Events","Antivirals, Standard of care",204
"NCT04408040","https://clinicaltrials.gov/show/NCT04408040",NA,"United States","Washington, Dc","2020-May",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality","Plasma based therapy",700
"NCT04426201","https://clinicaltrials.gov/show/NCT04426201",NA,"United States","Washington, Dc","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Lymphocyte Count","Other, Standard of care",48
"NCT04427501","https://clinicaltrials.gov/show/NCT04427501",NA,"United States","Washington, Dc","2020-Sep",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Viral Load or Clearance","mAB, Standard of care",3300
"NCT04427501","https://clinicaltrials.gov/show/NCT04427501",NA,"Puerto Rico","Puerto Rico","2020-Sep",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality, Hospitalization, Viral Load or Clearance","mAB, Standard of care",3300
"NCT04429555","https://clinicaltrials.gov/show/NCT04429555",NA,"United States","Washington, Dc","2020-Sep",NA,"Recruiting","Randomised","Triple",2,"Confirmed","Hospital",NA,"Other, Standard of care",40
"NCT04429854","https://clinicaltrials.gov/show/NCT04429854",NA,"Belgium","Brussels","2020-Sep",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","Hospital","Mortality, Invasive Mechanical Ventilation or ECMO","Plasma based therapy, Standard of care",483
"NCT04436276","https://clinicaltrials.gov/show/NCT04436276",NA,"United States","Washington, Dc","2020-Jun",NA,"Not Recruiting","Randomised","Double",5,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",1085
"NCT04436276","https://clinicaltrials.gov/show/NCT04436276",NA,"Belgium","Brussels","2020-Jun",NA,"Not Recruiting","Randomised","Double",5,"Healthy","Healthy Unexposed","Serious Adverse Events","Standard of care, Vaccine",1085
"NCT04442178","https://clinicaltrials.gov/show/NCT04442178",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Hospital Discharge, Lymphocyte Count","Other, Standard of care",48
"NCT04462783","https://clinicaltrials.gov/show/NCT04462783",NA,"United States","Michigan","2020-Jul",NA,"Not Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Outpatient",NA,"Other",200
"NCT04463004","https://clinicaltrials.gov/show/NCT04463004",NA,"United States","Washington, Dc","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"mAb, Standard of care",2
"NCT04463849","https://clinicaltrials.gov/show/NCT04463849",NA,"Italy","Rome","2020-Feb",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed Or Healthy","Healthy Unexposed, Hospital",NA,"Other",90
"NCT04467840","https://clinicaltrials.gov/show/NCT04467840",NA,"Brazil","Brasilia","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Non-invasive Ventilation","Other, Standard of care",464
"NCT04467840","https://clinicaltrials.gov/show/NCT04467840",NA,"Colombia","Bogota","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Non-invasive Ventilation","Other, Standard of care",464
"NCT04467840","https://clinicaltrials.gov/show/NCT04467840",NA,"Israel","Jerusalem","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Non-invasive Ventilation","Other, Standard of care",464
"NCT04467840","https://clinicaltrials.gov/show/NCT04467840",NA,"Italy","Rome","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Non-invasive Ventilation","Other, Standard of care",464
"NCT04467840","https://clinicaltrials.gov/show/NCT04467840",NA,"Mexico","Mexico","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Non-invasive Ventilation","Other, Standard of care",464
"NCT04467840","https://clinicaltrials.gov/show/NCT04467840",NA,"Poland","Warsaw","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Non-invasive Ventilation","Other, Standard of care",464
"NCT04467840","https://clinicaltrials.gov/show/NCT04467840",NA,"Russia","Moscow","2020-Sep",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Non-invasive Ventilation","Other, Standard of care",464
"NCT04470427","https://clinicaltrials.gov/show/NCT04470427",NA,"United States","Washington, Dc","2020-Nov",NA,"Not Recruiting","Randomised","Quadruple",2,"Healthy","Healthy Exposed","Adverse Events","Standard of care, Vaccine",30420
"NCT04472728","https://clinicaltrials.gov/show/NCT04472728",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality","Other, Standard of care",310
"NCT04472728","https://clinicaltrials.gov/show/NCT04472728",NA,"Belgium","Brussels","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality","Other, Standard of care",310
"NCT04472728","https://clinicaltrials.gov/show/NCT04472728",NA,"Brazil","Brasilia","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality","Other, Standard of care",310
"NCT04472728","https://clinicaltrials.gov/show/NCT04472728",NA,"France","Paris","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality","Other, Standard of care",310
"NCT04472728","https://clinicaltrials.gov/show/NCT04472728",NA,"Puerto Rico","Puerto Rico","2020-Jun",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital","Mortality","Other, Standard of care",310
"NCT04476953","https://clinicaltrials.gov/show/NCT04476953",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Serious Adverse Events","Alternative therapy, Standard of care",70
"NCT04477668","https://clinicaltrials.gov/show/NCT04477668",NA,"Saudi Arabia","Riyadh","2020-Sep",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","ICU","Mortality","Non-invasive respiratory support, Standard of care",320
"NCT04478019","https://clinicaltrials.gov/show/NCT04478019",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Healthy","Healthcare Workers","Viral Load or Clearance","Hygiene, Standard of care",94
"NCT04480411","https://clinicaltrials.gov/show/NCT04480411",NA,"United States","Washington, Dc","2020-Jul",NA,"Not Recruiting","Single-Arm","Open-Label",2,"Confirmed","Outpatient, Hospital",NA,"Psychological therapy, Standard of care",50
"NCT04486482","https://clinicaltrials.gov/show/NCT04486482",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Outpatient","Treatment-emergent Adverse Events","Other, Standard of care",50
"NCT04495816","https://clinicaltrials.gov/show/NCT04495816",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear",NA,"Nutrition, Standard of care",126
"NCT04497987","https://clinicaltrials.gov/show/NCT04497987",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Double",2,"Confirmed","Healthcare Workers",NA,"Other, Standard of care",5000
"NCT04510194","https://clinicaltrials.gov/show/NCT04510194",NA,"United States","Washington, Dc","2020-Jul",NA,"Recruiting","Randomised","Quadruple",4,"Confirmed Or Healthy","Outpatient","Visits or Returns to Emergency Department","Other, Standard of care",750
"NCT04530357","https://clinicaltrials.gov/show/NCT04530357",NA,"Kazakhstan","Astana","2020-Aug",NA,"Not Recruiting","Randomised","Single",6,"Healthy","Healthy Unexposed","Adverse Events, Antibodies","Standard of care, Vaccine",244
"NCT04534803","https://clinicaltrials.gov/show/NCT04534803",NA,"United States","Texas","2020-Aug",NA,"Not Recruiting","Randomised","Triple",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",2100
"NCT04535674","https://clinicaltrials.gov/show/NCT04535674",NA,"Russia","Moscow","2020-Aug",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed Or Suspected","Hospital",NA,"Other, Standard of care",400
"NCT04535674","https://clinicaltrials.gov/show/NCT04535674",NA,"Spain","Madrid","2020-Aug",NA,"Recruiting","Randomised","Open-Label",4,"Confirmed Or Suspected","Hospital",NA,"Other, Standard of care",400
"NCT04537299","https://clinicaltrials.gov/show/NCT04537299",NA,"United States","Washington, Dc","2020-Jan",NA,"Not Recruiting","Randomised","Double",2,"Confirmed","Outpatient",NA,"Alternative therapy, Standard of care",150
"NCT04634409","https://clinicaltrials.gov/show/NCT04634409",NA,"United States","Washington, Dc","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Viral Load or Clearance","Other, Other + Other, Standard of care",700
"NCT04634409","https://clinicaltrials.gov/show/NCT04634409",NA,"Puerto Rico","Puerto Rico","2020-Nov",NA,"Recruiting","Randomised","Double",3,"Confirmed","Outpatient","Viral Load or Clearance","Other, Other + Other, Standard of care",700
"NCT04644198","https://clinicaltrials.gov/show/NCT04644198",NA,"Jamaica","Kingston","2020-Nov",NA,"Recruiting","Non-Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, Viral Load or Clearance, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Procalcitonin, IgG, IgM or IgA, Antibodies","Plasma based therapy, Standard of care",30
"NCT04713553","https://clinicaltrials.gov/show/NCT04713553",NA,"United States","Washington, Dc","2021-Jan",NA,"Recruiting","Randomised","Triple",5,"Healthy","Healthy Unexposed","Serious Adverse Events, Antibodies","Vaccine",1530
"NCT04715932","https://clinicaltrials.gov/show/NCT04715932",NA,"Canada","Ottawa","2021-Jan",NA,"Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient",NA,"Other, Standard of care",216
"NCT04729595","https://clinicaltrials.gov/show/NCT04729595",NA,"United States","California","2021-Jan",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient",NA,"Other, Standard of care",310
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"United States","Washington, Dc","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Argentina","Buenos Aires","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Brazil","Brasilia","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Canada","Ottawa","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Colombia","Bogota","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"France","Paris","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Germany","Berlin","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Israel","Jerusalem","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Italy","Rome","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Mexico","Mexico","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Peru","Lima","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"South Africa","Pretoria","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Spain","Madrid","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"NCT04734873","https://clinicaltrials.gov/show/NCT04734873",NA,"Ukraine","Kyiv (Kiev)","2021-Jan",NA,"Recruiting","Randomised","Quadruple",3,"Confirmed","Hospital",NA,"Monoclonal antibody + Standard of care, Standard of care",1000
"ISRCTN48734830","http://isrctn.com/ISRCTN48734830",NA,"Sweden","Stockholm","2020-Oct",NA,"Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission","ARBs, Standard of care",750
"ISRCTN89951424","http://isrctn.com/ISRCTN89951424",NA,"Brazil","Brasilia","2020-Nov",NA,"Recruiting","Randomised","Single",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",10300
"NL8523","https://trialregister.nl/trial/8523",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed Or Suspected","ICU","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, PaO2-FiO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Anesthetic",20
"NL8521","https://trialregister.nl/trial/8521",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",3,NA,"Hospital","Clinical Improvement Score (Any), Dyspnea, Adverse Events, Heart Rate, PaO2-FiO2, Quality of Life","Device, Standard of care",13
"NL8578","https://trialregister.nl/trial/8578",NA,"Netherlands","Amsterdam","2020-Feb",NA,"Not Recruiting","Randomised","Double",2,"Confirmed Or Suspected","ICU","Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Renal Outcome (Unspecified)","Other, Standard of care",124
"NL8609","https://trialregister.nl/trial/8609",NA,"Netherlands","Amsterdam","2020-Nov",NA,"Not Recruiting","Randomised","Open-Label",5,"Healthy","Healthy Unexposed","Monocyte Count","Standard of care, Vaccine, Vaccine + Bisphosphonate, Vaccine + Vaccine",100
"NL8547","https://trialregister.nl/trial/8547",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Healthy","Healthy Unexposed",NA,"Standard of care, Vaccine",1600
"NL8633","https://trialregister.nl/trial/8633",NA,"Netherlands","Amsterdam","2020-May",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Plasma based therapy, Standard of care",430
"NL8490","https://trialregister.nl/trial/8490",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events",NA,950
"NL8538","https://trialregister.nl/trial/8538",NA,"Netherlands","Amsterdam","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital",NA,"Positioning, Standard of care",342
"NL8491","https://trialregister.nl/trial/8491",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Albumin, PaO2-FiO2",NA,386
"NL8504","https://trialregister.nl/trial/8504",NA,"Netherlands","Amsterdam","2020-Mar",NA,"Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-6, IL-8, Radiographic Findings","TCZ",354
"TCTR20200514001","www.thaiclinicaltrials.org/show/TCTR20200514001",NA,"Thailand","Nan","2020-May",NA,"Not Recruiting","Randomised","Unspecified",2,"Confirmed","Unclear","Fever, SpO2, Radiographic Findings","FPV, Standard of care",96
"TCTR20200409006","www.thaiclinicaltrials.org/show/TCTR20200409006",NA,"Thailand","Nan","2020-Sep",NA,"Not Recruiting","Randomised","Unspecified",2,NA,"ICU","Mortality, ICU Admission, Non-invasive Ventilation, IL-6","Hemoperfusion, Standard of care",206
"TCTR20200404004","www.thaiclinicaltrials.org/show/TCTR20200404004",NA,"Thailand","Nan","2020-Apr",NA,"Not Recruiting","Randomised","Unspecified",2,NA,"Healthy Exposed","Hospitalization, Anti SARS-COV-2 Titers","HCQ, Standard of care",400
"NCT04422275","https://ClinicalTrials.gov/show/NCT04422275",NA,"United States","Missouri","2020-Jun","2023-Jun","Not Recruiting","Randomised","Quadruple",4,"Resolved","Outpatient",NA,"Corticosteroids + Other, Other",200
"JPRN-JRCT2031200252","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200252",NA,"United States","Washington, Dc","2020-Dec",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, C-Reactive Protein, Platelet Count, Hemoglobin, Prothrombin, INR, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",20
"JPRN-JRCT2031200252","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200252",NA,"South Korea","Seoul","2020-Dec",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, C-Reactive Protein, Platelet Count, Hemoglobin, Prothrombin, INR, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",20
"JPRN-JRCT2031200252","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200252",NA,"Mexico","Mexico City","2020-Dec",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, C-Reactive Protein, Platelet Count, Hemoglobin, Prothrombin, INR, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",20
"JPRN-JRCT2031200252","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200252",NA,"Singapore","Singapore","2020-Dec",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, C-Reactive Protein, Platelet Count, Hemoglobin, Prothrombin, INR, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",20
"JPRN-JRCT2031200252","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200252",NA,"Japan","Toyama","2020-Dec",NA,"Recruiting","Randomised","Unspecified",2,"Confirmed Or Suspected","Hospital","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, C-Reactive Protein, Platelet Count, Hemoglobin, Prothrombin, INR, ALT, AST, Bilirubin, Glucose","Remdesivir + Dexamethasone, Remdesivir + JAKi",20
"JPRN-JRCT2031200368","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200368",NA,"Germany","Berlin","2021-Feb",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Outpatient","Mortality","mAb, Standard of care",20
"JPRN-JRCT2031200368","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200368",NA,"Italy","Rome","2021-Feb",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Outpatient","Mortality","mAb, Standard of care",20
"JPRN-JRCT2031200368","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200368",NA,"Hungary","Budapest","2021-Feb",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Outpatient","Mortality","mAb, Standard of care",20
"JPRN-JRCT2031200368","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200368",NA,"Russia","Moscow","2021-Feb",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Outpatient","Mortality","mAb, Standard of care",20
"JPRN-JRCT2031200368","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200368",NA,"Spain","Madrid","2021-Feb",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Outpatient","Mortality","mAb, Standard of care",20
"JPRN-JRCT2031200368","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200368",NA,"Ukraine","Kyiv (Kiev)","2021-Feb",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Outpatient","Mortality","mAb, Standard of care",20
"JPRN-JRCT2031200368","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200368",NA,"Japan","Tokyo","2021-Feb",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Outpatient","Mortality","mAb, Standard of care",20
"JPRN-JRCT2031200368","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200368",NA,"Mexico","Mexico City","2021-Feb",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Outpatient","Mortality","mAb, Standard of care",20
"JPRN-JRCT2031200368","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031200368",NA,"Japan","Osaka","2021-Feb",NA,"Not Recruiting","Unspecified","Unspecified",2,"Confirmed","Outpatient","Mortality","mAb, Standard of care",20
"NCT04388709","https://clinicaltrials.gov/show/NCT04388709",NA,"United States","Washington, Dc","2020-Dec",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Hypoxia","IFN, Standard of care",66
"NCT04342221","https://ClinicalTrials.gov/show/NCT04342221",NA,"Germany","Berlin","2020-Apr","2021-Mar","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO",NA,220
"NCT04342221","https://ClinicalTrials.gov/show/NCT04342221",NA,"Germany","Hamburg","2020-Apr","2021-Mar","Recruiting","Randomised","Quadruple",2,NA,"Hospital","Mortality, Invasive Mechanical Ventilation or ECMO",NA,220
"NCT04428268","https://clinicaltrials.gov/show/NCT04428268",NA,"Mexico","Mexico","2020-Apr",NA,"Recruiting","Randomised","Double",2,"Confirmed","Unclear","Mortality","HCQ, HCQ + losartan",20
"JPRN-JRCT2031200174","https://jrct.niph.go.jp/latest-detail/jRCT2031200174",NA,"Japan","Toyama","2020-Oct",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, Organ Failure or Dysfunction (SOFA)","Igs, Standard of care",10
"JPRN-JRCT2071200069","https://jrct.niph.go.jp/latest-detail/jRCT2071200069",NA,"Japan","Osaka","2020-Dec",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthy Unexposed","Mortality, Hospitalization, Fever, Other Mild Symptoms, Adverse Events, Antibodies, Pregnancy or Birth Outcomes","Standard of care, Vaccine",200
"NCT04679350","https://ClinicalTrials.gov/show/NCT04679350",NA,"South Korea","Daegu","2020-Dec","2021-Jun","Not Recruiting","Randomised","Quadruple",4,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), PaO2-FiO2","Monoclonal IgG4 + Standard of care, Standard of care",48
"NCT04679350","https://ClinicalTrials.gov/show/NCT04679350",NA,"South Korea","Daejeon","2020-Dec","2021-Jun","Not Recruiting","Randomised","Quadruple",4,"Confirmed","Hospital","Mortality, Clinical Improvement Score (Any), PaO2-FiO2","Monoclonal IgG4 + Standard of care, Standard of care",48
"NCT04584697","https://clinicaltrials.gov/show/NCT04584697",NA,"United States","California","2020-Jul",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Viral Load or Clearance, Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies","mAb, Standard of care",50
"NCT04370834","https://clinicaltrials.gov/show/NCT04370834",NA,"United States","Washington, Dc","2020-Apr",NA,"Not Recruiting","Single-Arm","Open-Label",1,NA,"Hospital",NA,"TCZ",217
"NCT04406064","https://clinicaltrials.gov/show/NCT04406064",NA,"United States","Washington, Dc","2020-May",NA,"Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Unclear",NA,"Other",100
"NCT04456088","https://clinicaltrials.gov/show/NCT04456088",NA,"United States","New York","2020-Jan",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"Non-invasive respiratory support, Standard of care",50
"NCT04605926","https://clinicaltrials.gov/show/NCT04605926",NA,"Colombia","Bogota","2020-Oct",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Hospital",NA,"mAb, Standard of care",800
"NCT04329195","https://ClinicalTrials.gov/show/NCT04329195",NA,"France","Paris","2020-Apr","2020-May","Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Antihypertensive",554
"NCT04355676","https://clinicaltrials.gov/show/NCT04355676",NA,"United States","Massachusetts","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH","Other",80
"NCT04362124","https://clinicaltrials.gov/show/NCT04362124",NA,"Colombia","Bogota","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",2,NA,"Healthcare Workers","Mortality, Viral Load or Clearance, Adverse Events, Serious Adverse Events","Standard of care, Vaccine",1000
"NCT04365231","https://clinicaltrials.gov/show/NCT04365231",NA,"France","Paris","2020-Apr",NA,"Not Recruiting","Randomised","Open-Label",2,NA,"Outpatient",NA,"HCQ + AZT, Standard of care",50
"NCT04351880","https://clinicaltrials.gov/show/NCT04351880",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Single",2,"Confirmed Or Healthy","Resolved Discharged","Depression, Anxiety","Other",640
"NCT04371640","https://clinicaltrials.gov/show/NCT04371640",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Randomised","Quadruple",2,NA,"Hospital",NA,"Other, Standard of care",40
"NCT04435808","https://clinicaltrials.gov/show/NCT04435808",NA,"United States","Washington, Dc","2020-Apr",NA,"Recruiting","Non-Randomised","Open-Label",2,"Healthy","Healthy Exposed, Healthcare Workers",NA,"HCQ, Standard of care",350
"NCT04386447","https://clinicaltrials.gov/show/NCT04386447",NA,"France","Paris","2020-Dec",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"Hormone therapy, Standard of care",145
"NCT04386447","https://clinicaltrials.gov/show/NCT04386447",NA,"Italy","Rome","2020-Dec",NA,"Not Recruiting","Randomised","Open-Label",3,"Confirmed","Hospital",NA,"Hormone therapy, Standard of care",145
"NCT04343001","https://clinicaltrials.gov/show/NCT04343001",NA,"Nigeria","Niger","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",7,"Suspected","Hospital","Mortality","ARBs, ARBs + Statins, NSAIDs, NSAIDs + ARBs, NSAIDs + ARBs + Statins, NSAIDs + Statins, Statins",10000
"NCT04343001","https://clinicaltrials.gov/show/NCT04343001",NA,"Pakistan","Islamabad","2020-Aug",NA,"Not Recruiting","Randomised","Open-Label",7,"Suspected","Hospital","Mortality","ARBs, ARBs + Statins, NSAIDs, NSAIDs + ARBs, NSAIDs + ARBs + Statins, NSAIDs + Statins, Statins",10000
"NCT04583995","https://clinicaltrials.gov/show/NCT04583995",NA,"United Kingdom","London","2020-Sep",NA,"Recruiting","Randomised","Quadruple",4,"Healthy","Unclear",NA,"Standard of care, Standard of care + Vaccine, Vaccine, Vaccine + Vaccine",9000
"JPRN-JRCT2071200045","https://jrct.niph.go.jp/latest-detail/jRCT2071200045",NA,"Japan","Tokyo","2020-Oct",NA,"Not Recruiting","Randomised","Double",2,"Healthy","Healthy Exposed","Fever, Other Mild Symptoms, IgG, IgM or IgA, Antibodies","Standard of care, Vaccine",160
"NCT04454398","https://clinicaltrials.gov/show/NCT04454398",NA,"United States","Washington, Dc","2020-Jun",NA,"Recruiting","Randomised","Double",2,"Confirmed","Hospital","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies","mAb, Standard of care",33
"NCT04603690","https://clinicaltrials.gov/show/NCT04603690",NA,"Pakistan","Sind","2020-Oct",NA,"Not Recruiting","Randomised","Open-Label",2,"Confirmed","Hospital","IL-6","Colchicine, Standard of care",102
"NCT04351516","https://clinicaltrials.gov/show/NCT04351516",NA,"Germany","Berlin","2020-Apr",NA,"Not Recruiting","Randomised","Quadruple",2,"Confirmed","Outpatient","Mortality, Hospitalization","HCQ, Standard of care",350
